<?xml version="1.0" encoding="Windows-31J"?>
<ArticleSet xmlns="http://www.openarchives.org/OAI/2.0/">
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2045-2322</Issn>
      <Volume>16</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Pseudohypoxia induced by iron chelators preserves working memory performance in aged mice</ArticleTitle>
    <FirstPage LZero="delete">11550</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Toshiaki</FirstName>
        <LastName>Ohara</LastName>
        <Affiliation>Department of Pathology and Experimental Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshiaki</FirstName>
        <LastName>Iwasaki</LastName>
        <Affiliation>Health Service Section, Environment Health &amp; Safety Intelligence Department, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomonari</FirstName>
        <LastName>Kasai</LastName>
        <Affiliation>Department of Applied Energy, Graduate School of Engineering, Nagoya University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toru</FirstName>
        <LastName>Yamashita</LastName>
        <Affiliation>Department of Neurology, Graduate School of Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shiho</FirstName>
        <LastName>Komaki</LastName>
        <Affiliation>Department of Pathology and Experimental Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yusuke</FirstName>
        <LastName>Hamada</LastName>
        <Affiliation>Department of Pathology and Experimental Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masayoshi</FirstName>
        <LastName>Fujisawa</LastName>
        <Affiliation>Department of Pathology and Experimental Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Akihiro</FirstName>
        <LastName>Matsukawa</LastName>
        <Affiliation>Department of Pathology and Experimental Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Pseudohypoxia refers to a physiological condition wherein hypoxia-inducible factor (HIF) is pharmacologically upregulated under normoxia, thereby modulating immune responses. We hypothesized that pseudohypoxia, induced by iron chelators, may similarly potentiate systemic immune responses in aged mice, concurrently triggering neuro-regenerative signaling pathways and enhancing cognitive performance. In this study, aged mice (43&#8211;48 weeks old) were orally administered two iron chelators, Super Polyphenol 10 (SP10) or Roxadustat, to induce a pseudohypoxia. An 8-week oral regimen of SP10 and Roxadustat significantly preserved working memory, as assessed by the Y-maze test (YMT). White blood cell counts and hippocampal volume, as assessed by magnetic resonance imaging (MRI), were elevated in the treatment groups relative to controls. Pseudohypoxia induced by SP10 tended to enhance neuro-regenerative signaling, specifically involving the Tau and JNK pathways, and potentially modulated Doublecortin (DCX) expression, although statistical significance was limited by sample size. Importantly, inflammatory markers, such as ionized calcium-binding adapter molecule 1 (Iba1) and glial fibrillary acidic protein (GFAP), were not elevated by treatment. Collectively, these findings suggest that pseudohypoxia induced by iron chelators preserves working memory performance accompanied by leukocytosis, without concomitant neuroinflammation.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Hypoxia-inducible factor</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Working memory</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Hippocampus</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Iron</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>American Astronomical Society</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0067-0049</Issn>
      <Volume>283</Volume>
      <Issue>2</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>The Simons Observatory: Detector Polarization Angle Calibration Using a Sparse Wire Grid with Initial Datasets of the Small-aperture Telescopes</ArticleTitle>
    <FirstPage LZero="delete">78</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Hironobu</FirstName>
        <LastName>Nakata</LastName>
        <Affiliation>Department of Physics, Faculty of Science, Kyoto University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shunsuke</FirstName>
        <LastName>Adachi</LastName>
        <Affiliation>Okayama University, Department of Physics</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kyohei</FirstName>
        <LastName>Yamada</LastName>
        <Affiliation>Joseph Henry Laboratories of Physics, Jadwin Hall, Princeton University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Michael</FirstName>
        <LastName>Randall</LastName>
        <Affiliation>Joseph Henry Laboratories of Physics, Jadwin Hall, Princeton University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yutaro</FirstName>
        <LastName>Kasai</LastName>
        <Affiliation>Department of Physics, Faculty of Science, Kyoto University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kam</FirstName>
        <LastName>Arnold</LastName>
        <Affiliation>Joseph Henry Laboratories of Physics, Jadwin Hall, Princeton University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Bryce</FirstName>
        <LastName>Bixler</LastName>
        <Affiliation>Department of Physics, University of California San Diego</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuji</FirstName>
        <LastName>Chinone</LastName>
        <Affiliation>QUP (WPI), KEK</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kevin T.</FirstName>
        <LastName>Crowley</LastName>
        <Affiliation>Joseph Henry Laboratories of Physics, Jadwin Hall, Princeton University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Nadia</FirstName>
        <LastName>Dachlythra</LastName>
        <Affiliation>Department of Physics, University of Milano-Bicocca</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Samuel</FirstName>
        <LastName>Day-Weiss</LastName>
        <Affiliation>Joseph Henry Laboratories of Physics, Jadwin Hall, Princeton University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Nicholas</FirstName>
        <LastName>Galitzki</LastName>
        <Affiliation>Department of Physics, University of Texas at Austin</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Serena</FirstName>
        <LastName>Giardiello</LastName>
        <Affiliation>School of Physics and Astronomy, Cardiff University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Bradley R.</FirstName>
        <LastName>Johnson</LastName>
        <Affiliation>University of Virginia, Department of Astronomy</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Brian</FirstName>
        <LastName>Keating</LastName>
        <Affiliation>Department of Physics, University of California San Diego</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Brian J.</FirstName>
        <LastName>Koopman</LastName>
        <Affiliation>Wright Laboratory, Department of Physics, Yale University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Akito</FirstName>
        <LastName>Kusaka</LastName>
        <Affiliation>Kavli IPMU (WPI), UTIAS, The University of Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Jack</FirstName>
        <LastName>Lashner</LastName>
        <Affiliation>Wright Laboratory, Department of Physics, Yale University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Federico</FirstName>
        <LastName>Nati</LastName>
        <Affiliation>Department of Physics, University of Milano-Bicocca</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Lyman</FirstName>
        <LastName>Page</LastName>
        <Affiliation>Joseph Henry Laboratories of Physics, Jadwin Hall, Princeton University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Daichi</FirstName>
        <LastName>Sasaki</LastName>
        <Affiliation>Department of Physics, The University of Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshinori</FirstName>
        <LastName>Sueno</LastName>
        <Affiliation>Joseph Henry Laboratories of Physics, Jadwin Hall, Princeton University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Junya</FirstName>
        <LastName>Suzuki</LastName>
        <Affiliation>Department of Physics, Faculty of Science, Kyoto University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Osamu</FirstName>
        <LastName>Tajima</LastName>
        <Affiliation>Department of Physics, Faculty of Science, Kyoto University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tran</FirstName>
        <LastName>Tsan</LastName>
        <Affiliation>Physics Division, Lawrence Berkeley National Laboratory</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Improved measurements of B-modes in the cosmic microwave background can be obtained through accurate calibration of the orientation of detector antennas as projected onto the sky. Miscalibration of the detector polarization angle leads to a leakage of E-modes into B-modes, which can bias the detection of the latter. To achieve a σ(r) of 0.003, the Simons Observatory small-aperture telescopes are required to calibrate the global polarization angle on the sky with an accuracy &#8818;0.°1. We demonstrate a fully remote-controllable calibration system using a “sparse wire grid,” which injects a rotatable linear polarized signal across the telescope’s focal plane. This calibration system is installed and operational on one of the small-aperture telescopes at its observing site at the Parque Astron&#243;mico in the Atacama desert in Chile. We developed a pipeline for the detector polarization angle calibration, and demonstrate it using initial data for 93 and 145 GHz frequency bands. The observed distribution of detector polarization angles is in agreement with the instrument design. Statistical uncertainties for the relatively calibrated polarization angles are 0.°02 and 0.°03 at 93 and 145 GHz, respectively. Systematic uncertainty was evaluated to be 0.°08 at the hardware development and fabrication stage. Their sum in quadrature is less than 0.°1.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList/>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>American Geophysical Union (AGU)</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2169-9097</Issn>
      <Volume>131</Volume>
      <Issue>4</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Investigating the Detectability of Body Wave Phases From Tidal Ice Cracking Events on Titan With the Dragonfly Short-Period Seismometer</ArticleTitle>
    <FirstPage LZero="delete">e2025JE009432</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">L.</FirstName>
        <LastName>Delaroque</LastName>
        <Affiliation>Universit&#233; Paris Cit&#233;, Institut de Physique du Globe de Paris, CNRS</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">T.</FirstName>
        <LastName>Kawamura</LastName>
        <Affiliation>Universit&#233; Paris Cit&#233;, Institut de Physique du Globe de Paris, CNRS</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">A.</FirstName>
        <LastName>Lucas</LastName>
        <Affiliation>Universit&#233; Paris Cit&#233;, Institut de Physique du Globe de Paris, CNRS</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">S.</FirstName>
        <LastName>Rodriguez</LastName>
        <Affiliation>Universit&#233; Paris Cit&#233;, Institut de Physique du Globe de Paris, CNRS</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">K.</FirstName>
        <LastName>Onodera</LastName>
        <Affiliation>Institute for Planetary Materials, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">H.</FirstName>
        <LastName>Shiraishi</LastName>
        <Affiliation>Institute of Space and Astronautical Science, Japan Aerospace Exploration Agency</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">R.</FirstName>
        <LastName>Yamada</LastName>
        <Affiliation>The University of Aizu</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">S.</FirstName>
        <LastName>Tanaka</LastName>
        <Affiliation>Institute of Space and Astronautical Science, Japan Aerospace Exploration Agency</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">M. P.</FirstName>
        <LastName>Panning</LastName>
        <Affiliation>Jet Propulsion Laboratory, California Institute of Technology</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">R. D.</FirstName>
        <LastName>Lorenz</LastName>
        <Affiliation>The Johns Hopkins University Applied Physics Laboratory</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Detecting seismic activity on Saturn's icy moon Titan during the Dragonfly mission could provide crucial information on its internal structure. The geological complexity of the moon's surface suggests significant cyclic tidal deformation, likely leading to the fracturing of the ice shell. Considering realistic source locations and fault geometries, we assess whether a vertical short-period seismometer can detect body waves from a Mw 4.0 icequake. Signal-to-noise ratios are evaluated by comparing the high-frequency content with the expected background noise and instrument capabilities for several ice attenuation scenarios and 1D interior models. Our results indicate that the high-frequency content (&#8805;1Hz) of Mw&#8804;4.0 tidal-induced icequakes is likely undetectable under the most unfavorable attenuation scenarios and atmospheric conditions. However, seismic signals in the 0.5&#8211;1 Hz band―where P wave reflections dominate―may still be observable for events occurring in potential seismically active regions at &#8764;800&#8211;1,000 km from the Dragonfly's landing site. These signals could provide constraints on the thickness of Titan's outer ice shell, provided that intrinsic attenuation is low and environmental conditions are favorable.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">body waves</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">planetary seismology</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">interior structure</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">dragonfly mission</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">icy moons</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Titan</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2045-2322</Issn>
      <Volume>16</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Liquid&#8211;liquid phase separation by caged coacervating peptides</ArticleTitle>
    <FirstPage LZero="delete">10464</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Akinari</FirstName>
        <LastName>Bando</LastName>
        <Affiliation>Department of Interdisciplinary Science and Engineering in Health Systems, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Mizuki</FirstName>
        <LastName>Kitamatsu</LastName>
        <Affiliation>Department of Applied Chemistry, Kindai University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuuki</FirstName>
        <LastName>Kanazaki</LastName>
        <Affiliation>Department of Applied Chemistry, Kindai University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Rika</FirstName>
        <LastName>Tojo</LastName>
        <Affiliation>Department of Applied Chemistry, Kindai University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazunori</FirstName>
        <LastName>Watanabe</LastName>
        <Affiliation>Department of Interdisciplinary Science and Engineering in Health Systems, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takashi</FirstName>
        <LastName>Ohtsuki</LastName>
        <Affiliation>Department of Interdisciplinary Science and Engineering in Health Systems, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Liquid&#8211;liquid phase separation is an important biomolecular process in the formation of membraneless intracellular organelles that has inspired the development of artificial droplet systems. We developed caged coacervating peptides (CCPs) based on a histidine-rich squid beak protein sequence. The peptides were caged with a photodeprotectable (7-diethylaminocoumarin-4-yl)methoxycarbonyl group. The CCPs formed coacervates in the caged state and were partially dispersed upon blue-light irradiation. Photo-uncaging occurred rapidly, inducing coacervate dispersion. A mutant CCP with reduced π&#8211;π interactions exhibited efficient photo-dependent disassembly and enabled the encapsulation and release of a fluorescently labeled adenosine 5′-triphosphate (Bodipy-ATP) upon irradiation. These CCPs offer an efficient light-controlled approach for biomolecular encapsulation within coacervates and targeted drug delivery.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Caged coacervating peptide</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Liquid&#8211;liquid phase separation</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Light</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1472-6831</Issn>
      <Volume>26</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Evaluation of contact-active antibacterial properties of cetylpyridinium chloride&#8211;graphene oxide coatings on dental restorative and titanium surfaces: an in vitro study</ArticleTitle>
    <FirstPage LZero="delete">558</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Keisuke</FirstName>
        <LastName>Okubo</LastName>
        <Affiliation>Department of Periodontics and Endodontics, Field of Medical Development, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Gen</FirstName>
        <LastName>Kano</LastName>
        <Affiliation>Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masato</FirstName>
        <LastName>Komoda</LastName>
        <Affiliation>Research Institute for Interdisciplinary Science, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hideyuki</FirstName>
        <LastName>Kamata</LastName>
        <Affiliation>Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shin</FirstName>
        <LastName>Nakamura</LastName>
        <Affiliation>Department of Pathophysiology - Periodontal Science, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuki</FirstName>
        <LastName>Shinoda-Ito</LastName>
        <Affiliation>Department of Pathophysiology - Periodontal Science, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuhiro</FirstName>
        <LastName>Omori</LastName>
        <Affiliation>Department of Pathophysiology - Periodontal Science, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuta</FirstName>
        <LastName>Nishina</LastName>
        <Affiliation>Research Institute for Interdisciplinary Science, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shogo</FirstName>
        <LastName>Takashiba</LastName>
        <Affiliation>Department of Pathophysiology - Periodontal Science, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Objective Biofilm formation on dental restorative materials and implant surfaces plays a central role in the development of dental caries, periodontal disease, and peri-implantitis. Durable antimicrobial surface treatments that inhibit bacterial adhesion and biofilm formation remain a significant unmet need in restorative and implant dentistry. Therefore, this study aimed to develop a composite coating combining cetylpyridinium chloride and graphene oxide, and to evaluate its durable antibacterial surface modification under in vitro conditions.&lt;br&gt;
Methods A composite coating consisting of cetylpyridinium chloride and graphene oxide was prepared and applied to composite resin and titanium surfaces. Antibacterial activity against Streptococcus mutans and Porphyromonas gingivalis was evaluated using adenosine triphosphate assays and fluorescence-based live/dead staining. Coating retention after washing and air-drying was assessed by optical microscopy and Raman spectroscopy.&lt;br&gt;
Results Cetylpyridinium chloride-graphene oxide-coated surfaces showed a significant reduction in bacterial viability compared with phosphate-buffered saline, ethanol, and cetylpyridinium chloride-only controls. Antibacterial effects were maintained after rinsing and air-drying on both composite resin and titanium surfaces. Raman spectroscopy confirmed the persistence of characteristic graphene oxide bands after washing, indicating stable retention of the coating on the material surfaces.&lt;br&gt;
Conclusions Cetylpyridinium chloride&#8211;graphene oxide coatings demonstrate sustained surface-associated antibacterial activity against key cariogenic and periodontal pathogens and remain stably adhered to common dental restorative and implant materials after washing. These findings suggest that cetylpyridinium chloride&#8211;graphene oxide coatings may serve as a durable contact-active surface modification strategy to reduce biofilm formation associated with dental caries and peri-implantitis.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Wash-resistant antibacterial coating</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Graphene oxide</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Cetylpyridinium chloride</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Oral pathogenic bacteria</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>MDPI AG</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1422-0067</Issn>
      <Volume>27</Volume>
      <Issue>2</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Porphyromonas gingivalis Vesicles Control Osteoclast&#8211;Macrophage Lineage Fate</ArticleTitle>
    <FirstPage LZero="delete">831</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Elizabeth</FirstName>
        <LastName>Leon</LastName>
        <Affiliation>Department of Oral Science and Translational Research, College of Dental Medicine, Nova Southeastern University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shin</FirstName>
        <LastName>Nakamura</LastName>
        <Affiliation>Department of Periodontics and Endodontics, Division of Dentistry, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Satoru</FirstName>
        <LastName>Shindo</LastName>
        <Affiliation>Department of Oral Science and Translational Research, College of Dental Medicine, Nova Southeastern University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Maria Rita</FirstName>
        <LastName>Pastore</LastName>
        <Affiliation>Department of Oral Science and Translational Research, College of Dental Medicine, Nova Southeastern University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomoki</FirstName>
        <LastName>Kumagai</LastName>
        <Affiliation>Department of Oral Science and Translational Research, College of Dental Medicine, Nova Southeastern University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Alireza</FirstName>
        <LastName>Heidari</LastName>
        <Affiliation>Department of Oral Science and Translational Research, College of Dental Medicine, Nova Southeastern University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Elaheh Dalir</FirstName>
        <LastName>Abdolahinia</LastName>
        <Affiliation>Department of Oral Science and Translational Research, College of Dental Medicine, Nova Southeastern University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomoya</FirstName>
        <LastName>Ueda</LastName>
        <Affiliation>Department of Oral Science and Translational Research, College of Dental Medicine, Nova Southeastern University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takumi</FirstName>
        <LastName>Memida</LastName>
        <Affiliation>Department of Oral Science and Translational Research, College of Dental Medicine, Nova Southeastern University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ana</FirstName>
        <LastName>Duran-Pinedo</LastName>
        <Affiliation>Department of Oral Biology, College of Dentistry, University of Florida</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Jorge</FirstName>
        <LastName>Frias-Lopez</LastName>
        <Affiliation>Department of Oral Biology, College of Dentistry, University of Florida</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Xiaozhe</FirstName>
        <LastName>Han</LastName>
        <Affiliation>Department of Oral Science and Translational Research, College of Dental Medicine, Nova Southeastern University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Xin</FirstName>
        <LastName>Chen</LastName>
        <Affiliation>Department of Oral Science and Translational Research, College of Dental Medicine, Nova Southeastern University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shengyuan</FirstName>
        <LastName>Huang</LastName>
        <Affiliation>Department of Oral Science and Translational Research, College of Dental Medicine, Nova Southeastern University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Guoqin</FirstName>
        <LastName>Cao</LastName>
        <Affiliation>Department of Oral Science and Translational Research, College of Dental Medicine, Nova Southeastern University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Sunniva</FirstName>
        <LastName>Ruiz</LastName>
        <Affiliation>Department of Oral Science and Translational Research, College of Dental Medicine, Nova Southeastern University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Jan</FirstName>
        <LastName>Potempa</LastName>
        <Affiliation>Department of Oral Immunology and Infectious Diseases, School of Dentistry, University of Louisville</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshihisa</FirstName>
        <LastName>Kawai</LastName>
        <Affiliation>Department of Oral Science and Translational Research, College of Dental Medicine, Nova Southeastern University, Fort Lauderdale, FL 33314, USA</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Porphyromonas gingivalis (Pg), a keystone pathogen of chronic periodontitis, releases outer membrane vesicles (OMVs) that act as nanoscale vehicles to disseminate virulence factors within periodontal tissues and systemically beyond the oral cavity. Although Pg-OMVs are increasingly recognized as critical mediators of host&#8211;pathogen interactions, their effects on the differentiation and function of monocyte&#8211;macrophage/osteoclast lineage cells remain unclear. Here, we examined the impact of Pg-OMVs on the differentiation of RAW264.7 monocyte/macrophage-like cells into osteoclasts (OC) and/or macrophages (MΦ) in the presence of receptor activator of nuclear factor-κB ligand (RANKL). OMVs were isolated from Pg W83 and applied to RANKL-primed RAW264.7 cells using three distinct stimulation schedules: (1) simultaneous treatment with Pg-OMVs and RANKL at Day 0; (2) RANKL priming at Day 0 followed by Pg-OMV stimulation at Day 1; and (3) RANKL priming at Day 0 followed by Pg-OMV stimulation at Day 3. In all schedules, cells were cultured for 7 days from the initial RANKL exposure. Remarkably, simultaneous exposure to Pg-OMVs and RANKL (Schedule 1) markedly suppressed osteoclastogenesis (OC-genesis) while promoting M1 macrophage polarization. In contrast, delayed Pg-OMV stimulation of RANKL-primed cells (Schedules 2 and 3) significantly enhanced OC-genesis while reducing M1 polarization. These schedule-dependent effects were consistent with altered expression of osteoclastogenic markers, including dc-stamp, oc-stamp, nfatc1, and acp5. Importantly, a monoclonal antibody against OC-STAMP counteracted the Pg-OMV-induced upregulation of OC-genesis in Schedules 2 and 3. Furthermore, levels of Pg-OMV phagocytosis were inversely correlated with osteoclast formation. Finally, co-stimulation with RANKL and Pg-OMVs (Schedule 1) enhanced macrophage migratory capacity, whereas delayed stimulation with Pg-OMVs (Schedules 2 and 3) did not. Collectively, these findings indicate that Pg-OMVs exert stage-specific effects on the OC/MΦ lineage: stimulation at early stages of RANKL priming suppresses OC-genesis and promotes M1 polarization, whereas stimulation at later stages enhances OC-genesis without inducing M1 differentiation. Thus, Pg-OMVs may critically influence the fate of the OC/MΦ unit in periodontal lesions, contributing to disease progression and tissue destruction.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Porphyromonas gingivalis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">outer membrane vesicle</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">periodontitis pathogenesis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">macrophage polarization</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">osteoclastogenesis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">OC/MΦ unit</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0971-5894</Issn>
      <Volume/>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Suppression of salt-enhanced apoplastic flow by salicylic acid in rice</ArticleTitle>
    <FirstPage LZero="delete"/>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Md. Asadulla Al</FirstName>
        <LastName>Galib</LastName>
        <Affiliation>Graduate School of Environmental and Life Science, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Maoxiang</FirstName>
        <LastName>Zhao</LastName>
        <Affiliation>Graduate School of Environmental and Life Science, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshiyuki</FirstName>
        <LastName>Nakamura</LastName>
        <Affiliation>Graduate School of Environmental and Life Science, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshimasa</FirstName>
        <LastName>Nakamura</LastName>
        <Affiliation>Graduate School of Environmental and Life Science, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshihiko</FirstName>
        <LastName>Hirai</LastName>
        <Affiliation>Graduate School of Environmental and Life Science, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshitaka</FirstName>
        <LastName>Nakashima</LastName>
        <Affiliation>Graduate School of Environmental and Life Science, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shintaro</FirstName>
        <LastName>Munemasa</LastName>
        <Affiliation>Graduate School of Environmental and Life Science, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Izumi C.</FirstName>
        <LastName>Mori</LastName>
        <Affiliation>Institute of Plant Science and Resources, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshiyuki</FirstName>
        <LastName>Murata</LastName>
        <Affiliation>Graduate School of Environmental and Life Science, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Salinity enhances apoplastic flow, resulting in an increment of Na+ uptake and a lower K+/Na+ ratio. Salicylic acid (SA) plays an important role in improving salinity tolerance in plants. The effect of exogenous SA on apoplastic flow in salt-treated rice seedlings was studied using an apoplastic tracer, 8-hydroxy-1,3,6-pyrenetrisulphonic acid (PTS) in light. Application of NaCl at 25 mM to the hydroponic solution significantly increased PTS uptake, while 25 mM NaCl did not affect seedling growth. Application of 25 mM NaNO3 increased PTS uptake to the same degree. Salinity significantly increased sodium (Na+) content but had no significant effect on potassium (K+) content, resulting in a lower K+/Na+ ratio. The application of SA at 0.05 mM and 0.1 mM to the hydroponic solution reduced Na-enhanced PTS uptake. Salicylic acid at 0.05 mM and 0.1 mM significantly reduced Na+ content and slightly increased K+ content in the shoots of rice seedlings, resulting in a higher K+/Na+ ratio. However, SA at up to 0.1 mM did not increase SA contents in shoots under salt stress. These results suggest that exogenous SA reduces Na+ uptake by suppressing Na+-enhanced apoplastic flow in rice seedlings. These findings provide insight into modulation of Na+ transport pathways from roots to shoots by SA and may allow us to utilize brackish water for rice cultivation and to improve salt-tolerant rice through suppression of salt-enhanced apoplastic flow by chemicals such as salicylic acid.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Apoplastic flow</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Salicylic acid</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Rice</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Salinity</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Trisodium-8-hydroxy-1,3,6-pyrenetrisulphonic acid</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2662-4435</Issn>
      <Volume>7</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Stability and distribution of dense hydrous magnesium silicates in the mantle transition zone under low water activity conditions</ArticleTitle>
    <FirstPage LZero="delete">265</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Yunke</FirstName>
        <LastName>Song</LastName>
        <Affiliation>Key Laboratory of High-temperature and High-pressure Study of the Earth’s Interior, Institute of Geochemistry, Chinese Academy of Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Xinzhuan</FirstName>
        <LastName>Guo</LastName>
        <Affiliation>State Key Laboratory of Critical Mineral Research and Exploration, Institute of Geochemistry, Chinese Academy of Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kuan</FirstName>
        <LastName>Zhai</LastName>
        <Affiliation>Key Laboratory of High-temperature and High-pressure Study of the Earth’s Interior, Institute of Geochemistry, Chinese Academy of Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Wei</FirstName>
        <LastName>Guo</LastName>
        <Affiliation>State Key Laboratory of Geomicrobiology and Environmental Changes, School of Earth Sciences, China University of Geosciences (Wuhan)</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takashi</FirstName>
        <LastName>Yoshino</LastName>
        <Affiliation>Institute for Planetary Materials, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Water plays a central role in controlling the physical and chemical properties of Earth’s deep interior. It remains uncertain how water is stored in subducting slabs within the mantle transition zone, between depths of about 410 and 660 kilometers, and whether dense hydrous magnesium silicates act as major water carriers to greater depths. Here we report high-pressure and high-temperature laboratory experiments on the Mg-Si-H system at pressures of 16 and 21.5&#8201;GPa and a temperature of 1400&#8201;K to evaluate hydrous phase stability under transition zone conditions. We find that when bulk water content is below 1.22&#8201;wt%, H2O is predominantly incorporated into wadsleyite and ringwoodite rather than forming dense hydrous magnesium silicates. Because estimated water contents in subducted oceanic slabs are typically lower than one weight percent, formation of these silicates is unlikely, suggesting that the mantle transition zone may restrict large scale water transport into the lower mantle.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList/>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2662-4443</Issn>
      <Volume>6</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>From localized 4f electrons to anisotropic exchange interactions in ferromagnetic CeRh6Ge4</ArticleTitle>
    <FirstPage LZero="delete">269</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Shoichiro</FirstName>
        <LastName>Itokazu</LastName>
        <Affiliation>Department of Physics, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Akimitsu</FirstName>
        <LastName>Kirikoshi</LastName>
        <Affiliation>Research Institute for Interdisciplinary Science, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Harald O.</FirstName>
        <LastName>Jeschke</LastName>
        <Affiliation>Research Institute for Interdisciplinary Science, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Junya</FirstName>
        <LastName>Otsuki</LastName>
        <Affiliation>Research Institute for Interdisciplinary Science, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>CeRh6Ge4 is a cerium-based ferromagnetic material exhibiting a quantum critical behavior under pressure. We derive effective exchange interactions, using the framework of density functional theory combined with dynamical mean-field theory. Our results reveal that the nearest-neighbor ferromagnetic interaction along the c axis is isotropic in spin space, leading to a formation of spin chains. On the other hand, the inter-chain coupling is highly anisotropic: The in-plane moment weakly interacts ferromagnetically in the a&#8211;b plane to stabilize the ferromagnetic state, whereas the z-component couples antiferromagnetically, contributing to its destabilization. The magnetic anisotropy of the interchain interactions as well as of the local 4f wavefunctions characterizes the magnetic properties underlying the ferromagnetic transition and the quantum critical behavior in CeRh6Ge4.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList/>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>岡山大学教育推進機構 教師教育開発センター</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2186-1323</Issn>
      <Volume>16</Volume>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>スクールカウンセラーは発達支持的生徒指導へいかに貢献できるか ―プランニングシートの活用を通した支援の拡充に向けた検討―</ArticleTitle>
    <FirstPage LZero="delete">253</FirstPage>
    <LastPage>266</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Noriyuki</FirstName>
        <LastName>HARA</LastName>
        <Affiliation/>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryo</FirstName>
        <LastName>MISAWA</LastName>
        <Affiliation/>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tazuko</FirstName>
        <LastName>AOKI</LastName>
        <Affiliation/>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi">10.18926/CTED/70373</ArticleId>
    </ArticleIdList>
    <Abstract>　2022年に改訂された「生徒指導提要」では，すべての児童生徒の成長を支援する発達支持的生徒指導の重要性が明確に示されている。しかし，その定着には，教員の多忙化や組織的支援体制の不十分さなど，学校現場における多くの課題が指摘されている。さらに，スクールカウンセラー（SC）による支援も十分に展開されているとは言い難い。そこで本稿では，発達支持的生徒指導におけるSCの支援の拡充可能性を検討するため，現状と課題を整理した。また，プランニングシートを活用した実践事例（原他, 2024）の再分析を通して，SCと学校が教育目標を共有しながら協働的に支援を計画する枠組みの有用性を吟味した。</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">発達支持的生徒指導 (developmentally supportive student guidance)</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">プランニングシート (Planning Sheet)</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">スクールカウンセラー (school counselor)</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">チーム学校 (school as a team)</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>岡山大学教育推進機構 教師教育開発センター</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2186-1323</Issn>
      <Volume>16</Volume>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>ドイツ付近の夏の気候とシューベルトの歌曲《春に》 異質な他者との出会いを促す大学での学際的授業の報告</ArticleTitle>
    <FirstPage LZero="delete">75</FirstPage>
    <LastPage>89</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Kuranoshin</FirstName>
        <LastName>KATO</LastName>
        <Affiliation>Faculty of Education, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Isao</FirstName>
        <LastName>NAGAOKA</LastName>
        <Affiliation>Faculty of Education, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Haruko</FirstName>
        <LastName>KATO</LastName>
        <Affiliation>Faculty of Education, Gufu Shotoku Gakuen University (Former affiliation)</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi">10.18926/CTED/70361</ArticleId>
    </ArticleIdList>
    <Abstract>　「異質な他者」への出会いを促す授業例の更なる蓄積のため，ドイツ付近の「夏」の気候と季節感に注目した教科横断的な授業を大学で実践した。授業では，ドイツ付近の気候と季節サイクルの中での「夏」の特徴を把握すると共に，シューベルトの歌曲《春に》を鑑賞した。《春に》の3 番の「夏の間じゅう，ずっと」という歌詞で歌われている情景や情感が，ドイツ付近と日本付近を想定した場合にどう違い得るか，に関する受講生の記述を分析した。その結果，日本の夏の高温多湿な環境からは原詩の情感そのものが成立し難いと感じた学生もいるなど，本実践は，自分たちの「当たり前」とは異なる気候や季節感にも目を向ける機会になり得たといえる。一方，日本とはかなり違う気候背景の中でシューベルトが思い描いたであろう情景・心情に授業で深く迫るための，音楽表現自体への踏み込み方についても，今後検討する必要性が示唆された。</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">気候と音楽</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">ドイツ付近の夏の気候と季節感</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">気候と文化理解の学際的ESD教師教育</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">異質な他者への理解</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1432-0851</Issn>
      <Volume>75</Volume>
      <Issue>3</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>A real-world comparison of nivolumab plus cabozantinib and pembrolizumab plus lenvatinib focusing on safety outcomes in metastatic renal cell carcinoma: results from the JK-FOOT consortium</ArticleTitle>
    <FirstPage LZero="delete">84</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Takafumi</FirstName>
        <LastName>Yanagisawa</LastName>
        <Affiliation>Department of Urology, The Jikei University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Keiichiro</FirstName>
        <LastName>Mori</LastName>
        <Affiliation>Department of Urology, The Jikei University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tatsushi</FirstName>
        <LastName>Kawada</LastName>
        <Affiliation>Department of Urology, Comprehensive Cancer Center, Medical University of Vienna</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Satoshi</FirstName>
        <LastName>Katayama</LastName>
        <Affiliation>Department of Urology, Comprehensive Cancer Center, Medical University of Vienna</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takuya</FirstName>
        <LastName>Tsujino</LastName>
        <Affiliation>Department of Urology, Osaka Medical and Pharmaceutical University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryoichi</FirstName>
        <LastName>Maenosono</LastName>
        <Affiliation>Department of Urology, Osaka Medical and Pharmaceutical University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shingo</FirstName>
        <LastName>Toyoda</LastName>
        <Affiliation>Department of Urology, Faculty of Medicine, Kindai University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takuhisa</FirstName>
        <LastName>Nukaya</LastName>
        <Affiliation>Department of Urology, Fujita-Health University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hirofumi</FirstName>
        <LastName>Morinaka</LastName>
        <Affiliation>Department of Urology, Kawasaki Medical School</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Keita</FirstName>
        <LastName>Tamura</LastName>
        <Affiliation>Department of Urology, Hamamatsu Medical University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Wataru</FirstName>
        <LastName>Fukuokaya</LastName>
        <Affiliation>Department of Urology, The Jikei University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Fumihiko</FirstName>
        <LastName>Urabe</LastName>
        <Affiliation>Department of Urology, The Jikei University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masaya</FirstName>
        <LastName>Murakami</LastName>
        <Affiliation>Department of Urology, The Jikei University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kensuke</FirstName>
        <LastName>Bekku</LastName>
        <Affiliation>Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kiyoshi</FirstName>
        <LastName>Takahara</LastName>
        <Affiliation>Department of Urology, Fujita-Health University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazutoshi</FirstName>
        <LastName>Fujita</LastName>
        <Affiliation>Department of Urology, Faculty of Medicine, Kindai University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Haruhito</FirstName>
        <LastName>Azuma</LastName>
        <Affiliation>Department of Urology, Osaka Medical and Pharmaceutical University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Motoo</FirstName>
        <LastName>Araki</LastName>
        <Affiliation>Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Teruo</FirstName>
        <LastName>Inamoto</LastName>
        <Affiliation>Department of Urology, Hamamatsu Medical University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazumasa</FirstName>
        <LastName>Komura</LastName>
        <Affiliation>Department of Urology, Kawasaki Medical School</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takahiro</FirstName>
        <LastName>Kimura</LastName>
        <Affiliation>Department of Urology, The Jikei University School of Medicine</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Purpose Immune checkpoint inhibitor (ICI)-based combination therapy is a standard first-line treatment for metastatic renal cell carcinoma (mRCC), with combinations such as nivolumab plus cabozantinib (Nivo&#8201;+&#8201;Cabo) and pembrolizumab plus lenvatinib (Pem&#8201;+&#8201;Len) demonstrating favorable oncologic outcomes. However, no direct comparisons between these two regimens have been conducted. This study aimed to compare the safety and oncologic outcomes of Nivo&#8201;+&#8201;Cabo and Pem&#8201;+&#8201;Len in patients with mRCC.&lt;br&gt;
Methods This retrospective study included 185 patients with mRCC treated with Nivo&#8201;+&#8201;Cabo (n&#8201;=&#8201;81) or Pem&#8201;+&#8201;Len (n&#8201;=&#8201;104) between January 2018 and June 2025 across multiple institutions. The primary outcome was a comparison of treatment-related adverse events (TrAEs). Oncologic outcomes, including objective response rate (ORR), progression-free survival (PFS), cancer-specific survival (CSS), and overall survival (OS), were compared using one-to-one propensity score matching.&lt;br&gt;
Results Any-grade TrAEs occurred in 90% of patients in the Nivo&#8201;+&#8201;Cabo group and 92% in the Pem&#8201;+&#8201;Len group (p&#8201;=&#8201;0.6). Severe TrAEs (grade&#8201;&#8805;&#8201;3) were more frequent in the Pem&#8201;+&#8201;Len group (44%) than in the Nivo&#8201;+&#8201;Cabo group (30%, p&#8201;=&#8201;0.048). Tyrosine kinase inhibitor dose reduction and treatment discontinuation rates were similar between groups. In the matched cohort (Nivo&#8201;+&#8201;Cabo: n&#8201;=&#8201;74; Pem&#8201;+&#8201;Len: n&#8201;=&#8201;74), ORRs were comparable (66% vs. 71%, p&#8201;=&#8201;0.6). With a median follow-up of 17 months, no significant differences were observed in PFS (p&#8201;=&#8201;0.4), CSS (p&#8201;=&#8201;0.9), or OS (p&#8201;=&#8201;0.5).&lt;br&gt;
Conclusions Nivo&#8201;+&#8201;Cabo and Pem&#8201;+&#8201;Len demonstrated similar oncologic efficacy as first-line treatments for mRCC. However, Pem&#8201;+&#8201;Len was associated with more severe TrAEs. Careful toxicity management and shared decision-making are essential when selecting ICI-based combinations.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Metastatic renal cell carcinoma</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Immune checkpoint inhibitor</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Pembrolizumab</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Lenvatinib</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Nivolumab</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Cabozantinib</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2192-4449</Issn>
      <Volume>15</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>A case of tubulointerstitial nephritis with infiltration of neutrophils and interleukin-17-positive cells associated with Beh&#231;et’s disease</ArticleTitle>
    <FirstPage LZero="delete">35</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Naruhiko</FirstName>
        <LastName>Uchida</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Faculty of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Keiko</FirstName>
        <LastName>Tanaka</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Faculty of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Natsuki</FirstName>
        <LastName>Kubota</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Faculty of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takayuki</FirstName>
        <LastName>Katsuyama</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Faculty of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Katsuyuki</FirstName>
        <LastName>Tanabe</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Faculty of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Haruhito A.</FirstName>
        <LastName>Uchida</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Faculty of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Jun</FirstName>
        <LastName>Wada</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Faculty of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Beh&#231;et’s disease (BD) is a non-infectious inflammatory condition characterized by neutrophilic infiltration. In addition to primary symptoms, including oral and genital ulcers, ocular involvement, and skin lesions, BD can also affect various organs. However, renal involvement, particularly in tubulointerstitial nephritis, has rarely been described. Herein, a rare case of acute tubulointerstitial nephritis in a patient clinically diagnosed with BD is reported. The renal lesion presented with other symptoms of BD and fever, and was considered to be BD-related due to the presence of neutrophilic infiltration and its responsiveness to BD-directed therapy. Alterations in T-helper (Th) 1, Th2, and Th17 cytokine profiles are associated with BD activity. Interleukin (IL)-17 plays a central role in neutrophil activation, and recent studies have demonstrated a strong correlation between IL-17A levels and BD activity. In the present case, elevated serum IL-17A levels and infiltration of IL-17A-positive cells into the renal tissue reflected an active phase of BD and a BD-associated renal lesion.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Tubulointerstitial nephritis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Beh&#231;et’s disease</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Neutrophils</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Interleukin-17</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">T-helper (Th) 1/Th2/Th17  cytokines</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>John Wiley &amp; Sons Ltd.</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2314-6133</Issn>
      <Volume>2025</Volume>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Comparing the Activity of Peripheral Blood Mononuclear Cells Frozen Under Electromagnetic Field Freezing and Standard Slow-Freezing</ArticleTitle>
    <FirstPage LZero="delete">9884345</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Takehiro</FirstName>
        <LastName>Matsubara</LastName>
        <Affiliation>Okayama University Hospital Biobank</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Mina</FirstName>
        <LastName>Takagi</LastName>
        <Affiliation>Faculty of Health Sciences, Okayama University Medical School</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takahiro</FirstName>
        <LastName>Uwabo</LastName>
        <Affiliation>Department of Biorepository Research and Networking, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Junichi</FirstName>
        <LastName>Soh</LastName>
        <Affiliation>Department of Thoracic Surgery, Osaka Metropolitan University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shinichi</FirstName>
        <LastName>Toyooka</LastName>
        <Affiliation>Okayama University Hospital Biobank</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Mizuki</FirstName>
        <LastName>Morita</LastName>
        <Affiliation>Okayama University Hospital Biobank</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Peripheral blood mononuclear cells (PBMCs) are cells obtained from the blood that are used not only in clinical tests but also in various research applications. The slow-freezing (SLF) method, currently the standard for PBMC cryopreservation, involves extended storage at −80°C before transfer to liquid nitrogen. Delays in this transfer, such as overnight or weekend holds, risk a gradual decline in cell viability. Additionally, variability in freezing duration can lead to inconsistent cell quality, emphasizing the need for an alternative freezing method that allows for more timely transfer to liquid nitrogen. This study is aimed at clarifying whether the method of using a freezer with an applied electromagnetic field (EMF) is superior to the currently used standard SLF method for PBMC cryopreservation. A comparison of the number of viable cells, cell viability, and cell activity showed that the EMF method was equivalent to the SLF method. However, the shortest time required for freezing was significantly shorter with the EMF method than the SLF method (0.25 vs. 3&#8201;h), allowing for earlier transfer of PBMC to liquid nitrogen. This demonstrates that the EMF method offers an advantage in operational efficiency, particularly for facilities that routinely process and store PBMCs, such as biobanks and other storage-focused departments.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList/>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2045-2322</Issn>
      <Volume>16</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Tribolium castaneum with longer duration of tonic immobility have more variations corresponding to the human Parkinson’s disease genomic region</ArticleTitle>
    <FirstPage LZero="delete">8840</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Keisuke</FirstName>
        <LastName>Tanaka</LastName>
        <Affiliation>NODAI Genome Research Center, Tokyo University of Agriculture</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ken</FirstName>
        <LastName>Sasaki</LastName>
        <Affiliation>Graduate School of Agriculture, Tamagawa University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shunsuke</FirstName>
        <LastName>Yajima</LastName>
        <Affiliation>NODAI Genome Research Center, Tokyo University of Agriculture</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takahisa</FirstName>
        <LastName>Miyatake</LastName>
        <Affiliation>Faculty of Environmental, Life, Natural Science and Technology, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Parkinson’s disease (PD) is a common neurodegenerative syndrome characterized by the loss of dopaminergic neurons and is also a progressive neurodegenerative disorder that is characterized by dopamine deficiency. We established strains artificially selected for longer and shorter durations of tonic immobility, an antipredator behavior that has received much attention recently, in the red flour beetle, Tribolium castaneum, a model insect species for molecular analyses different from Drosophila melanogaster. Previous studies have shown that the long strains (L-strain) have significantly lower levels of dopamine expression in the brain than the short strains (S-strain) and that they have an abnormal pattern of locomotor activity. Furthermore, previous studies have shown that administering dopamine to L-strain beetles reduces the duration of tonic immobility. Transcriptome analysis of brain and thorax of the L- and S-strains also showed differences in mRNA expression of genes involved in dopamine synthesis and tyrosine metabolism. These results indicate that the phenotype and molecular basis of the L-strain are similar to those of Parkinson’s syndrome symptoms. In order to establish a link between T. castaneum and PD, we compared the DNA sequences of the L- and S-strains to human genes affecting dopaminergic pathways. The DNA comparison revealed many mutated regions in these genes in the L-strain. We discuss the relationship between dopaminergic pathway genes and PD-like phenotypes across humans, Drosophila, and the red flour beetle.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList/>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Universitas Islam Negeri Alauddin Makassar</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2548-5334</Issn>
      <Volume>17</Volume>
      <Issue>2</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Trend of adjusted antenatal care visits on pregnant women and neonatal during the COVID-19 pandemic: Findings from a three districts survey in 2021</ArticleTitle>
    <FirstPage LZero="delete">110</FirstPage>
    <LastPage>118</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Juliani</FirstName>
        <LastName>Ibrahim</LastName>
        <Affiliation>Departement of Public Health, Faculty of Medicine and Health Science, Universitas Muhammadiyah Makassar</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoko</FirstName>
        <LastName>Takahata</LastName>
        <Affiliation>Nursing of Department, Graduate School of Health Science, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Sukaeni</FirstName>
        <LastName>Ibrahim</LastName>
        <Affiliation>Faculty of Medicine, Bosowa University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Sustainable health development efforts amid infectious disease outbreaks such as Coronavirus disease 2019 (COVID-19) require a resilient maternal health system. With cases rising globally and across Asia, Indonesia faces significant disruptions in essential services. A critical research gap exist in utilizing adjusted time-series analysis to isolated pandemic  impact from seasonal variation in urban Indonesia. This study evaluates trends in antenatal care (ANC) visits (January 2019&#8211;December 2020) at three Community Health Centres in Makassar: Bara-Baraya, Jongaya and Batua using Interrupted Time Series (ITS) analysis. Findings reveal a significant decline in visits during the second and third quarters of 2020, primarily due to transmission fears. We suggest integration of telemedicine and home visits to maintain continuity of care. Although focused on urban Makassar, these results are an important reference for health and offer applicable solutions for other developing countries facing resource constraints. This study emphasizes the need for inclusive prevention strategies to protect maternal health in urban and rural areas in low- to middle-income countries during systemic health crises.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">antenatal care</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">covid-19</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">interrupted time series</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">maternal health</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">neonatal birth</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1046-1310</Issn>
      <Volume>45</Volume>
      <Issue>6</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Adolescent screen use in the pre-internet era and subsequent health and well-being: an outcome-wide longitudinal study</ArticleTitle>
    <FirstPage LZero="delete">657</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Pedro Antonio</FirstName>
        <LastName>de la Rosa Fern&#225;ndez-Pacheco</LastName>
        <Affiliation>Youth in Transition, Institute for Culture and Society, Universidad de Navarra</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Renae</FirstName>
        <LastName>Wilkinson</LastName>
        <Affiliation>Human Flourishing Program, Institute for Quantitative Social Science, Harvard University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Richard G.</FirstName>
        <LastName>Cowden</LastName>
        <Affiliation>Human Flourishing Program, Institute for Quantitative Social Science, Harvard University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ying</FirstName>
        <LastName>Chen</LastName>
        <Affiliation>Human Flourishing Program, Institute for Quantitative Social Science, Harvard University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Brendan</FirstName>
        <LastName>Case</LastName>
        <Affiliation>Human Flourishing Program, Institute for Quantitative Social Science, Harvard University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Etsuji</FirstName>
        <LastName>Suzuki</LastName>
        <Affiliation>Department of Epidemiology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tyler J.</FirstName>
        <LastName>VanderWeele</LastName>
        <Affiliation>Department of Epidemiology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>This study used data from the National Longitudinal Study of Adolescent to Adult Health (Add Health, N&#8201;=&#8201;11,054) to assess whether increases in screen-based leisure during adolescence (Wave II, from 1996) predicted adult well-being (Wave IV, from 2008-09), adjusting for a wide range of covariates (Wave I, from 1995). Using an outcome-wide analytic approach, we examined associations between screen time and 38 adult outcomes, adjusting for prior screen time, values of most outcomes, and confounders. Most associations were null. Modest evidence was found for links between screen time (continuous) and reduced sense of control, illicit drug use, and allostatic load. High screen time (14 h/week) or more also showed weak associations with lower depression and preventive care use. Because the data predate widespread internet use, the findings help establish a baseline for the long-term effects of non-internet screen activities, which appeared to behave had limited impact on adult health and well-being.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Leisure</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Television</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Outcome-wide epidemiology</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Video games</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Adolescence</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Well-being</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Wiley</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0012-1592</Issn>
      <Volume>68</Volume>
      <Issue>3</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>A Simple Method for RNA-Seq of Manually Isolated Chromatophores in Oryzias Fishes</ArticleTitle>
    <FirstPage LZero="delete">e70044</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Makoto</FirstName>
        <LastName>Goda</LastName>
        <Affiliation>Institute of Photonics Medicine, Hamamatsu University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Asuka</FirstName>
        <LastName>Miyagi</LastName>
        <Affiliation>Institute of Photonics Medicine, Hamamatsu University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Keisuke</FirstName>
        <LastName>Sugiwaka</LastName>
        <Affiliation>Department of Biological Science, Division of Natural Science, Graduate School of Science, Nagoya University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masakatsu</FirstName>
        <LastName>Watanabe</LastName>
        <Affiliation>Cellular and Structural Physiology Institute (CeSPI) and Graduate School of Pharmaceutical Sciences, Nagoya University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Manabu</FirstName>
        <LastName>Bessho‐Uehara</LastName>
        <Affiliation>Frontier Research Institute for Interdisciplinary Science, Tohoku University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masahiko</FirstName>
        <LastName>Hibi</LastName>
        <Affiliation>Department of Biological Science, Division of Natural Science, Graduate School of Science, Nagoya University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Atsushi</FirstName>
        <LastName>Toyoda</LastName>
        <Affiliation>Comparative Genomics Laboratory, National Institute of Genetics</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Rieko</FirstName>
        <LastName>Tanaka</LastName>
        <Affiliation>World Medaka Aquarium, Nagoya Higashiyama Zoo and Botanical Gardens</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kawilarang W. A.</FirstName>
        <LastName>Masengi</LastName>
        <Affiliation>Faculty of Fisheries and Marine Science, Sam Ratulangi University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazunori</FirstName>
        <LastName>Yamahira</LastName>
        <Affiliation>Tropical Biosphere Research Center, University of the Ryukyus</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Satoshi</FirstName>
        <LastName>Ansai</LastName>
        <Affiliation>Ushimado Marine Institute, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hisashi</FirstName>
        <LastName>Hashimoto</LastName>
        <Affiliation>Department of Biological Science, Division of Natural Science, Graduate School of Science, Nagoya University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>RNA sequencing (RNA-seq) has become an essential tool for analyzing gene expression and exploring cell type&#8211;specific transcriptomes. However, sample preparation and quality control remain challenging, as current approaches typically rely on dissecting tissues containing mixed cell populations or using flow cytometry to isolate fluorescently labeled cells. Here we present a simple and reliable method for RNA-seq of chromatophores (pigment cells) by manually isolating cells based on their natural pigmentation. We analyzed four chromatophore types―melanophores, xanthophores, iridophores, and leucophores―in medaka (Oryzias latipes). Remarkably, as few as 100 cells per type yielded reasonably high-quality transcriptomes sufficient to identify differentially expressed genes (DEGs). Furthermore, this method was successfully applied to a non-model medaka species, O. woworae, which shares the same four chromatophore types. Our approach enables efficient, low-cost, and cross-species transcriptome analysis of chromatophores without requiring transgenic markers or flow cytometry.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList/>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2397-4648</Issn>
      <Volume>11</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Band-selective plasmonic polaron in thermoelectric semimetal Ta2PdSe6 with ultra-high power factor</ArticleTitle>
    <FirstPage LZero="delete">23</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Daiki</FirstName>
        <LastName>Ootsuki</LastName>
        <Affiliation>Research Institute for Interdisciplinary Science, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Akitoshi</FirstName>
        <LastName>Nakano</LastName>
        <Affiliation>Present address: Department of Applied Physics, Nagoya University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Urara</FirstName>
        <LastName>Maruoka</LastName>
        <Affiliation>Present address: Department of Applied Physics, Nagoya University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takumi</FirstName>
        <LastName>Hasegawa</LastName>
        <Affiliation>Graduate School of Advanced Science and Engineering, Hiroshima University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masashi</FirstName>
        <LastName>Arita</LastName>
        <Affiliation>Research Institute for Synchrotron Radiation Science, Hiroshima University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Miho</FirstName>
        <LastName>Kitamura</LastName>
        <Affiliation>Present address: NanoTerasu Center, National Institutes for Quantum Science and Technology (QST)</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Koji</FirstName>
        <LastName>Horiba</LastName>
        <Affiliation>Present address: NanoTerasu Center, National Institutes for Quantum Science and Technology (QST)</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Teppei</FirstName>
        <LastName>Yoshida</LastName>
        <Affiliation>Graduate School of Human and Environmental Studies, Kyoto University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ichiro</FirstName>
        <LastName>Terasaki</LastName>
        <Affiliation>Present address: Department of Applied Physics, Nagoya University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>We report the electronic structure of the thermoelectric semimetal Ta2PdSe6 with a large thermoelectric power factor and giant Peltier conductivity by means of angle-resolved photoemission spectroscopy (ARPES). The ARPES spectra reveal the coexistence of a sharp hole band with a light electron mass and a broad electron band with a relatively heavy electron mass, which originate from different quasi-one-dimensional (Q1D) chains in Ta2PdSe6. Moreover, the electron band around the Brillouin-zone (BZ) boundary shows a replica structure with respect to the energy originating from plasmonic polarons due to electron-plasmon interactions. The different scattering effects and interactions in each atomic chain lead to asymmetric transport lifetimes of carriers: a large Seebeck coefficient can be realized even in a semimetal. Our findings pave the way for exploring the thermoelectric materials in previously overlooked semimetals and provide a new platform for low-temperature thermoelectric physics, which has been challenging with semiconductors.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList/>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Wiley</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2398-8835</Issn>
      <Volume>9</Volume>
      <Issue>3</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Effects of Overload on Imiquimod‐Induced Psoriasis Model Mice: A Basic Experimental Study</ArticleTitle>
    <FirstPage LZero="delete">e72040</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Tomoki</FirstName>
        <LastName>Furutani</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Section of Medicine, Division of Medicine, Dentistry, and Pharmaceutical Sciences, Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Taichi</FirstName>
        <LastName>Saito</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Asahi</FirstName>
        <LastName>Ikeda</LastName>
        <Affiliation>Okayama University Medical School Faculty of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kenta</FirstName>
        <LastName>Mashima</LastName>
        <Affiliation>Okayama University Medical School Faculty of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Natsumi</FirstName>
        <LastName>Yukihiro</LastName>
        <Affiliation>Okayama University Medical School Faculty of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Satoki</FirstName>
        <LastName>Kusakabe</LastName>
        <Affiliation>Okayama University Medical School Faculty of Medicine Okayama Japan</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryo</FirstName>
        <LastName>Nakamichi</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Aki</FirstName>
        <LastName>Yoshida</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Keiichiro</FirstName>
        <LastName>Nishida</LastName>
        <Affiliation>Locomotive Pain Center, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshifumi</FirstName>
        <LastName>Ozaki</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Background and Aim: Psoriasis is a skin disorder complicated by arthritis and enthesitis. The cytokines interleukin (IL)-17, IL-23, and tumor necrosis factor (TNF)-α are reportedly key effectors of psoriasis. Additionally, gamma delta (γδ) T cells exacerbate inflammation by producing inflammatory cytokines such as IL-17 and TNF-α. However, details regarding the mechanisms linking pathogenesis and mechanical stress remain unclear. This study aimed to investigate the effect of strenuous exercise on the pathology of psoriasis using mouse models of imiquimod (IMQ)-induced psoriasis.&lt;br&gt;
Methods: Twenty mice were randomly assigned to four groups: IMQ&#8201;−&#8201;TRED− (control), IMQ&#8201;−&#8201;TRED+ (treadmill running mice), IMQ&#8201;+&#8201;TRED− group (IMQ treated mice), and IMQ&#8201;+&#8201;TRED+ group (IMQ treated and treadmill running mice). The tissue sections from back skin and thymus were immunostained with antibodies against IL-17, IL-23, and γδ T cells. Shoulder sections were stained using hematoxylin and eosin, and Toluidine Blue and Picrosirius Red. Additionally, the shoulder tissue sections were immunostained with antibodies against TNF-α and matrix metalloproteinase (MMP)-13. Serum cytokine level was measured to evaluate systemic inflammation.&lt;br&gt;
Results: Strenuous exercise exacerbated pathological changes associated with psoriasis, including increased γδ T cell infiltration and upregulated IL-17 and IL-23 expression in the skin, as well as enhanced γδ T cell development and IL-17 expression in the thymus. Although strenuous exercise did not further worsen the modified PASI scores, histological and immunological markers of inflammation were significantly enhanced. Serum levels of TNF-α and IL-17 were significantly elevated in IMQ-induced psoriasis model mice. Moreover, pathological changes induced by strenuous exercise were observed in the enthesis, including angiogenesis and upregulated expression of TNF-α and MMP-13.&lt;br&gt;
Conclusion: This study revealed that strenuous exercise exacerbates pathological changes in IMQ-induced psoriasis model mice.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">enthesis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">psoriasis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">strenuous exercise</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Wiley</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2572-1143</Issn>
      <Volume>9</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Mechanosensitive Ion Channel PIEZO1 Suppresses BMP2-Induced Ossification of the Annulus Fibrosus Cells</ArticleTitle>
    <FirstPage LZero="delete">e70168</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Hisakazu</FirstName>
        <LastName>Shitozawa</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Science of Functional Recovery and Reconstruction, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryo</FirstName>
        <LastName>Nakamichi</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Okayama University Graduate School Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Aki</FirstName>
        <LastName>Yoshida</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Science of Functional Recovery and Reconstruction, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masataka</FirstName>
        <LastName>Ueda</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Science of Functional Recovery and Reconstruction, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Taichi</FirstName>
        <LastName>Saito</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Koji</FirstName>
        <LastName>Uotani</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshiaki</FirstName>
        <LastName>Oda</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryo</FirstName>
        <LastName>Takatori</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Science of Functional Recovery and Reconstruction, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazutaka</FirstName>
        <LastName>Yamashita</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Science of Functional Recovery and Reconstruction, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshifumi</FirstName>
        <LastName>Ozaki</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Objective: Major cause of low-back pain is intervertebral disc degeneration (IVDD), with mechanical stress playing a crucial role in its progression. A mechanosensitive ion channel, PIEZO1, is involved in various musculoskeletal tissues, but its role in the annulus fibrosus (AF) remains unclear. This study aimed to elucidate the function of PIEZO1 in AF cells under mechanical stimulation.&lt;br&gt;
Methods: Primary rat AF cells were subjected to cyclic tensile strain (CTS) at low (2%) and high (12%) strain levels to investigate strain-dependent effects on osteogenic gene expression. We evaluated the effects of Piezo1, Piezo2, and Trpv4 knockdown by RNA interference to identify the upstream mechanotransducer. Furthermore, PIEZO1 was activated using the agonist Yoda1, followed by RNA-sequencing analysis and evaluation of its effects on BMP2-induced osteogenesis in rat AF cells. We also examined the effects of Yoda1 in primary human AF cells.&lt;br&gt;
Results: Low-strain CTS significantly suppressed osteogenic marker expression, which was not observed with high strain. Piezo1 knockdown reversed this suppression, whereas Piezo2 and Trpv4 had no effect. Piezo1 activation by Yoda1 produced similar anti-osteogenic effects in both rat and human AF cells. RNA sequencing revealed the enrichment of ossification and calcineurin signaling pathways in rat cells. Furthermore, Piezo1 activation inhibited BMP2-induced osteogenesis and nuclear translocation of p-Smad1/5/9.&lt;br&gt;
Conclusions: Piezo1 maintains AF cell homeostasis under mechanical stress by suppressing osteogenic changes via calcineurin-mediated inhibition of BMP signaling, which may represent a novel therapeutic target for IVDD.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">annulus fibrosus</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">calcification</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">ossification</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">PIEZO1</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1478-811X</Issn>
      <Volume>24</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>MMP-3 cleavage of Lamin A induces pro-migratory nuclear deformity, nucleophagy, and their autophagic secretion with extracellular vesicles in metastatic cancer</ArticleTitle>
    <FirstPage LZero="delete">146</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Takanori</FirstName>
        <LastName>Eguchi</LastName>
        <Affiliation>Department of Dental Pharmacology, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Eman A.</FirstName>
        <LastName>Taha</LastName>
        <Affiliation>Department of Biochemistry, Faculty of Science, Ain Shams University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Keisuke</FirstName>
        <LastName>Nakano</LastName>
        <Affiliation>Department of Oral Pathology and Medicine, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Vikas</FirstName>
        <LastName>Tiwari</LastName>
        <Affiliation>Council of Scientific &amp; Industrial Research-Indian Institute of Toxicological Research</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Katsuki</FirstName>
        <LastName>Takebe</LastName>
        <Affiliation>Department of Dental Pharmacology, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomohiro</FirstName>
        <LastName>Inoue</LastName>
        <Affiliation>Department of Dental Pharmacology, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Lizi</FirstName>
        <LastName>Xing</LastName>
        <Affiliation>Department of Dental Pharmacology, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Chiharu</FirstName>
        <LastName>Sogawa</LastName>
        <Affiliation>Department of Food and Health Sciences, Faculty of Environmental Studies, Hiroshima Institute of Technology</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kuniaki</FirstName>
        <LastName>Okamoto</LastName>
        <Affiliation>Department of Dental Pharmacology, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Stuart K.</FirstName>
        <LastName>Calderwood</LastName>
        <Affiliation>Division of Molecular and Cellular Biology, Department of Radiation Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Matrix metalloproteinases (MMPs) are a family of zinc-dependent proteinases that cleave a plethora of substrates, including components of the extracellular matrix and cell-surface-associated proteins, as well as intracellular targets. MMPs have also been found in extracellular vesicles (EVs), such as exosomes. MMP-3 promotes tumor growth, epithelial-to-mesenchymal transition, genome instability, migration, invasion, and metastasis of cancer cells, and nuclear MMP-3 controls gene transcription. Intranuclear proteolysis by MMPs may significantly alter cancer progression. However, the nuclear substrates of MMP-3 have not been well investigated. In this study, we performed proteomic analyses to identify the nuclear substrates and EV proteins regulated by MMP-3. While rabidly metastatic colon cancer (LuM1) three-dimensionally cultured tumoroids secreted EVs containing 30 protein types, including Lamin A (LMNA), MMP-3, fibronectin (FN1), HSPA8 (Hsc70), β-actin (ACTB), and vimentin (VIM), CRISPR/Cas9-based knockout of MMP-3 reduced the secretion of these proteins in EVs. Notably, EV-bound cleaved Lamin secretion was confirmed by immunoelectron microscopy. Also, MMP-3 formed proteolytic dimers via its hemopexin-like repeat domains in nuclei. Many nuclear MMP-3-binding proteins, including Lamin A/C, histones, topoisomerases, and hnRNPs, were screened by co-immunoprecipitation followed by proteomics. Proteolytic MMP-3 overexpression generated a C-terminal 30-kDa fragment of Lamin A, whose cleavage site was defined via structural analysis. MMP-3 digestion of Lamin A induced nuclear deformity (atypia) required for cell migration in confined space. The cleaved Lamin A and MMP-3 were transported with autophagosomes (LC3B+), nucleophagosomes, and amphisomes (CD63&#8201;+&#8201;LC3B+) and co-secreted with EVs. Proteolytic MMP-3 also induced nuclear speckles of Lamin A, suggesting their roles in transcription and splicing. Clinical analysis revealed that high expressions of MMP3 and LMNA were significantly seen in head and neck squamous cell carcinoma (HNSC) than in the other 16 cancer types, and predicted poor prognosis of patients suffering from HNSC, pancreatic, rectum and lung adenocarcinomas at specific stages. Immunohistochemistry revealed that nuclear MMP-3 and cleaved Lamin were significantly higher expressed in stage IV metastatic HNSC cases than in stage I non-metastatic cases. Taken together, MMP3-cleavage of Lamin A induces nuclear deformity, nucleophagy, and their autophagic co-secretion with EVs in metastatic cancer. Also, high expression of MMP-3 and secretion of Lamin A can predict poor prognosis in multiple cancer types at specific stages.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Lamin A (LMNA)</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Matrix metalloprotease (MMP)</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Proteolysis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Extracellular vesicle (EV)</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Exosome</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Autophagy</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Amphisome</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Proteome</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Nuclear deformity</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Migration</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Metastatic cancer</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Head and neck squamous cell carcinoma</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Colorectal cancer</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2055-0294</Issn>
      <Volume>12</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Association between the incidence of infusion-related reactions by obinutuzumab and the dose of corticosteroid as premedication: a multicenter retrospective cohort study</ArticleTitle>
    <FirstPage LZero="delete">27</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Tatsuya</FirstName>
        <LastName>Ohtsubo</LastName>
        <Affiliation>Department of Pharmacy, Japanese Red Cross Kyoto Daini Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuhiro</FirstName>
        <LastName>Yamamoto</LastName>
        <Affiliation>Department of Integrated Clinical and Basic Pharmaceutical Sciences, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Saori</FirstName>
        <LastName>Matumoto</LastName>
        <Affiliation>Department of Pharmacy, Japanese Red Cross Osaka Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kaori</FirstName>
        <LastName>Ito</LastName>
        <Affiliation>Faculty of Pharmacy, Meijo University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuzuka</FirstName>
        <LastName>Sasa</LastName>
        <Affiliation>Department of Pharmacy, Kindai University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kosuke</FirstName>
        <LastName>Tomishima</LastName>
        <Affiliation>Department of Pharmacy, Japanese Red Cross Kyoto Daiichi Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Satoshi</FirstName>
        <LastName>Dote</LastName>
        <Affiliation>Department of Pharmacy, Kyoto-Katsura Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Katuya</FirstName>
        <LastName>Makihara</LastName>
        <Affiliation>Department of Pharmacy, Yodogawa Christian Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshinori</FirstName>
        <LastName>Wakasugi</LastName>
        <Affiliation>Department of Pharmacy, Shiga University of Medical Science Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tsutomu</FirstName>
        <LastName>Mitsuie</LastName>
        <Affiliation>Department of Pharmacy, Japanese Red Cross Otsu Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kouhei</FirstName>
        <LastName>Yamagiwa</LastName>
        <Affiliation>Department of Pharmacy, Saiseikai Shiga Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuo</FirstName>
        <LastName>Sato</LastName>
        <Affiliation>Department of Pharmacy, Japan Baptist Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroki</FirstName>
        <LastName>Hasegawa</LastName>
        <Affiliation>Department of Pharmacy, Rakuwakai Otowa Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Nobuhiko</FirstName>
        <LastName>Uoshima</LastName>
        <Affiliation>Department of Hematology, Japanese Red Cross Kyoto Daini Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yumi</FirstName>
        <LastName>Kitahiro</LastName>
        <Affiliation>Department of Pharmacy, Kobe University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kanji</FirstName>
        <LastName>Tomogane</LastName>
        <Affiliation>Department of Pharmacy, Japanese Red Cross Kyoto Daini Hospital</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Background Premedication with corticosteroids is recommended for prophylaxis against infusion-related reactions (IRRs) caused by obinutuzumab despite a lack of solid evidence regarding the dose of corticosteroids.&lt;br&gt;
Methods The incidence rates of IRR in the high-dose and low-dose corticosteroid groups were investigated and compared using Student’s t-test.Univariable and multivariable logistic regression analyses were performed on patients to explore the risk of developing IRRs with obinutuzumab.&lt;br&gt;
Results The incidence of IRRs in the high-dose and low-dose corticosteroid groups at the initial administration of obinutuzumab was 27.0% (41/152) and 48.4% (31/64), respectively, indicating that the high-dose group had a lower incidence of IRRs (p&#8201;=&#8201;0.002). The incidence of IRRs at the initial administration of obinutuzumab was significantly associated with the administration of first-generation histamine 1 receptor antagonist (OR&#8201;=&#8201;3.31, 95% CI: 1.16&#8211;9.47; reference: second-generation histamine 1 receptor antagonist), hydrocortisone (OR&#8201;=&#8201;7.21, 95% CI: 1.57&#8211;33.15; reference: dexamethasone), and methylprednisolone (OR&#8201;=&#8201;3.99, 95% CI :1.13&#8211;14.10; reference: dexamethasone), although no association was found with the lower dose of corticosteroids.&lt;br&gt;
Conclusions Although no association was found between corticosteroid dosage and IRR when considering multiple factors, dexamethasone may be a better option than hydrocortisone or methylprednisolone for preventing IRR. Additionally, second-generation H1-receptor antagonists may be a better option than first-generation drugs. Certain combinations of premedications may influence infusion reaction incidence.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Obinutuzumab</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Infusion-related reaction</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Premedication</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Corticosteroids</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Histamine 1 receptor antagonists</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1478-6362</Issn>
      <Volume>28</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Real-world comparative effectiveness of sarilumab versus Janus kinase inhibitors as monotherapy in rheumatoid arthritis</ArticleTitle>
    <FirstPage LZero="delete">32</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Yuji</FirstName>
        <LastName>Nozaki</LastName>
        <Affiliation>Department of Hematology and Rheumatology, Kindai University Faculty of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuya</FirstName>
        <LastName>Kishimoto</LastName>
        <Affiliation>Department of Hematology and Rheumatology, Kindai University Faculty of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tetsu</FirstName>
        <LastName>Itami</LastName>
        <Affiliation>Department of Hematology and Rheumatology, Kindai University Faculty of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Daisuke</FirstName>
        <LastName>Tomita</LastName>
        <Affiliation>Department of Hematology and Rheumatology, Kindai University Faculty of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yumiko</FirstName>
        <LastName>Wada</LastName>
        <Affiliation>Department of Internal Medicine (IV), Osaka Medical and Pharmaceutical University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takuya</FirstName>
        <LastName>Kotani</LastName>
        <Affiliation>Department of Internal Medicine (IV), Osaka Medical and Pharmaceutical University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tohru</FirstName>
        <LastName>Takeuchi</LastName>
        <Affiliation>Department of Internal Medicine (IV), Osaka Medical and Pharmaceutical University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshihiko</FirstName>
        <LastName>Hidaka</LastName>
        <Affiliation>Rheumatology Center, Miyazaki Zenjinkai Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shoichi</FirstName>
        <LastName>Hino</LastName>
        <Affiliation>Department of Rheumatology and Clinical Immunology, Izumi City General Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshiaki</FirstName>
        <LastName>Miyamoto</LastName>
        <Affiliation>Miyamoto Internal Medicine and Rheumatology Clinic</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hirofumi</FirstName>
        <LastName>Miyake</LastName>
        <Affiliation>Department of General Internal Medicine, Tenri Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazunari</FirstName>
        <LastName>Hatta</LastName>
        <Affiliation>Department of General Internal Medicine, Tenri Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kenji</FirstName>
        <LastName>Mamoto</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Graduate School of Medicine, Osaka Metropolitan University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yutaro</FirstName>
        <LastName>Yamada</LastName>
        <Affiliation>Center for Senile Degenerative Disorders (CSDD), Osaka Metropolitan University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tadashi</FirstName>
        <LastName>Okano</LastName>
        <Affiliation>Center for Senile Degenerative Disorders (CSDD), Osaka Metropolitan University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takaichi</FirstName>
        <LastName>Okano</LastName>
        <Affiliation>Department of Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Jun</FirstName>
        <LastName>Saegusa</LastName>
        <Affiliation>Department of Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masahiro</FirstName>
        <LastName>Horita</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Faculty of Medical Development Field, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Keiichiro</FirstName>
        <LastName>Nishida</LastName>
        <Affiliation>Locomotive Pain Center, Faculty of Medical Development Field, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Koji</FirstName>
        <LastName>Kinoshita</LastName>
        <Affiliation>Department of Hematology and Rheumatology, Kindai University Faculty of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shinya</FirstName>
        <LastName>Rai</LastName>
        <Affiliation>Department of Hematology and Rheumatology, Kindai University Faculty of Medicine</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Background: Sarilumab (SAR), an interleukin-6 receptor inhibitor (IL-6Ri), and Janus kinase inhibitors (JAKi) are approved options for rheumatoid arthritis (RA) when methotrexate (MTX) cannot be used. Real-world evidence for MTX-free monotherapy remains limited.&lt;br&gt;
Methods: We conducted a multicenter retrospective cohort study of RA patients receiving SAR or JAKi as MTX-free monotherapy. To reduce confounding, 1:1 propensity score matching was performed in the overall cohort (n&#8201;=&#8201;252, 126 per group) and separately within treatment-line strata: Phase 2 first-line biologic/targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs: 45 per group), Phase 3 second-line b/tsDMARDs (53 per group), and Phase 3&#8201;&#8805;&#8201;third-line b/tsDMARDs (47 per group). Outcomes over 12 months included drug retention, change in Clinical Disease Activity Index (CDAI), glucocorticoid (GC) tapering and discontinuation, low disease activity (LDA, CDAI&#8201;&#8804;&#8201;10), and safety profiles. Predictors of LDA were evaluated with logistic regression. This multicenter real-world.&lt;br&gt;
Results: Across matched strata by prior b/tsDMARDs, retention and CDAI change did not differ significantly between SAR and JAKi through 12 months. When classified by cause, adverse events (AEs)-related discontinuation was higher with JAKi, yielding lower AE-specific retention. Both groups demonstrated GC sparing overtime, with a greater increase in GC discontinuation for SAR than for JAKi in Phase 2. Baseline predictors of achieving LDA at 12 months included higher C-reactive protein (CRP) and platelet count (Plt) in both groups, with additional associations of younger age and lower hemoglobin (Hb) in the SAR. In safety analyses, overall AEs were less frequent with SAR than with JAKi, driven by lower risks of infection including herpes zoster, while other categories were similarly infrequent.&lt;br&gt;
Conclusion: SAR and JAKi showed no statistically significant differences in 12-month retention or disease control in MTX-free monotherapy settings. Higher CRP and Plt with lower Hb, particularly in younger patients, identified better response to SAR and support biomarker guided selection between IL-6Ri and JAKi. In Phase 2, GC discontinuation with SAR suggests a practical strategy to reduce AEs while maintaining efficacy. Prospective studies should validate these findings and define actionable thresholds.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Rheumatoid arthritis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Methotrexate</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Biological DMARDs</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>BMJ</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2056-5933</Issn>
      <Volume>12</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Dental infection is associated with early relapse in patients with ANCA-associated vasculitis</ArticleTitle>
    <FirstPage LZero="delete">e006392</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Shoichi</FirstName>
        <LastName>Nawachi</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takayuki</FirstName>
        <LastName>Katsuyama</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshia</FirstName>
        <LastName>Miyawaki</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Moe</FirstName>
        <LastName>Sakamoto-Tokunaga</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Natsuki</FirstName>
        <LastName>Kubota</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuya</FirstName>
        <LastName>Terajima</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuya</FirstName>
        <LastName>Matsumoto</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kei</FirstName>
        <LastName>Hirose</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takato</FirstName>
        <LastName>Nakadoi</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Manami</FirstName>
        <LastName>Hirata-Watanabe</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yu</FirstName>
        <LastName>Katayama</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Keigo</FirstName>
        <LastName>Hayashi</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Haruki</FirstName>
        <LastName>Watanabe</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Eri</FirstName>
        <LastName>Katsuyama</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Mariko</FirstName>
        <LastName>Takano-Narazaki</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shigetomo</FirstName>
        <LastName>Tsuji</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshinori</FirstName>
        <LastName>Matsumoto</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ken-Ei</FirstName>
        <LastName>Sada</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Jun</FirstName>
        <LastName>Wada</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Objectives Anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV) is a systemic autoimmune disease where infections can trigger relapses. Dental infections, being common and associated with systemic inflammation, may play a role in AAV relapse, though their impact remains unclear. We aimed to evaluate the association between severe dental infections and early relapse in patients with AAV.&lt;br&gt;
Methods This retrospective cohort study included patients newly diagnosed with AAV between January 2011 and July 2022. Patients with severe dental infections requiring tooth extraction were placed in the dental infection group, while the remaining patients were assigned to the control group. The primary outcome was defined as either vasculitis relapse or all-cause mortality within 1 year of treatment initiation. Adjusted HRs (aHRs) and 95% CIs were estimated using Cox proportional hazards models.&lt;br&gt;
Results A total of 93 patients were enrolled with a median age of 74 years. 41 patients (44.1%) had severe dental infections in this cohort. Over the 1-year follow-up period, 13 patients experienced a relapse and two died, resulting in a composite event rate of 20.9 per 100 person-years. Dental infection was independently associated with the composite outcome (aHR, 3.78 (95% CI 1.13 to 12.66); p=0.031). Exploratory analysis indicated that composite outcome rates were similar regardless of tooth extraction among patients with dental infections.&lt;br&gt;
Conclusions Severe dental infections were associated with increased risk of early relapse or mortality in AAV. These findings highlight the importance of early dental evaluation in AAV management.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList/>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>American Society for Clinical Investigation</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2379-3708</Issn>
      <Volume>11</Volume>
      <Issue>3</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Collagen-binding C-type natriuretic peptide enhances chondrogenesis and osteogenesis</ArticleTitle>
    <FirstPage LZero="delete">e198959</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Kenta</FirstName>
        <LastName>Hirai</LastName>
        <Affiliation>Department of Pediatrics, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kenta</FirstName>
        <LastName>Sawamura</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Nagoya University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryusaku</FirstName>
        <LastName>Esaki</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Nagoya University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryusuke</FirstName>
        <LastName>Sawada</LastName>
        <Affiliation>Department of Pharmacology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuka</FirstName>
        <LastName>Okusha</LastName>
        <Affiliation>Department of Pharmacology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Eriko</FirstName>
        <LastName>Aoyama</LastName>
        <Affiliation>Advanced Research Center for Oral and Craniofacial Sciences, Okayama University Dental School</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroki</FirstName>
        <LastName>Saito</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Kitasato University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kentaro</FirstName>
        <LastName>Uchida</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Kitasato University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takehiko</FirstName>
        <LastName>Mima</LastName>
        <Affiliation>Department of Medical Technology, Faculty of Health Sciences, Ehime Prefectural University of Health Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Satoshi</FirstName>
        <LastName>Kubota</LastName>
        <Affiliation>Department of Biochemistry and Molecular DentistryBacteriology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hirokazu</FirstName>
        <LastName>Tsukahara</LastName>
        <Affiliation>Department of Pediatrics, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shiro</FirstName>
        <LastName>Imagama</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Nagoya University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masaki</FirstName>
        <LastName>Matsushita</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Nagoya University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Osamu</FirstName>
        <LastName>Matsushita</LastName>
        <Affiliation>Department of Bacteriology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yasuyuki</FirstName>
        <LastName>Hosono</LastName>
        <Affiliation>Department of Pharmacology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>C-type natriuretic peptide (CNP) is known to promote chondrocyte proliferation and bone formation; however, CNP’s extremely short half-life necessitates continuous intravascular administration to achieve bone-lengthening effects. Vosoritide, a CNP analog designed for resistance to neutral endopeptidase, allows for once-daily administration. Nonetheless, it distributes systemically rather than localizing to target tissues, which may result in adverse effects such as hypotension. To enhance local drug delivery and therapeutic efficacy, we developed a potentially novel synthetic protein by fusing a collagen-binding domain (CBD) to CNP, termed CBD-CNP. This fusion protein exhibited stability under heat conditions and retained the collagen-binding ability and bioactivity as CNP. CBD-CNP localized to articular cartilage in fetal murine tibiae and promoted bone elongation. Spatial transcriptomic analysis revealed that the upregulation of chondromodulin expression may contribute to its therapeutic effects. Treatment of CBD-CNP mixed with collagen powder to a fracture site of a mouse model increased bone mineral content and bone volume compared with CNP-22. Intraarticular injection of CBD-CNP to a mouse model of knee osteoarthritis suppressed subchondral bone thickening. By addressing the limitations of CNP’s rapid degeneration, CBD-CNP leverages its collagen-binding capacity to achieve targeted, sustained delivery in collagen-rich tissues, offering a promising strategy for enhancing chondrogenesis and osteogenesis.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList/>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0021-5155</Issn>
      <Volume/>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Real-world six-month outcomes after switching from aflibercept 2 mg to aflibercept 8 mg for neovascular age-related macular degeneration</ArticleTitle>
    <FirstPage LZero="delete"/>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Hiroya</FirstName>
        <LastName>Kindo</LastName>
        <Affiliation>Department of Ophthalmology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Mio Morizane</FirstName>
        <LastName>Hosokawa</LastName>
        <Affiliation>Department of Ophthalmology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Chihiro</FirstName>
        <LastName>Ouchi</LastName>
        <Affiliation>Department of Ophthalmology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryo</FirstName>
        <LastName>Matoba</LastName>
        <Affiliation>Department of Ophthalmology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tetsuro</FirstName>
        <LastName>Morita</LastName>
        <Affiliation>Department of Ophthalmology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Junko</FirstName>
        <LastName>Hayashi</LastName>
        <Affiliation>Department of Ophthalmology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuki</FirstName>
        <LastName>Morizane</LastName>
        <Affiliation>Department of Ophthalmology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Purpose To investigate 6-month outcomes in eyes with neovascular age-related macular degeneration (nAMD) switched from intravitreal aflibercept 2 mg to intravitreal aflibercept 8 mg.&lt;br&gt;
Study design Retrospective observational study.&lt;br&gt;
Methods We reviewed records of consecutive nAMD eyes switched from aflibercept 2 mg to 8 mg. In eyes continuing aflibercept 8 mg, best-corrected visual acuity (BCVA), treatment intervals, and anatomical/exudative parameters were evaluated at 6 months. In eyes that could not continue, reasons for discontinuation were examined.&lt;br&gt;
Results Forty-four eyes from 44 patients were included. At 6 months, 35 eyes (79.5%) continued and 9 (20.5%) discontinued aflibercept 8 mg. Discontinuing eyes had significantly shorter pre-switch treatment intervals and more frequent prior therapies than continuing eyes. In the continuation group, BCVA remained stable (median 0.05 to 0.00 logMAR, P = 0.351), while the treatment interval was significantly extended (median 7.0 to 9.0 weeks, P &lt; 0.001). Central retinal thickness and pigment epithelial detachment height decreased significantly (P = 0.035 and P = 0.021, respectively). The proportion of eyes with subretinal fluid significantly decreased from 74.3 to 37.1% (P = 0.003). Of the discontinuations, 4 were due to worsening exudation and 5 to inability to extend to &#8805;8 weeks as required by labeling. No intraocular inflammation or serious adverse events occurred.&lt;br&gt;
Conclusions Switching to aflibercept 8&#8239;mg achieved anatomical improvements and longer treatment intervals in ~80% of nAMD cases, suggesting it may be a useful alternative to aflibercept 2 mg. However, continuation may be difficult in refractory cases requiring frequent injections before switching.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Aflibercept 8 mg</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Neovascular age-related macular degeneration</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Treat-and-extend</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Switching</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Treatment interval</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2041-4889</Issn>
      <Volume>16</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>TRPV2 in muscle satellite cells is crucial for skeletal muscle remodelling</ArticleTitle>
    <FirstPage LZero="delete">888</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Yanzhu</FirstName>
        <LastName>Chen</LastName>
        <Affiliation>Department of Cardiovascular Physiology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kimiaki</FirstName>
        <LastName>Katanosaka</LastName>
        <Affiliation>Department of Biomedical Sciences, College of Life and Health Sciences, Chubu University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Makoto</FirstName>
        <LastName>Shibuya</LastName>
        <Affiliation>Department of Cardiovascular Physiology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yubing</FirstName>
        <LastName>Dong</LastName>
        <Affiliation>Department of Cardiovascular Physiology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Lidan</FirstName>
        <LastName>Zhang</LastName>
        <Affiliation>Laboratory of Stem Cell Regeneration and Adaptation, Graduate School of Pharmaceutical Sciences, The University of Osaka</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Motoi</FirstName>
        <LastName>Kanagawa</LastName>
        <Affiliation>Department of Cell Biology and Molecular Medicine, Ehime University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">So-ichiro</FirstName>
        <LastName>Fukada</LastName>
        <Affiliation>Laboratory of Stem Cell Regeneration and Adaptation, Graduate School of Pharmaceutical Sciences, The University of Osaka</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Keiji</FirstName>
        <LastName>Naruse</LastName>
        <Affiliation>Department of Cardiovascular Physiology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuki</FirstName>
        <LastName>Katanosaka</LastName>
        <Affiliation>Department of Cardiovascular Physiology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Skeletal muscle remodelling relies on muscle stem cells (MuSCs) for regeneration after injury and hypertrophy in response to mechanical loading. However, the mechanisms that trigger MuSC activation and proliferation remain unclear. Transient receptor potential vanilloid 2 (TRPV2) ion channels respond to insulin-like growth factor-1 and mechanical stimuli to regulate the biological characteristics of various cells. Using a temporally inducible MuSC-specific conditional knockout (cKO) mouse, we show that TRPV2 regulates MuSC function and is essential for muscle remodelling. In cultured myofibre, MuSCs express TRPV2 and exhibit Ca2+ responses to the TRPV2 agonists 2-aminoethoxydiphenyl borate and probenecid, which are abolished upon TRPV2 deletion. TRPV2-deficient MuSCs exhibit reduced paired box 7 (Pax7) expression and impaired proliferation, suggesting TRPV2 is a factor that regulates the early stage of MuSC function. Myotube formation in MuSCs was enhanced by overexpression of TRPV2 and suppressed by TRPV2 deficiency, suggesting that TRPV2 is a factor that promotes myogenesis. Muscle-administered cardiotoxin promoted muscle regeneration and resulted in the appearance of numerous Pax7-positive MuSCs between myofibres. MuSC-specific TRPV2 cKO mice exhibit substantially impaired muscle regeneration after cardiotoxin-induced injury, drastically reducing Pax7-positive MuSCs between myofibres. In floxed mice, mechanical loading via synergist ablation induces hypertrophy and greatly increases the number of myonuclei per myofibre. In contrast, MuSC-specific TRPV2 cKO mice show no changes in myofibre thickness or nuclear number, either at baseline or after mechanical loading. Mechanical loading of floxed mice increased TRPV2+/Pax7+ double-positive MuSCs, but MuSC-specific TRPV2 cKO mice showed no change. Additionally, MuSCs exhibit Ca2+ responses to hypo-osmotic stimuli, which are suppressed by TRPV2 inhibitors and TRPV2 deletion, suggesting that MuSCs exhibit TRPV2-dependent mechanical responses. These results establish TRPV2 as a critical regulator of MuSC-mediated muscle remodelling, an important finding that may lead to therapeutic strategies for muscle repair and adaptation.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList/>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1435-2451</Issn>
      <Volume>411</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>The impact of liver transection depth on surgical difficulty in robotic versus laparoscopic limited liver resection (TAKUMI-5)</ArticleTitle>
    <FirstPage LZero="delete">22</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Tomokazu</FirstName>
        <LastName>Fuji</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Dentistry, and Pharmaceutical Sciences, Okayama University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kosei</FirstName>
        <LastName>Takagi</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Dentistry, and Pharmaceutical Sciences, Okayama University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuya</FirstName>
        <LastName>Yasui</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Dentistry, and Pharmaceutical Sciences, Okayama University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Atene</FirstName>
        <LastName>Ito</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Dentistry, and Pharmaceutical Sciences, Okayama University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takeyoshi</FirstName>
        <LastName>Nishiyama</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Dentistry, and Pharmaceutical Sciences, Okayama University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yasuo</FirstName>
        <LastName>Nagai</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Dentistry, and Pharmaceutical Sciences, Okayama University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shohei</FirstName>
        <LastName>Yokoyama</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Dentistry, and Pharmaceutical Sciences, Okayama University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshiyoshi</FirstName>
        <LastName>Fujiwara</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Dentistry, and Pharmaceutical Sciences, Okayama University Graduate School of Medicine</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Purpose Although robotic liver resection (RLR) has gained popularity worldwide, limited liver resection remains the mainstay of RLR. This study aimed to investigate the effect of parameters, including liver transection depth (LTD), on surgical difficulty in limited RLR compared with limited laparoscopic liver resection (LLR).&lt;br&gt;
Methods This retrospective study included 105 patients who underwent limited RLR (n&#8201;=&#8201;56) or LLR (n&#8201;=&#8201;49) at our institution between January 2018 and December 2024. After comparing outcomes of RLR and LLR, multivariate analyses were performed to examine effect of LTD on surgical difficulty (defined as prolonged operative time). Moreover, outcomes stratified by LTD cut-off values were compared between the groups.&lt;br&gt;
Results Median LTD was similar between groups (RLR vs. LLR: 2.6 vs. 2.6 cm, P&#8201;=&#8201;0.77). LTD was significantly correlated with operative time for both procedures (RLR, R&#178; = 0.07, P&#8201;=&#8201;0.042; LLR, R&#178; = 0.08, P&#8201;=&#8201;0.046). Multivariate analyses demonstrated that LLR (odds ratio, 6.9; P&#8201;&lt;&#8201;0.001) and LTD (odds ratio, 2.0; P&#8201;=&#8201;0.004) were significant risk factors of surgical difficulty. Among patients with deeper LTD (&gt;&#8201;2.5 cm), the RLR group had significantly shorter operative time (145 vs. 231 min, P&#8201;&lt;&#8201;0.001), less blood loss (nil vs. 100 mL, P&#8201;=&#8201;0.006), and a higher rate of textbook outcomes (76.7% vs. 42.3%, P&#8201;=&#8201;0.01).&lt;br&gt;
Conclusion This study investigated impact of LTD on surgical outcomes in patients who underwent limited RLR compared to those who underwent limited LLR. LTD may be a useful parameter for estimating surgical difficulty in limited RLR. Moreover, robotic surgery may be favorable for deeper and limited liver resections.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Robotic surgery</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Laparoscopic surgery</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Limited liver resection</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Textbook outcome</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Wiley</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1462-8910</Issn>
      <Volume>27</Volume>
      <Issue>10</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>D3 lymph node dissection in colon cancer patients aged 90&#8201;years and over: Is it justified? A multi‐institutional retrospective study</ArticleTitle>
    <FirstPage LZero="delete">e70269</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Fuminori</FirstName>
        <LastName>Teraishi</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Satoe</FirstName>
        <LastName>Takanaga</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryo</FirstName>
        <LastName>Inada</LastName>
        <Affiliation>Department of Surgery, Kochi Health Sciences Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshiharu</FirstName>
        <LastName>Mitsuhashi</LastName>
        <Affiliation>Center for Innovative Clinical Medicine, Medical Development Field, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshiaki</FirstName>
        <LastName>Toshima</LastName>
        <Affiliation>Department of Surgery, Kagawa Rosai Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tsuyoshi</FirstName>
        <LastName>Ohtani</LastName>
        <Affiliation>Department of Surgery, Saiseikai Okayama Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryosuke</FirstName>
        <LastName>Yoshida</LastName>
        <Affiliation>Department of Surgery, Okayama Rosai Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryohei</FirstName>
        <LastName>Shoji</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshiyoshi</FirstName>
        <LastName>Fujiwara</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N"/>
        <LastName>Setouchi Colorectal Neoplasm Registration study group collaborators</LastName>
        <Affiliation/>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Aim: The oncological benefit of D3 lymph node dissection (D3 LND) for colon cancer in patients aged &#8805;90&#8201;years remains unclear. This study aimed to evaluate the impact of D3 LND on outcomes in this specific, vulnerable population.&lt;br&gt;
Method: This retrospective cohort study evaluated 166 patients aged &#8805;90&#8201;years with pathological Stages II&#8211;III colon cancer undergoing non-D3 or D3 LND from a multicentre database (2011&#8211;2022). Postoperative complications, overall survival and cancer-specific survival were compared between LND groups using propensity score-weighted analyses.&lt;br&gt;
Results: D3 LND group had significantly more females and laparoscopic procedures. Operation time was longer, and blood loss was lower in the D3 LND group. Postoperative complications and severe complications were significantly fewer, and postoperative hospital stay was shorter in the D3 LND group. The number of harvested lymph nodes and distal margin was significantly higher in the D3 group. While unadjusted analysis showed better overall survival with D3 LND (p&#8201;&lt;&#8201;0.001), adjusted cancer-specific survival showed no significant difference (p&#8201;=&#8201;0.10). Adjusted mortality risk was significantly higher in the non-D3 group (p&#8201;=&#8201;0.001).&lt;br&gt;
Conclusion: In nonagenarian colon cancer patients, D3 LND is safe and feasible without increasing complications, but lacks survival benefit. Careful consideration is warranted, and high-quality D2 LND must be consistently ensured when limited surgery is chosen.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">colon cancer</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">lymph node dissection</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">nonagenarian</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">postoperative complication</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">survival benefit</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2168-8184</Issn>
      <Volume>17</Volume>
      <Issue>6</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Severe Anemia Caused by a Colorectal Lipoma With Central Erosions: A Case Report</ArticleTitle>
    <FirstPage LZero="delete">e85768</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Yusuke</FirstName>
        <LastName>Yoshida</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryohei</FirstName>
        <LastName>Shoji</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuki</FirstName>
        <LastName>Matsumi</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ko</FirstName>
        <LastName>Watanabe</LastName>
        <Affiliation>Department of Pathology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshiyoshi</FirstName>
        <LastName>Fujiwara</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Colorectal lipomas are benign tumors that are often asymptomatic and discovered incidentally. In most cases, they can be managed conservatively with observation. We report the case of a man in his 70s with a colorectal lipoma located in the cecum. An investigation into his severe anemia led to the suspicion that the cecal lipoma was the underlying cause. An ileocecal resection was performed. Erosions were observed at the center of the lipoma. Although small colorectal lipomas are generally asymptomatic and rarely cause anemia, periodic endoscopic examinations are recommended. These lesions should be considered in the differential diagnosis of lower gastrointestinal bleeding.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">anemia</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">bleeding lipoma</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">colorectal lipoma</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">laparoscopic surgery</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">mucosal erosion</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1435-2451</Issn>
      <Volume>411</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Surgical outcomes and patient selection in nonagenarians with colon cancer: a comparative multi-institutional study of laparoscopic and open approaches</ArticleTitle>
    <FirstPage LZero="delete">21</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Ryohei</FirstName>
        <LastName>Shoji</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Fuminori</FirstName>
        <LastName>Teraishi</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Satoe</FirstName>
        <LastName>Takanaga</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshiharu</FirstName>
        <LastName>Mitsuhashi</LastName>
        <Affiliation>Center for Innovative Clinical Medicine, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryo</FirstName>
        <LastName>Inada</LastName>
        <Affiliation>Department of Surgery, Kochi Health Sciences Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshiaki</FirstName>
        <LastName>Toshima</LastName>
        <Affiliation>Department of Surgery, Kagawa Rosai Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tsuyoshi</FirstName>
        <LastName>Ohtani</LastName>
        <Affiliation>Department of Surgery, Saiseikai Okayama Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryosuke</FirstName>
        <LastName>Yoshida</LastName>
        <Affiliation>Department of Surgery, Okayama Rosai Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Naoto</FirstName>
        <LastName>Hori</LastName>
        <Affiliation>Department of Surgery, Tottori Municipal Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kaoru</FirstName>
        <LastName>Shigemitsu</LastName>
        <Affiliation>Department of Surgery, Tsuyama Chuo Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Sumiharu</FirstName>
        <LastName>Yamamoto</LastName>
        <Affiliation>Department of Surgery, Okayama City Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tetsushi</FirstName>
        <LastName>Kubota</LastName>
        <Affiliation>Department of Surgery, Kobe Red Cross Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuka</FirstName>
        <LastName>Okano</LastName>
        <Affiliation>Department of Surgery, Onomichi City Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tetsuji</FirstName>
        <LastName>Nobuhisa</LastName>
        <Affiliation>Department of Surgery, Himeji Red Cross Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Fumitaka</FirstName>
        <LastName>Taniguchi</LastName>
        <Affiliation>Department of Surgery, National Hospital Organization Iwakuni Clinical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Wataru</FirstName>
        <LastName>Ishikawa</LastName>
        <Affiliation>Department of Surgery, Fukuyama City Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tatsuo</FirstName>
        <LastName>Matsuda</LastName>
        <Affiliation>Department of Surgery, Matsuda Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tatsuo</FirstName>
        <LastName>Umeoka</LastName>
        <Affiliation>Department of Surgery, Matsuyama City Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshiyoshi</FirstName>
        <LastName>Fujiwara</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N"/>
        <LastName>Setouchi Colorectal Neoplasm Registration study group collaborators</LastName>
        <Affiliation/>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Purpose The appropriate surgical approach for colon cancer (CC) in nonagenarian patients remains a subject of clinical debate. This study aimed to compare the short-term outcomes of laparoscopic (Lap) versus open (Open) surgery in patients aged&#8201;&#8805;&#8201;90 years with resectable colon cancer.&lt;br&gt;
Methods This multi-institutional retrospective cohort study included oldest-old patientswith pathological Stage II/III CC who underwent elective surgery at 15 hospitals between 2011 and 2022. Patients with rectal cancer, Stage 0/I/IV disease, or emergency surgery were excluded. To address selection bias, inverse-probability-weighted regression adjustment and stabilized inverse probability of treatment weighting (sIPTW) were applied. The primary outcome was postoperative complications; secondary outcomes included overall survival (OS).&lt;br&gt;
Results Median age was 92 years in both groups. Before adjustment, the Lap group had a higher proportion of female patients (p&#8201;=&#8201;0.038) and lower ASA scores (p&#8201;=&#8201;0.01). Laparoscopic surgery was associated with a significantly longer operative time (220 vs. 171 min, p&#8201;=&#8201;0.046) but less intraoperative blood loss (10 vs. 78 mL, p&#8201;&lt;&#8201;0.01). Postoperative complication rates were comparable (Lap: 31.8%, Open: 33.8%), while the Lap group had a significantly shorter hospital stay (13 vs. 17 days, p&#8201;&lt;&#8201;0.01). D3 lymph node dissection was more frequently performed in the Lap group (p&#8201;&lt;&#8201;0.01). After sIPTW, overall survival did not differ significantly between groups (p&#8201;=&#8201;0.61).&lt;br&gt;
Conclusion Both laparoscopic and open surgery are feasible options for selected nonagenarians with colon cancer. Laparoscopic surgery may offer benefits in terms of reduced blood loss and shorter hospitalization, despite longer operative times. Careful patient selection considering frailty and comorbidities is essential in determining the most appropriate surgical approach.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Oldest-old patients</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Colon cancer</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Laparoscopic surgery</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Surgical outcome</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Overall survival</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2038-131X</Issn>
      <Volume/>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Early C-reactive protein as a predictive biomarker for postoperative complications following robot-assisted surgery for rectal cancer</ArticleTitle>
    <FirstPage LZero="delete"/>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Fuminori</FirstName>
        <LastName>Teraishi</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryusei</FirstName>
        <LastName>Takahashi</LastName>
        <Affiliation>Department of Surgery, NHO Fukuyama Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroki</FirstName>
        <LastName>Okabayashi</LastName>
        <Affiliation>Department of Surgery, NHO Fukuyama Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masashi</FirstName>
        <LastName>Utsumi</LastName>
        <Affiliation>Department of Surgery, NHO Fukuyama Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hideaki</FirstName>
        <LastName>Miyaso</LastName>
        <Affiliation>Department of Surgery, NHO Fukuyama Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryohei</FirstName>
        <LastName>Shoji</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshiyoshi</FirstName>
        <LastName>Fujiwara</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshiharu</FirstName>
        <LastName>Mitsuhashi</LastName>
        <Affiliation>Center for Innovative Clinical Medicine, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masaru</FirstName>
        <LastName>Inagaki</LastName>
        <Affiliation>Department of Surgery, NHO Fukuyama Medical Center</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>This retrospective cohort study aimed to assess the predictive value of early postoperative C-reactive protein (CRP) levels for complications following robot-assisted rectal surgery (RARS) for rectal cancer. We analyzed data from 117 consecutive patients who underwent elective RARS at Okayama University Hospital between September 2020 and January 2025. Serum CRP levels were routinely measured preoperatively and on postoperative days (POD) 1 and 4. The primary outcome was the occurrence of any postoperative complication within 30 days, classified according to the Clavien&#8211;Dindo grading system. Postoperative complications were observed in 26 patients, representing 22.2% of the cohort. Univariate analysis revealed that several factors were significantly associated with complications, including older age, higher ASA score, neoadjuvant therapy, stoma creation, prolonged operative time, and elevated CRP levels on POD1 and POD4. Notably, multivariate logistic regression analysis identified POD1 CRP as a robust independent predictor of overall postoperative complications (adjusted odds ratio 0.77, 95% confidence interval (CI) [0.63&#8211;0.93], p&#8201;&lt;&#8201;0.01). In the ROC analysis, the AUC was 0.735 (bootstrap bias-corrected 95% CI 0.544&#8211;0.848). The optimal cutoff value of POD1 CRP was 5.63 mg/dl, at which Youden’s index, yielding a sensitivity of 0.615 and specificity of 0.868. In conclusion, early postoperative measurement of CRP on POD1 serves as a valuable and independent biomarker for predicting complications following RARS for rectal cancer. Incorporating POD1 CRP into postoperative surveillance may facilitate the early identification of high-risk patients, thereby facilitating timely interventions and ultimately improving surgical outcomes in this patient population.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Robot-assisted surgery</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Rectal cancer</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Postoperative complication</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">C-reactive protein</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2045-2322</Issn>
      <Volume>16</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Comparative efficacy of immune checkpoint inhibitor combination therapies by metastatic site in metastatic renal cell carcinoma</ArticleTitle>
    <FirstPage LZero="delete">3303</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Shingo</FirstName>
        <LastName>Toyoda</LastName>
        <Affiliation>Department of Urology, Faculty of Medicine, Kindai University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Lan</FirstName>
        <LastName>Inoki</LastName>
        <Affiliation>Department of Urology, Faculty of Medicine, Kindai University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Mamoru</FirstName>
        <LastName>Hashimoto</LastName>
        <Affiliation>Department of Urology, Faculty of Medicine, Kindai University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Wataru</FirstName>
        <LastName>Fukuokaya</LastName>
        <Affiliation>Department of Urology, The Jikei University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Keiichiro</FirstName>
        <LastName>Mori</LastName>
        <Affiliation>Department of Urology, The Jikei University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shingo</FirstName>
        <LastName>Nishimura</LastName>
        <Affiliation>Department of Urology, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryoichi</FirstName>
        <LastName>Maenosono</LastName>
        <Affiliation>Department of Urology, Osaka Medical and Pharmaceutical University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takehiro</FirstName>
        <LastName>Iwata</LastName>
        <Affiliation>Department of Urology, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kensuke</FirstName>
        <LastName>Bekku</LastName>
        <Affiliation>Department of Urology, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takuhisa</FirstName>
        <LastName>Nukaya</LastName>
        <Affiliation>Department of Urology, Fujita-Health University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takafumi</FirstName>
        <LastName>Yanagisawa</LastName>
        <Affiliation>Department of Urology, The Jikei University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takuya</FirstName>
        <LastName>Tsujino</LastName>
        <Affiliation>Department of Urology, Osaka Medical and Pharmaceutical University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazumasa</FirstName>
        <LastName>Komura</LastName>
        <Affiliation>Department of Urology, Kawasaki University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kiyoshi</FirstName>
        <LastName>Takahara</LastName>
        <Affiliation>Department of Urology, Fujita-Health University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Teruo</FirstName>
        <LastName>Inamoto</LastName>
        <Affiliation>Department of Urology, Hamamatsu University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Haruhito</FirstName>
        <LastName>Azuma</LastName>
        <Affiliation>Department of Urology, Osaka Medical and Pharmaceutical University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazutoshi</FirstName>
        <LastName>Fujita</LastName>
        <Affiliation>Department of Urology, Faculty of Medicine, Kindai University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N"/>
        <LastName>JK-FOOT study group</LastName>
        <Affiliation/>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Few studies have investigated the efficacy of immuno-oncology (IO) combinations at different metastatic sites in renal cell carcinoma (RCC). We evaluated the differential efficacy of IO&#8211;IO and IO&#8211;tyrosine kinase inhibitor (TKI) combinations by metastatic site in metastatic RCC (mRCC). This retrospective multicenter study by the JK-FOOT Study Group included 579 patients with intermediate- or poor-risk mRCC (per International Metastatic RCC Database Consortium criteria) treated with first-line IO combinations between September 2018 and December 2024. Metastatic sites were lymph nodes, lungs, bones, liver, brain, and others. The primary endpoints were progression-free survival (PFS) and overall survival (OS); the secondary endpoint was objective response rate. Efficacy was compared between IO&#8211;IO and IO&#8211;TKI for each site. For lymph node (n = 36), lung (n = 132), or brain (n = 16) metastases, OS or PFS was not significantly different between IO&#8211;IO and IO&#8211;TKI. In bone metastases (n = 80), OS tended to favor IO&#8211;TKI (P = 0.053). In liver metastases (n = 22), OS was significantly longer with IO&#8211;TKI (P = 0.011). IO&#8211;TKI may be a more appropriate first-line option than IO&#8211;IO for mRCC with bone or liver metastases, while efficacy is similar for other sites.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Metastatic renal cell carcinoma</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Bone metastasis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">liver metastasis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Immuno-oncology</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2045-2322</Issn>
      <Volume>16</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Objective assessment of cesarean section suturing techniques using a uterine simulator</ArticleTitle>
    <FirstPage LZero="delete">7456</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Hikari</FirstName>
        <LastName>Nakato</LastName>
        <Affiliation>Department of Obstetrics and Gynecology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Jota</FirstName>
        <LastName>Maki</LastName>
        <Affiliation>Department of Obstetrics and Gynecology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Chiaki</FirstName>
        <LastName>Kuriyama</LastName>
        <Affiliation>Department of Obstetrics and Gynecology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shujiro</FirstName>
        <LastName>Sakata</LastName>
        <Affiliation>Department of Obstetrics and Gynecology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Keiichi</FirstName>
        <LastName>Oishi</LastName>
        <Affiliation>Department of Obstetrics and Gynecology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ayano</FirstName>
        <LastName>Suemori</LastName>
        <Affiliation>Department of Obstetrics and Gynecology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hikaru</FirstName>
        <LastName>Ooba</LastName>
        <Affiliation>Department of Obstetrics and Gynecology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomohiro</FirstName>
        <LastName>Mitoma</LastName>
        <Affiliation>Department of Obstetrics and Gynecology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masakazu</FirstName>
        <LastName>Kato</LastName>
        <Affiliation>Department of Obstetrics and Gynecology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Sakurako</FirstName>
        <LastName>Mishima</LastName>
        <Affiliation>Department of Obstetrics and Gynecology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Akiko</FirstName>
        <LastName>Ohira</LastName>
        <Affiliation>Department of Obstetrics and Gynecology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Satoe</FirstName>
        <LastName>Kirino</LastName>
        <Affiliation>Department of Obstetrics and Gynecology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Eriko</FirstName>
        <LastName>Eto</LastName>
        <Affiliation>Department of Obstetrics and Gynecology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hisashi</FirstName>
        <LastName>Masuyama</LastName>
        <Affiliation>Department of Obstetrics and Gynecology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Cesarean wound healing is influenced by surgeon experience, suture type, and technique. This study utilized a simulation model to quantify these effects. Obstetricians&#8211;gynecologists and junior residents performed two-layer continuous suturing on uterine models, forming eight groups based on experience level (expert, novice), suture type (conventional, barbed), and technique (Albert&#8211;Lembert, layer-to-layer). The ideal wound condition was defined as that achieved by an expert using barbed sutures and the layer-to-layer technique. Wound characteristics were quantified and compared to this ideal. Experts using barbed sutures in Albert&#8211;Lembert suturing showed higher wound density but greater deformation and larger endometrial openings (both P&#8201;&lt;&#8201;0.01). Novices using barbed sutures in Albert&#8211;Lembert suturing showed similar wound density but significantly greater deformation and opening (both P&#8201;&lt;&#8201;0.01). Novices using conventional sutures in layer-to-layer suturing showed the lowest wound density and longest suturing time (both P&#8201;&lt;&#8201;0.01). Notably, novices using barbed sutures achieved wound characteristics comparable to experts using conventional sutures in Albert&#8211;Lembert suturing and results closer to the ideal in layer-to-layer suturing. These findings establish a quantifiable standard for cesarean suturing and suggest that optimizing suture types and techniques may help compensate for differences in surgical expertise.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Cesarean section</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Simulation</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Cesarean scar defects</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Barbed suture</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>eLife Sciences Publications, Ltd</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2050-084X</Issn>
      <Volume>13</Volume>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Stimulatory and inhibitory G-protein signaling relays drive cAMP accumulation for timely metamorphosis in the chordate Ciona</ArticleTitle>
    <FirstPage LZero="delete">RP99825</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Akiko</FirstName>
        <LastName>Hozumi</LastName>
        <Affiliation>Shimoda Marine Research Center, University of Tsukuba</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Nozomu M</FirstName>
        <LastName>Totsuka</LastName>
        <Affiliation>Department of Biosciences and Informatics, Faculty of Science and Technology, Keio University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Arata</FirstName>
        <LastName>Onodera</LastName>
        <Affiliation>Shimoda Marine Research Center, University of Tsukuba</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yanbin</FirstName>
        <LastName>Wang</LastName>
        <Affiliation>Shimoda Marine Research Center, University of Tsukuba</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Mayuko</FirstName>
        <LastName>Hamada</LastName>
        <Affiliation>Ushimado Marine Institute, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Akira</FirstName>
        <LastName>Shiraishi</LastName>
        <Affiliation>Bioorganic Research Institute, Suntory Foundation for Life Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Honoo</FirstName>
        <LastName>Satake</LastName>
        <Affiliation>Bioorganic Research Institute, Suntory Foundation for Life Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takeo</FirstName>
        <LastName>Horie</LastName>
        <Affiliation>Laboratory for Single-cell Neurobiology, Graduate School of Frontier Biosciences, Osaka University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kohji</FirstName>
        <LastName>Hotta</LastName>
        <Affiliation>Department of Biosciences and Informatics, Faculty of Science and Technology, Keio University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yasunori</FirstName>
        <LastName>Sasakura</LastName>
        <Affiliation>Shimoda Marine Research Center, University of Tsukuba</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Larvae of the ascidian Ciona initiate metamorphosis tens of minutes after adhesion to a substratum via their adhesive organ. The gap between adhesion and metamorphosis initiation is suggested to ensure the rigidity of adhesion, allowing Ciona to maintain settlement after losing locomotive activity through metamorphosis. The mechanism producing the gap is unknown. Here, by combining gene functional analyses, pharmacological analyses, and live imaging, we propose that the gap represents the time required for sufficient cyclic adenosine monophosphate (cAMP) accumulation to trigger metamorphosis. Not only the Gs pathway but also the Gi and Gq pathways are involved in the initiation of metamorphosis in the downstream signaling cascade of the neurotransmitter GABA, the known initiator of Ciona metamorphosis. The mutual crosstalk of stimulatory and inhibitory G-proteins functions as the accelerator and brake for cAMP production, ensuring the faithful initiation of metamorphosis at an appropriate time and in the right situation.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList/>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1863-9941</Issn>
      <Volume>52</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Preferential sacral fracture sites in fragility fractures of the pelvis type IVb and comparison of internal fixation methods: CT-based morphological mapping and finite element analysis</ArticleTitle>
    <FirstPage LZero="delete">72</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Shuichi</FirstName>
        <LastName>Naniwa</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Section of Medicine, Division of Medicine, Dentistry and Pharmaceutical Sciences, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masanori</FirstName>
        <LastName>Yorimitsu</LastName>
        <Affiliation>Department of Musculoskeletal Traumatology, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University,</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tsubasa</FirstName>
        <LastName>Hasegawa</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Section of Medicine, Division of Medicine, Dentistry and Pharmaceutical Sciences, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Teruhiko</FirstName>
        <LastName>Ando</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Section of Medicine, Division of Medicine, Dentistry and Pharmaceutical Sciences, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryuichiro</FirstName>
        <LastName>Okuda</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Section of Medicine, Division of Medicine, Dentistry and Pharmaceutical Sciences, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shiro</FirstName>
        <LastName>Fukuoka</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Kagawa Prefectural Central Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yusuke</FirstName>
        <LastName>Mochizuki</LastName>
        <Affiliation>Department of Emergency Health Care and Disaster Medicine, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yasuaki</FirstName>
        <LastName>Yamakawa</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Kochi Health Sciences Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryuichi</FirstName>
        <LastName>Nakahara</LastName>
        <Affiliation>Department of Musculoskeletal Health Promotion, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shiro</FirstName>
        <LastName>Hanakawa</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Okayama Saidaiji Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshifumi</FirstName>
        <LastName>Ozaki</LastName>
        <Affiliation>Department of Orthopedic Surgery, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Purpose Fragility fractures of the pelvis (FFP) classified as Rommens-Hoffman type IVb are associated with spinopelvic dissociation and are generally considered to require surgical intervention. This study aimed to clarify the localization patterns of FFP type IVb and compare the biomechanical stability of different internal fixation techniques.&lt;br&gt;
Methods In this retrospective study, morphologic mapping of sacral fracture lines was performed in 36 patients with FFP type IVb. Based on the mapping results, a finite element (FE) model of FFP type IVb was developed to evaluate the biomechanical stability of ilio-sacral screw (ISS) fixation, trans-sacral screw (TSS) fixation, spinopelvic fixation (SPF; On each side, L5 pedicle screw was connected to two iliac screws with a rod, and the bilateral constructs were linked using a cross-connector.), and bilateral triangular fixation (one TSS at S1 combined with SPF mentioned above) using finite element analysis (FEA).&lt;br&gt;
Results Morphologic mapping showed that the sacrum fracture transverse line tended to pass between the S1-2 transverse lines. Although bilateral triangular fixation and SPF provided the highest stability in both U-type and H-type fractures, a TSS for U-type and two TSSs for H-type also demonstrated comparable levels of stability. ISS-based methods showed greater displacements.&lt;br&gt;
Conclusion TSS-based fixation may provide stability comparable to bilateral triangular fixation and SPF in FFP type IVb, with less invasiveness when anatomy permits. Further studies are needed to optimize treatment strategies for this complex injury.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Fragility fractures of the pelvis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Spinopelvic dissociation</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Finite element analysis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Internal fixation</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Wiley</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2574-173X</Issn>
      <Volume>46</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Lifestyle Factors and Current Alcohol Consumption Among Japanese Adolescents During the COVID-19 Pandemic: A Nationwide Cross-Sectional Study</ArticleTitle>
    <FirstPage LZero="delete">e70089</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Masatake</FirstName>
        <LastName>Nishiwaki</LastName>
        <Affiliation>Department of Public Health, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hideyuki</FirstName>
        <LastName>Kanda</LastName>
        <Affiliation>Department of Public Health, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Keita</FirstName>
        <LastName>Yoshida</LastName>
        <Affiliation>Department of Public Health, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takashi</FirstName>
        <LastName>Hisamatsu</LastName>
        <Affiliation>Department of Public Health, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Aya</FirstName>
        <LastName>Kinjo</LastName>
        <Affiliation>Division of Environmental and Preventive Medicine, Department of Social Medicine, Faculty of Medicine, Tottori University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuki</FirstName>
        <LastName>Kuwabara</LastName>
        <Affiliation>Division of Environmental and Preventive Medicine, Department of Social Medicine, Faculty of Medicine, Tottori University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hongja</FirstName>
        <LastName>Kim</LastName>
        <Affiliation>Division of Environmental and Preventive Medicine, Department of Social Medicine, Faculty of Medicine, Tottori University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Aya</FirstName>
        <LastName>Imamoto</LastName>
        <Affiliation>Division of Environmental and Preventive Medicine, Department of Social Medicine, Faculty of Medicine, Tottori University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hisashi</FirstName>
        <LastName>Yoshimoto</LastName>
        <Affiliation>Department of Family Medicine, General Practice and Community Health, Institute of Medicine, University of Tsukuba</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Teruna</FirstName>
        <LastName>Ito</LastName>
        <Affiliation>Department of Food and Nutrition, Koriyama Women's University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hideaki</FirstName>
        <LastName>Kasuga</LastName>
        <Affiliation>Department of Hygiene and Preventive Medicine, Fukushima Medical University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ruriko</FirstName>
        <LastName>Minobe</LastName>
        <Affiliation>National Institute of Alcoholism, Kurihama National Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hitoshi</FirstName>
        <LastName>Maesato</LastName>
        <Affiliation>National Institute of Alcoholism, Kurihama National Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Maki</FirstName>
        <LastName>Jike</LastName>
        <Affiliation>Department of Food Science and Nutrition, Faculty of Life and Environmental Science, Showa Women's University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuichiro</FirstName>
        <LastName>Otsuka</LastName>
        <Affiliation>Division of Public Health, Department of Social Medicine, Nihon University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Osamu</FirstName>
        <LastName>Itani</LastName>
        <Affiliation>Division of Public Health, Department of Social Medicine, Nihon University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshitaka</FirstName>
        <LastName>Kaneita</LastName>
        <Affiliation>Division of Public Health, Department of Social Medicine, Nihon University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Susumu</FirstName>
        <LastName>Higuchi</LastName>
        <Affiliation>National Institute of Alcoholism, Kurihama National Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoneatsu</FirstName>
        <LastName>Osaki</LastName>
        <Affiliation>Division of Environmental and Preventive Medicine, Department of Social Medicine, Faculty of Medicine, Tottori University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Background: The COVID-19 pandemic may have influenced drinking behaviors in minors by disrupting daily routines and increasing psychosocial stress, although alcohol use among Japanese adolescents has declined in recent years. We aimed to clarify the relationships between current alcohol consumption and lifestyle factors during the COVID-19 pandemic based on a nationwide cross-sectional survey.&lt;br&gt;
Methods: This cross-sectional study analyzed data from the 2021 Lifestyle Survey of Adolescents, a nationwide survey conducted in Japan during the COVID-19 pandemic. A total of 15&#8201;549 junior and senior high school students (7645 boys and 7904 girls) were included. Current alcohol consumption was defined as drinking on at least 1&#8201;day in the past 30&#8201;days. Multivariable logistic regression analyses were used to examine associations between current alcohol consumption and lifestyle factors, including irregular sleep patterns, irregular dietary habits, and increased screen time. Sex-stratified analyses and interaction tests were also performed.&lt;br&gt;
Results: The overall prevalence of current alcohol consumption was 2.1%, with slightly higher rates among boys (2.2%) than girls (2.0%). Current alcohol consumption was significantly associated with irregular sleep patterns (odds ratio [OR]&#8201;=&#8201;1.51; 95% confidence interval [CI], 1.17&#8211;1.95) and irregular dietary habits (OR&#8201;=&#8201;1.68; 95% CI, 1.18&#8211;2.40). An association with increased screen time was also observed (OR&#8201;=&#8201;1.29; 95% CI, 1.00&#8211;1.69), particularly among boys. A significant interaction by sex was detected for irregular sleep patterns (p for interaction&#8201;=&#8201;0.013).&lt;br&gt;
Conclusions: Alcohol consumption among Japanese adolescents was associated with irregular sleep and dietary habits and, among boys, with increased screen time. These findings highlight the importance of promoting regular routines and addressing lifestyle-related risks to prevent current alcohol consumption among adolescents during public health crises.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">adolescent</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">alcohol drinking</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">COVID-19</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Japan</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">lifestyle</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1471-2261</Issn>
      <Volume>25</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Prognostic value of right atrial strain in patients with chronic heart failure</ArticleTitle>
    <FirstPage LZero="delete">908</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Rie</FirstName>
        <LastName>Nakayama</LastName>
        <Affiliation>Department of Cardiovascular Medicine, Dentistry and Pharmaceutical Science, Okayama University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoichi</FirstName>
        <LastName>Takaya</LastName>
        <Affiliation>Department of Cardiovascular Medicine, Dentistry and Pharmaceutical Science, Okayama University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Mitsutaka</FirstName>
        <LastName>Nakashima</LastName>
        <Affiliation>Department of Cardiovascular Medicine, Dentistry and Pharmaceutical Science, Okayama University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takahiro</FirstName>
        <LastName>Nishihara</LastName>
        <Affiliation>Department of Cardiovascular Medicine, Dentistry and Pharmaceutical Science, Okayama University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Norihisa</FirstName>
        <LastName>Toh</LastName>
        <Affiliation>Department of Cardiovascular Medicine, Dentistry and Pharmaceutical Science, Okayama University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Miyoshi</FirstName>
        <LastName>Toru</LastName>
        <Affiliation>Department of Cardiovascular Medicine, Dentistry and Pharmaceutical Science, Okayama University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazufumi</FirstName>
        <LastName>Nakamura</LastName>
        <Affiliation>Department of Cardiovascular Medicine, Dentistry and Pharmaceutical Science, Okayama University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shinsuke</FirstName>
        <LastName>Yuasa</LastName>
        <Affiliation>Department of Cardiovascular Medicine, Dentistry and Pharmaceutical Science, Okayama University Graduate School of Medicine</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Aims Right ventricular dysfunction is a well-established prognostic marker in patients with heart failure (HF). However, the prognostic significance of right atrial (RA) function remains unclear. Given its sensitivity to systemic congestion, RA function may provide additional insights into HF disease progression and management. This study aimed to investigate whether RA reservoir function serves as an independent prognostic indicator in patients with chronic HF.&lt;br&gt;
Methods A total of 613 patients with chronic HF and a left ventricular (LV) ejection fraction of less than 50% who underwent echocardiographic assessment at Okayama University Hospital between January 2018 and March 2023 were included (median age: 68 (58&#8211;76) years; 69% male). RA reservoir function was quantified using two-dimensional speckle-tracking echocardiography. The primary endpoint was cardiovascular death or HF-related hospitalization. Kaplan&#8211;Meier survival analysis was performed to examine the association between RA reservoir function and clinical outcomes.&lt;br&gt;
Results During a median follow-up period of 41 months (range: 12&#8211;91 months), 119 patients experienced cardiac events. Compared with event-free patients, those with cardiac events exhibited a significantly larger RA maximum volume index (38 mL/m2 vs. 31 mL/m2, P&#8201;&lt;&#8201;0.001) and a significantly lower RA reservoir longitudinal strain (RASr) (17% vs. 22%, P&#8201;&lt;&#8201;0.001). Kaplan&#8211;Meier analysis demonstrated that patients with RASr&#8201;&#8804;&#8201;20% had significantly poorer event-free survival than those with RASr&#8201;&gt;&#8201;20%, even without RA volume enlargement (log-rank test, P&#8201;&lt;&#8201;0.001). Multivariate Cox regression analysis identified RASr as an independent predictor of cardiac events (hazard ratio: 0.95, 95% confidence interval: 0.93 to 0.97, P&#8201;&lt;&#8201;0.001).&lt;br&gt;
Conclusions In patients who experienced adverse cardiac events, a reduced RASr and an increased RA maximum volume were observed. Furthermore, a reduced RASr was independently associated with an increased risk of cardiovascular death and HF-related hospitalization in patients with chronic HF and LV dysfunction. These findings indicate that RASr may serve as a valuable prognostic marker for the risk stratification and management of chronic HF.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Right atrial function</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Right atrial strain</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Chronic heart failure</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Echocardiography</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1364-6753</Issn>
      <Volume>27</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Compound heterozygosity of a novel missense variant and exonic deletion in hypomyelinating leukodystrophy 15</ArticleTitle>
    <FirstPage LZero="delete">16</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Akihiko</FirstName>
        <LastName>Mitsutake</LastName>
        <Affiliation>Department of Neurology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan Department of Neurology</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takashi</FirstName>
        <LastName>Matsukawa</LastName>
        <Affiliation>Department of Neurology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan Department of Neurology</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kenta</FirstName>
        <LastName>Orimo</LastName>
        <Affiliation>Department of Neurology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan Department of Neurology</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kunihiro</FirstName>
        <LastName>Ueda</LastName>
        <Affiliation>Department of Neurology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan Department of Neurology</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomonari</FirstName>
        <LastName>Seki</LastName>
        <Affiliation>Department of Neurology, Tokyo Teishin Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yasushi</FirstName>
        <LastName>Shiio</LastName>
        <Affiliation>Department of Neurology, Tokyo Teishin Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Jun</FirstName>
        <LastName>Mitsui</LastName>
        <Affiliation>Department of Precision Medicine Neurology, Graduate School of Medicine, The University of Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroyuki</FirstName>
        <LastName>Ishiura</LastName>
        <Affiliation>Department of Neurology, Dentistry, and Pharmaceutical Sciences, Okayama University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Harushi</FirstName>
        <LastName>Mori</LastName>
        <Affiliation>Department of Radiology, School of Medicine, Jichi Medical University,</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shoji</FirstName>
        <LastName>Tsuji</LastName>
        <Affiliation>Institute of Medical Genomics, International University of Health and Welfare</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tatsushi</FirstName>
        <LastName>Toda</LastName>
        <Affiliation>Department of Neurology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan Department of Neurology</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Hypomyelinating leukodystrophy 15 (HLD15) results from biallelic pathogenic variants in EPRS1, but exonic deletions have not been reported. We describe a 40-year-old woman with mild intellectual disability, ataxia, dystonia, and MRI showing hypomyelination. Whole-exome sequencing identified a heterozygous missense variant in the prolyl-tRNA synthetase domain of EPRS1 (c.3430 C&#8201;&gt;&#8201;G; p.Leu1144Val, NM_004446.3), without second variant. Whole-genome sequencing revealed a heterozygous 220-bp deletion spanning exon 15 (c.1743-30_1932del), and segregation analysis confirmed compound heterozygosity. RT-PCR from lymphoblastoid cells demonstrated exon-15 skipping leading to a frameshift (p.Asn582Serfs*10) and nonsense-mediated decay, leaving predominant expression of the paternally inherited missense allele. These findings support loss-of-function for the deletion and classify c.3430 C&#8201;&gt;&#8201;G as likely pathogenic under ACMG/AMP criteria (PM1, PM2, PM3, PP3). This case represents the first exonic deletion reported in EPRS1. The relatively mild, adult-onset phenotype broadens both mutational and clinical spectra of HLD15 and highlights the importance of structural-variant anal</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Hypomyelinating leukodystrophy</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">EPRS1</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Structural variant</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Exon deletion</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Nonsense&#8209;mediated decay</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Whole&#8209;genome sequencing</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Wiley</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1613-6810</Issn>
      <Volume>21</Volume>
      <Issue>50</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Collagen Signaling via DDR1 Exacerbates Barriers to Macromolecular Drug Delivery in a 3D Model of Pancreatic Cancer Fibrosis</ArticleTitle>
    <FirstPage LZero="delete">e06926</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Mayu</FirstName>
        <LastName>Ohira</LastName>
        <Affiliation>Department of Pharmaceutical Biomedicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Moe</FirstName>
        <LastName>Kitamura</LastName>
        <Affiliation>Department of Pharmaceutical Biomedicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroyo</FirstName>
        <LastName>Iwasaki</LastName>
        <Affiliation>Department of Pharmaceutical Biomedicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Haruko</FirstName>
        <LastName>Ohta‐Okano</LastName>
        <Affiliation>Department of Pharmaceutical Biomedicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiyori</FirstName>
        <LastName>Tsujii</LastName>
        <Affiliation>Department of Pharmaceutical Biomedicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Reika</FirstName>
        <LastName>Nakamura</LastName>
        <Affiliation>Department of Pharmaceutical Biomedicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takuya</FirstName>
        <LastName>Nakazawa</LastName>
        <Affiliation>Department of Pharmaceutical Biomedicine, Graduate School of Interdisciplinary Science and Engineering in Health Systems, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Akihiro</FirstName>
        <LastName>Nishiguchi</LastName>
        <Affiliation>Biomaterials Field, Research Center for Macromolecules and Biomaterials, National Institute for Materials Science</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masaya</FirstName>
        <LastName>Yamamoto</LastName>
        <Affiliation>Department of Materials Processing, Graduate School of Engineering, Tohoku University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kensuke</FirstName>
        <LastName>Osada</LastName>
        <Affiliation>Department of Molecular Imaging and Theranostics, Institute for Quantum Medical Science, National Institutes for Quantum Sciences and Technology (QST)</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shinichi</FirstName>
        <LastName>Toyooka</LastName>
        <Affiliation>Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Horacio</FirstName>
        <LastName>Cabral</LastName>
        <Affiliation>Department of Bioengineering, Graduate School of Engineering, The University of Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Atsushi</FirstName>
        <LastName>Masamune</LastName>
        <Affiliation>Division of Gastroenterology, Graduate School of Medicine, Tohoku University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Mitsunobu R.</FirstName>
        <LastName>Kano</LastName>
        <Affiliation>Department of Pharmaceutical Biomedicine, Graduate School of Interdisciplinary Science and Engineering in Health Systems, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroyoshi Y.</FirstName>
        <LastName>Tanaka</LastName>
        <Affiliation>Department of Pharmaceutical Biomedicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Fibrosis is a significant barrier to drug delivery in pancreatic ductal adenocarcinoma (PDAC) and contributes to its dismal prognosis. Pancreatic stellate cells (PSCs) drive fibrosis by excessively secreting extracellular matrix proteins such as collagen I. Collagen I is thought to physically obstruct the delivery of macromolecules, such as albumin, antibodies, and nanomedicines. Apart from its structural role, collagen signals through dedicated cell surface receptors, such as the discoidin domain receptors (DDR) 1/2. However, whether and how collagen signaling contributes to fibrotic barrier generation remains uncharacterized. Here, a 3D culture model of PDAC fibrosis constructed from patient PSCs is used to assess the contribution of DDR1/2-mediated collagen signaling. DDR1/2 inhibition diminishes collagen I expression in PSCs to enhance macromolecular delivery. Moreover, MEK inhibitors exacerbate the fibrotic barrier by up-regulating collagen I, an effect reversed by inhibiting DDR1/2. Through isoform-specific targeting, inhibiting DDR1, but not DDR2, is shown to be effective. Downstream of DDR, the involvement of the PI3K/AKT/mTOR pathway is demonstrated, particularly alternative mTOR complexes involving MEAK7 and GIT1. Altogether, the results show in vitro that DDR1-mediated collagen signaling exacerbates the fibrotic barrier and may be targeted to enhance macromolecular drug delivery in PDAC.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">collagen</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">fibrosis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">nanomedicine</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">pancreatic cancer</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">pancreatic stellate cell</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1546-0096</Issn>
      <Volume>23</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Comparison of clinical practices during the transitional and young adult phases between patients with oligoarticular/polyarticular juvenile idiopathic arthritis and those with rheumatoid arthritis in Japan</ArticleTitle>
    <FirstPage LZero="delete">120</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Sho</FirstName>
        <LastName>Mori</LastName>
        <Affiliation>Division of Rheumatology and Allergology, Department of Internal Medicine, St. Marianna University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kosuke</FirstName>
        <LastName>Shabana</LastName>
        <Affiliation>Department of Pediatrics, Osaka Medical and Pharmaceutical University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshihiro</FirstName>
        <LastName>Matsui</LastName>
        <Affiliation>Department of Rheumatology Research, Clinical Research Center for Allergy and Rheumatology, National Hospital Organization Sagamihara National Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomo</FirstName>
        <LastName>Nozawa</LastName>
        <Affiliation>Department of Pediatrics, Graduate School of Medicine, Yokohama City University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuko</FirstName>
        <LastName>Sugita</LastName>
        <Affiliation>Department of Pediatrics, Osaka Medical and Pharmaceutical University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Minako</FirstName>
        <LastName>Tomiita</LastName>
        <Affiliation>Department of Allergy and Rheumatology, Chiba Children’s Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yasuo</FirstName>
        <LastName>Nakagishi</LastName>
        <Affiliation>Department of Pediatric Rheumatology, Hyogo Prefectural Kobe Children’s Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuichi</FirstName>
        <LastName>Yamasaki</LastName>
        <Affiliation>Department of Pediatrics, Kagoshima University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroaki</FirstName>
        <LastName>Umebayashi</LastName>
        <Affiliation>Department of General Pediatrics, Miyagi Children’s Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masato</FirstName>
        <LastName>Yashiro</LastName>
        <Affiliation>Department of Pediatrics, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Naomi</FirstName>
        <LastName>Iwata</LastName>
        <Affiliation>Department of Infection and Immunology, Allergy and Immunology Center, Aichi Children’s Health and Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Junko</FirstName>
        <LastName>Yasumura</LastName>
        <Affiliation>Department of Pediatrics, Hiroshima University Graduate School of Biomedical and Health Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroyuki</FirstName>
        <LastName>Wakiguchi</LastName>
        <Affiliation>Department of Pediatrics, Yamaguchi University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takeshi</FirstName>
        <LastName>Yamamoto</LastName>
        <Affiliation>Department of Pediatrics, Chiba University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shunichiro</FirstName>
        <LastName>Takezaki</LastName>
        <Affiliation>Department of Pediatrics, Faculty of Medicinea and Graduate School of Medicine, Hokkaido University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuka</FirstName>
        <LastName>Okura</LastName>
        <Affiliation>Center for Pediatric Allergy and Rheumatology, KKR Sapporo Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tadafumi</FirstName>
        <LastName>Yokoyama</LastName>
        <Affiliation>Department of Pediatrics, Kanazawa University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masaki</FirstName>
        <LastName>Shimizu</LastName>
        <Affiliation>Department of Pediatrics, Perinatal and Maternal Medicine, Graduate School of Medical and Dental Sciences, Institute of Science Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masahiro</FirstName>
        <LastName>Hirayama</LastName>
        <Affiliation>Department of Pediatrics, Mie University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shigeto</FirstName>
        <LastName>Tohma</LastName>
        <Affiliation>Department of Rheumatology, National Hospital Organization Tokyo National Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Nami</FirstName>
        <LastName>Okamoto</LastName>
        <Affiliation>Department of Pediatrics, Osaka Medical and Pharmaceutical University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masaaki</FirstName>
        <LastName>Mori</LastName>
        <Affiliation>Division of Rheumatology and Allergology, Department of Internal Medicine, St. Marianna University School of Medicine</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Background Juvenile idiopathic arthritis (JIA) is a chronic inflammatory condition that frequently persists into adulthood, posing long-term challenges in disease control and quality of life. However, clinical management during the transitional and young adult phases remains insufficiently characterized, especially in comparison with adult-onset rheumatoid arthritis (RA). This study aimed to compare disease activity, medication use, and treatment practices between patients with oligoarticular/polyarticular JIA and those with RA, focusing on individuals aged 16&#8211;30 years.&lt;br&gt;
Methods Data were derived from two nationwide multicenter databases in Japan―NinJa (National Database of Rheumatic Diseases in Japan) for RA and CoNinJa (a pediatric counterpart of NinJa) for JIA. A total of 176 JIA and 152 RA patients, all aged 16&#8211;30 years, were analyzed. Clinical parameters, disease activity indices, and medication profiles were compared using the Mann&#8211;Whitney U test and Fisher’s exact test.&lt;br&gt;
Results Compared to RA patients, JIA patients demonstrated significantly lower disease activity (median SDAI 0.6 vs. 2.4) and higher remission rates, particularly Boolean remission (70% vs. 44%) (p&#8201;&lt;&#8201;0.001). MTX usage was less frequent in JIA (49% vs. 68%, p&#8201;&lt;&#8201;0.001), whereas biologic use was notably more common (69% vs. 38%, p&#8201;&lt;&#8201;0.001), with 31% involving off-label prescriptions. Among patients in CDAI remission, biologic monotherapy was observed more frequently in JIA (29% vs. 7%, p&#8201;&lt;&#8201;0.001). Discontinuation of MTX was most commonly attributed to disease improvement (58%) or gastrointestinal intolerance (nausea, 29%). Subcutaneous tocilizumab, though unapproved for JIA in Japan, had the lowest discontinuation rate (4%), suggesting favorable tolerability.&lt;br&gt;
Conclusions Despite an overlap in age, patients with JIA and RA exhibit distinct disease characteristics and therapeutic patterns. These differences underscore the need to expand approved treatment options for JIA, promote equitable access to biologics, and strengthen transitional care frameworks. Further research is warranted to explore long-term outcomes, reproductive health considerations, and socioeconomic barriers that influence treatment continuity in young adults with childhood-onset arthritis.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Juvenile idiopathic arthritis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Rheumatoid arthritis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Disease activity</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Biologics</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Methotrexate</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Wiley</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2688-4526</Issn>
      <Volume>7</Volume>
      <Issue>2</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Safety and efficacy of Rez&#363;m water vapour energy therapy in BPH patients receiving antithrombotic therapy: A Japanese single‐centre experience</ArticleTitle>
    <FirstPage LZero="delete">e70170</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Takatoshi</FirstName>
        <LastName>Moriwake</LastName>
        <Affiliation>Department of Urology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yusuke</FirstName>
        <LastName>Tominaga</LastName>
        <Affiliation>Department of Urology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Satoshi</FirstName>
        <LastName>Katayama</LastName>
        <Affiliation>Department of Urology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Haruki</FirstName>
        <LastName>Kaku</LastName>
        <Affiliation>Department of Urology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ichiro</FirstName>
        <LastName>Tsuboi</LastName>
        <Affiliation>Department of Urology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kasumi</FirstName>
        <LastName>Yoshinaga</LastName>
        <Affiliation>Department of Urology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomoaki</FirstName>
        <LastName>Yamanoi</LastName>
        <Affiliation>Department of Urology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tatsushi</FirstName>
        <LastName>Kawada</LastName>
        <Affiliation>Department of Urology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takuya</FirstName>
        <LastName>Sadahira</LastName>
        <Affiliation>Department of Urology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takehiro</FirstName>
        <LastName>Iwata</LastName>
        <Affiliation>Department of Urology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shingo</FirstName>
        <LastName>Nishimura</LastName>
        <Affiliation>Department of Urology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kensuke</FirstName>
        <LastName>Bekku</LastName>
        <Affiliation>Department of Urology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yasuhiro</FirstName>
        <LastName>Katayama</LastName>
        <Affiliation>Department of Urology, Okamura Isshindo Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Motoo</FirstName>
        <LastName>Araki</LastName>
        <Affiliation>Department of Urology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Objectives: The objective of this study is to evaluate the safety and efficacy of Rez&#363;m water vapour energy therapy (WAVE) in Japanese patients with benign prostatic hyperplasia (BPH) continuing antithrombotic therapy and to validate the Okayama University Modified Clavien-Dindo classification (OU-mCD) for perioperative hematuria.&lt;br&gt;
Patients and Methods: We retrospectively analysed 80 consecutive patients who underwent WAVE from August 2023 to July 2024, including 37 (46.2%) continuing antithrombotic therapy perioperatively. Hematuria within 30&#8201;days was graded using conventional Clavien-Dindo classification and the OU-mCD, a novel classification focusing on intervention necessity. We assessed clinically significant hematuria (Grade &#8805; Ib), catheter-free rate, prostate volume reduction and haemoglobin change.&lt;br&gt;
Results: Clinically significant hematuria occurred in 21.6% (8/37) of patients continuing antithrombotic therapy versus 4.7% (2/43) without (p&#8201;=&#8201;0.038). All 10 Grade &#8805; Ib cases occurred during hospitalization with the catheter in place and were managed conservatively with continuous bladder irrigation (median 1 day); none required transfusion or surgical reintervention. Only one patient required temporary drug discontinuation. Treatment efficacy did not differ by antithrombotic status: 86.2% achieved PVR&#8201;&lt;&#8201;50&#8201;ml with 44% mean prostate volume reduction. Multivariate analysis identified antithrombotic therapy as the sole independent risk factor for Grade &#8805; Ib hematuria (OR 5.46, 95% CI 1.06&#8211;28.16, p&#8201;=&#8201;0.042).&lt;br&gt;
Conclusion: WAVE can be safely performed with continued antithrombotic therapy. Whereas Grade &#8805;Ib hematuria occurred in 25% of antiplatelet/anticoagulant users (vs. 5% without), 75% had no significant bleeding, and all complications were managed conservatively without transfusion. The OU-mCD provides precise complication stratification. These findings suggest outpatient procedures may be feasible with appropriate patient selection.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">benign prostatic hyperplasia</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">hematuriaantithrombotic therapy</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Japanese</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">OU-mCD</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">water vapour energy therapy</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>American Medical Association (AMA)</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2574-3805</Issn>
      <Volume>8</Volume>
      <Issue>11</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Trastuzumab Deruxtecan for ERBB2-Mutant Metastatic Non&#8211;Small Cell Lung Cancer With or Without Brain Metastases: A Secondary Analysis of Randomized Clinical Trials</ArticleTitle>
    <FirstPage LZero="delete">e2543107</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Pasi A.</FirstName>
        <LastName>J&#228;nne</LastName>
        <Affiliation>Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">David</FirstName>
        <LastName>Planchard</LastName>
        <Affiliation>Department of Medical Oncology, Thoracic Cancer Group, Gustave Roussy, Medical Oncology</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Koichi</FirstName>
        <LastName>Goto</LastName>
        <Affiliation>Department of Thoracic Oncology, Nation Cancer Center Hospital East</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Egbert F.</FirstName>
        <LastName>Smit</LastName>
        <Affiliation>Department of Pulmonary Diseases, Leiden University Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Adrianus Johannes</FirstName>
        <LastName>de Langen</LastName>
        <Affiliation>Department of Thoracic Oncology, Netherlands Cancer Institute</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yasushi</FirstName>
        <LastName>Goto</LastName>
        <Affiliation>Department of Thoracic Oncology, National Cancer Center Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kiichiro</FirstName>
        <LastName>Ninomiya</LastName>
        <Affiliation>Center for Comprehensive Genomic Medicine, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshio</FirstName>
        <LastName>Kubo</LastName>
        <Affiliation>Center for Clinical Oncology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Maurice</FirstName>
        <LastName>P&#233;rol</LastName>
        <Affiliation>Department of Medical Oncology, Centre L&#233;on B&#233;rard</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Enriqueta</FirstName>
        <LastName>Felip</LastName>
        <Affiliation>Department of Medical Oncology, Vall d’Hebron University and Vall d’Hebron Institute of Oncology</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hidetoshi</FirstName>
        <LastName>Hayashi</LastName>
        <Affiliation>Department of Medical Oncology, Kindai University Faculty of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuhiko</FirstName>
        <LastName>Nakagawa</LastName>
        <Affiliation>Department of Medical Oncology, Kindai University Faculty of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Junichi</FirstName>
        <LastName>Shimizu</LastName>
        <Affiliation>Department of Thoracic Oncology, Aichi Cancer Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Misako</FirstName>
        <LastName>Nagasaka</LastName>
        <Affiliation>Division of Hematology-Oncology, Department of Medicine, University of California Irvine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kaline</FirstName>
        <LastName>Pereira</LastName>
        <Affiliation>Daiichi Sankyo Inc</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ayumi</FirstName>
        <LastName>Taguchi</LastName>
        <Affiliation>Daiichi Sankyo Co Ltd</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ahmed</FirstName>
        <LastName>Ali</LastName>
        <Affiliation>Daiichi Sankyo Europe GmbH</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Maha</FirstName>
        <LastName>Karnoub</LastName>
        <Affiliation>Daiichi Sankyo Inc</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Rie</FirstName>
        <LastName>Yonemochi</LastName>
        <Affiliation>Daiichi Sankyo Inc</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">David</FirstName>
        <LastName>Leung</LastName>
        <Affiliation>Daiichi Sankyo Inc</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Bob T.</FirstName>
        <LastName>Li</LastName>
        <Affiliation>Thoracic Oncology and Early Drug Development Service, Global Research Program, Memorial Sloan Kettering Cancer Center</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Importance  Brain metastases reduce overall survival rates of patients with non&#8211;small cell lung cancer (NSCLC); patients with epidermal growth factor receptor 2 (ERBB2 [formerly HER2])&#8211;mutant NSCLC are more likely to have baseline brain metastases. Trastuzumab deruxtecan (T-DXd) is an approved ERBB2-directed treatment for previously treated unresectable or metastatic ERBB2-mutant NSCLC.&lt;br&gt;
Objective  To assess the clinical effectiveness and safety of T-DXd 5.4 mg/kg and 6.4 mg/kg doses in patients with previously treated ERBB2-mutant metastatic NSCLC with or without untreated or previously treated stable brain metastases.&lt;br&gt;
Design, Setting, and Participants  This post hoc secondary analysis pooled patients from the DESTINY-Lung01 (data cutoff date: December 3, 2021) and DESTINY-Lung02 (data cutoff date: December 23, 2022) clinical trials by T-DXd dose (5.4 mg/kg and 6.4 mg/kg). DESTINY-Lung01 was a multicenter, open-label, 2-cohort, nonrandomized phase 2 study, while DESTINY-Lung02 was a dose-blinded, multicenter, 2-cohort, randomized phase 2 study. Participants had a previously treated ERBB2-mutant metastatic NSCLC with or without untreated or previously treated stable brain metastases at baseline. All statistical analyses were performed from April 2023 to October 2024.&lt;br&gt;
Intervention  Patients received a T-DXd dose of either 5.4 mg/kg or 6.4 mg/kg intravenously every 3 weeks.&lt;br&gt;
Main Outcome and Measure  Systemic and intracranial effectiveness by blinded independent central review using RECIST (Response Evaluation Criteria in Solid Tumors) version 1.1, sites of progression, and safety.&lt;br&gt;
Results  This analysis included 102 patients in the T-DXd 5.4-mg/kg dose group (65 females [64%]; median [range] age, 57.5 [37.0-83.0] years and 59.5 [30.0-79.0] years in patients with and without brain metastases, respectively) and 141 patients in the T-DXd 6.4-mg/kg dose group (94 females [67%]; median [range] age, 62.5 [29.0-88.0] years and 59.0 [27.0-83.0] years in patients with and without brain metastases, respectively). In each group, 31% (32 of 102) and 38% (54 of 141) of patients, respectively, had baseline brain metastases and 53% (17 of 32) and 44% (24 of 54), respectively, received prior brain metastasis treatment. In patients with and without brain metastases, systemic confirmed objective response rates (ORRs) were 47% (15 of 32; 95% CI, 29%-65%) and 50% (35 of 70; 95% CI, 38%-62%), respectively, with the T-DXd 5.4-mg/kg dose, and 50% (27 of 54; 95% CI, 36%-64%) and 59% (51 of 87; 95% CI, 48%-69%) with the T-DXd 6.4-mg/kg dose. Median progression-free survival was 7.1 (95% CI, 5.5-9.7) months in the T-DXd 5.4-mg/kg dose group and 7.1 (95% CI, 4.5-9.6) months in the T-DXd 6.4-mg/kg dose group of patients with baseline brain metastases. Among patients with measurable baseline brain metastases, intracranial confirmed ORRs were 50% (7 of 14; 95% CI, 23%-77%) with the T-DXd 5.4-mg/kg dose and 30% (9 of 30; 95% CI, 15%-49%) with the T-DXd 6.4-mg/kg dose. At both doses, the safety profile of T-DXd was generally manageable, regardless of baseline brain metastases, favoring the T-DXd 5.4 mg/kg dose.&lt;br&gt;
Conclusions and Relevance  In this secondary analysis, T-DXd at the approved dose of 5.4 mg/kg showed antitumor activity in patients with previously treated ERBB2-mutant metastatic NSCLC with or without brain metastases. This finding supports T-DXd 5.4 mg/kg use in this population.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList/>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Elsevier BV</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1556-0864</Issn>
      <Volume>20</Volume>
      <Issue>12</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Final Analysis Results and Patient-Reported Outcomes From DESTINY-Lung02―A Dose-Blinded, Randomized, Phase 2 Study of Trastuzumab Deruxtecan in Patients With HER2-Mutant Metastatic NSCLC</ArticleTitle>
    <FirstPage LZero="delete">1814</FirstPage>
    <LastPage>1828</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Pasi A.</FirstName>
        <LastName>J&#228;nne</LastName>
        <Affiliation>Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yasushi</FirstName>
        <LastName>Goto</LastName>
        <Affiliation>Department of Thoracic Oncology, National Cancer Central Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshio</FirstName>
        <LastName>Kubo</LastName>
        <Affiliation>Center for Clinical Oncology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kiichiro</FirstName>
        <LastName>Ninomiya</LastName>
        <Affiliation>Center for Comprehensive Genomic Medicine, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Sang-We</FirstName>
        <LastName>Kim</LastName>
        <Affiliation>Oncology Department, Asan Medical Center, Seoul, and University of Ulsan College of Medicine, Ulsan</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">David</FirstName>
        <LastName>Planchard</LastName>
        <Affiliation>Department of Medical Oncology, Thoracic Cancer Group, Gustave Roussy, and Faculty of Medicine, Paris-Saclay University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Myung-Ju</FirstName>
        <LastName>Ahn</LastName>
        <Affiliation>Department of Hematology and Oncology, Samsung Medical Center Sungkyunkwan, and University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Egbert</FirstName>
        <LastName>Smit</LastName>
        <Affiliation>Department of Pulmonary Diseases, Leiden University Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Adrianus</FirstName>
        <LastName>Johannes de Langen</LastName>
        <Affiliation>Department of Thoracic Oncology, Netherlands Cancer Institute</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Maurice</FirstName>
        <LastName>P&#233;rol</LastName>
        <Affiliation>Department of Medical Oncology, L&#233;on Berard Centre</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Elvire</FirstName>
        <LastName>Pons-Tostivint</LastName>
        <Affiliation>Centre Hospitalier Universitaire Nantes, Nantes University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Silvia</FirstName>
        <LastName>Novello</LastName>
        <Affiliation>Department of Oncology, University of Turin, Turin, and Azienda Ospedaliero-Universitaria San Luigi Gonzaga</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hidetoshi</FirstName>
        <LastName>Hayashi</LastName>
        <Affiliation>Department of Medical Oncology, Kindai University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Junichi</FirstName>
        <LastName>Shimizu</LastName>
        <Affiliation>Department of Thoracic Oncology, Aichi Cancer Center Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Dong-Wan</FirstName>
        <LastName>Kim</LastName>
        <Affiliation>Department of Internal Medicine, Seoul National University College of Medicine and Seoul National University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kaline</FirstName>
        <LastName>Pereira</LastName>
        <Affiliation>Daiichi Sankyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Fu-Chih</FirstName>
        <LastName>Cheng</LastName>
        <Affiliation>Daiichi Sankyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ayumi</FirstName>
        <LastName>Taguchi</LastName>
        <Affiliation>Daiichi Sankyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yingkai</FirstName>
        <LastName>Cheng</LastName>
        <Affiliation>Daiichi Sankyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kyle</FirstName>
        <LastName>Dunton</LastName>
        <Affiliation>Daiichi Sankyo UK</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ahmed</FirstName>
        <LastName>Ali</LastName>
        <Affiliation>Daiichi Sankyo Europe GmbH</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Koichi</FirstName>
        <LastName>Goto</LastName>
        <Affiliation>Department of Thoracic Oncology, National Cancer Center Hospital East</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Introduction: Trastuzumab deruxtecan (T-DXd) demonstrated strong and durable responses in patients with previously treated HER2 (ERBB2) mutant (HER2m) metastatic NSCLC (mNSCLC) in the DESTINY-Lung02 primary analysis (December 23, 2022, data cutoff). This final analysis evaluated T-DXd efficacy and safety after 8 additional months of follow-up, including clinically relevant subgroups and patient-reported outcomes.&lt;br&gt;
Methods: DESTINY-Lung02 was a randomized, dose-blinded, multicenter, phase 2 trial. Patients with previously treated HER2m mNSCLC were randomized 2:1 to receive T-DXd 5.4 or 6.4 mg/kg once every 3 weeks. Primary end point was confirmed objective response rate by blinded independent central review.&lt;br&gt;
Results: As of August 25, 2023, 102 and 50 patients had received T-DXd 5.4 or 6.4 mg/kg, respectively. Median follow-up (Q1&#8211;Q3) was 15.8 (8.2&#8211;20.7) months and 16.5 (9.4&#8211;20.8) months, respectively. Confirmed objective response rate (95% confidence interval) was 50.0% (51/102; 39.9%&#8211;60.1%) and 56.0% (28/50; 41.3%&#8211;70.0%), respectively. Safety profile was acceptable and generally manageable. Accordingly, median treatment duration (Q1&#8211;Q3) was 7.7 (3.7&#8211;14.4) months and 8.3 (2.8&#8211;13.1) months; drug-related grade 3 or higher treatment-emergent adverse events occurred in 39.6% (40/101) and 60.0% (30/50), with nausea most common (67.3% [68/101], 82.0% [41/50]). Adjudicated drug-related interstitial lung disease occurred in 14.9% (15/101) and 32.0% (16/50), mostly grade 1 or 2 with one grade 5 in each arm. Health-related quality of life was preserved for the duration of T-DXd treatment while sample size was sufficient for analysis, with no adverse effects on health-related quality of life observed at either dose.&lt;br&gt;
Conclusions: T-DXd demonstrated strong and durable responses at both doses, with no clinically significant changes in toxicity. The approved 5.4-mg/kg dose demonstrated a more favorable benefit-risk profile, including lower adjudicated drug-related interstitial lung disease incidence.&lt;br&gt;
ClinicalTrials.gov identifier: NCT04644237</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">HER2-directed therapy</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">HER2-mutant</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">HER2-targeted</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Non&#8211;small cell lung cancer</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Trastuzumab deruxtecan</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2168-8184</Issn>
      <Volume>17</Volume>
      <Issue>7</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>The Challenge of Diagnosing Scirrhous Gastric Cancer by Endoscopic Biopsy: A Case Report</ArticleTitle>
    <FirstPage LZero="delete">e87334</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Yuka</FirstName>
        <LastName>Ikeda</LastName>
        <Affiliation>Department of Internal Medicine, Clinic IkedaDepartment of Internal Medicine, Clinic Ikeda</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masaya</FirstName>
        <LastName>Iwamuro</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tadashi</FirstName>
        <LastName>Yoshino</LastName>
        <Affiliation>Department of Pathology, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takehiro</FirstName>
        <LastName>Tanaka</LastName>
        <Affiliation>Department of Pathology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Nobumasa</FirstName>
        <LastName>Ikeda</LastName>
        <Affiliation>Department of Internal Medicine, Clinic Ikeda</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Motoyuki</FirstName>
        <LastName>Otsuka</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Scirrhous gastric cancer, also known as linitis plastica, is a rare and aggressive subtype of gastric carcinoma that poses significant diagnostic challenges due to its submucosal infiltration and often normal-appearing mucosa. We report a case involving a 30-year-old Japanese woman who presented with a six-month history of epigastric pain and postprandial vomiting. Initial endoscopic examination revealed erythema and mucosal swelling, with limited antral distensibility and resistance during duodenal intubation. Despite 12 mucosal biopsies, histopathological examination revealed no evidence of malignancy. Given the strong clinical and endoscopic suspicion of scirrhous gastric cancer, additional deep sections and immunohistochemical staining were performed. These revealed scattered signet-ring cell carcinoma and poorly differentiated adenocarcinoma, with positive immunostaining for p53 and Ki67. The patient underwent total gastrectomy, and the diagnosis of scirrhous gastric cancer was confirmed on the resected specimen. This case highlights the importance of a high index of clinical suspicion, close collaboration between endoscopists and pathologists, and the utility of ancillary diagnostic tools, such as immunohistochemistry, in identifying subepithelial gastric malignancies that may be missed on conventional biopsy.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">endoscopic biopsy</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">esophagogastroduodenoscopy</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">immunohistochemistry</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">linitis plastica</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">scirrhous gastric cancer</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Wiley</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1347-9032</Issn>
      <Volume/>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Clinical and Genetic Landscape of Glioblastoma, IDH-Wildtype With FGFR Gene Family Alterations</ArticleTitle>
    <FirstPage LZero="delete"/>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Yasuhito</FirstName>
        <LastName>Kegoya</LastName>
        <Affiliation>Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshihiro</FirstName>
        <LastName>Otani</LastName>
        <Affiliation>Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryo</FirstName>
        <LastName>Mizuta</LastName>
        <Affiliation>Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryosuke</FirstName>
        <LastName>Ikemachi</LastName>
        <Affiliation>Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Mako</FirstName>
        <LastName>Kamiura</LastName>
        <Affiliation>Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Joji</FirstName>
        <LastName>Ishida</LastName>
        <Affiliation>Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shinichi</FirstName>
        <LastName>Toyooka</LastName>
        <Affiliation>Center for Comprehensive Genomic Medicine, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Daisuke</FirstName>
        <LastName>Ennishi</LastName>
        <Affiliation>Center for Comprehensive Genomic Medicine, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shuta</FirstName>
        <LastName>Tomida</LastName>
        <Affiliation>Center for Comprehensive Genomic Medicine, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shota</FirstName>
        <LastName>Tanaka</LastName>
        <Affiliation>Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Glioblastoma, isocitrate dehydrogenase wildtype (GBM, IDH-wt), is a highly aggressive brain tumor with a poor prognosis. Alterations in the fibroblast growth factor receptor (FGFR) gene family―such as FGFR::TACC fusions and FGFR1 mutations―have emerged as potential therapeutic targets; however, their clinical and genetic features in GBM, IDH-wt remain unclear. We analyzed 1076 GBM, IDH-wt cases using comprehensive genomic profiling data from the Center for Cancer Genomics and Advanced Therapeutics (C-CAT) database in Japan. FGFR alterations were detected in 8.0% of patients, including FGFR::TACC fusions (3.3%) and FGFR1 mutations (2.9%). The FGFR::TACC fusion-positive group was older at diagnosis and showed higher frequencies of TERT promoter mutation and MDM2 amplification, and lower frequencies of EGFR amplification and TP53 mutation, compared with the fusion-negative group. The FGFR1 mutation-positive group was enriched for ATRX, NF1, and PIK3CA mutations and had significantly fewer TERT promoter and PTEN mutations, compared with the mutation-negative group. No significant differences in overall survival were observed, although both groups tended to have longer median overall survival compared with their respective negative groups. This study represents the largest genomic cohort to date of FGFR alterations in GBM, IDH-wt. FGFR::TACC fusion-positive and FGFR1 mutation-positive GBMs exhibited distinct genetic profiles, highlighting the clinical relevance of molecular subclassification and providing insight for future therapeutic strategies.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">comprehensive genomic profiling</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">copy number alteration</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">FGFR</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">glioblastoma</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">single-nucleotide variant</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0916-9636</Issn>
      <Volume/>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Distinct associations of blood pressure phenotypes with subclinical cerebrovascular disease and coronary artery calcification in Japanese men</ArticleTitle>
    <FirstPage LZero="delete"/>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Nomin</FirstName>
        <LastName>Bayaraa</LastName>
        <Affiliation>NCD Epidemiology Research Center, Shiga University of Medical Science</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuichiro</FirstName>
        <LastName>Yano</LastName>
        <Affiliation>NCD Epidemiology Research Center, Shiga University of Medical Science</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Aya</FirstName>
        <LastName>Kadota</LastName>
        <Affiliation>NCD Epidemiology Research Center, Shiga University of Medical Science</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Nazar Mohd</FirstName>
        <LastName>Azahar</LastName>
        <Affiliation/>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tran Ngoc Hoang</FirstName>
        <LastName>Phap</LastName>
        <Affiliation>National Institutes of Biomedical Innovation, Health and Nutrition</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takashi</FirstName>
        <LastName>Hisamatsu</LastName>
        <Affiliation>Department of Public Health, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Keiko</FirstName>
        <LastName>Kondo</LastName>
        <Affiliation>NCD Epidemiology Research Center, Shiga University of Medical Science</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Sayuki</FirstName>
        <LastName>Torii</LastName>
        <Affiliation>NCD Epidemiology Research Center, Shiga University of Medical Science</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Akira</FirstName>
        <LastName>Fujiyoshi</LastName>
        <Affiliation>Department of Hygiene, School of Medicine, Wakayama Medical University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takayoshi</FirstName>
        <LastName>Ohkubo</LastName>
        <Affiliation>Department of Hygiene and Public Health, Teikyo University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Akihiko</FirstName>
        <LastName>Shiino</LastName>
        <Affiliation>Molecular Neuroscience Research Center, Shiga University of Medical Science</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuhiko</FirstName>
        <LastName>Nozaki</LastName>
        <Affiliation>Department of Neurosurgery, Shiga University of Medical Science</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Katsuyuki</FirstName>
        <LastName>Miura</LastName>
        <Affiliation>NCD Epidemiology Research Center, Shiga University of Medical Science</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Hypertension, encompassing white-coat hypertension (WCH), masked hypertension (MH), and sustained hypertension (SH), is an established risk factor for cardiovascular diseases (CVDs), including atherosclerosis. However, among the general population, findings on which target organ is affected by the different phenotypes of hypertension remain unclear. In this community-based observational study of Shiga Epidemiological Study of Subclinical Atherosclerosis, 740 Japanese men underwent brain magnetic resonance imaging to assess the presence of lacunar infarction, white-matter hyperintensities, microbleeds, and intracranial artery stenosis (ICAS) between 2012 and 2015. They also underwent office blood pressure (BP) measurements, home BP monitoring for at least five consecutive days, and coronary artery calcification (CAC) assessments between 2010 and 2014. The final analysis included 686 participants without a history of CVDs. Of the 686 participants, the mean age (&#8201;±&#8201;SD) was 68.0 (&#8201;±&#8201;8.3) years, and 39.3% were taking antihypertensive medication. In multivariable-adjusted models, each of WCH, MH, and SH was significantly associated with a higher risk of microbleeds compared to normotension. However, the association of WCH with microbleeds was evident only among those on antihypertensive medication (adjusted odds ratio [OR] 6.75 [95% CI 1.83&#8211;24.86]) and absent in those not on such medication (adjusted OR 1.20 [95% CI 0.31&#8211;4.73]). SH was associated with lacunar infarction, ICAS, and CAC. Among Japanese men, WCH, MH, SH were associated with subclinical cerebrovascular diseases, whereas only SH was associated with CAC. Moreover, any elevated BP phenotype increased the risk of microbleeds. Our findings suggest that different hypertension phenotypes distinctly affect target organs, particularly the brain and heart.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Blood pressure phenotypes</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Morning hypertension</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Home blood pressure</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Subclinical cerebrovascular disease</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Coronary artery calcification</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1345-2630</Issn>
      <Volume/>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Tabtoxin biosynthetic gene cluster in Pseudomonas syringae pv. tabaci 6605 genomic island 1 (GI-1Pta6605) is required for severe disease symptoms</ArticleTitle>
    <FirstPage LZero="delete"/>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Kotomi</FirstName>
        <LastName>Kunishi</LastName>
        <Affiliation>The Graduate School of Environmental, Life, Natural Science and Technology, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Norika</FirstName>
        <LastName>Fujisawa</LastName>
        <Affiliation>The Graduate School of Environmental, Life, Natural Science and Technology, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hidenori</FirstName>
        <LastName>Matsui</LastName>
        <Affiliation>The Graduate School of Environmental, Life, Natural Science and Technology, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Nanami</FirstName>
        <LastName>Sakata</LastName>
        <Affiliation>The Graduate School of Environmental, Life, Natural Science and Technology, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshiteru</FirstName>
        <LastName>Noutoshi</LastName>
        <Affiliation>The Graduate School of Environmental, Life, Natural Science and Technology, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuhiro</FirstName>
        <LastName>Toyoda</LastName>
        <Affiliation>The Graduate School of Environmental, Life, Natural Science and Technology, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuki</FirstName>
        <LastName>Ichinose</LastName>
        <Affiliation>The Graduate School of Environmental, Life, Natural Science and Technology, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>One of the genomic islands in Pseudomonas syringae pv. tabaci 6605 (GI-1Pta6605) has been identified as a pathogenicity island required for virulence because the deletion almost completely eliminated disease symptoms in inoculation tests at 4&#8201;×&#8201;105 CFU/ml. GI-1Pta6605 contains four cargo regions (CRs) named CR-1 to CR-4. The &#8710;CR-4 mutant did not produce tabtoxin like &#8710;GI-1 and disease symptoms did not develop in tobacco. However, it grew, although to a lesser extent than the wild-type strain. These results indicate that the tabtoxin biosynthetic gene cluster in GI-1 is required for virulence but not for establishment of compatibility.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">GI-1Pta6605</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Pathogenicity island</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Pseudomonas syringae</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Tabtoxin</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2045-2322</Issn>
      <Volume>16</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Calcium ions play a critical role in calcification of Corynebacterium matruchotii</ArticleTitle>
    <FirstPage LZero="delete">4591</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Naoko</FirstName>
        <LastName>Ohara</LastName>
        <Affiliation>Department of Operative Dentistry, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Midori</FirstName>
        <LastName>Ogawa</LastName>
        <Affiliation>Department of Microbiology, School of Medicine, University of Occupational and Environmental Health</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Katsuki</FirstName>
        <LastName>Takebe</LastName>
        <Affiliation>Department of Dental Pharmacology, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ikue</FirstName>
        <LastName>Tosa</LastName>
        <Affiliation>Department of Oral Microbiology, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Serina</FirstName>
        <LastName>Ono</LastName>
        <Affiliation>Department of Operative Dentistry, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Mitsumasa</FirstName>
        <LastName>Saito</LastName>
        <Affiliation>Department of Microbiology, School of Medicine, University of Occupational and Environmental Health</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Naoya</FirstName>
        <LastName>Ohara</LastName>
        <Affiliation>Department of Oral Microbiology, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Dental calculus is a hardened deposit composed of calcium phosphate precipitated within dental plaque. While the involvement of dental calculus in the progression of periodontal disease is well established, many aspects of its formation process remain poorly understood. In this study, we focused on Corynebacterium matruchotii, a key bacterium involved in dental calculus formation, and investigated the role of calcium ions in calcification, as well as the associated internal and external changes in the bacterium through long-term observation. In the absence of calcium ions, no intracellular calcification was observed, and the lipid bilayer with the formation of holes in bacterial body was evident. In contrast, in the presence of calcium ions, lipid bilayer remained intact, and intracellular needle- and plate- like crystals were formed. Furthermore, calcified C. matruchotii showed increased flocculation compared to non-calcified C. matruchotii. These results indicate that the influx of calcium ions is essential for intracellular calcification. Calcium ions entry appears to reinforce the integrity of the lipid bilayer, providing a stable intracellular environment conductive to calcification. Moreover, calcified C. matruchotii may contribute to the nucleation of dental calculus by forming aggregates composed of both bacterial components and calcified material.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Calcification</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Corynebacterium matruchotii</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Dental calculus</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Calcium ions</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1123-6337</Issn>
      <Volume>29</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Safety and feasibility of D3 lymph node dissection in oldest-old patients undergoing colorectal cancer surgery: a multi-institutional, retrospective analysis</ArticleTitle>
    <FirstPage LZero="delete">146</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">R.</FirstName>
        <LastName>Inada</LastName>
        <Affiliation>Department of Surgery, Kochi Health Sciences Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">F.</FirstName>
        <LastName>Teraishi</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">T.</FirstName>
        <LastName>Mitsuhashi</LastName>
        <Affiliation>Center for Innovative Clinical Medicine, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">S.</FirstName>
        <LastName>Takanaga</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">T.</FirstName>
        <LastName>Toshima</LastName>
        <Affiliation>Department of Surgery, Kagawa Rosai Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">T.</FirstName>
        <LastName>Ohtani</LastName>
        <Affiliation>Department of Surgery, Saiseikai Okayama Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">R.</FirstName>
        <LastName>Yoshida</LastName>
        <Affiliation>Department of Surgery, Okayama Rosai Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">N.</FirstName>
        <LastName>Hori</LastName>
        <Affiliation>Department of Surgery, Tottori Municipal Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">K.</FirstName>
        <LastName>Shigemitsu</LastName>
        <Affiliation>Department of Surgery, Tsuyama Chuo Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">S.</FirstName>
        <LastName>Yamamoto</LastName>
        <Affiliation>Department of Surgery, Okayama City Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">T.</FirstName>
        <LastName>Kubota</LastName>
        <Affiliation>Department of Surgery, Kobe Red Cross Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Y.</FirstName>
        <LastName>Okano</LastName>
        <Affiliation>Department of Surgery, Onomichi City Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">T.</FirstName>
        <LastName>Nobuhisa</LastName>
        <Affiliation>Department of Surgery, Himeji Red Cross Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">F.</FirstName>
        <LastName>Taniguchi</LastName>
        <Affiliation>Department of Surgery, National Hospital Organization Iwakuni Clinical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">W.</FirstName>
        <LastName>Ishikawa</LastName>
        <Affiliation>Department of Surgery, Fukuyama City Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">R.</FirstName>
        <LastName>Shoji</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">T.</FirstName>
        <LastName>Matsuda</LastName>
        <Affiliation>Department of Surgery, Matsuda Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">T.</FirstName>
        <LastName>Umeoka</LastName>
        <Affiliation>Department of Surgery, Matsuyama City Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">T.</FirstName>
        <LastName>Fujiwara</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N"/>
        <LastName>Setouchi Colorectal Neoplasm Registration Study Group Collaborators</LastName>
        <Affiliation/>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Background Colorectal cancer (CRC) is a significant health burden, with lymph node dissection (LND) playing a critical role in staging and guiding treatment. However, the optimal extent of LND for the oldest-old population (aged&#8201;&#8805;&#8201;90 years) remains undefined because of insufficient targeted clinical data. This study aimed to compare the short-term outcomes of D3 versus non-D3 LND in Stage II&#8211;III CRC in oldest-old patients.&lt;br&gt;
Methods This retrospective cohort study utilized data from the Setouchi Colorectal Neoplasm Registration database, including 282 oldest-old patients with CRC treated between 2011 and 2022. Patients were stratified into D3 and non-D3 LND groups, with inverse-probability-weighted regression adjustment implemented to address potential confounding factors. Postoperative complications and hospital stays were analyzed using regression models and descriptive statistics.&lt;br&gt;
Results D3 LND resulted in significantly higher lymph node harvests in both Stage II and Stage III patients (p&#8201;&lt;&#8201;0.01). There were no significant differences in overall or major postoperative complications between D3 and non-D3 groups. Hospital stays were comparable for Stage II patients but shorter for Stage III patients in the D3 group (p&#8201;&lt;&#8201;0.01). Complication rates ranged from 28% to 47.7%, with surgical site infections and pneumonia being the most common.&lt;br&gt;
Conclusions D3 LND can be safely performed in oldest-old patients with CRC without increasing postoperative complications or extending hospital stays. These findings support the feasibility of extensive LND in this age gr</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Lymph node dissection</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Colorectal cancer</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Oldest-old patients</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Postoperative complication</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2168-8184</Issn>
      <Volume>17</Volume>
      <Issue>11</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>A Case of Psoas Abscess Diagnosed With Oral Bacteria as the Causative Pathogen</ArticleTitle>
    <FirstPage LZero="delete">e97584</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Koki</FirstName>
        <LastName>Umemori</LastName>
        <Affiliation>Oral and Maxillofacial Surgery, Okayama University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kyoichi</FirstName>
        <LastName>Obata</LastName>
        <Affiliation>Oral and Maxillofacial Surgery, Okayama University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Mayumi</FirstName>
        <LastName>Yao</LastName>
        <Affiliation>Dentistry and Dental Surgery, Tsuyama Central Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Koji</FirstName>
        <LastName>Fujita</LastName>
        <Affiliation>General Internal Medicine and Infectious Diseases, Tsuyama Central Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Soichiro</FirstName>
        <LastName>Ibaragi</LastName>
        <Affiliation>Oral and Maxillofacial Surgery, Okayama University Graduate School of Medicine</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>We report a rare case of a psoas abscess in an 87-year-old woman, in which oral commensal bacteria may have disseminated hematogenously from a chronic oral infection site and served as the causative pathogens. The patient presented with persistent left buttock pain, fever, and swelling, and imaging revealed a fracture of the left iliac bone with an associated psoas abscess. Bacterial cultures identified Streptococcus oralis and Pseudomonas aeruginosa. Her symptoms improved following antibiotic therapy and CT-guided drainage. Although the presence of P. aeruginosa in the oral cavity is generally considered transient, it has been isolated from the oral cavities of elderly and immunocompromised individuals. In the absence of lacerations or other direct portals of entry, and considering the identification of both pathogens, the oral cavity was regarded as the most likely source of infection. This case highlights the importance of correlating culture results with the most probable source of infection to improve the prognosis of systemic infections.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">hematogenous spread</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">oral diseases</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">oral health care</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">pseudomonas aeruginosa</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">psoas muscle abscess</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">streptococcus oralis</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1746-6148</Issn>
      <Volume>22</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Genetic and phenotypic identities of Staphylococcus coagulans isolated from pustules of dogs with superficial bacterial folliculitis</ArticleTitle>
    <FirstPage LZero="delete">98</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Takafumi</FirstName>
        <LastName>Osumi</LastName>
        <Affiliation>Animal Medical Center, Faculty of Agriculture, Tokyo University of Agriculture and Technology</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuuki</FirstName>
        <LastName>Shinomiya</LastName>
        <Affiliation>Department of Veterinary Medicine, Faculty of Agriculture, Tokyo University of Agriculture and Technology</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Thamonwan</FirstName>
        <LastName>Wanganuttara</LastName>
        <Affiliation>Department of Bacteriology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ichiro</FirstName>
        <LastName>Imanishi</LastName>
        <Affiliation>Kimberly and Eric J. Waldman Department of Dermatology, Icahn School of Medicine at Mount Sinai</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yotaro</FirstName>
        <LastName>Shimazaki</LastName>
        <Affiliation>Animal Medical Center, Faculty of Agriculture, Tokyo University of Agriculture and Technology</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Keita</FirstName>
        <LastName>Iyori</LastName>
        <Affiliation>1sec Co. Ltd.</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoichi</FirstName>
        <LastName>Toyoda</LastName>
        <Affiliation>1sec Co. Ltd.</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kaori</FirstName>
        <LastName>Ide</LastName>
        <Affiliation>Animal Medical Center, Faculty of Agriculture, Tokyo University of Agriculture and Technology</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Jumpei</FirstName>
        <LastName>Uchiyama</LastName>
        <Affiliation>Department of Bacteriology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Koji</FirstName>
        <LastName>Nishifuji</LastName>
        <Affiliation>Animal Medical Center, Faculty of Agriculture, Tokyo University of Agriculture and Technology</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Background Staphylococcus coagulans, formerly called Staphylococcus schleiferi subsp. coagulans is the second most common isolate from skin lesions of dogs with superficial bacterial folliculitis (SBF). However, the clinical significance of S. coagulans in pustules of canine SBF remains uncertain. This study aimed to investigate the prevalence and genotypic and phenotypic diversity of S. coagulans isolated from pustules in two dogs with SBF.&lt;br&gt;
Results Two dogs with SBF were included in this study. S. schleiferi/coagulans was isolated as the sole organism from three pustules in case #1, whereas it coexisted with S. pseudintermedius in two of seven pustules in case #2. S. pseudintermedius was the sole organism in the remaining five pustules in case #2. Whole genome sequences revealed that all isolates tested were annotated as S. coagulans. The isolates from the same pustules exhibited identical genotypic and phenotypic profiles, indicating clonal multiplication. S. coagulans isolated from different pustules exhibited similar yet distinct genotypic and phenotypic profiles.&lt;br&gt;
Conclusions S. coagulans with identical genetic and phenotypic profiles can be identified as the sole pathogen or coexist with S. pseudintermedius in the pustules of the same dogs with SBF.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Staphylococcus coagulans</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Staphylococcus pseudintermedius</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Dog</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Superficial bacterial folliculitis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Antimicrobial susceptibility</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Disk diffusion test</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1757-2215</Issn>
      <Volume>19</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Pan-cancer profiling links C1orf50 to DNA repair and immune modulation in ovarian cancer</ArticleTitle>
    <FirstPage LZero="delete">13</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Anna</FirstName>
        <LastName>Rogachevskaya</LastName>
        <Affiliation>Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yusuke</FirstName>
        <LastName>Otani</LastName>
        <Affiliation>Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Akira</FirstName>
        <LastName>Ohtsu</LastName>
        <Affiliation>Harvard Medical School</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Vanessa D.</FirstName>
        <LastName>Chin</LastName>
        <Affiliation>UMass Chan Medical School, UMass Memorial Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tirso</FirstName>
        <LastName>Pe&#241;a</LastName>
        <Affiliation>Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Seiji</FirstName>
        <LastName>Arai</LastName>
        <Affiliation>Department of Urology, Gunma University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shinichi</FirstName>
        <LastName>Toyooka</LastName>
        <Affiliation>Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Atsushi</FirstName>
        <LastName>Fujimura</LastName>
        <Affiliation>Department of Molecular Physiology, Faculty of Medicine, Graduate School of Medicine, Kagawa University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Atsushi</FirstName>
        <LastName>Tanaka</LastName>
        <Affiliation>Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Background C1orf50 encodes a small, evolutionarily conserved protein, the function of which remains unclear. Its significance across various human cancers, particularly its specific role in ovarian cancer within an immunogenomic context, is not yet fully understood. Utilizing The Cancer Genome Atlas and single-cell RNA sequencing (scRNA-seq) public datasets, we conducted a comprehensive profiling of C1orf50 across multiple cancer types, with a particular focus on ovarian cancer, to investigate its associations with copy-number status, genomic instability, tumor programs, and the immune microenvironment.&lt;br&gt;
Results Across cancer types, copy-number gain or amplification of C1orf50 was most frequent in ovarian cancer and closely tracked with higher messenger RNA levels. Higher C1orf50 expression was associated with a greater tumor mutational burden and homologous recombination deficiency, as indicated by gene-set patterns that suggested heightened cell-cycle and cellular stress responses accompanied by reduced oxidative phosphorylation, enrichment of regulatory T cells, and depletion of resting memory CD4 T cells. In ovarian cancer, focal events at chromosome 1p34.2 were accompanied by stepwise increases in C1orf50 expression by clinical stage and were linked to higher tumor mutational burden, homologous recombination deficiency, and greater loss of heterozygosity, together with more frequent gene alterations in BRCA1 or BRCA2. Immune composition clustered into profiles consistent with an immunosuppressive context in tumors with higher C1orf50 expression. The scRNA-seq data further revealed that cancer cells enhanced immune-suppressive interactions with various immune cell populations and diminished antigen-presentation signals. Analyses of genomic instability in ovarian cancer suggested mutational processes compatible with base-substitution patterns associated with cytidine deaminase activity and with insertion-deletion patterns characteristic of homologous recombination failure, while transcript-level patterns pointed to a broad downshift of canonical DNA repair activity with apparent compensatory adjustments in related pathways rather than a uniform change in any single pathway.&lt;br&gt;
Conclusions The overexpression of C1orf50 characterizes an aggressive immunogenomic phenotype in ovarian cancer, distinguished by genomic instability, impaired DNA repair mechanisms, and extensive immunosuppression. These findings indicate that C1orf50 warrants consideration as a potential biomarker and a prospective target for therapeutic investigation. Furthermore, they advocate for the progression to prospective validation and functional studies to ascertain its clinical significance.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">C1orf50</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Pan-cancer analysis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">DNA repair</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Gene expression</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Tumor microenvironment</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Immune evasion</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Single-cell RNA-seq</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1546-0096</Issn>
      <Volume>24</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>TeMPRA: advancing continuing professional development in pediatric rheumatology in Japan</ArticleTitle>
    <FirstPage LZero="delete"/>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Hiroyuki</FirstName>
        <LastName>Wakiguchi</LastName>
        <Affiliation>Division of General Pediatrics and Emergency Medicine, Department of Pediatrics, Oita University Faculty of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kunio</FirstName>
        <LastName>Hashimoto</LastName>
        <Affiliation>Department of Pediatrics, Nagasaki University Graduate School of Biomedical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masato</FirstName>
        <LastName>Yashiro</LastName>
        <Affiliation>Department of Pediatrics, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kenichi</FirstName>
        <LastName>Nishimura</LastName>
        <Affiliation>Department of Pediatrics, Yokohama City University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takasuke</FirstName>
        <LastName>Ebato</LastName>
        <Affiliation>Department of Pediatrics, Kitasato University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Keiji</FirstName>
        <LastName>Akamine</LastName>
        <Affiliation>Department of Nephrology and Rheumatology, Tokyo Metropolitan Children’s Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoji</FirstName>
        <LastName>Uejima</LastName>
        <Affiliation>Division of Infectious Diseases and Immunology, Saitama Children’s Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomomi</FirstName>
        <LastName>Sato</LastName>
        <Affiliation>Clinical Education Center for Physicians, Shiga University of Medical Science</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuichi</FirstName>
        <LastName>Yamasaki</LastName>
        <Affiliation>Department of Pediatrics, Kagoshima University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Junko</FirstName>
        <LastName>Yasumura</LastName>
        <Affiliation>Department of Pediatrics, Hiroshima Prefectural Hospital Organization Futabanosato Prefectural Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Fumiko</FirstName>
        <LastName>Okazaki</LastName>
        <Affiliation>Department of Pediatrics, Yamaguchi University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshitaka</FirstName>
        <LastName>Kizawa</LastName>
        <Affiliation>Department of Pediatrics, Japan Community Health Care Organization Sapporo Hokushin Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryuhei</FirstName>
        <LastName>Yasuoka</LastName>
        <Affiliation>Department of Pediatrics, Hamamatsu University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomoaki</FirstName>
        <LastName>Ishikawa</LastName>
        <Affiliation>Department of Pediatrics, Nara Medical University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takeshi</FirstName>
        <LastName>Yamamoto</LastName>
        <Affiliation>Department of Pediatrics, Chiba University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuji</FirstName>
        <LastName>Fujita</LastName>
        <Affiliation>Department of Pediatrics, Dokkyo Medical University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Naohiro</FirstName>
        <LastName>Itoh</LastName>
        <Affiliation>Department of Pediatrics, Faculty of Medical Sciences, University of Fukui</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Asami</FirstName>
        <LastName>Takasaki</LastName>
        <Affiliation>Department of Pediatrics, School of Medicine, University of Toyama</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Nodoka</FirstName>
        <LastName>Sakurai</LastName>
        <Affiliation>Department of Pediatrics, NTT East Medical Center Sapporo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuo</FirstName>
        <LastName>Suzuki</LastName>
        <Affiliation>Suzuki Kids Clinic</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tasuku</FirstName>
        <LastName>Tamai</LastName>
        <Affiliation>Division of General Pediatrics and Emergency Medicine, Department of Pediatrics, Oita University Faculty of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Naoki</FirstName>
        <LastName>Hirano</LastName>
        <Affiliation>Department of Public Health and Epidemiology, Faculty of Medicine, Oita University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Nami</FirstName>
        <LastName>Okamoto</LastName>
        <Affiliation>Department of Pediatrics, Osaka Rosai Hospital, Japan Organization of Occupational Health and Safety</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masaki</FirstName>
        <LastName>Shimizu</LastName>
        <Affiliation>Department of Pediatrics, Perinatal and Maternal Medicine, Graduate School of Medical and Dental Sciences, Institute of Science Tokyo</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Background In the context of the global shortage of pediatric rheumatologists, mid-career specialists who can play key roles in regional education, research, and clinical practice have become increasingly important. In Japan, the Team of Mid-career Pediatric Rheumatologists Alliance (TeMPRA) was founded in 2014 to support continuing professional development (CPD) and foster collaboration among mid-career pediatric rheumatologists. The aim of this study was to characterize the current status and future perspectives of the TeMPRA members.&lt;br&gt;
Methods In 2024, a cross-sectional, web-based survey was conducted among all 37 active members of the TeMPRA across Japan. Data were collected on career trajectories, educational roles, research activities, clinical practices, and international engagement. Categorical variables were compared using appropriate statistical tests, with a significance level of 0.05.&lt;br&gt;
Results Responses were obtained from 35 members (response rate: 95%). Most respondents (71%) were affiliated with university hospitals, and 60% had&#8201;&gt;&#8201;10 years of experience in pediatric rheumatology. Compared with those working in community hospitals, respondents affiliated with university hospitals were significantly more likely to be involved in research activities (50% vs. 0%, P&#8201;=&#8201;0.0261) and global professional contributions (88% vs. 0%, P&#8201;&lt;&#8201;0.0001). Overall, 54% of respondents were engaged in teaching students or early-career pediatric rheumatologists, while 43% were involved in clinical or basic research, most commonly focusing on juvenile idiopathic arthritis and systemic lupus erythematosus. Collectively, respondents were responsible for the care of 1,677 children with pediatric rheumatic diseases. While all respondents reported willingness to contribute to pediatric rheumatology at the regional level, 94% and 71% reported willingness to contribute at the national and global levels, respectively.&lt;br&gt;
Conclusions This nationwide survey highlights the substantial educational roles, research activities, and clinical practices of mid-career pediatric rheumatologists in Japan and suggests that the TeMPRA framework can serve as a valuable model for supporting CPD and workforce sustainability. Similar alliance-based approaches may be applicable in other countries facing comparable challenges in pediatric rheumatology.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Child</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Education</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Juvenile idiopathic arthritis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Practice</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Rheumatic diseases</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Systemic lupus erythematosus</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Team of mid-career pediatric rheumatologists alliance</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Institute of Electrical and Electronics Engineers (IEEE)</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2644-1349</Issn>
      <Volume>6</Volume>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Ultrafast Time-Compressive CMOS Image Sensors Based on Multitap Charge Modulators for Filming Light-In Flight</ArticleTitle>
    <FirstPage LZero="delete">47</FirstPage>
    <LastPage>60</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Keiichiro</FirstName>
        <LastName>Kagawa</LastName>
        <Affiliation>Research Institute of Electronics, Shizuoka University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Daisuke</FirstName>
        <LastName>Hayashi</LastName>
        <Affiliation>Graduate School of Integrated Science and Technology, Shizuoka University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Arashi</FirstName>
        <LastName>Takakura</LastName>
        <Affiliation>Faculty of Engineering, Shizuoka University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuto</FirstName>
        <LastName>Umeki</LastName>
        <Affiliation>Graduate School of Integrated Science and Technology, Shizuoka University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Michitaka</FirstName>
        <LastName>Yoshida</LastName>
        <Affiliation>Faculty of Environmental, Life, Natural Science and Technology, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Keita</FirstName>
        <LastName>Yasutomi</LastName>
        <Affiliation>Research Institute of Electronics, Shizuoka University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shoji</FirstName>
        <LastName>Kawahito</LastName>
        <Affiliation>Research Institute of Electronics, Shizuoka University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Youngcheol</FirstName>
        <LastName>Chae</LastName>
        <Affiliation>Department of Electrical and Electronic Engineering, Yonsei University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hajime</FirstName>
        <LastName>Nagahara</LastName>
        <Affiliation>D3 Center, The University of Osaka</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Ultrafast time-compressive CMOS image sensors based on multitap charge modulators can capture light-in flight using coded exposure masks on the focal plane. Transient images can then be reconstructed using iterative methods or deep learning models. Although the image sensor is based on indirect time-of-flight (ToF) image sensors, the reconstructed images are equivalent to those captured by direct ToF (D-ToF) image sensors. Important design parameters of the image sensor include the pixel block size and the number of taps of the charge modulator. Several constraints regarding the charge transfer of the multitap charge modulator, the hamming distance between exposure codes at adjacent timings, and the minimal time window duration must be considered when designing exposure codes. The influence of these factors on the fidelity of the reconstructed images is analyzed numerically. The results show that a pixel block size of 4×4 is optimal and that four or more taps are required for light detection and ranging (LiDAR) applications when 32 transient images of light-in flight are reconstructed. To demonstrate LiDAR in a scene with multipath interference, two objects were observed through a weakly diffusive sheet. The temporal resolution, as defined by the clock period of the exposure codes, was 1.65 ns. Multiple reflections were reconstructed using an iterative method (TVAL3) and a deep learning model (ADMM-Net). Although the waveforms of optical pulses reconstructed by TVAL3 are distorted, the amplitudes are more accurate. Conversely, although ADMM-Net reconstructs sharper optical pulses, the amplitudes are inaccurate. To achieve the shorter temporal resolution required for time-resolved diffuse optical tomography (DOT) and fluorescence lifetime imaging (FLIm), the feasibility of heterodyne compression was demonstrated through simulation.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">CMOS image sensor</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">compressive imaging</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">computational photography (CP)</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">multitap charge modulator</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">transient imaging</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1068-9265</Issn>
      <Volume>32</Volume>
      <Issue>12</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Mesenteric Route Superior Mesenteric Artery First Approach in Robot-Assisted Pancreatoduodenectomy</ArticleTitle>
    <FirstPage LZero="delete">8903</FirstPage>
    <LastPage>8905</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Kosei</FirstName>
        <LastName>Takagi</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Atene</FirstName>
        <LastName>Ito</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomokazu</FirstName>
        <LastName>Fuji</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuya</FirstName>
        <LastName>Yasui</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takeyoshi</FirstName>
        <LastName>Nishiyama</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tsubasa</FirstName>
        <LastName>Yanagihara</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshiyoshi</FirstName>
        <LastName>Fujiwara</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Background. The superior mesenteric artery (SMA) approach is crucial for the successful implementation of robot-assisted pancreatoduodenectomy (RPD). Herein, we present a novel technique, the mesenteric route SMA-first approach, for RPD.&lt;br&gt;
Patients and Methods. A 20-year-old woman with a 50 mm intraductal papillary mucinous neoplasm underwent RPD. As the tumor was large and located close to the mesenteric vessels, we developed the mesenteric route SMA-first approach.&lt;br&gt;
Results. Following the mesenteric Kocher maneuver, the mesenteric route SMA-first approach was applied. With appropriate retraction of the pancreatic head, dissection around the mesenteric vessels was performed and their branches were divided. The uncinate process dissection (PL, ph II) was performed via the mesenteric route. This approach facilitated dorsal dissection, particularly around the large tumor. After dissection of the hepatoduodenal ligament, the remaining pancreatic nerve plexus (PL ph I) was dissected. Finally, the pancreas was divided on the superior mesenteric vein, and the specimen was resected. Operative time was 390 min with minimal blood loss.&lt;br&gt;
Conclusions. The mesenteric route SMA-first approach enables uncinate process dissection via the mesenteric route. This technique may be a safe and feasible option for selected patients, such as nonobese individuals with a large pancreatic head tumor near major vessels.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Robotic pancreaticoduodenectomy</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Superior mesenteric artery approach</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Mesenteric route</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1435-2451</Issn>
      <Volume>410</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Robotic distal pancreatectomy using two-surgeon technique (TAKUMI-4): a technical note and initial outcomes</ArticleTitle>
    <FirstPage LZero="delete">171</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Kosei</FirstName>
        <LastName>Takagi</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomokazu</FirstName>
        <LastName>Fuji</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuya</FirstName>
        <LastName>Yasui</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshiyoshi</FirstName>
        <LastName>Fujiwara</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Purpose With the increasing use of minimally invasive distal pancreatectomy, the use of robotic distal pancreatectomy (RDP) is also increasing worldwide. Standardized surgical protocols are essential for safe implementation of RDP. In this study, we present our surgical protocol and initial outcomes of RDP using “two-surgeon technique”.&lt;br&gt;
Methods Our standard RDP protocol included a two-surgeon technique for cooperation, rationality, and education. Short-term outcomes of RDP were also investigated. This retrospective study included 77 consecutive patients who underwent RDP at our institution between April 2021 and January 2025.&lt;br&gt;
Results The median operative time, estimated blood loss, and postoperative hospital stay were 214 min (interquartile range [IQR], 176&#8211;253), 10 mL (IQR, 0&#8211;50), and 9 days (IQR, 8&#8211;10), respectively. A textbook outcome was achieved in 84.4% of patients. Moreover, superior outcomes of RDP (n&#8201;=&#8201;77) compared with those of laparoscopic distal pancreatectomy (n&#8201;=&#8201;62) were confirmed in this study.&lt;br&gt;
Conclusion Using the two-surgeon technique, we successfully standardized and introduced the RDP program. The two-surgeon technique can contribute to the safe introduction of RDP and expansion of the program.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Distal pancreatectomy</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Robotic surgery: minimally invasive surgery</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Training</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Outcomes</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0930-2794</Issn>
      <Volume>39</Volume>
      <Issue>5</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Impact of visceral fat area on surgical difficulty during robotic distal pancreatectomy (TAKUMI-2)</ArticleTitle>
    <FirstPage LZero="delete">3137</FirstPage>
    <LastPage>3145</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Kosei</FirstName>
        <LastName>Takagi</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Motohiko</FirstName>
        <LastName>Yamada</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomokazu</FirstName>
        <LastName>Fuji</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuya</FirstName>
        <LastName>Yasui</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takeyoshi</FirstName>
        <LastName>Nishiyama</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yasuo</FirstName>
        <LastName>Nagai</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Noriyuki</FirstName>
        <LastName>Kanehira</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshiyoshi</FirstName>
        <LastName>Fujiwara</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Background: Difficulty scoring systems (DSS) have been developed to quantify the surgical complexity of laparoscopic distal pancreatectomy (LDP). However, few studies have validated these systems in the context of robotic distal pancreatectomy (RDP). Moreover, the impact of body composition on RDP outcomes remains unexplored. This study aimed to investigate the risk factors of surgical difficulty in RDP, including body composition.&lt;br&gt;
Methods: This retrospective study included 72 consecutive patients who underwent RDP at our institution between April 2021 and October 2024. Using a modified DSS for LDP, patients were divided into three difficulty index groups. The association between the difficulty index and outcomes was investigated. Multivariate analyses were performed to identify risk factors associated with surgical difficulty (prolonged operative time) in RDP.&lt;br&gt;
Results: Patients were classified into three difficulty index groups: low (n&#8201;=&#8201;28), intermediate (n&#8201;=&#8201;25), and high (n&#8201;=&#8201;19). Operative time was significantly associated with the surgical index (P&#8201;=&#8201;0.01). Moreover, visceral fat area (VFA) was significantly correlated with operative time (r2&#8201;=&#8201;0.10, P&#8201;=&#8201;0.008). The multivariate analyses found that VFA (&#8805;&#8201;100 cm2) (odds ratio [OR] 5.03, 95% confidence interval [CI] 1.32&#8211;22.4, P&#8201;=&#8201;0.02), malignancy (OR 4.92, 95% CI 1.50&#8211;18.9, P&#8201;=&#8201;0.01), and pancreatic resection on the portal vein (OR 4.14, 95% CI 1.24&#8211;15.9, P&#8201;=&#8201;0.02) were significant risk factors associated with surgical difficulty.&lt;br&gt;
Conclusion: VFA could be a novel and useful factor for assessing the surgical difficulty associated with RDP.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Robotic distal pancreatectomy</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Difficulty score</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Visceral fat area</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1341-9625</Issn>
      <Volume>30</Volume>
      <Issue>7</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>How to report and discuss subgroup analyses in clinical practice guidelines? Evaluation procedure of the clinical and statistical relevancy</ArticleTitle>
    <FirstPage LZero="delete">1259</FirstPage>
    <LastPage>1267</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Kiichiro</FirstName>
        <LastName>Ninomiya</LastName>
        <Affiliation>Center for Comprehensive Genomic Medicine, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Satoru</FirstName>
        <LastName>Miura</LastName>
        <Affiliation>Department of Internal Medicine, Niigata Cancer Center Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuko</FirstName>
        <LastName>Oya</LastName>
        <Affiliation>Department of Respiratory Medicine and Allergy, Fujita Health University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomohiro</FirstName>
        <LastName>Sakamoto</LastName>
        <Affiliation>Division of Respiratory Medicine and Rheumatology, Department of Multidisciplinary Internal Medicine, Tottori University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kentaro</FirstName>
        <LastName>Tanaka</LastName>
        <Affiliation>Graduate School of Medical Sciences, Research Institute for Diseases of the Chest, Kyushu University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shunsuke</FirstName>
        <LastName>Teraoka</LastName>
        <Affiliation>Internal Medicine III, Wakayama Medical University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masahiro</FirstName>
        <LastName>Morise</LastName>
        <Affiliation>Department of Respiratory Medicine, Nagoya University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Satoshi</FirstName>
        <LastName>Morita</LastName>
        <Affiliation>Department of Biomedical Statistics and Bioinformatics, Graduate School of Medicine, Kyoto University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>The results of subgroup analyses of clinical trials are important reference information when considering the generalizability of a study treatment, i.e., providing the best treatment for each individual patient. The results of subgroup analyses are often presented in publications, etc. as forest plots focusing on patient backgrounds. However, it is important to fully understand and grasp some of the issues involved in subgroup analyses and to interpret the results carefully to apply them in clinical practice. Although the literature includes some reports on how subgroup analyses should be evaluated and handled for the purpose of establishing medical practice guidelines, most of the papers have mainly evaluated the reliability of subgroup analyses from a statistical perspective; few of them have incorporated clinical importance in their evaluations. Therefore, in December 2019, we established a Subgroup Analysis Review Committee consisting of oncologists specializing in lung cancer treatment and statistical experts among the members of the Guidelines Review Committee of the Japanese Lung Cancer Association, with the aim of appropriately reflecting subgroup analysis in Japanese lung cancer practice guidelines. We developed a new evaluation strategy to incorporate clinical aspects as well as reliability assessment. Specifically, on the basis of a clinical and statistical review of the problems with subgroup analyses presented as clinical trial results, we developed criteria and procedures to ensure consistency and fairness in the citation of clinical guidelines.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Subgroup analysis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Guideline</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Lung cancer</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2168-8184</Issn>
      <Volume>17</Volume>
      <Issue>6</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Retreatment With EGFR-Tyrosine Kinase Inhibitor After Disease Progression Following Gefitinib Induction and Chemoradiotherapy in EGFR-Mutant Stage III Non-small Lung Cancer: An Efficacy and Safety Analysis of the LOGIK0902/OLCSG0905 Study</ArticleTitle>
    <FirstPage LZero="delete">e86575</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Sho</FirstName>
        <LastName>Saeki</LastName>
        <Affiliation>Department of Respiratory Medicine, Kumamoto University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Katsuyuki</FirstName>
        <LastName>Hotta</LastName>
        <Affiliation>Center for Innovative Clinical Medicine, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shinya</FirstName>
        <LastName>Sakata</LastName>
        <Affiliation>Department of Respiratory Medicine, Kumamoto University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Naohiro</FirstName>
        <LastName>Oda</LastName>
        <Affiliation>Department of Respiratory Medicine, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Koji</FirstName>
        <LastName>Inoue</LastName>
        <Affiliation>Department of Respiratory Medicine, Kitakyushu Municipal Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomoki</FirstName>
        <LastName>Tamura</LastName>
        <Affiliation>Department of Respiratory Medicine, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryo</FirstName>
        <LastName>Toyozawa</LastName>
        <Affiliation>Department of Thoracic Oncology, National Hospital Organization Kyushu Cancer Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Daijiro</FirstName>
        <LastName>Harada</LastName>
        <Affiliation>Department of Thoracic Oncology, National Hospital Organization Shikoku Cancer Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kentaro</FirstName>
        <LastName>Tanaka</LastName>
        <Affiliation>Department of Respiratory Medicine, Graduate School of Medical Sciences, Kyushu University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Koji</FirstName>
        <LastName>Inoue</LastName>
        <Affiliation>Department of Respiratory Medicine, Ehime Prefectural Central Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshiyuki</FirstName>
        <LastName>Shioyama</LastName>
        <Affiliation>Radiation Oncology, Ion Beam Therapy Center, SAGA HIMAT Foundation</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kenichi</FirstName>
        <LastName>Gemba</LastName>
        <Affiliation>Department of Respiratory Medicine, Chugoku Central Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomonari</FirstName>
        <LastName>Sasaki</LastName>
        <Affiliation>Department of Radiation Oncology, Iizuka Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Akihiro</FirstName>
        <LastName>Bessho</LastName>
        <Affiliation>Department of Respiratory Medicine, Japanese Red Cross Okayama Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Junji</FirstName>
        <LastName>Kishimoto</LastName>
        <Affiliation>Center for Clinical and Translational Research, Kyushu University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kuniaki</FirstName>
        <LastName>Katsui</LastName>
        <Affiliation>Department of Radiology, Division of Radiation Oncology, Kawasaki Medical School</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Katsuyuki</FirstName>
        <LastName>Kiura</LastName>
        <Affiliation>Department of Respiratory Medicine, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kenji</FirstName>
        <LastName>Sugio</LastName>
        <Affiliation>Thoracic and Breast Surgery, Oita University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Background and objective: We had previously conducted a phase II study (LOGIK0902/OLCSG0905 study) involving the eight-week administration of gefitinib, followed by cisplatin-based chemoradiotherapy, to treat locally advanced, epidermal growth factor receptor (EGFR)-mutated, non-small cell lung cancer (NSCLC). Despite favorable overall survival outcomes, more than half of the patients relapsed after the protocol therapy, highlighting the need to clarify the clinical significance of retreatment with EGFR-tyrosine kinase inhibitors (TKIs). We investigated the efficacy and safety of EGFR-TKI retreatment after disease progression.&lt;br&gt;
Materials and methods: We included 14 patients who relapsed after the protocol treatment and received any type of EGFR-TKI as post-progression treatment in this sub-analysis. We evaluated the efficacy and safety of retreatment with EGFR-TKI in these patients.&lt;br&gt;
Results: Among the 14 patients, 11 (78.6%) responded to the induction of gefitinib in the treatment protocol. After relapse, 9/14 patients (64.3%) received gefitinib, 3/14 (21.4%) received afatinib, and 2/14 (14.3%) received erlotinib monotherapy, respectively. The median duration of post-progression EGFR-TKI treatment was 17.9 (0.7-45.5) months. The overall response rate (ORR) and disease control rate were 64.3% [9/14 patients; 95% confidence interval (CI): 35.1%-87.2%] and 85.7% (12/14 patients; 95% CI: 57.2%-98.2%), respectively. The median progression-free survival (PFS) and median survival durations after the initiation of EGFR-TKI retreatment were 11.8 months (95% CI: 5.7-20.7 months) and 47.4 months (95% CI: 31.8 months to not estimable), respectively. Adverse events were comparable to those previously reported.&lt;br&gt;
Conclusions: Patients with disease progression after protocol therapy demonstrated sensitivity to retreatment with an EGFR-TKI, with acceptable safety.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">chemoradiotherapy</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">egfr</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">locally advanced setting</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">non-small cell lung cancer</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">progression</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">retreatment</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">safety</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">targeted therapy</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2168-8184</Issn>
      <Volume>17</Volume>
      <Issue>5</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Pseudoachalasia Due to Malignant Pleural Mesothelioma Involving the Esophagus</ArticleTitle>
    <FirstPage LZero="delete">e84161</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Manami</FirstName>
        <LastName>Honda</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masaya</FirstName>
        <LastName>Iwamuro</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuya</FirstName>
        <LastName>Miyamoto</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takehiro</FirstName>
        <LastName>Tanaka</LastName>
        <Affiliation>Department of Pathology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Motoyuki</FirstName>
        <LastName>Otsuka</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>We report a rare case of pseudoachalasia secondary to malignant pleural mesothelioma involving the esophagus. A 66-year-old man presented with progressive dysphagia, weight loss, and postprandial hiccups. Endoscopic examination showed esophageal dilation with luminal narrowing at the esophagogastric junction, but no mucosal abnormalities. Computed tomography revealed an irregular-shaped mass extending from the peri-esophagogastric junction to the retroperitoneum, accompanied by pleural effusion, right-sided hydronephrosis, and multiple hepatic lesions. Endoscopic ultrasound-guided fine-needle aspiration from the mass lesion through the esophageal lumen revealed epithelioid malignant mesothelioma. This case highlights the importance of considering malignant mesothelioma in the differential diagnosis of pseudoachalasia, particularly when imaging reveals extrinsic esophageal compression without mucosal lesions.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">endoscopic ultrasound-guided fine-needle aspiration</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">esophageal diseases</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">esophagogastroduodenoscopy (egd)</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">malignant mesothelioma</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">pseudoachalasia</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2168-8184</Issn>
      <Volume>17</Volume>
      <Issue>4</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Gastrointestinal Stromal Tumors in the Stomach With Tumor Growth and Hemorrhage During Conservative Management: A Report of Two Cases</ArticleTitle>
    <FirstPage LZero="delete">e82046</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Masaya</FirstName>
        <LastName>Iwamuro</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Satoru</FirstName>
        <LastName>Kikuchi</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shinji</FirstName>
        <LastName>Kuroda</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takehiro</FirstName>
        <LastName>Tanaka</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Motoyuki</FirstName>
        <LastName>Otsuka</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Gastrointestinal stromal tumors (GISTs) are often detected incidentally during esophagogastroduodenoscopy. Although surgical resection is the standard treatment for GISTs, patients with significant comorbidities may not be eligible for surgery and are managed conservatively. Herein, we report two cases of gastric GISTs that were initially observed during the management of other comorbidities but subsequently became enlarged, resulting in gastrointestinal bleeding. These cases highlight the potential risks of tumor progression and bleeding in patients undergoing conservative management.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">conservative management</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">gastric subepithelial lesion</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">gastrointestinal bleeding</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">gastrointestinal stromal tumor</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">tumor growth</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1865-7257</Issn>
      <Volume>18</Volume>
      <Issue>2</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Microsatellite-high intrahepatic cholangiocarcinoma with favorable treatment outcome using pembrolizumab</ArticleTitle>
    <FirstPage LZero="delete">363</FirstPage>
    <LastPage>368</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Shigeru</FirstName>
        <LastName>Horiguchi</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hironari</FirstName>
        <LastName>Kato</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuya</FirstName>
        <LastName>Miyamoto</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kosaku</FirstName>
        <LastName>Morimoto</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Akihiro</FirstName>
        <LastName>Matsumi</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroyuki</FirstName>
        <LastName>Terasawa</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuki</FirstName>
        <LastName>Fujii</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuyuki</FirstName>
        <LastName>Matsumoto</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takehiro</FirstName>
        <LastName>Tanaka</LastName>
        <Affiliation>Department of Pathology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Motoyuki</FirstName>
        <LastName>Otsuka</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Hospital</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Intrahepatic cholangiocarcinoma has a poor prognosis. In unresectable cases, the survival period is short despite combination therapy with cytotoxic anticancer agents and immune checkpoint inhibitors. The usefulness of immune checkpoint inhibitors against malignant tumors with microsatellite instability-high (MSI-H) mutations was shown in the KEYNOTE158 study; however, data for intrahepatic cholangiocarcinoma are insufficient. In the present case, a 65-year-old man with intrahepatic cholangiocarcinoma and lymph node metastasis could not be treated with a combination of gemcitabine, CDDP, and S-1. A comprehensive cancer genomic profiling (CGP) test showed MLH1 pathogenic mutation and MSI-H. When pembrolizumab was administered, the tumor shrinkage effect was rapidly observed, which was sustained even after 30 months. No pathogenic mutations were observed in the germline test, and MSI-high was considered to be due to the MLH1 pathogenic mutation occurring sporadically in somatic cells. MSI-H intrahepatic cholangiocarcinoma is extremely rare. However, because pembrolizumab is expected to be effective, CGP testing should be actively performed.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Microsatellite instability (MSI)-high</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Tumor mutation burden (TMB)-high</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Intrahepatic cholangiocarcinoma</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Comprehensive genome profiling</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2168-8184</Issn>
      <Volume>17</Volume>
      <Issue>2</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Gastric Metastasis of Renal Cell Carcinoma Initially Diagnosed by Esophagogastroduodenoscopy</ArticleTitle>
    <FirstPage LZero="delete">e79651</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Masaya</FirstName>
        <LastName>Iwamuro</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomohiro</FirstName>
        <LastName>Kamio</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shoichiro</FirstName>
        <LastName>Hirata</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takehiro</FirstName>
        <LastName>Tanaka</LastName>
        <Affiliation>Department of Pathology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Motoyuki</FirstName>
        <LastName>Otsuka</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Here, we report a rare case of renal cell carcinoma (RCC) initially detected as a gastric metastasis. A 58-year-old man with epigastric discomfort underwent esophagogastroduodenoscopy, which revealed a reddish semi-pedunculated lesion with a whitish coating. Biopsy and imaging confirmed clear cell RCC metastasis. Contrast-enhanced computed tomography (CT) revealed a primary renal tumor with pancreatic and lymph node metastases. Despite chemotherapy treatment, the patient died after 10 months. Gastric metastases from RCC, although rare, should be considered in highly vascular gastric lesions with white coatings. Clinicians must be vigilant for metastatic diseases with atypical gastric findings.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">clear renal cell carcinoma</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">esophagogastroduodenoscopy (egd)</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">gastric metastasis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">metastatic tumor, renal cell carcinoma (rcc)</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>IOP Publishing</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1742-6588</Issn>
      <Volume>3027</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>LES analysis to investigate a random-phase forcing scheme for steadying anisotropic turbulence fields</ArticleTitle>
    <FirstPage LZero="delete">012009</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Koki</FirstName>
        <LastName>Minami</LastName>
        <Affiliation>Graduate School of Environmental, Life, Natural Science and Technology, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroki</FirstName>
        <LastName>Suzuki</LastName>
        <Affiliation>Graduate School of Environmental, Life, Natural Science and Technology, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshinori</FirstName>
        <LastName>Kouchi</LastName>
        <Affiliation>Graduate School of Environmental, Life, Natural Science and Technology, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kento</FirstName>
        <LastName>Tanaka</LastName>
        <Affiliation>Graduate School of Environmental, Life, Natural Science and Technology, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>The aim of this study is to investigate the effect of phase randomization on forcing mechanisms that stabilize localized turbulence. A trigonometric forcing based on vector potential is combined with uniform random numbers to create a spatially homogeneous forcing field. The analysis is performed using large-eddy simulation (LES) with the Smagorinsky model as the subgrid scale model. The results demonstrate that steady flows are generated regardless of the presence of phase randomization, successfully forming isotropic turbulence. In contrast, for anisotropic turbulent fields, the addition of phase randomization reduces the degree of anisotropy, indicating a smoothing effect on the anisotropy of the flow.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList/>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>IOP Publishing</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1742-6588</Issn>
      <Volume>3027</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Fundamental examination of coherent structure model prediction using vortex cores in a two-dimensional Taylor’s analytical solution</ArticleTitle>
    <FirstPage LZero="delete">012008</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Xuanyou</FirstName>
        <LastName>Gong</LastName>
        <Affiliation>Graduate School of Environmental, Life, Natural Science and Technology, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroki</FirstName>
        <LastName>Suzuki</LastName>
        <Affiliation>Graduate School of Environmental, Life, Natural Science and Technology, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshinori</FirstName>
        <LastName>Kouchi</LastName>
        <Affiliation>Graduate School of Environmental, Life, Natural Science and Technology, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kento</FirstName>
        <LastName>Tanaka</LastName>
        <Affiliation>Graduate School of Environmental, Life, Natural Science and Technology, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>This study focuses on the possibility that flow around vortex tubes in turbulence may resemble laminar flow, and aims to describe the characteristics of turbulent fields using analytical solutions to the governing equations. In the two-dimensional analytical Taylor solution, the velocity and pressure fields are expressed by trigonometric functions, and a structure in which counter-rotating vortices are arranged in a grid pattern is demonstrated. This solution is used to verify the accuracy of numerical analyses and is expected to contribute to a simple yet unambiguous description of turbulent fields based on vortex structures. Predictions of sub-grid scale components and validation of a coherent structure model using invariants of the velocity gradient tensor are also performed.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList/>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1865-1380</Issn>
      <Volume>19</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Association of Wet-Bulb Globe Temperature with heat-related illness hospitalizations in Japan: a time-stratified, case-crossover study</ArticleTitle>
    <FirstPage LZero="delete">11</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Yuka</FirstName>
        <LastName>Yamamura</LastName>
        <Affiliation>Department of Epidemiology, Okayama University Faculty of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takashi</FirstName>
        <LastName>Hongo</LastName>
        <Affiliation>Department of Emergency, Critical Care, and Disaster Medicine, Okayama University Faculty of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tetsuya</FirstName>
        <LastName>Yumoto</LastName>
        <Affiliation>Department of Emergency, Critical Care, and Disaster Medicine, Okayama University Faculty of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Fumiya</FirstName>
        <LastName>Sasai</LastName>
        <Affiliation>Department of Epidemiology, Okayama University Faculty of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kohei</FirstName>
        <LastName>Tokioka</LastName>
        <Affiliation>Department of Emergency, Critical Care, and Disaster Medicine, Okayama University Faculty of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takafumi</FirstName>
        <LastName>Obara</LastName>
        <Affiliation>Department of Emergency, Critical Care, and Disaster Medicine, Okayama University Faculty of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tsuyoshi</FirstName>
        <LastName>Nojima</LastName>
        <Affiliation>Department of Emergency, Critical Care, and Disaster Medicine, Okayama University Faculty of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Jun</FirstName>
        <LastName>Kanda</LastName>
        <Affiliation>Emergency and Critical Care Medicine, Nippon Medical School Musashikosugi Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shoji</FirstName>
        <LastName>Yokobori</LastName>
        <Affiliation>Department of Emergency and Critical Care Medicine, Nippon Medical School</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiromichi</FirstName>
        <LastName>Naito</LastName>
        <Affiliation>Department of Emergency, Critical Care, and Disaster Medicine, Okayama University Faculty of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takashi</FirstName>
        <LastName>Yorifuji</LastName>
        <Affiliation>Department of Epidemiology, Okayama University Faculty of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Atsunori</FirstName>
        <LastName>Nakao</LastName>
        <Affiliation>Department of Emergency, Critical Care, and Disaster Medicine, Okayama University Faculty of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Background Heat-related illnesses are a serious public health concern and are exacerbated by global warming. Wet-Bulb Globe Temperature (WBGT) is widely used as a heat stress indicator, but its clinical impact remains unclear. This study aimed to investigate the association between hourly variations in WBGT and the incidence of hospitalizations for heat-related illness in Japan using a nationwide database. By incorporating individual-level clinical data and performing stratified analyses, we sought to provide a more granular understanding of how heat exposure affects the risk of heat-related illness requiring hospitalization.&lt;br&gt;
Methods We conducted a time-stratified, case-crossover study using data collected from July to September in 2020 and 2021 in the Heatstroke STUDY registry. The inclusion criteria were patients registered in the Heatstroke STUDY registry, specifically hospitalized patients with heat-related illness who were transported to participating hospitals during the study period. Hourly WBGT values were assigned based on the nearest monitoring station to each hospital. Conditional logistic regression and distributed lag models were used to estimate associations between WBGT and the risk of hospitalization.&lt;br&gt;
Results A total of 1,653 heat-related illness hospitalizations were analyzed. The mean patient age was 67.9 years; 67.6% were male. Each 1 °C increase in WBGT at onset (hospital arrival) was associated with a significantly increased risk of hospitalization (OR 1.10, 95% CI: 1.05&#8211;1.15). The cumulative effect over the prior six hours was also significant (OR 1.56, 95% CI: 1.50&#8211;1.62). Compared with WBGT&#8201;&lt;&#8201;25 °C, adjusted ORs were 3.39 (25&#8211;27 °C), 8.81 (28&#8211;30 °C), and 22.10 (&#8805;&#8201;31 °C). Stratified analyses suggested stronger associations among several subgroups; however, only patients with mental disorders showed statistically significant effect modification, whereas elevated WBGT posed a risk across all groups.&lt;br&gt;
Conclusions Higher WBGT levels were associated with an increased risk of heat-related hospitalization. Although the effect appeared greater in some subgroups, only patients with mental disorders demonstrated statistically significant effect modification, suggesting elevated WBGT confers risk broadly.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Wet-Bulb Globe Temperature</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Heat stroke</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Heat related illness</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Global warming</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2168-8184</Issn>
      <Volume>17</Volume>
      <Issue>11</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Association of Carboxyhemoglobin With Severity and Outcomes in Hypothermic Patients: A Retrospective Cohort Study</ArticleTitle>
    <FirstPage LZero="delete">e97962</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Yuya</FirstName>
        <LastName>Miyoshi</LastName>
        <Affiliation>Department of Emergency, Critical Care, and Disaster Medicine, Faculty of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tetsuya</FirstName>
        <LastName>Yumoto</LastName>
        <Affiliation>Department of Emergency, Critical Care, and Disaster Medicine, Faculty of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takashi</FirstName>
        <LastName>Hongo</LastName>
        <Affiliation>Department of Emergency, Critical Care, and Disaster Medicine, Faculty of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takafumi</FirstName>
        <LastName>Obara</LastName>
        <Affiliation>Department of Emergency, Critical Care, and Disaster Medicine, Faculty of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tsuyoshi</FirstName>
        <LastName>Nojima</LastName>
        <Affiliation>Department of Emergency, Critical Care, and Disaster Medicine, Faculty of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiromichi</FirstName>
        <LastName>Naito</LastName>
        <Affiliation>Department of Emergency, Critical Care, and Disaster Medicine, Faculty of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Atsunori</FirstName>
        <LastName>Nakao</LastName>
        <Affiliation>Department of Emergency, Critical Care, and Disaster Medicine, Faculty of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Introduction&lt;br&gt;
Carboxyhemoglobin (COHb), an endogenous marker of carbon monoxide production mediated by heme oxygenase-1, may reflect physiological stress responses in critically ill patients. However, its clinical relevance in accidental hypothermia remains unclear.&lt;br&gt;
&lt;br&gt;
Methods&lt;br&gt;
We conducted a single-center retrospective cohort study of adult patients admitted to the emergency ICU with accidental hypothermia between January 1, 2019, and March 31, 2025. Patients were categorized into low- and high-COHb groups based on median COHb levels upon emergency department arrival. Associations between COHb levels, disease severity (Acute Physiology and Chronic Health Evaluation II (APACHE II) and Sequential Organ Failure Assessment (SOFA) scores), and 28-day mortality were analyzed using regression models adjusted for clinical confounders.&lt;br&gt;
&lt;br&gt;
Results&lt;br&gt;
Among the 88 patients, who had a median admission temperature of 28.7°C, 45 were classified into the low-COHb group and 43 into the high-COHb group, based on a median COHb level of 0.3%. Lower COHb levels on admission were significantly associated with higher APACHE II scores (β = −4.20; 95% CI, −7.56 to −0.85), but not with SOFA scores. Admission and minimum COHb levels were not associated with 28-day mortality. However, higher maximum COHb levels within the first 24 hours were independently associated with lower 28-day mortality (adjusted OR, 0.17; 95% CI, 0.023 to 0.93).&lt;br&gt;
&lt;br&gt;
Conclusions&lt;br&gt;
Lower COHb levels were associated with greater disease severity, and higher maximum COHb levels were associated with lower 28-day mortality. COHb may reflect systemic stress in accidental hypothermia, but its prognostic value appears limited.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">carbon monoxide</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">carboxyhemoglobin</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">heme oxygenase</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">hypothermia</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">sepsis</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1341-9625</Issn>
      <Volume/>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Turning pancreatic cancer from cold to hot: the promise of a p53-expressing oncolytic adenovirus (OBP-702)</ArticleTitle>
    <FirstPage LZero="delete"/>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Shinji</FirstName>
        <LastName>Kuroda</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroshi</FirstName>
        <LastName>Tazawa</LastName>
        <Affiliation>Center for Innovative Clinical Medicine, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masashi</FirstName>
        <LastName>Hashimoto</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Nobuhiko</FirstName>
        <LastName>Kanaya</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshihiko</FirstName>
        <LastName>Kakiuchi</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shunsuke</FirstName>
        <LastName>Kagawa</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yasuo</FirstName>
        <LastName>Urata</LastName>
        <Affiliation>Oncolys BioPharma Inc</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshiyoshi</FirstName>
        <LastName>Fujiwara</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Pancreatic cancer remains one of the most lethal malignancies, with limited therapeutic options and poor responsiveness to immune checkpoint inhibitors (ICIs). This resistance is largely attributed to its profoundly immunosuppressive and desmoplastic tumor microenvironment (TME), characterized by low tumor mutational burden, dense stroma, and abundant immunosuppressive cell populations. Therefore, strategies capable of enhancing tumor immunogenicity and overcoming immune evasion are urgently needed. Oncolytic virotherapy is a promising approach, offering not only tumor-selective cytotoxicity, but also potent immunomodulatory effects. Of these agents, Telomelysin (OBP-301, Suratadenoturev), a telomerase-specific oncolytic adenovirus, demonstrated clinical safety but limited efficacy in refractory tumors. To address this challenge, we developed OBP-702, a next-generation, p53-armed, oncolytic adenovirus designed to augment antitumor activity. Preclinical studies have shown that OBP-702 exerts robust cytotoxicity through multiple mechanisms, including p53-mediated apoptosis and autophagy, E1A&#8211;E2F1-mediated p21 suppression, and inhibition of oncogenic KRAS pathways. Importantly, OBP-702 induces strong immunogenic cell death, activates dendritic cells, and promotes tumor-specific T-cell responses, effectively converting immunologically “cold” pancreatic tumors into “hot” tumors. OBP-702 also remodels the immunosuppressive TME by reducing granulocyte&#8211;macrophage colony-stimulating factor (GM-CSF) secretion, suppressing myeloid-derived suppressor cells (MDSCs), and targeting stromal components, such as cancer-associated fibroblasts (CAFs). These effects contribute to enhanced responses to ICIs and standard chemotherapies. Given its multifaceted antitumor functions and ability to overcome key barriers in pancreatic cancer, OBP-702 represents a highly promising therapeutic candidate. A first-in-human clinical trial evaluating endoscopic ultrasonography-guided intratumoral injection of OBP-702 is currently in preparation, expected to advance clinical translation of this novel virotherapeutic strategy.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Oncolytic adenovirus</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">p53</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">OBP-702</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Immunogenic cell death</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Tumor microenvironment</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Pancreatic cancer</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2730-664X</Issn>
      <Volume>6</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Effects of an oral exercise intervention on pre-frailty or frailty in older people: a randomized clinical trial</ArticleTitle>
    <FirstPage LZero="delete">96</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Noriko</FirstName>
        <LastName>Takeuchi</LastName>
        <Affiliation>Department of Preventive Dentistry, Division of Dentistry, Medical Development Field, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Nanami</FirstName>
        <LastName>Sawada</LastName>
        <Affiliation>Section of Preventive and Public Health Dentistry, Division of Oral Health, Growth and Development, Faculty of Dental Science, Kyushu University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Sakura</FirstName>
        <LastName>Inada</LastName>
        <Affiliation>Division of Health Promotion, Okayama-City Health Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Manabu</FirstName>
        <LastName>Morita</LastName>
        <Affiliation>Department of Oral Health Sciences, Faculty of Health Care Sciences, Takarazuka University of Medical and Health Care</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Daisuke</FirstName>
        <LastName>Ekuni</LastName>
        <Affiliation>Department of Preventive Dentistry, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Background: Frailty is often experienced by older adults, which can lead to long-term health problems. We aimed to examine associations with improvements in nutritional status, sarcopenia (age-related loss of skeletal muscle mass and strength), and frailty in four groups with different oral exercise frequencies.&lt;br&gt;
Methods: We conducted a prospective, parallel multi-arm randomized controlled trial (Japan Registry of Clinical Trials (jRCT) 1062210063) to test the effects of oral exercise on frailty in older adults. Each intervention consisted of a standardized oral exercise protocol including neck exercises, lip exercises, and tongue movements, designed to improve oral function and reduce frailty. The primary outcome was the change in the number of frailty criteria from baseline to follow-up. Individuals aged &#8805;60 years were screened for frailty status using standardized criteria at the Department of Preventive Dentistry at Okayama University Hospital between October 2022 and December 2023. Those identified as pre-frailty or frailty were eligible and enrolled in the study. After screening 60 individuals, 58 eligible participants were randomly assigned using block randomization to one of four oral exercise frequency groups: 3 times/day &amp; everyday, 3 times/day &amp; 3 days/week, once/day &amp; everyday, and once/day &amp; 3 days/week. A two-way repeated measures analysis of variance was used to evaluate the impact of the four frequencies of oral exercise methods on frailty in older adults. Outcome assessors were blinded; participants were not.&lt;br&gt;
Results: Here we show the results of the 58 participants. Group sizes are: 3 times/day &amp; everyday (n&#8201;=&#8201;14), 3 times/day &amp; 3 days/week (n&#8201;=&#8201;15), once/day &amp; everyday (n&#8201;=&#8201;14), once/day &amp; 3 days/week (n&#8201;=&#8201;15). The trial is completed as planned, and all randomized participants are analyzed. The main effect of time is significant for the number of frailty criteria (F&#8201;=&#8201;14.803, p&#8201;&lt;&#8201;0.001, partial eta squared = 0.215). The mean changes from baseline to follow-up are −0.357 (95% Confidence Interval −0.787 to 0.073) in the 3 times/day &amp; everyday group, −0.600 (95% Confidence Interval −1.255 to 0.055) in the 3 times/day &amp; 3 days/week group, −0.571 (95% Confidence Interval −1.379 to 0.236) in the once/day &amp; everyday group, and −0.600 (95% Confidence Interval −1.008 to −0.192) in the once/day &amp; 3 days/week group. The main effect of time is also significant for the number of oral hypofunction criteria (F&#8201;=&#8201;16.456, p&#8201;&lt;&#8201;0.001, partial eta squared = 0.234). No important adverse events or side effects related to the intervention were observed.&lt;br&gt;
Conclusions: After conducting oral exercises for 3 months on older adults with pre-frailty or frailty, improvements in frailty are observed. Overall, these exercises could be a simple, low-cost way to support healthy aging in the community.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList/>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2168-8184</Issn>
      <Volume>18</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Saliva as a Reliable and Non-invasive Sample for Detecting Influenza A in Severe Acute Respiratory Infection Cases</ArticleTitle>
    <FirstPage LZero="delete">e100872</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Junko S</FirstName>
        <LastName>Takeuchi</LastName>
        <Affiliation>Department of Academic-Industrial Partnerships Promotion, Center for Clinical Sciences, Japan Institute for Health Security</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Nobuaki</FirstName>
        <LastName>Matsunaga</LastName>
        <Affiliation>Antimicrobial Resistance (AMR) Clinical Reference Center, Japan Institute for Health Security</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ai</FirstName>
        <LastName>Tsukada</LastName>
        <Affiliation>Antimicrobial Resistance (AMR) Clinical Reference Center, Japan Institute for Health Security</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Noriko</FirstName>
        <LastName>Iwamoto</LastName>
        <Affiliation>Disease Control and Prevention Center, Japan Institute for Health Security</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Noriko</FirstName>
        <LastName>Fuwa</LastName>
        <Affiliation>Disease Control and Prevention Center, Japan Institute for Health Security</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takahiro</FirstName>
        <LastName>Ichikawa</LastName>
        <Affiliation>Department of Infectious Diseases, Sapporo City General Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yasuyuki</FirstName>
        <LastName>Kato</LastName>
        <Affiliation>Department of Infectious Diseases, International University of Health and Welfare (IUHW) Narita Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuka</FirstName>
        <LastName>Tomita</LastName>
        <Affiliation>Department of Infectious Diseases, Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroki</FirstName>
        <LastName>Kitagawa</LastName>
        <Affiliation>Department of Infectious Diseases, Hiroshima University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masaya</FirstName>
        <LastName>Yamato</LastName>
        <Affiliation>Department of General Internal Medicine and Infectious Diseases, Rinku General Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tetsuji</FirstName>
        <LastName>Aoyagi</LastName>
        <Affiliation>Department of Clinical Infectious Diseases, Tohoku University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hideharu</FirstName>
        <LastName>Hagiya</LastName>
        <Affiliation>Department of Infectious Diseases, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryota</FirstName>
        <LastName>Hase</LastName>
        <Affiliation>Department of Infectious Diseases, Japanese Red Cross Narita Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shuji</FirstName>
        <LastName>Hatakeyama</LastName>
        <Affiliation>Division of Infectious Diseases, Jichi Medical University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tohru</FirstName>
        <LastName>Inaba</LastName>
        <Affiliation>Department of Infection Control and Laboratory Medicine, Kyoto Prefectural University of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Koichi</FirstName>
        <LastName>Izumikawa</LastName>
        <Affiliation/>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshio</FirstName>
        <LastName>Takesue</LastName>
        <Affiliation>Department of Infectious Diseases, Nagasaki University Graduate School of Biomedical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Moto</FirstName>
        <LastName>Kimura</LastName>
        <Affiliation>Department of Academic-Industrial Partnerships Promotion, Center for Clinical Sciences, Japan Institute for Health Security</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Norio</FirstName>
        <LastName>Ohmagari</LastName>
        <Affiliation>Disease Control and Prevention Center, Japan Institute for Health Security</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Background&lt;br&gt;
Nasopharyngeal swab sampling remains the gold standard for influenza diagnosis; however, it has several limitations, including dependence on medical staff, invasiveness, potential for nosocomial transmission, and occupational exposure risk. Non-invasive alternatives, such as saliva and nasal vestibular swabs, may improve patient comfort and participation in clinical studies. In addition, diagnosis with reverse transcription real-time quantitative polymerase chain reaction (RT-qPCR) is often delayed because it requires trained laboratory technicians and facilities with appropriate laboratory settings. Although rapid diagnostic devices such as the GenPad&#174; offer potential alternatives to RT-qPCR, their performance with non-invasive samples remains insufficiently explored. This study addresses the two key questions for influenza detection in severe acute respiratory infection (SARI) cases: (i) whether saliva or nasal vestibular swab samples serve as suitable alternatives to nasopharyngeal swab samples, and (ii) whether the GenPad&#174; provides a reliable option for detecting influenza using saliva samples.&lt;br&gt;
Methodology&lt;br&gt;
A prospective observational study was conducted with 16 inpatients classified as having SARIs and diagnosed with influenza between December 2024 and March 2025 in Japan. Paired saliva and nasal vestibular swab samples were collected 1-9 (median = 3.5) days after symptom onset. RT-qPCR testing was performed according to the National Institute of Infectious Diseases protocol. Saliva samples were also tested using the GenPad&#174; system. Comparisons between sample types and diagnostic methods were analyzed using the exact McNemar's test.&lt;br&gt;
Results&lt;br&gt;
Among the 16 influenza-positive patients, saliva samples demonstrated higher sensitivity (87.5%) than nasal vestibular swabs (31.3%) in RT-qPCR when compared with the diagnostic results obtained from nasopharyngeal swabs. A comparison of RT-qPCR results between saliva and nasal vestibular swabs revealed a total agreement of 43.8%, with exact McNemar's test showing a significant difference (p = 0.0039). While nasal vestibular swabs showed inconsistent results, saliva samples consistently tested positive, particularly within seven days of symptom onset (100% positive agreement). The GenPad&#174;, a rapid diagnostic device, showed promising performance (92.9%) using saliva samples compared to RT-qPCR.&lt;br&gt;
Conclusions&lt;br&gt;
Saliva is a reliable non-invasive alternative to nasopharyngeal swabs for influenza detection in SARI cases, particularly within seven days of symptom onset, whereas nasal vestibular swabs show lower sensitivity. Additionally, the GenPad&#174; provides comparable performance to RT-qPCR using saliva samples, offering a rapid, portable diagnostic option. These approaches may mitigate discomfort, minimize infection risk for healthcare workers, and improve testing capacity. However, the absence of influenza-negative controls and the small sample size (n = 16) substantially limit the assessment of diagnostic accuracy and specificity. As a result, the broader applicability of our findings should be interpreted with caution, and further studies are required to validate these observations.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">influenza a</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">nasal vestibular swab</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">nasopharyngeal swab</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">rapid diagnostics</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">rt-qpcr</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">saliva</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">sari</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2168-8184</Issn>
      <Volume>17</Volume>
      <Issue>12</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Streptococcal Toxic Shock Syndrome Following Intestinal Obstruction in a Patient With Crohn’s Disease</ArticleTitle>
    <FirstPage LZero="delete">e100138</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Ayano</FirstName>
        <LastName>Nishio</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masaya</FirstName>
        <LastName>Iwamuro</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshihiro</FirstName>
        <LastName>Inokuchi</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Mikako</FirstName>
        <LastName>Ishiguro</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuki</FirstName>
        <LastName>Aoyama</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masahiro</FirstName>
        <LastName>Takahara</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Sakiko</FirstName>
        <LastName>Hiraoka</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kohei</FirstName>
        <LastName>Oguni</LastName>
        <Affiliation>Department of Infectious Diseases, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hideharu</FirstName>
        <LastName>Hagiya</LastName>
        <Affiliation>Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuto</FirstName>
        <LastName>Matsuoka</LastName>
        <Affiliation>Department of Anesthesiology and Resuscitology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomoyuki</FirstName>
        <LastName>Kanazawa</LastName>
        <Affiliation>Department of Anesthesiology and Resuscitology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Motoyuki</FirstName>
        <LastName>Otsuka</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Streptococcal toxic shock syndrome (STSS) is a rare, life-threatening complication of invasive group A streptococcal (iGAS) infections. We report the case of a 24-year-old woman with Crohn's disease receiving immunosuppressive therapy who developed STSS following intestinal obstruction. On day 2, she developed fever, altered mental status, hypoxemia, erythema, and hypotension. Chest CT revealed bilateral pulmonary infiltrates, and blood cultures grew emm1-positive M1UK Streptococcus pyogenes, confirming STSS. Early multidisciplinary intervention resulted in rapid recovery without sequelae. This case emphasizes the importance of considering iGAS-induced STSS in septic shock, especially in immunocompromised patients, and highlights the need for prompt recognition and treatment.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">crohn’s disease (cd)</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">group a streptococcus</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">immunosuppression</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">intestinal obstruction</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">streptococcal toxic shock syndrome (stss)</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Okayama University Medical School</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0386-300X</Issn>
      <Volume>80</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Effective Treatment of Advanced Hepatocellular Carcinoma with Extensive Peritoneal Dissemination Using Lenvatinib</ArticleTitle>
    <FirstPage LZero="delete">69</FirstPage>
    <LastPage>74</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Shinya</FirstName>
        <LastName>Wakatsuki</LastName>
        <Affiliation>Department of Obstetrics and Gynecology, Kochi Health Sciences Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shinya</FirstName>
        <LastName>Sakamoto</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Kochi Health Sciences Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Akiko</FirstName>
        <LastName>Ueno</LastName>
        <Affiliation>Department of Obstetrics and Gynecology, Kochi Health Sciences Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takaomi</FirstName>
        <LastName>Namba</LastName>
        <Affiliation>Department of Obstetrics and Gynecology, Kochi Health Sciences Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yorito</FirstName>
        <LastName>Yamamoto</LastName>
        <Affiliation>Department of Obstetrics and Gynecology, Kochi Health Sciences Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Manabu</FirstName>
        <LastName>Matsumoto</LastName>
        <Affiliation>Department of Diagnostic Pathology, Kochi Health Sciences Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Jun</FirstName>
        <LastName>Iwata</LastName>
        <Affiliation>Department of Diagnostic Pathology, Kochi Health Sciences Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takehiro</FirstName>
        <LastName>Okabayashi</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Kochi Health Sciences Center</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType>Case Report</PublicationType>
    <ArticleIdList>
      <ArticleId IdType="doi">10.18926/AMO/70075</ArticleId>
    </ArticleIdList>
    <Abstract>Patients with hepatocellular carcinoma (HCC) and extensive peritoneal dissemination generally have a poor prognosis and are often resistant to systemic therapy. We report the case of a 47-year-old woman with HCC and massive peritoneal dissemination who presented with malignant ascites requiring repeated cell-free and concentrated ascites reinfusion therapy and peritoneovenous shunt placement, as well as malignant pleural effusion requiring pleurodesis. Combined immunotherapy with durvalumab/tremelimumab was initiated;however, disease progression was observed after three treatment courses, prompting a switch to lenvatinib therapy. Two months after initiation of lenvatinib, CT imaging demonstrated complete disappearance of arterial enhancement in the primary hepatic lesion, along with reduction in the size of peritoneal dissemination nodules. Thirteen months after switching to lenvatinib (16 months after the initial diagnosis), the alpha-fetoprotein level continued to decrease, and the disease remained stable under treatment. Despite the extremely high tumor burden, lenvatinib achieved disease stabilization and symptomatic improvement.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">diagnostic laparoscopy</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">hepatocellular carcinoma</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">peritoneal dissemination</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">lenvatinib</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Okayama University Medical School</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0386-300X</Issn>
      <Volume>80</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Metastatic Intraocular Tumor Likely from Hepatocellular Carcinoma Mimicking Panuveitis</ArticleTitle>
    <FirstPage LZero="delete">63</FirstPage>
    <LastPage>67</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Eri</FirstName>
        <LastName>Takasu</LastName>
        <Affiliation>Department of Ophthalmology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yusuke</FirstName>
        <LastName>Shiode</LastName>
        <Affiliation>Department of Ophthalmology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroya</FirstName>
        <LastName>Kindo</LastName>
        <Affiliation>Department of Ophthalmology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shuhei</FirstName>
        <LastName>Kimura</LastName>
        <Affiliation>Department of Ophthalmology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Mio</FirstName>
        <LastName>Hosokawa</LastName>
        <Affiliation>Department of Ophthalmology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryo</FirstName>
        <LastName>Matoba</LastName>
        <Affiliation>Department of Ophthalmology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuki</FirstName>
        <LastName>Kanzaki</LastName>
        <Affiliation>Department of Ophthalmology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tetsuro</FirstName>
        <LastName>Morita</LastName>
        <Affiliation>Department of Ophthalmology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takuya</FirstName>
        <LastName>Adachi</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Motoyuki</FirstName>
        <LastName>Otsuka</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuki</FirstName>
        <LastName>Morizane</LastName>
        <Affiliation>Department of Ophthalmology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType>Case Report</PublicationType>
    <ArticleIdList>
      <ArticleId IdType="doi">10.18926/AMO/70074</ArticleId>
    </ArticleIdList>
    <Abstract>A 77-year-old man undergoing treatment for hepatocellular carcinoma (HCC) presented with blurred vision in his right eye, persisting for 2 months. Slit-lamp microscopy and fundus examination revealed inflammatory cells in the anterior chamber, severe vitreous opacities, and retinal vasculitis in the right eye. The patient underwent vitreous surgery with biopsy, and vitreous cytology confirmed a metastatic intraocular tumor originating from the HCC. Radiotherapy was administered to the right eye, with no recurrence of intraocular inflammation observed at 10 months post-irradiation.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">metastatic intraocular tumor</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">hepatocellular carcinoma</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">panuveitis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">uveitis masquerade syndrome</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Okayama University Medical School</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0386-300X</Issn>
      <Volume>80</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Changes in Prescribing Patterns of Antiviral Drugs before and after Public Coverage Termination among Hospitalized COVID-19 Patients in Regional Hospitals in Japan: A Retrospective, Multicenter Study</ArticleTitle>
    <FirstPage LZero="delete">55</FirstPage>
    <LastPage>62</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Hidemasa</FirstName>
        <LastName>Akazawa</LastName>
        <Affiliation>Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences,</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hideharu</FirstName>
        <LastName>Hagiya</LastName>
        <Affiliation>Department of Infectious Diseases, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shinnosuke</FirstName>
        <LastName>Fukushima</LastName>
        <Affiliation>Department of Infectious Diseases, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shohei</FirstName>
        <LastName>Yamamoto</LastName>
        <Affiliation>Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences,</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yasuhiro</FirstName>
        <LastName>Nakano</LastName>
        <Affiliation>Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences,</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Fumio</FirstName>
        <LastName>Otsuka</LastName>
        <Affiliation>Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences,</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType>Original Article</PublicationType>
    <ArticleIdList>
      <ArticleId IdType="doi">10.18926/AMO/70073</ArticleId>
    </ArticleIdList>
    <Abstract>In Japan, antiviral agents for COVID-19 were freely available until September 2023 as part of national policy. This study evaluated changes in these agents’ prescribing patterns and the patient outcomes following the policy shift. We conducted a multicenter retrospective study at four hospitals in Japan’s Okayama and Kagawa prefectures from January 2022 to March 2024. The study period was divided into the public-expenditure phase (January 2022 to September 2023) and the post-expenditure phase (October 2023 to March 2024). We extracted the hospitalized patients’ clinical data from the electronic database. The study’s primary outcome was the antiviral prescription rate; the secondary outcome was in-hospital mortality. Among the 302 hospitalized patients (median age 85 years), 52.0% were classified as having a mild condition. Of the patients with mild conditions, 37.7% were diagnosed in outpatient settings prior to hospitalization. During the public-expenditure phase, 47.4% of the patients received antivirals as outpatients, mainly molnupiravir (80.9%). In the post-expenditure period, 80.0% of the patients were prescribed antivirals, mostly molnupiravir (91.7%). The antiviral prescription rate was significantly higher after the policy change. The overall in-hospital mortality was 15.8%, with no significant difference between the two periods (17.0% vs. 10.5%). Despite the termination of government funding, antiviral prescriptions remained frequent at community hospitals located in highly aging regions of western Japan such as Okayama and Kagawa prefectures. Mortality remains high among the elderly, highlighting the need for continued antiviral therapy and booster vaccinations.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">coronavirus disease 2019</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">public expenditure</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">prescribing pattern</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">prognosis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Japan</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Okayama University Medical School</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0386-300X</Issn>
      <Volume>80</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>A Novel Nomogram that Predicts Chronic Hemodialysis Patients’ Survival Based on Their Sedentary Behavior</ArticleTitle>
    <FirstPage LZero="delete">9</FirstPage>
    <LastPage>16</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Kentaro</FirstName>
        <LastName>Sugahara</LastName>
        <Affiliation>Department of Hygiene, Faculty of Medicine, Kagawa University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takashi</FirstName>
        <LastName>Kondo</LastName>
        <Affiliation>Innoshima General Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Nobuyuki</FirstName>
        <LastName>Miyatake</LastName>
        <Affiliation>Department of Hygiene, Faculty of Medicine, Kagawa University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroyuki</FirstName>
        <LastName>Nishi</LastName>
        <Affiliation>Innoshima General Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuhiro</FirstName>
        <LastName>Ujike</LastName>
        <Affiliation>Innoshima General Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kiichi</FirstName>
        <LastName>Koumoto</LastName>
        <Affiliation>Innoshima General Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Keiichi</FirstName>
        <LastName>Namio</LastName>
        <Affiliation>Department of Hygiene, Faculty of Medicine, Kagawa University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shuhei</FirstName>
        <LastName>Hishii</LastName>
        <Affiliation>Department of Hygiene, Faculty of Medicine, Kagawa University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Akihiko</FirstName>
        <LastName>Katayama</LastName>
        <Affiliation>Faculty of Social Studies, Shikokugakuin University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiromi</FirstName>
        <LastName>Suzuki</LastName>
        <Affiliation>Department of Hygiene, Faculty of Medicine, Kagawa University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yorimasa</FirstName>
        <LastName>Yamamoto</LastName>
        <Affiliation>Innoshima General Hospital</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType>Original Article</PublicationType>
    <ArticleIdList>
      <ArticleId IdType="doi">10.18926/AMO/70068</ArticleId>
    </ArticleIdList>
    <Abstract>Appropriate treatments for chronic hemodialysis patients are a public health challenge in Japan. Sedentary behavior appears to be closely associated with these patients’ survival. We thus sought to develop a nomogram that predicts survival based on the duration of chronic hemodialysis patients’ sedentary behavior. One hundred twenty-four patients under chronic hemodialysis (73 men, 51 women, age 71.7±11.1 years) were enrolled in this cohort study. The patients wore a triaxial accelerometer that measured both their sedentary behavior, i.e., total sedentary behavior (minutes) and their maximum sedentary bouts (min) on non-hemodialysis days. We obtained the Kaplan-Meier curve and used the log-rank test and a Cox proportional hazards model to evaluate the relationship between the patients’ sedentary behavior and their survival. We also used a Cox proportional hazards model to develop a nomogram for the patients’ 5-year survival rate. Forty-six patients died during the follow-up period. When we stratified the patients by the medians of total sedentary behavior and maximum sedentary bouts, we observed significant between-group differences. After adjustment for confounding factors in a Cox proportional hazards model, total sedentary behavior and maximum sedentary bouts were identified as critical survival factors, and we generated a nomogram using an index of sedentary behavior. Our analysis results demonstrated that sedentary behavior on non-dialysis days was closely associated with the survival of the chronic hemodialysis patients, suggesting that a decrease in sedentary behavior would prolong their survival. The nomogram developed herein based on sedentary behavior may be useful for predicting the outcomes of chronic hemodialysis patients.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">nomogram</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">chronic hemodialysis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">sedentary behavior</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Cox proportional hazards model</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Kaplan- Meier curve</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Okayama University Medical School</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0386-300X</Issn>
      <Volume>80</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Usefulness of D-dimer Assay to Confirm the Course of Overt Venous Thromboembolism (VTE) in Cancer Patients</ArticleTitle>
    <FirstPage LZero="delete">1</FirstPage>
    <LastPage>7</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Hidenaru</FirstName>
        <LastName>Yamaoka</LastName>
        <Affiliation>Department of Cardiovascular Medicine, IMS Tokyo Katsushika General Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masashi</FirstName>
        <LastName>Yoshida</LastName>
        <Affiliation>Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshihiro</FirstName>
        <LastName>Sarashina</LastName>
        <Affiliation>Seisukai Kuroda Clinic</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Satoshi</FirstName>
        <LastName>Akagi</LastName>
        <Affiliation>Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toru</FirstName>
        <LastName>Miyoshi</LastName>
        <Affiliation>Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Mitsuru</FirstName>
        <LastName>Munemasa</LastName>
        <Affiliation>Department of Cardiovascular Medicine, Okayama Rosai Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazufumi</FirstName>
        <LastName>Nakamura</LastName>
        <Affiliation>Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroshi</FirstName>
        <LastName>Ito</LastName>
        <Affiliation>Department of General Internal Medicine 3, Kawasaki Medical School General Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shinsuke</FirstName>
        <LastName>Yuasa</LastName>
        <Affiliation>Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType>Original Article</PublicationType>
    <ArticleIdList>
      <ArticleId IdType="doi">10.18926/AMO/70067</ArticleId>
    </ArticleIdList>
    <Abstract>Venous thromboembolism (VTE) is a serious complication in patients with cancer. In this population, the presence of thrombi is often assessed at cancer diagnosis by measuring D-dimer levels, which have high sensitivity but low specificity for identifying VTE at this clinical time point. However, the usefulness of D-dimer measurement during anticoagulation therapy has not been fully established, despite its widespread use. In this retrospective observational study, we investigated whether D-dimer measurement during anticoagulation therapy in cancer patients could predict overt VTE at follow-up. The study included patients who underwent D-dimer testing and contrast-enhanced computed tomography between 30 and 100 days after initiation of anticoagulation therapy. Eighty-two patients were included: 60 with cancer and 22 without. The diagnostic performance of D-dimer for overt VTE was as follows: sensitivity, 85.7%; specificity, 87.2%; positive predictive value, 78.3%; and negative predictive value, 89.2%. These findings suggest that D-dimer measurement at follow-up has high sensitivity and specificity for overt VTE in cancer patients and may aid in assessing thrombotic status. Clinically, if anticoagulation therapy is continued until D-dimer levels become negative, the absence of overt VTE could be inferred without additional invasive testing.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">D-dimer</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">venous</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">thromboembolism</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">cancer</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Wiley</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0001-690X</Issn>
      <Volume>153</Volume>
      <Issue>3</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Impact of Schizophrenia Spectrum Disorders on the Receipt of Invasive and Systemic Therapy for Colorectal Cancer: A Nationwide Multicenter Retrospective Cohort Study in Japan</ArticleTitle>
    <FirstPage LZero="delete">191</FirstPage>
    <LastPage>199</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Masaki</FirstName>
        <LastName>Fujiwara</LastName>
        <Affiliation>Department of Neuropsychiatry, Medical Development Field, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuto</FirstName>
        <LastName>Yamada</LastName>
        <Affiliation>Department of Neuropsychiatry, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Taisuke</FirstName>
        <LastName>Ishii</LastName>
        <Affiliation>Division of Health Services Research, National Cancer Center Institute for Cancer Control, National Cancer Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomone</FirstName>
        <LastName>Watanabe</LastName>
        <Affiliation>Division of Health Services Research, National Cancer Center Institute for Cancer Control, National Cancer Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Maiko</FirstName>
        <LastName>Fujimori</LastName>
        <Affiliation>Division of Survivorship Research, National Cancer Center Institute for Cancer Control, National Cancer Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Naoki</FirstName>
        <LastName>Nakaya</LastName>
        <Affiliation>Tohoku Medical Megabank Organization, Tohoku University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshihiko</FirstName>
        <LastName>Kawamura</LastName>
        <Affiliation>Department of Medical Informatics, Shimane University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Koji</FirstName>
        <LastName>Otsuki</LastName>
        <Affiliation>Department of Psychiatry, Faculty of Medicine, Shimane University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kunitoshi</FirstName>
        <LastName>Shigeyasu</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Medical Development Field, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Taichi</FirstName>
        <LastName>Shimazu</LastName>
        <Affiliation>Division of Behavioral Sciences, National Cancer Center Institute for Cancer Control, National Cancer Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shiro</FirstName>
        <LastName>Hinotsu</LastName>
        <Affiliation>Department of Biostatistics and Data Management, Sapporo Medical University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yosuke</FirstName>
        <LastName>Uchitomi</LastName>
        <Affiliation>Department of Cancer Survivorship and Digital Medicine, The Jikei University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masatoshi</FirstName>
        <LastName>Inagaki</LastName>
        <Affiliation>Department of Psychiatry, Faculty of Medicine, Shimane University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Introduction: This study examined treatment disparities for colorectal cancer among patients diagnosed with schizophrenia spectrum disorders (SSD), focusing on invasive treatments and stage-appropriate systemic therapy within a universal healthcare system.&lt;br&gt;
Method: In this nationwide retrospective cohort study (2018&#8211;2021), we identified 248,966 colorectal cancer patients, including 2337 diagnosed with SSD, using linked cancer registry and insurance claims data in Japan. The presence of SSD was classified according to ICD-10 codes F20&#8211;29. We used multivariable logistic regression to compare the odds of receiving stage-appropriate adjuvant chemotherapy and systemic therapy, as well as the odds of receiving surgical or endoscopic treatments, between the two groups. The analysis adjusted for age, sex, clinical stage, and scores on the Charlson Comorbidity Index and Barthel Index.&lt;br&gt;
Results: The clinical stage distribution at diagnosis for colorectal cancer differed significantly between patients with SSD and those without psychiatric disorders (p&#8201;&lt;&#8201;0.001). After adjusting for clinical stage and other covariates, patients with SSD demonstrated significantly lower odds of receiving surgical or endoscopic treatment (adjusted odds ratio [aOR], 0.83; 95% CI, 0.73&#8211;0.94). The disparities were more pronounced for systemic therapy; patients with SSD had substantially lower odds of receiving adjuvant chemotherapy for stage III disease (aOR, 0.33; 95% CI, 0.26&#8211;0.41) and systemic therapy for stage IV disease (aOR, 0.23; 95% CI, 0.17&#8211;0.31).&lt;br&gt;
Conclusion: Patients with SSD encounter substantial disparities in accessing standard colorectal cancer care, particularly systemic therapies. These findings highlight the urgent need for interventions to ensure equitable cancer treatment for this vulnerable population.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">colorectal cancer</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">healthcare disparities</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">psycho-oncology</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">schizophrenia spectrum disorders</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Wiley</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0031-9317</Issn>
      <Volume>178</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Reactive Carbonyl Species Mediate Isothiocyanate Signaling Pathway in Arabidopsis thaliana Guard Cells</ArticleTitle>
    <FirstPage LZero="delete">e70775</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Sumaiya</FirstName>
        <LastName>Farzana</LastName>
        <Affiliation>Graduate School of Environmental and Life Science, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Md. Moshiul</FirstName>
        <LastName>Islam</LastName>
        <Affiliation>Graduate School of Environmental and Life Science, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshiyuki</FirstName>
        <LastName>Nakamura</LastName>
        <Affiliation>Graduate School of Environmental and Life Science, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshimasa</FirstName>
        <LastName>Nakamura</LastName>
        <Affiliation>Graduate School of Environmental and Life Science, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shintaro</FirstName>
        <LastName>Munemasa</LastName>
        <Affiliation>Graduate School of Environmental and Life Science, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Jun'ichi</FirstName>
        <LastName>Mano</LastName>
        <Affiliation>Science Research Center, Yamaguchi University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshiyuki</FirstName>
        <LastName>Murata</LastName>
        <Affiliation>Graduate School of Environmental and Life Science, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Our previous results demonstrated that depletion of glutathione (GSH) rather than elevation of levels of reactive oxygen species (ROS) is highly correlated with the decrease in stomatal aperture induced by isothiocyanates (ITCs), although ROS is considered a key second messenger in stomatal closure, suggesting that another signal component regulates stomatal apertures along with GSH depletion. This study, using Arabidopsis, clarified that reactive carbonyl species (RCS), especially acrolein and 4-hydroxy-(E)-2-nonenal, are determinants of stomatal aperture responses to ITCs. All tested ITCs, allyl isothiocyanate (AITC), sulforaphane (SFN), benzyl isothiocyanate (BITC), and phenethyl isothiocyanate (PEITC), significantly induced stomatal closure, which was inhibited by the RCS scavengers, carnosine and pyridoxamine. The RCS scavengers suppressed ITC-induced depletion of GSH but not elevation of ROS levels. All tested ITCs (AITC, SFN, BITC, and PEITC) increased levels of RCS and non-RCS aldehydes in the epidermal tissues. However, acrolein, 4-hydroxy-(E)-2-nonenal, crotonaldehyde, and (E)-2-pentenal induced stomatal closure at 10 and 100&#8201;μM, whereas propionaldehyde, butyraldehyde, and n-pentanal did not at concentrations up to 100&#8201;μM. Acrolein and 4-hydroxy-(E)-2-nonenal more effectively induced stomatal closure and GSH depletion than crotonaldehyde and (E)-2-pentenal did. The contents of RCS were more strongly correlated with GSH levels and stomatal closure than with ROS levels. These results suggest that RCS, especially acrolein and 4-hydroxy-(E)-2-nonenal, acts as key regulators of stomatal closure in guard cells in response to ITCs.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">arabidopsis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">GSH depletion</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">isothiocyanate</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">reactive carbonyl species</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">reactive oxygen species</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1757-4749</Issn>
      <Volume>18</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Sodium butyrate augments the antibacterial activity of tetracycline against clinical isolates of multidrug-resistant Vibrio cholerae</ArticleTitle>
    <FirstPage LZero="delete">9</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Sushmita</FirstName>
        <LastName>Kundu</LastName>
        <Affiliation>Division of Biochemistry, ICMR- National Institute for Research in Bacterial Infections</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Sourin</FirstName>
        <LastName>Alu</LastName>
        <Affiliation>Division of Biochemistry, ICMR- National Institute for Research in Bacterial Infections</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Abhishek</FirstName>
        <LastName>Singh</LastName>
        <Affiliation>Division of Biochemistry, ICMR- National Institute for Research in Bacterial Infections</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Animesh</FirstName>
        <LastName>Gope</LastName>
        <Affiliation>Division of General Medicine, ICMR- National Institute for Research in Bacterial Infections</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ranjan Kumar</FirstName>
        <LastName>Nandy</LastName>
        <Affiliation>Division of Bacteriology, ICMR- National Institute for Research in Bacterial Infections</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Asish K.</FirstName>
        <LastName>Mukhopadhyay</LastName>
        <Affiliation>Division of Bacteriology, ICMR- National Institute for Research in Bacterial Infections</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shin-ichi</FirstName>
        <LastName>Miyoshi</LastName>
        <Affiliation>Division of Pharmaceutical Sciences, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Nabendu Sekhar</FirstName>
        <LastName>Chatterjee</LastName>
        <Affiliation>Division of Biochemistry, ICMR- National Institute for Research in Bacterial Infections</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Sushmita</FirstName>
        <LastName>Bhattacharya</LastName>
        <Affiliation>Division of Biochemistry, ICMR- National Institute for Research in Bacterial Infections</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Background Antibiotic resistance poses a major challenge in treating Vibrio cholerae infections. One promising method to counter resistance is the co-administration of antibiotics with non-antibiotic adjuvants to enhance their efficacy. This study investigated the combined action of sodium butyrate (SB) and tetracycline on tetracycline-resistant V. cholerae strains.&lt;br&gt;
Results The combined activity of SB and antibiotics was assessed on eight V. cholerae clinical isolates using the Fractional Inhibitory Concentration Index (FICI), with SB-Tetracycline showing strong synergy (FICI: 0.09&#8211;0.5). Functional and mechanistic studies, including time-kill kinetics, live/dead staining, SEM-based morphological analysis, and fluorometric assays, demonstrated a synergistic antibacterial effect of SB and Tetracycline. This effect was associated with increased membrane permeability, disruption of membrane integrity, dissipation of the proton motive force, and suppression of efflux activity. These changes collectively led to membrane damage, enhanced intracellular accumulation of Tetracycline, decreased intracellular ATP levels, and ultimately, bacterial cell death. Moreover, GM1-CT ELISA and fluorescence microscopy revealed the synergistic anti-virulence activity of the SB- Tetracycline combination. Finally, the combination of SB and Tetracycline showed enhanced efficacy in animal models compared with monotherapy.&lt;br&gt;
Conclusion: The observed SB-Tetracycline synergy provides a promising therapeutic approach to overcome tetracycline resistance in V. cholerae, offering a potential adjunct strategy for the management of antibiotic-resistant cholera infections.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">V. cholerae</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Sodium butyrate</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Tetracycline</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Synergy</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Antibiotic adjuvant</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>eLife Sciences Publications, Ltd</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2050-084X</Issn>
      <Volume>14</Volume>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Dorsoventral-mediated Shh induction is required for axolotl limb regeneration</ArticleTitle>
    <FirstPage LZero="delete">RP106917</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Sakiya</FirstName>
        <LastName>Yamamoto</LastName>
        <Affiliation>Okayama University, Graduate School of Environmental, Life, Natural Science and Technology</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Saya</FirstName>
        <LastName>Furukawa</LastName>
        <Affiliation>Okayama University, Graduate School of Environmental, Life, Natural Science and Technology</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ayaka</FirstName>
        <LastName>Ohashi</LastName>
        <Affiliation>Okayama University, Graduate School of Environmental, Life, Natural Science and Technology</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Mayuko</FirstName>
        <LastName>Hamada</LastName>
        <Affiliation>Okayama University, Graduate School of Environmental, Life, Natural Science and Technology</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Akira</FirstName>
        <LastName>Satoh</LastName>
        <Affiliation>Okayama University, Graduate School of Environmental, Life, Natural Science and Technology</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Axolotls (Ambystoma mexicanum) exhibit a remarkable ability to regenerate limbs. Classical experiments have suggested that contact between cells derived from distinct orientations―dorsal, ventral, anterior, and posterior―within the regenerating blastema is necessary for accurate limb pattern formation. However, the molecular basis for this requirement has remained largely unknown. Here, we demonstrate that both dorsal and ventral tissues are required for limb formation via induction of Shh expression, which plays a crucial role in limb patterning. Using the accessory limb model, we induced position-specific blastemas lacking cells derived from a single orientation (anterior, posterior, dorsal, or ventral). Limb patterning occurred only in blastemas containing both dorsal- and ventral-derived cells. We further observed that Shh expression requires dorsoventral contact within a blastema, highlighting the necessity of dorsoventral contact for inducing Shh expression. Additionally, we identified WNT10B and FGF2 as dorsal- and ventral-mediated signals, respectively, that create the inductive environment for Shh expression. Our findings clarify the role of dorsal and ventral cells in inducing Shh, a mechanism that has rarely been studied in the context of limb regeneration and pattern formation. This model provides new insights into how cells with different positional identities drive the regeneration process.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList/>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Wiley</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0041-1132</Issn>
      <Volume/>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Pediatric autologous peripheral blood stem cell collection without heparin using a highly concentrated sodium citrate anticoagulant: A retrospective comparison with standard ACD-A</ArticleTitle>
    <FirstPage LZero="delete"/>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Keiko</FirstName>
        <LastName>Fujii</LastName>
        <Affiliation>Department of Hematology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Wataru</FirstName>
        <LastName>Kitamura</LastName>
        <Affiliation>Department of Hematology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kana</FirstName>
        <LastName>Washio</LastName>
        <Affiliation>Department of Pediatrics, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuhiro</FirstName>
        <LastName>Ikeuchi</LastName>
        <Affiliation>Department of Hematology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Joji</FirstName>
        <LastName>Shimono</LastName>
        <Affiliation>Department of Hematology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroyuki</FirstName>
        <LastName>Murakami</LastName>
        <Affiliation>Department of Hematology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Fumio</FirstName>
        <LastName>Otsuka</LastName>
        <Affiliation>Division of Clinical Laboratory, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshinobu</FirstName>
        <LastName>Maeda</LastName>
        <Affiliation>Department of Hematology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Nobuharu</FirstName>
        <LastName>Fujii</LastName>
        <Affiliation>Department of Hematology, Okayama University Hospital</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Background: Heparin combined with sodium citrate has been used in leukocytapheresis for pediatric patients. Since 2022, we have performed leukocytapheresis using a highly concentrated sodium citrate solution (HSC, 5.32%) instead of acid citrate dextrose solution A (ACD-A). We conducted this study to determine whether HSC use reduces run time and the total amount of anticoagulant solution in children.&lt;br&gt;
Study Design and Methods: We retrospectively analyzed data from consecutive autologous peripheral blood stem cell harvests (auto-PBSCHs) between June 2012 and May 2025, including patient characteristics, mobilization methods, protocol used, anticoagulant type, run time, total anticoagulant solution volume, and collection efficiency.&lt;br&gt;
Results: Auto-PBSCH was performed using the mononuclear cell collection (MNC) protocol in 28 procedures and the continuous MNC protocol in 20 procedures. ACD-A was used in 35 procedures and HSC in 13. The run time was significantly shorter (204 [range, 117&#8211;302] vs. 157&#8201;min [range, 103&#8211;227], p&#8201;=&#8201;.02) in the HSC group and also confirmed in multivariable regression analysis (coefficient, −55.6; 95% confidence interval, −106.2 to −5.04; p&#8201;=&#8201;.03). In a subgroup analysis of cMNC procedures, CD34+ collection efficiency showed a strong negative correlation with the proportion of run time devoted to establishing the initial interface (r&#8201;=&#8201;−.73, p&#8201;=&#8201;.0003).&lt;br&gt;
Conclusion: Delays in establishing the initial interface can reduce the duration of the effective MNC collection phase and may negatively affect collection efficiency. Careful attention to the initial interface phase is therefore warranted when using HSC.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">acid citrate dextrose solution</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">autologous</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">continuous mononuclear cell collection</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">highly concentrated sodium</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">pediatric</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">peripheral blood stem cells</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1349-4147</Issn>
      <Volume>54</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Mycobacterium mageritense-associated refractory cutaneous infection and lymphadenitis in an immunocompetent adult: insights from genomic sequencing</ArticleTitle>
    <FirstPage LZero="delete">19</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Shinnosuke</FirstName>
        <LastName>Fukushima</LastName>
        <Affiliation>Department of Bacteriology, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Jumpei</FirstName>
        <LastName>Uchiyama</LastName>
        <Affiliation>Department of Bacteriology, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshio</FirstName>
        <LastName>Kawakami</LastName>
        <Affiliation>Department of Dermatology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshiko</FirstName>
        <LastName>Matsuura</LastName>
        <Affiliation>Konohana Dermatology Clinic</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Satoru</FirstName>
        <LastName>Sugihara</LastName>
        <Affiliation>Department of Dermatology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shin</FirstName>
        <LastName>Morizane</LastName>
        <Affiliation>Department of Dermatology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Poowadon</FirstName>
        <LastName>Muenraya</LastName>
        <Affiliation>Department of Bacteriology, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hideharu</FirstName>
        <LastName>Hagiya</LastName>
        <Affiliation>Department of Infectious Diseases, Okayama University Hospital</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Background Nontuberculous mycobacteria are increasingly recognized as causes of chronic and refractory skin and soft tissue infections, even in individuals without immunodeficiency. Among them, Mycobacterium mageritense is a rare, rapidly growing species that can lead to persistent lesions requiring prolonged antimicrobial therapy. Reports of M. mageritense infections involving both the skin and regional lymph nodes are limited, and this case adds new clinical and genomic insights.&lt;br&gt;
Case presentation A 48-year-old previously healthy man presented with a slowly enlarging cutaneous lesion on his lower leg and ipsilateral inguinal lymphadenitis. Empirical antibacterial therapy with β-lactams and macrolides was ineffective. Wound cultures subsequently grew M. mageritense, confirmed by whole-genome sequencing. Several antimicrobial regimens were attempted, and the final successful therapy consisted of oral levofloxacin and minocycline for 4 months, leading to complete clinical resolution. Genomic analysis identified resistance-related genes, including erm(40), aac(2′)-Ib, tet(V), and RbpA, although in vitro minimum inhibitory concentrations showed variable susceptibility. Phylogenetic comparison revealed that the isolate was closely related to previously reported M. mageritense strains from Japan.&lt;br&gt;
Conclusions This case demonstrates that M. mageritense can cause cutaneous infection with secondary lymphadenitis in an immunocompetent host. Accurate species identification using molecular or genomic methods and selection of appropriate combination antibiotic therapy based on susceptibility testing are crucial for successful management of such infections.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Genome sequence</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Lymphadenitis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Mycobacterium mageritense</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Skin and soft tissue infections</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Rapidly growing mycobacteria</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2168-8184</Issn>
      <Volume>17</Volume>
      <Issue>3</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Prospective Evaluation of the Safety and Compression Performance of Novel Compression Denim Jeans in Healthy Volunteers and Patients With Lymphedema</ArticleTitle>
    <FirstPage LZero="delete">e80971</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Daiki</FirstName>
        <LastName>Ousaka</LastName>
        <Affiliation>Department of Pharmacology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kiyoshi</FirstName>
        <LastName>Yamada</LastName>
        <Affiliation>Departments of Plastic and Reconstructive Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Noriko</FirstName>
        <LastName>Sakano</LastName>
        <Affiliation>Department of Cardiovascular Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Satoe</FirstName>
        <LastName>Kirino</LastName>
        <Affiliation>Department of Obstetrics and Gynecology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazumasa</FirstName>
        <LastName>Miyake</LastName>
        <Affiliation>Department of Rehabilitation, Lymphedema Treatment Center, Kousei Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takumi</FirstName>
        <LastName>Takahashi</LastName>
        <Affiliation>Division of Business Management, Matsuoka Corporation</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Akihiro</FirstName>
        <LastName>Matsuoka</LastName>
        <Affiliation>Division of Production Engineering, Matsuoka Corporation</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shintaro</FirstName>
        <LastName>Yamada</LastName>
        <Affiliation>Division of Sales, Kaihara Corporation</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Akira</FirstName>
        <LastName>Shinaoka</LastName>
        <Affiliation>Department of Lymphatics and Edematology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Susumu</FirstName>
        <LastName>Oozawa</LastName>
        <Affiliation>Department of Clinical Safety, Okayama University Hospital</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Objectives: The treatment of lower-extremity lymphedema, whether congenital or acquired, remains challenging. Long-term management aimed at reducing complications and maximizing quality of life is essential. Compression stockings are crucial in this management; however, their application is limited by patient experience (ease of wear, texture, breathability, and appearance). This highlights the need to evaluate alternative compression garments that maintain therapeutic efficacy while improving patient adherence.&lt;br&gt;
Methods: We developed a novel compression denim product (Flow plus Jeans&#174;) using advanced sewing technology. Its baseline performance (compression ability) was evaluated by measuring pressure gradients at three points (ankle, calf, and thigh) using a mannequin-based compression testing system and compared with those of existing stockings. Thereafter, a safety assessment was conducted on healthy volunteers to evaluate potential adverse effects, including changes in lower limb circumference, signs of deep vein thrombosis (DVT) via ultrasound, and skin complications. A clinical trial in patients with lymphedema was then performed to compare its efficacy with that of conventional compression stockings.&lt;br&gt;
Results: Baseline performance testing with a mannequin revealed that Flow plus Jeans demonstrated compression levels and pressure gradients at three calf points comparable to those of standard compression stockings. A safety study involving nine healthy volunteers confirmed that Flow plus Jeans caused no significant changes in lower-limb circumferences after three days of wear, with no cases of DVT or skin complications. In a subsequent clinical trial involving nine female patients with lymphedema, the jeans showed non-inferiority to existing stockings concerning lower-limb circumference measurements at six points (pre-use vs. six months post-use), with patient-reported experiences assessed via questionnaires. Notably, patients reported enhanced satisfaction regarding the jeans' fashionability, which could serve as an incentive for long-term adherence.&lt;br&gt;
Conclusion: Our findings suggest that Flow plus Jeans represent a promising novel option for the long-term management of lymphedema, offering an alternative that balances medical efficiency with improved patient satisfaction and demonstrates safety in healthy individuals.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">compression garments</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">denim jeans</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">long-term management</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">lower-extremity lymphedema</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">quality of life</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Wiley</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0022-3492</Issn>
      <Volume/>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>A retrospective cohort study comparing periodontal regeneration using fibroblast growth factor‐2 versus autologous bone graft</ArticleTitle>
    <FirstPage LZero="delete"/>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Toshiki</FirstName>
        <LastName>Matsumoto</LastName>
        <Affiliation>Department of Pathophysiology&#8211;Periodontal Science, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shin</FirstName>
        <LastName>Nakamura</LastName>
        <Affiliation>Department of Pathophysiology&#8211;Periodontal Science, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuki</FirstName>
        <LastName>Ito‐Shinoda</LastName>
        <Affiliation>Department of Pathophysiology&#8211;Periodontal Science, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Mai</FirstName>
        <LastName>Sakamoto</LastName>
        <Affiliation>Department of Pathophysiology&#8211;Periodontal Science, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takayuki</FirstName>
        <LastName>Ishii</LastName>
        <Affiliation>Department of Pathophysiology&#8211;Periodontal Science, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yasuki</FirstName>
        <LastName>Nonomura</LastName>
        <Affiliation>Department of Pathophysiology&#8211;Periodontal Science, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hidetaka</FirstName>
        <LastName>Ideguchi</LastName>
        <Affiliation>Department of Pathophysiology&#8211;Periodontal Science, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Keisuke</FirstName>
        <LastName>Okubo</LastName>
        <Affiliation>Department of Periodontics and Endodontics, Division of Dentistry, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazu</FirstName>
        <LastName>Takeuchi‐Hatanaka</LastName>
        <Affiliation>Department of Periodontics and Endodontics, Division of Dentistry, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuhiro</FirstName>
        <LastName>Omori</LastName>
        <Affiliation>Department of Pathophysiology&#8211;Periodontal Science, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tadashi</FirstName>
        <LastName>Yamamoto</LastName>
        <Affiliation>The Center for Graduate Medical Education (Dental Division), Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shogo</FirstName>
        <LastName>Takashiba</LastName>
        <Affiliation>Department of Pathophysiology&#8211;Periodontal Science, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Background: Fibroblast growth factor-2 (FGF-2) is a novel agent utilized in periodontal regeneration therapy. However, its clinical efficacy compared with autologous bone graft (ABG), a long-established treatment, remains unclear. This study aimed to compare the clinical outcomes of FGF-2 and ABG and to assess the impact of patient background factors on outcomes when using FGF-2.&lt;br&gt;
Methods: We collected the subjects from January 2013 to September 2023. Clinical outcomes included the vertical bone defect improvement rate (VBDIR) and the probing pocket depth improvement (PPDI). Clinical outcomes between the two groups were compared using analysis of covariance (ANCOVA), adjusting for age, sex, smoking history, and hypertension. Additionally, a multilevel linear analysis was performed to assess factors influencing outcomes in FGF-2.&lt;br&gt;
Results: A total of 180 sites from 141 patients (FGF-2: 150 sites; ABG: 30 sites) were evaluated. Both VBDIR and PPDI significantly improved postoperatively in both groups. There were no significant differences in clinical outcomes between FGF-2 and ABG. In FGF-2, smoking history was positively associated, while the preoperative bone defect angle (BDA) was negatively associated with clinical outcomes.&lt;br&gt;
Conclusions: FGF-2 might exhibit clinical outcomes comparable to those of ABG, suggesting it is a clinically viable alternative for vertical bone defects. When using FGF-2, patient-specific factors such as smoking history and preoperative BDA should be considered carefully.&lt;br&gt;
The name in the trial registry: A survey of clinical practice and evaluation of treatment outcomes of periodontal regenerative therapy using REGROTH at Okayama University Hospital</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">autologous bone graft</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">fibroblast growth factor-2</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">periodontal pocket</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">periodontal regeneration</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">periodontitis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">vertical bone defect</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2059-3635</Issn>
      <Volume>11</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Osimertinib inhibits the MYLK4-mediated phosphorylation of CDKAL1 to suppress stemness and chemoresistance in rhabdomyosarcoma</ArticleTitle>
    <FirstPage LZero="delete">26</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Takuto</FirstName>
        <LastName>Itano</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Rongsheng</FirstName>
        <LastName>Huang</LastName>
        <Affiliation>Department of Cellular Physiology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshifumi</FirstName>
        <LastName>Ozaki</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Eiji</FirstName>
        <LastName>Nakata</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Atsushi</FirstName>
        <LastName>Fujimura</LastName>
        <Affiliation>Department of Cellular Physiology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract/>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList/>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2168-8184</Issn>
      <Volume>18</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Central Serous Chorioretinopathy in Parallel With Onset and Relapses of Minimal Change Nephrotic Syndrome: A 28-Year Case Follow-Up</ArticleTitle>
    <FirstPage LZero="delete">e102426</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Toshihiko</FirstName>
        <LastName>Matsuo</LastName>
        <Affiliation>Department of Ophthalmology, Graduate School of Interdisciplinary Science and Engineering in Health Systems, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takehiro</FirstName>
        <LastName>Tanaka</LastName>
        <Affiliation>Department of Pathology, Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Jun</FirstName>
        <LastName>Wada</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology, and Metabolism, Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Central serous chorioretinopathy is an idiopathic disease that manifests as one or several localized, small, dome-shaped serous retinal detachments on fundus examination. The pathophysiology involves fluid leakage from the choroidal capillaries, known as the choriocapillaris, into the subretinal space through sites of damage in the retinal pigment epithelium. This case report discusses the underlying causes of central serous chorioretinopathy-like findings in minimal change nephrotic syndrome.&lt;br&gt;
&lt;br&gt;
The patient was a 33-year-old woman who developed nephrotic syndrome that was confirmed to be minimal change disease by renal biopsy. She experienced two major relapses of nephrotic syndrome at the ages of 36 and 41 years. She also had a minor relapse at the age of 37 years, five months after the first major relapse at the age of 36 years, as well as four additional minor relapses at the ages of 44, 46, 50, and 51 years. The onset of central serous chorioretinopathy-like manifestations, which were localized to the left eye, occurred three months after the initial onset of nephrotic syndrome at the age of 33 years. Two subsequent episodes of relapse of central serous chorioretinopathy-like manifestations were observed in both eyes at intervals of five months and one month, respectively, after major relapses of nephrotic syndrome at the ages of 36 and 41 years. Thereafter, she did not develop further central serous chorioretinopathy-like manifestations.&lt;br&gt;
&lt;br&gt;
She discontinued oral prednisolone at the age of 54 years and experienced no further relapses of nephrotic syndrome through her latest visit at the age of 61 years. She maintained normal renal function and good visual acuity in both eyes. The long-term, consistent temporal association between episodes of central serous chorioretinopathy and the onset and relapses of minimal change nephrotic syndrome is strongly supported by longitudinal clinical observations spanning 28 years. This parallel course suggests a possible shared pathophysiological mechanism or common triggering factors underlying both diseases.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">central serous chorioretinopathy</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">corticosteroid</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">cyclosporine</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">fluorescein angiography</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">minimal change disease</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">minimal change nephrotic syndrome</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">photoreceptor ellipsoid zone</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">renal biopsy</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">steroid-induced retinal pigment epitheliopathy</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">steroid pulse therapy</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Wiley</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1687-8728</Issn>
      <Volume>2026</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Experimental Analysis of Automatic Discrimination Performance Between Simulated Bruxism and Non‐Bruxism Under Conscious Conditions Using Electromyography and Machine Learning</ArticleTitle>
    <FirstPage LZero="delete">7874254</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Hajime</FirstName>
        <LastName>Minakuchi</LastName>
        <Affiliation>Department of Oral Rehabilitation and Regenerative Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Mitsuhiro</FirstName>
        <LastName>Nagasaki</LastName>
        <Affiliation>Department of Electrical Engineering and Information Systems, Graduate School of Engineering, The University of Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">L&#7897;c Ho&#224;ng</FirstName>
        <LastName>&#272;&#236;nh</LastName>
        <Affiliation>Department of Oral Rehabilitation and Regenerative Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Haruna</FirstName>
        <LastName>Miki</LastName>
        <Affiliation>Department of Oral Rehabilitation and Regenerative Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ko</FirstName>
        <LastName>Omori</LastName>
        <Affiliation>Department of Oral Rehabilitation and Regenerative Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tazuko</FirstName>
        <LastName>Nishimura</LastName>
        <Affiliation>Department of Electrical Engineering and Information Systems, Graduate School of Engineering, The University of Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takuo</FirstName>
        <LastName>Kuboki</LastName>
        <Affiliation>Department of Oral Rehabilitation and Regenerative Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Nobuaki</FirstName>
        <LastName>Minematsu</LastName>
        <Affiliation>Department of Electrical Engineering and Information Systems, Graduate School of Engineering, The University of Tokyo</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Purpose: This study aimed to evaluate the potential use of machine learning to automatically classify electromyography (EMG) data into bruxism simulated movement with tooth contact (BMwTC), bruxism simulated movement without tooth contact (BMwoTC), and non-bruxism movement (non-BM).&lt;br&gt;
Methods: Twelve eligible healthy participants (female/male: 2/10, mean age: 35.3&#8201;±&#8201;8.4&#8201;years) were asked to perform the simulated movements (all the tasks were performed five times for 5&#8201;s each with a 30-s rest interval). The electrodes were placed on the masseter, infrahyoid, inframandibular, and chin muscles. A sound sensor was placed adjacent to the masseter. The EMG and sound data were sampled at 1 and 44.1&#8201;kHz, respectively. Single- and multi-stream hidden Markov models (HMMs) were used to automatically discriminate the tested behavior from the others using a hamming window with 100&#8201;ms and shift length of 50&#8201;ms. The leave-one-out method was used for training and testing the model, with data from 11 participants used for training and one for testing. Each participant was evaluated, and the final performance was measured by averaging the results of 12 classification trials. The validity of the discrimination was assessed by calculating the harmony mean values using six EMG signals and the sound data.&lt;br&gt;
Results: The masseter EMG demonstrated significantly higher discrimination accuracy in the single-stream model (p&#8201; &lt; 0.05, One-way ANOVA, Tukey HDS). The multi-stream model also demonstrated higher accuracy; however, no significant difference was observed. Notably, the accuracy of BMwoTC was less than 0.5.&lt;br&gt;
Conclusion: The machine-learning-based discriminative system accurately discriminates BMwTC from non-BM using masseter EMG.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">bruxism</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">dentistry</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">electromyography</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">EMG discrimination</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">machine learning</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>China Anti-cancer Association</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2095-3941</Issn>
      <Volume/>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>SPRED2 suppresses the stemness of hepatocellular carcinoma through the p53/miR-506-3p/KLF4 pathway</ArticleTitle>
    <FirstPage LZero="delete"/>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Tong</FirstName>
        <LastName>Gao</LastName>
        <Affiliation>Department of Pathology and Experimental Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Sachio</FirstName>
        <LastName>Ito</LastName>
        <Affiliation>Department of Pathophysiology and Drug Discovery, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Aye</FirstName>
        <LastName>Moh-Moh-Aung</LastName>
        <Affiliation>Department of Pathology and Experimental Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tianyi</FirstName>
        <LastName>Wang</LastName>
        <Affiliation>Department of Pathology and Experimental Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masayoshi</FirstName>
        <LastName>Fujisawa</LastName>
        <Affiliation>Department of Pathology and Experimental Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshiaki</FirstName>
        <LastName>Ohara</LastName>
        <Affiliation>Department of Pathology and Experimental Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Teizo</FirstName>
        <LastName>Yoshimura</LastName>
        <Affiliation>Department of Pathology and Experimental Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Akihiro</FirstName>
        <LastName>Matsukawa</LastName>
        <Affiliation>Department of Pathology and Experimental Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Objective: We previously reported that endogenous Sprouty-related, EVH1 domain-containing protein 2 (SPRED2), an inhibitor of the Ras/Raf/ERK-MAPK pathway, controls hepatocellular carcinoma (HCC) cell stemness by downregulating the expression of pluripotency factors, such as Nanog, c-Myc, and KLF4, in an ERK-dependent fashion. However, the exact mechanisms by which SPRED2 regulates HCC cell stemness have not been established.&lt;br&gt;
Methods: Three human HCC cell lines [HepG2 (parental and SPRED2-deficient), HLE, and Hep3B] were used. Cells were transfected to downregulate or overexpress proteins. Western blot and RT-qPCR were used to evaluate the level of protein and mRNA expression. Co-immunoprecipitation and ChIP-qPCR were used to examine protein-protein interactions and the activation of gene transcription. Clinical HCC tissues were also used to validate in vitro data.&lt;br&gt;
Results: KLF4 was identified as the major pluripotency factor responsible for SPRED2-mediated downregulation of HCC cell stemness and KLF4 expression was regulated by miR-506-3p. SPRED2 formed a protein complex with the tumor suppressor (p53) and upregulated miR-506 gene transcription by binding to the promoter region, resulting in subsequent downregulation of KLF4 mRNA expression. There was a negative correlation between KLF4 expression and miR-506-3p and a positive correlation between miR-506-3p expression and SPRED2 in human HCC samples, highlighting the relevance of the study findings.&lt;br&gt;
Conclusions: The current study revealed a novel SPRED2/p53/miR-506-3p/KLF4 axis through which SPRED2 contributes to the suppression of HCC cell stemness and provides a potential new target to prevent HCC progression.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">SPRED2</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">p53</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">KLF4</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">miR-506-3p</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">stemness</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>BMJ</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2044-6055</Issn>
      <Volume>15</Volume>
      <Issue>12</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Effectiveness of education programme to increase competency of health cadres in Indonesia: a cluster non-randomised controlled trial</ArticleTitle>
    <FirstPage LZero="delete">e095428</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Dewie</FirstName>
        <LastName>Sulistyorini</LastName>
        <Affiliation>Graduate School of Biomedical and Health Sciences, Hiroshima University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">K A T M Ehsanul</FirstName>
        <LastName>Huq</LastName>
        <Affiliation>Graduate School of Biomedical and Health Sciences, Hiroshima University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Abdulfatai Olamilekan</FirstName>
        <LastName>Babaita</LastName>
        <Affiliation>Graduate School of Biomedical and Health Sciences, Hiroshima University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Sadia A</FirstName>
        <LastName>Aivey</LastName>
        <Affiliation>Graduate School of Biomedical and Health Sciences, Hiroshima University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Gao</FirstName>
        <LastName>Huiying</LastName>
        <Affiliation>Graduate School of Biomedical and Health Sciences, Hiroshima University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kana</FirstName>
        <LastName>Kazawa</LastName>
        <Affiliation>Faculty of Health Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yasuko</FirstName>
        <LastName>Fukushima</LastName>
        <Affiliation>Graduate School of Biomedical and Health Sciences, Hiroshima University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Mayumi</FirstName>
        <LastName>Kako</LastName>
        <Affiliation>Graduate School of Biomedical and Health Sciences, Hiroshima University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Michiko</FirstName>
        <LastName>Moriyama</LastName>
        <Affiliation>Graduate School of Biomedical and Health Sciences, Hiroshima University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Objectives Health cadres, who assist midwives in supporting pregnant women in community settings, need to enhance their competencies in identifying risk factors and referring high-risk pregnant women to midwives for further care. Since the capabilities of these health cadres are influenced by maternal complications, an educational programme was implemented to strengthen their skills. Therefore, this study aimed to evaluate the competency of health cadres by providing a researcher-developed educational programme.&lt;br&gt;
Design An open-label, cluster non-randomised controlled trial.&lt;br&gt;
Setting and participants Health cadres with at least 1 year of work experience were recruited at six public health centres (PHCs) in Banjarnegara Regency, Indonesia.&lt;br&gt;
Interventions Six PHCs were selected and allocated into intervention group (IG=3 PHCs) and control group (CG=3 PHCs) groups. A total of 133 female health cadres were enrolled across the selected PHCs. At each PHC, a systematic random sampling method was used to select the participants. The researchers and health professionals provided a 3-week period of theoretical and scenario-based simulations to the IG, while the CG received no education.&lt;br&gt;
Outcome measures Researcher-developed questionnaires and checklists were used to assess the knowledge, skills (health assessment, communication, attitude) and confidence. The primary endpoint was competency, a total score of knowledge and skills. The outcome domains were compared between the two groups, and a linear mixed-effect model was used to account for cluster-level variation.&lt;br&gt;
Results A total of 130 (97.7%) completed the study (IG:64, CG:66). The competency score showed significant improvement at endline (CG=49.5&#8201;and IG=52.5; p=0.002). The median scores for health assessment skills (CG=12&#8201;vs IG=14; p&lt;0.001) and communication skills (CG=7&#8201;vs IG=8; p&lt;0.001) were increased in the IG compared with the CG. Mixed-effect model indicated that groups (β (95%&#8201;CI) 2.49 (0.57 to 4.41), p=0.012), baseline knowledge (β(95%&#8201;CI) 0.73 (0.54 to 0.92), p&lt;0.001) and midline health assessment skills (β (95%&#8201;CI) 0.54 (0.25 to 0.82), p&lt;0.001) were significant positive predictors, while age was negatively associated with competency (β (95%&#8201;CI) −0.20 (−0.30 to −0.10), p&lt;0.001)).&lt;br&gt;
Conclusion Education effectively increased the competency of health cadres. A well-structured education programme is necessary for health cadres to improve and maintain their competencies in monitoring high-risk pregnant women.&lt;br&gt;
Trial registration number NCT06134518.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList/>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2045-2322</Issn>
      <Volume>16</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Salivary short chain fatty acids serve as biomarkers of periodontal inflammatory burden</ArticleTitle>
    <FirstPage LZero="delete">1786</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Kazu</FirstName>
        <LastName>Takeuchi-Hatanaka</LastName>
        <Affiliation>Division of Periodontics and Endodontics, Department of Dentistry, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yasushi</FirstName>
        <LastName>Shirahase</LastName>
        <Affiliation>Sysmex Corporation</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshiyuki</FirstName>
        <LastName>Yoshida</LastName>
        <Affiliation>Sysmex Corporation</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Mari</FirstName>
        <LastName>Kono</LastName>
        <Affiliation>Sysmex Corporation</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Naoki</FirstName>
        <LastName>Toya</LastName>
        <Affiliation>Sysmex Corporation</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kenji</FirstName>
        <LastName>Konishi</LastName>
        <Affiliation>Present address: Diagnostics Division, IVD Enzyme Department, Nagase Diagnostics</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuhiro</FirstName>
        <LastName>Omori</LastName>
        <Affiliation>Department of Pathophysiology-Periodontal Science, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shogo</FirstName>
        <LastName>Takashiba</LastName>
        <Affiliation>Department of Pathophysiology-Periodontal Science, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Periodontitis is a chronic inflammatory condition associated with systemic diseases. Early detection and intervention are crucial; however, conventional diagnostic methods require specialized dental procedures. Therefore, we aimed to develop a noninvasive saliva-based screening method that can be easily performed outside dental clinics. This cross-sectional pilot study evaluated three periodontal indices―probing depth, Periodontal Inflamed Surface Area (PISA), and periodontal epithelial surface area―in relation to short-chain fatty acids (SCFAs) and bacterial profiles in the saliva. Saliva samples collected during the day exhibited stronger correlations with periodontal indices than waking time samples, demonstrating a significant association with periodontal pathogens, protease activity, and elevated levels of butyric acid. The diagnostic thresholds for PISA were 300 mm2 and 600 mm2. Multivariate logistic regression and likelihood ratio analyses identified the combination of enzymatic SCFA markers and dipstick-based occult blood or leukocyte detection as a promising biomarker pair. Combining enzymatic SCFA markers with occult blood demonstrated a positive likelihood ratio of 3.4 and a negative likelihood ratio of 0.19 for PISA&#8201;&#8805;&#8201;600 mm2, with a post-test probability of 77%, sensitivity of 86%, and specificity of 75%. These findings suggest that combining salivary enzymatic and dipstick-based biomarkers provides a simple, cost-effective, and moderately informative screening strategy for periodontitis.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Periodontitis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Screening</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Saliva</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Short-chain fatty acid</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Periodontal inflamed surface area</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Crosssectional studies</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>American Society of Clinical Oncology (ASCO)</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2473-4276</Issn>
      <Volume>9</Volume>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Development and Validation of an Ipsilateral Breast Tumor Recurrence Risk Estimation Tool Incorporating Real-World Data and Evidence From Meta-Analyses: A Retrospective Multicenter Cohort Study</ArticleTitle>
    <FirstPage LZero="delete">e2500182</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Yasuaki</FirstName>
        <LastName>Sagara</LastName>
        <Affiliation>Department of Breast and Thyroid Surgical Oncology, Hakuaikai Sagara Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Atsushi</FirstName>
        <LastName>Yoshida</LastName>
        <Affiliation>Department of Breast Surgical Oncology, St Luke's International Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuri</FirstName>
        <LastName>Kimura</LastName>
        <Affiliation>Department of Breast Surgical Oncology, The Cancer Institute Hospital of JFCR</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Makoto</FirstName>
        <LastName>Ishitobi</LastName>
        <Affiliation>Department of Breast Surgery, Osaka Habikino Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuka</FirstName>
        <LastName>Ono</LastName>
        <Affiliation>Department of Radiation Oncology and Image-Applied Therapy, Kyoto University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuko</FirstName>
        <LastName>Takahashi</LastName>
        <Affiliation>Department of Breast and Endocrine Surgery, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takahiro</FirstName>
        <LastName>Tsukioki</LastName>
        <Affiliation>Department of Breast and Endocrine Surgery, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Koji</FirstName>
        <LastName>Takada</LastName>
        <Affiliation>Department of Breast Surgical Oncology, Osaka Metropolitan University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuri</FirstName>
        <LastName>Ito</LastName>
        <Affiliation>Department of Medical Statistics, Osaka Medical and Pharmaceutical University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomo</FirstName>
        <LastName>Osako</LastName>
        <Affiliation>Division of Pathology, The Cancer Institute of Japanese Foundation for Cancer Research</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takehiko</FirstName>
        <LastName>Sakai</LastName>
        <Affiliation>Department of Breast Surgical Oncology, The Cancer Institute Hospital of JFCR</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Purpose Ipsilateral breast tumor recurrence (IBTR) remains a critical concern for patients undergoing breast-conserving surgery (BCS). Reliable risk estimation tools for IBTR risk can support personalized surgical and adjuvant treatment decisions, especially in the era of evolving systemic therapies. We aimed to develop and validate models to estimate IBTR risk.&lt;br&gt;
Patients and Methods This multicenter retrospective cohort study included 8,938 women who underwent partial mastectomy for invasive breast cancer between 2008 and 2017. Prediction models were developed using Cox proportional hazards regression and validated via bootstrap resampling. Model performance was assessed using Harrell's C-index, Brier scores, calibration plots, and goodness-of-fit tests.&lt;br&gt;
Results During a median follow-up of 9.0 years (IQR, 6.6-10.9), IBTR occurred in 320 patients (3.6%). The initial model, based on variables from Sanghani et al, achieved a Harrell's C-index of 0.74. Incorporating hormonal receptor status, human epidermal growth factor receptor 2 status, radiotherapy, and targeted therapy as predictors reduced the C-index to 0.65, despite their clinical relevance. Importantly, the inclusion of these factors improved calibration, demonstrating better alignment between predicted and observed IBTR probabilities. Although the hazard ratios (HRs) for radiotherapy aligned with the Early Breast Cancer Trialists’ Collaborative Group meta-analyses (MA), those for chemotherapy and endocrine therapy showed slight differences. Therefore, HRs from the MA were used to represent treatment effects in our model.&lt;br&gt;
Conclusion We have developed and internally validated a new risk estimation model for IBTR using Cox regression and bootstrap methods. A Web-based risk estimation tool is now available to facilitate individualized risk assessment and treatment planning.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList/>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2168-8184</Issn>
      <Volume>18</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Endoscopic Topical Application (ETA) Therapy for Refractory Overactive Bladder: A First-in-Human Report</ArticleTitle>
    <FirstPage LZero="delete">e101143</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Takuya</FirstName>
        <LastName>Sadahira</LastName>
        <Affiliation>Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masahiro</FirstName>
        <LastName>Sugihara</LastName>
        <Affiliation>Department of Surgery, Nishi Fukuyama Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yosuke</FirstName>
        <LastName>Mitsui</LastName>
        <Affiliation>Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toyohiko</FirstName>
        <LastName>Watanabe</LastName>
        <Affiliation>Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Motoo</FirstName>
        <LastName>Araki</LastName>
        <Affiliation>Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masami</FirstName>
        <LastName>Watanabe</LastName>
        <Affiliation>Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Refractory overactive bladder (OAB) remains a clinical challenge despite established therapies, such as anticholinergics, β3-agonists, and intradetrusor botulinum toxin (BTX). Emerging evidence suggests that sensory mechanisms within the bladder, including those involving the trigone where superficial afferent networks are present, may contribute to persistent urinary urgency and frequency in some patients. Although intradetrusor BTX injection is effective in selected patients, its impact on these superficial pathways may be limited because the injected drug predominantly distributes within the detrusor. Endoscopic topical application (ETA) therapy delivers BTX directly to the trigone under air cystoscopy, potentially providing targeted modulation of sensory hyperexcitability. We report a 72-year-old woman with long-standing refractory OAB who experienced only partial improvement with repeated intradetrusor BTX injections but achieved clinically meaningful symptom relief after ETA therapy. Nocturia, urgency, urgency urinary incontinence, and voided volume were improved, with no complications other than transient postoperative urethral pain. This case suggests that ETA therapy may represent a promising sensory-focused option for refractory OAB.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">bladder trigone</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">botulinum toxin</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">endoscopic topical application</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">new drug delivery systems</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">refractory overactive bladder</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Wiley</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0029-6473</Issn>
      <Volume>2026</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Knowledge and Attitudes Toward Pain Management Among Nurses in University-Affiliated Hospitals in Western Japan: A Cross-Sectional Study</ArticleTitle>
    <FirstPage LZero="delete">9991157</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Mengyao</FirstName>
        <LastName>Xi</LastName>
        <Affiliation>Graduate School of Health Sciences, Okayama University,</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuki</FirstName>
        <LastName>Kajiwara</LastName>
        <Affiliation>Faculty of Health Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takako</FirstName>
        <LastName>Hiramatsu</LastName>
        <Affiliation>Department of Nursing, Kawasaki Medical School Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Michiko</FirstName>
        <LastName>Morimoto</LastName>
        <Affiliation>Faculty of Health Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Background: Pain is a major global concern. Nurses’ knowledge and attitudes toward pain management are critical determinants of pain care quality and patient outcomes, making them essential for effective clinical practice.&lt;br&gt;
Objective: This study aimed to assess nurses’ pain management knowledge and attitudes using the Japanese version of the Knowledge and Attitudes Survey Regarding Pain (J-KASRP), applied for the first time in Japan, and to examine how background factors affect these aspects.&lt;br&gt;
Methods: A descriptive, cross-sectional survey was conducted with 1589 nurses in three university-affiliated hospitals in Western Japan. Data were collected using a questionnaire capturing sociodemographic information and the J-KASRP. Descriptive statistics, t-tests, one-way ANOVA, and effect size were used to analyze J-KASRP scores and subdomains. Tukey’s honestly significant difference test was applied for post hoc comparisons across clinical experience patterns.&lt;br&gt;
Results: Of 1001 respondents, 856 valid responses (85.5%) were analyzed. The mean age was 30.1&#8201;years (SD&#8201;=&#8201;8.3), and the mean total correct response rate for the J-KASRP was 59.8%; only 1.3% scored &#8805;&#8201;80%. Cancer-related pain had the lowest J-KASRP subdomain score (42.5%, SD = 20.3%). Higher total J-KASRP scores were found for those with a higher level of education, prior clinical pain education, and recent opioid administration experience (all p &lt; 0.001, effect size &gt; 0.2). In an exploratory pattern analysis, regardless of education level, respondents with both education and opioid administering experience had the highest total and pharmacology subdomains’ scores. No significant differences in cancer-related pain subdomain were observed across patterns of clinical experiences.&lt;br&gt;
Conclusions: This first application of the J-KASRP in Japan revealed that nurses’ pain management knowledge and attitudes need to be strengthened, especially for cancer-related pain and opioid pharmacology. The study findings highlight the importance of pain management strengthening education and training to enhance nurses’ evidence-based knowledge and clinical competence.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">knowledge andattitudes</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">nurses</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">painmanagement</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>American Society for Microbiology</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0099-2240</Issn>
      <Volume/>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Efficient resuscitation of early-stage viable but non-culturable cells of Vibrio cholerae using treatment with proteolytic enzymes</ArticleTitle>
    <FirstPage LZero="delete"/>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Shin-ichi</FirstName>
        <LastName>Miyoshi</LastName>
        <Affiliation>Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Mona</FirstName>
        <LastName>Ogasawara</LastName>
        <Affiliation>Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shiho</FirstName>
        <LastName>Niwaki</LastName>
        <Affiliation>Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Rena</FirstName>
        <LastName>Sugihara</LastName>
        <Affiliation>Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Basilua Andre</FirstName>
        <LastName>Muzembo</LastName>
        <Affiliation>Research Institute of Nursing Care for People and Community, University of Hyogo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Daisuke</FirstName>
        <LastName>Imamura</LastName>
        <Affiliation>Research Center for Intestinal Health Science, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Vibrio cholerae, the etiological agent of cholera, is ubiquitous in environmental brackish waters. Exposure to low water temperatures induces the bacterium to enter a viable but non-culturable (VBNC) state. In this study, a stepwise decrease in water temperature to 4°C was found to delay the transition to the non-culturable state compared to an abrupt temperature drop, suggesting that V. cholerae cells partially adapt to low temperatures. V. cholerae VBNC cells maintained at 4°C gradually lost their ability to revert to a culturable state. However, VBNC cells in the early stage of dormancy were efficiently resuscitated following treatment with proteolytic enzymes, including proteinase K. The abundance of culturable V. cholerae cells in brackish estuarine waters was quantified using the most probable number (MPN)&#8211;quantitative polymerase chain reaction (qPCR) method. Although culturable cells were undetectable in samples treated with bovine serum albumin, they were estimated at 93 and 1,500 MPN/mL in two water samples collected on different days and pre-incubated with proteinase K. Similarly, the abundance of Vibrio species increased markedly following treatment with this enzyme. Additionally, cells of Vibrio species were enumerated by the plating method using CHROMagar Vibrio plates. Consistent with the results of the MPN&#8211;qPCR method, treatment with proteinase K resulted in over a 100-fold increase in colony formation. Collectively, these findings suggest that treatment with proteinase K is effective for resuscitating and quantifying V. cholerae VBNC cells in environmental water samples.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Vibrio cholerae</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">viable but non-culturable</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">VBNC</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">protease</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">proteolytic enzyme</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2045-2322</Issn>
      <Volume>15</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Single cell spatial transcriptomics links Wnt signaling disruption to extracellular matrix development in a cleft palate model</ArticleTitle>
    <FirstPage LZero="delete">29639</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Jeremie Oliver</FirstName>
        <LastName>Pi&#241;a</LastName>
        <Affiliation>Section on Craniofacial Genetic Disorders, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institutes of Health (NIH)</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Resmi</FirstName>
        <LastName>Raju</LastName>
        <Affiliation>Section on Craniofacial Genetic Disorders, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institutes of Health (NIH)</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Evan</FirstName>
        <LastName>Stipano</LastName>
        <Affiliation>Section on Craniofacial Genetic Disorders, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institutes of Health (NIH)</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Aye Chan</FirstName>
        <LastName>Myo</LastName>
        <Affiliation>Section on Craniofacial Genetic Disorders, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institutes of Health (NIH)</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ziyi</FirstName>
        <LastName>Wang</LastName>
        <Affiliation>Graduate School of Medicine Dentistry and Pharmaceutical Sciences, Department of Molecular Biology and Biochemistry, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Mitsuaki</FirstName>
        <LastName>Ono</LastName>
        <Affiliation>Graduate School of Medicine Dentistry and Pharmaceutical Sciences, Department of Molecular Biology and Biochemistry, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Parna</FirstName>
        <LastName>Chattaraj</LastName>
        <Affiliation>Section on Craniofacial Genetic Disorders, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institutes of Health (NIH)</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masae</FirstName>
        <LastName>Furukawa</LastName>
        <Affiliation>Section on Craniofacial Genetic Disorders, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institutes of Health (NIH)</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Rena N.</FirstName>
        <LastName>D’Souza</LastName>
        <Affiliation>Section on Craniofacial Genetic Disorders, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institutes of Health (NIH)</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Despite advances in understanding the morphological disruptions that lead to defects in palate formation, the precise perturbations within the signaling microenvironment of palatal clefts remain poorly understood. To explore in greater depth the genomic basis of palatal clefts, we designed and implemented the first single cell spatial RNA-sequencing study in a cleft palate model, utilizing the Pax9−/− murine model at multiple developmental timepoints, which exhibits a consistent cleft palate defect. Visium HD, an emerging platform for true single-cell resolution spatially resolved transcriptomics, was employed using custom bins of 2&#8201;×&#8201;2 μm spatial gene expression data. Validation of spatial gene expression was then validated using custom designed Xenium In Situ mRNA spatial profiling and RNAscope Multiplex assays. Functional enrichment analysis revealed a palate cell-specific perturbation in Wnt signaling effector function in tandem with disrupted expression of extracellular matrix genes in developing mesenchyme. As a key step toward laying the framework for identifying key molecular targets these data can be used for translational studies aimed at developing effective therapies for human palatal clefts.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Spatial biology</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Cleft palate</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Genomics</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Single cell</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Gene expression</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Profiling</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Extracellular matrix</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Wnt</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Transcriptome</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2168-8184</Issn>
      <Volume>17</Volume>
      <Issue>11</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Perioperative Multidisciplinary Intervention Led to Complete Minimally Invasive Transthoracic Esophagectomy for a Patient With Severe Lung Dysfunction: A Case Report</ArticleTitle>
    <FirstPage LZero="delete">e97931</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Makoto</FirstName>
        <LastName>Matsumoto</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masashi</FirstName>
        <LastName>Hashimoto</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kento</FirstName>
        <LastName>Kawasaki</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomoyoshi</FirstName>
        <LastName>Kunitomo</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Naoaki</FirstName>
        <LastName>Maeda</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shunsuke</FirstName>
        <LastName>Tanabe</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuhiro</FirstName>
        <LastName>Noma</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshiyoshi</FirstName>
        <LastName>Fujiwara</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Risk factors for postoperative pneumonia after esophagectomy include smoking, severe lung dysfunction, and sarcopenia. Heavy smokers often have chronic obstructive pulmonary disease (COPD), which is associated with poor physical activity and low muscle strength. Sarcopenia is also associated with decreased physical function and malnutrition. These factors lead to a close relationship between COPD and sarcopenia. This report describes the case of a 74-year-old man who presented with dysphagia and was diagnosed with advanced esophageal cancer with lymph node metastasis. Preoperative respiratory function testing showed a forced expiratory volume in one second (FEV1) of 0.76 L because of his past smoking and COPD. Multidisciplinary intervention was started, along with neoadjuvant chemotherapy. Preoperative management improved his physical function. Robot-assisted thoracoscopic subtotal esophagectomy with the patient in the prone position was performed with curative resection and no severe postoperative complications. The perioperative multidisciplinary intervention improved physical functions and enabled safe robot-assisted thoracoscopic esophagectomy for the patient with severe lung dysfunction in the prone position. This case highlights that not only respiratory status but also physical parameters should be taken into account when considering whether a patient can tolerate surgery safely.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">copd</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">esophagectomy</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">perioperative multidisciplinary intervention</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">perioperative rehabilitation</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">respiratory function training and rehabilitation</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">sarcopenia</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">severe pulmonary dysfunction</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>American Association for the Advancement of Science (AAAS)</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2375-2548</Issn>
      <Volume>11</Volume>
      <Issue>44</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Structural insights into the divergent evolution of a photosystem I supercomplex in Euglena gracilis</ArticleTitle>
    <FirstPage LZero="delete">eaea6241</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Koji</FirstName>
        <LastName>Kato</LastName>
        <Affiliation>Research Institute for Interdisciplinary Science, Advanced Research Field, and Graduate School of Environmental, Life, Natural Science and Technology, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshiki</FirstName>
        <LastName>Nakajima</LastName>
        <Affiliation>Research Institute for Interdisciplinary Science, Advanced Research Field, and Graduate School of Environmental, Life, Natural Science and Technology, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Runa</FirstName>
        <LastName>Sakamoto</LastName>
        <Affiliation>Research Institute for Interdisciplinary Science, Advanced Research Field, and Graduate School of Environmental, Life, Natural Science and Technology, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Minoru</FirstName>
        <LastName>Kumazawa</LastName>
        <Affiliation>Institute of Low Temperature Science, Hokkaido University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kentaro</FirstName>
        <LastName>Ifuku</LastName>
        <Affiliation>Graduate School of Agriculture, Kyoto University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takahiro</FirstName>
        <LastName>Ishikawa</LastName>
        <Affiliation>Institute of Agricultural and Life Sciences, Academic Assembly, Shimane University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Jian-Ren</FirstName>
        <LastName>Shen</LastName>
        <Affiliation>Research Institute for Interdisciplinary Science, Advanced Research Field, and Graduate School of Environmental, Life, Natural Science and Technology, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Atsushi</FirstName>
        <LastName>Takabayashi</LastName>
        <Affiliation>Institute of Low Temperature Science, Hokkaido University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryo</FirstName>
        <LastName>Nagao</LastName>
        <Affiliation>Faculty of Agriculture, Shizuoka University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Photosystem I (PSI) forms supercomplexes with light-harvesting complexes (LHCs) to perform oxygenic photosynthesis. Here, we report a 2.82-angstrom cryo&#8211;electron microscopy structure of the PSI-LHCI supercomplex from Euglena gracilis, a eukaryotic alga with secondary green alga-derived plastids. The structure reveals a PSI monomer core with eight subunits and 13 asymmetrically arranged LHCI proteins. Euglena LHCIs bind diadinoxanthin, which is one of the carotenoids typically associated with red-lineage LHCs and is not present in the canonical LHCI belt found in green-lineage PSI-LHCI structures. Phylogenetic analysis shows that the Euglena LHCIs originated from LHCII-related clades rather than from the green-lineage LHCI group and that the nuclear-encoded PSI subunit PsaD likely originated from cyanobacteria via horizontal gene transfer. These observations indicate a mosaic origin of the Euglena PSI-LHCI. Our findings uncover a noncanonical light-harvesting architecture and highlight the structural and evolutionary plasticity of photosynthetic systems, illustrating how endosymbiotic acquisition and lineage-specific adaptation shape divergent light-harvesting strategies.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList/>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Spandidos Publications</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2049-9450</Issn>
      <Volume>23</Volume>
      <Issue>5</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Prolonged exposure to axitinib alters the molecular profile of Caki&#8209;2 renal cell carcinoma cells</ArticleTitle>
    <FirstPage LZero="delete">101</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Yuko</FirstName>
        <LastName>Nakayama</LastName>
        <Affiliation>Department of Clinical Pharmaceutics, Faculty of Pharmaceutical Sciences, Himeji Dokkyo University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Aya</FirstName>
        <LastName>Ino</LastName>
        <Affiliation>Department of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmaceutical Sciences, Hyogo Medical University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuhiro</FirstName>
        <LastName>Yamamoto</LastName>
        <Affiliation>Department of Integrated Clinical and Basic Pharmaceutical Sciences, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kohji</FirstName>
        <LastName>Takara</LastName>
        <Affiliation>Department of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmaceutical Sciences, Hyogo Medical University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Axitinib, an oral second&#8209;generation multitargeted tyrosine kinase inhibitor, is used as a second&#8209;line treatment for metastatic renal cell carcinoma (RCC). However, patients often develop resistance after initial responsiveness, necessitating the elucidation of the underlying resistance mechanisms. Therefore, the present study aimed to investigate the mechanisms underlying axitinib resistance using the Caki&#8209;2 human papillary RCC model cells. Cells tolerating 0.1 &#181;M axitinib were designated as Caki/AX cells. Cell viability was assessed using the water&#8209;soluble tetrazolium salt assay. Notably, the 50% inhibitory concentration (IC50) values of axitinib and sunitinib were significantly higher in Caki/AX cells than those in Caki&#8209;2 cells, indicating 2.83&#8209; and 1.2&#8209;fold resistance, respectively. By contrast, the IC50 values of sorafenib and erlotinib were decreased in Caki/AX cells. Moreover, Caki/AX cells showed resistance to everolimus, temsirolimus and rapamycin, and decreased sensitivity to vinblastine, vincristine, paclitaxel, doxorubicin and SN&#8209;38 compared with Caki&#8209;2 cells. Notably, etoposide, 5&#8209;fluorouracil, cisplatin and carboplatin sensitivities were comparable in both cell types. Reverse transcription&#8209;quantitative polymerase chain reaction (PCR) analysis revealed that the mRNA levels of the ATP&#8209;binding cassette subfamily B member 1 and subfamily G member 2 were significantly higher in Caki/AX cells than those in Caki&#8209;2 cells. A PCR array related to vascular endothelial growth factor signalling showed that the mRNA levels of FIGF (also known as vascular endothelial growth factor D) and sphingosine kinase 1 were upregulated, whereas those of Rac family small GTPase 2 were downregulated in Caki/AX cells. Overall, these findings suggested that the upregulation of the ATP&#8209;binding cassette subfamily B member 1, FIGF and sphingosine kinase 1 mRNA levels, and downregulation of the Rac family small GTPase 2 mRNA levels may contribute to acquired resistance in Caki/AX cells.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">axitinib</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">renal cell carcinoma</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">drug resistance</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">ABC transporter</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Wiley</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1347-9032</Issn>
      <Volume/>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Genotype&#8211;Phenotype Correlations of Li&#8211;Fraumeni Syndrome in Japan Children's Cancer Group LFS20 Study Cohort</ArticleTitle>
    <FirstPage LZero="delete"/>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Fumito</FirstName>
        <LastName>Yamazaki</LastName>
        <Affiliation>Department of Pediatrics, Keio University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshiko</FirstName>
        <LastName>Nakano</LastName>
        <Affiliation>Department of Genetic Medicine and Services, National Cancer Center Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masashi</FirstName>
        <LastName>Sanada</LastName>
        <Affiliation>Department of Advanced Diagnosis, Clinical Research Center, NHO Nagoya Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroki</FirstName>
        <LastName>Kurahashi</LastName>
        <Affiliation>Division of Molecular Genetics, Center for Medical Science, Fujita Health University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shunsuke</FirstName>
        <LastName>Miyai</LastName>
        <Affiliation>Division of Molecular Genetics, Center for Medical Science, Fujita Health University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Arisa</FirstName>
        <LastName>Ueki</LastName>
        <Affiliation>Department of Clinical Genetic Oncology, Cancer Institute Hospital of Japanese Foundation for Cancer Research</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuko</FirstName>
        <LastName>Watanabe</LastName>
        <Affiliation>Department of Pediatric Oncology, National Cancer Center Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Daisuke</FirstName>
        <LastName>Hasegawa</LastName>
        <Affiliation>Department of Pediatrics, St. Luke's International Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shuhei</FirstName>
        <LastName>Karakawa</LastName>
        <Affiliation>Department of Pediatrics, Hiroshima University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshifumi</FirstName>
        <LastName>Ozaki</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Akira</FirstName>
        <LastName>Hirasawa</LastName>
        <Affiliation>Department of Clinical Genomic Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Akiko M.</FirstName>
        <LastName>Saito</LastName>
        <Affiliation>Clinical Research Center, NHO Nagoya Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Eisuke</FirstName>
        <LastName>Inoue</LastName>
        <Affiliation>Showa Medical University Research Administration Center, Showa Medical University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Motohiro</FirstName>
        <LastName>Kato</LastName>
        <Affiliation>Department of Pediatrics, The University of Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroyoshi</FirstName>
        <LastName>Hattori</LastName>
        <Affiliation>Department of Clinical Genetics, NHO Nagoya Medical Center</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Li&#8211;Fraumeni syndrome (LFS) is a cancer predisposition syndrome caused by germline pathogenic variants in the TP53 gene. With the increasing use of multi-gene panel testing, TP53 variants have been identified in individuals who do not meet established TP53 testing criteria, such as the Chompret criteria. The term “attenuated LFS” has been proposed for some of these cases, particularly those with adult-onset cancer. We analyzed participants of the Japanese nationwide prospective clinical trial of the cancer surveillance program (Japan Children's Cancer Group LFS-20), along with clinical information including their family histories, to better understand their genotypic and phenotypic characteristics. We identified 32 distinct TP53 variants from 41 families (45 participants), including four missense variants with conflicting classifications of pathogenicity in ClinVar. Among these families, 36 (88%) met the LFS criteria (hereafter referred to as “LFS” in contrast to attenuated LFS), while 5 (12%) were classified as attenuated LFS. Including 30 additional family members carrying the same variant, we analyzed 75 individuals with TP53 variants. Of these, 40 with LFS and 6 with attenuated LFS had cancer. Multiple primary cancers occurred in 22 individuals (21 LFS, 1 attenuated LFS). LFS-core tumors accounted for 66% (58/88) of cancers in the LFS group and 63% (5/8) in the attenuated LFS group; of note, all core tumors in the attenuated group were limited to breast cancer. Hotspot missense variants were detected in 11 of 36 LFS families and in none of 5 attenuated LFS families, and non-hotspot null variants were found in 14 and 1, respectively. Our study revealed genotype&#8211;phenotype correlations in several respects. UMIN-CTR: UMIN000045855.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">cancer predisposition</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">genotype&#8211;phenotype correlations</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">hotspot variants</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Li&#8211;Fraumeni syndrome</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">TP53</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Wiley</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1347-9032</Issn>
      <Volume/>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Atezolizumab + Chemotherapy for Advanced Non-Small Cell Lung Cancer in Japanese Clinical Practice (J-TAIL-2)</ArticleTitle>
    <FirstPage LZero="delete"/>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Hiroshige</FirstName>
        <LastName>Yoshioka</LastName>
        <Affiliation>Department of Thoracic Oncology, Kansai Medical University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Makoto</FirstName>
        <LastName>Nishio</LastName>
        <Affiliation>Department of Thoracic Medical Oncology, Cancer Institute Hospital of Japanese Foundation for Cancer Research</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kadoaki</FirstName>
        <LastName>Ohashi</LastName>
        <Affiliation>Department of Respiratory Medicine, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Atsushi</FirstName>
        <LastName>Osoegawa</LastName>
        <Affiliation>Department of Thoracic and Breast Surgery, Oita University Faculty of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Eiki</FirstName>
        <LastName>Kikuchi</LastName>
        <Affiliation>Department of Respiratory Medicine, Faculty of Medicine, Hokkaido University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hideharu</FirstName>
        <LastName>Kimura</LastName>
        <Affiliation>Department of Respiratory Medicine, Kanazawa University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yasushi</FirstName>
        <LastName>Goto</LastName>
        <Affiliation>Department of Thoracic Oncology, National Cancer Center Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Junichi</FirstName>
        <LastName>Shimizu</LastName>
        <Affiliation>Department of Thoracic Oncology, Aichi Cancer Center Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Eisaku</FirstName>
        <LastName>Miyauchi</LastName>
        <Affiliation>Department of Respiratory Medicine, Tohoku University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ichiro</FirstName>
        <LastName>Yoshino</LastName>
        <Affiliation>International University of Health and Welfare, Narita Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshihiro</FirstName>
        <LastName>Misumi</LastName>
        <Affiliation>Department of Data Science, National Cancer Center Hospital East</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yasutaka</FirstName>
        <LastName>Watanabe</LastName>
        <Affiliation>Department of Thoracic Oncology, Saitama Cancer Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Akito</FirstName>
        <LastName>Hata</LastName>
        <Affiliation>Division of Thoracic Oncology, Kobe Minimally Invasive Cancer Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Akira</FirstName>
        <LastName>Kisohara</LastName>
        <Affiliation>Department of Respiratory Medicine, Kasukabe Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shoichi</FirstName>
        <LastName>Kuyama</LastName>
        <Affiliation>Department of Respiratory Medicine, NHO Iwakuni Clinical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masafumi</FirstName>
        <LastName>Yamaguchi</LastName>
        <Affiliation>Department of Thoracic Oncology, NHO Kyushu Cancer Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Asako</FirstName>
        <LastName>Miwa</LastName>
        <Affiliation>Chugai Pharmaceutical Co., Ltd.</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shunichiro</FirstName>
        <LastName>Iwasawa</LastName>
        <Affiliation>Chugai Pharmaceutical Co., Ltd.</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Misa</FirstName>
        <LastName>Tanaka</LastName>
        <Affiliation>Chugai Pharmaceutical Co., Ltd.</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Akihiko</FirstName>
        <LastName>Gemma</LastName>
        <Affiliation>Nippon Medical School</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>First-line atezolizumab combination therapies were approved for the treatment of metastatic non-small cell lung cancer (NSCLC) based on results from the global phase 3 trials IMpower130, IMpower132, and IMpower150. These trials reported 12-month overall survival (OS) rates of 60%&#8211;67% with atezolizumab combination therapy. J-TAIL-2 (NCT04501497), a prospective, multicenter, observational study, evaluated atezolizumab combination therapy in routine clinical practice in Japan. Patients &#8805;&#8201;20&#8201;years old with NSCLC received atezolizumab plus carboplatin and nab-paclitaxel (atezo + CnP), atezolizumab plus carboplatin or cisplatin plus pemetrexed (atezo + PP), or atezolizumab plus bevacizumab plus carboplatin and paclitaxel (atezo + bev&#8201;+&#8201;CP) in clinical practice. The primary endpoint was the 12-month OS rate. Secondary endpoints included OS, progression-free survival, and subgroup analyses, including IMpower-unlike (did not meet the main eligibility criteria of each IMpower trial) and IMpower-like patients. In total, 814 patients were enrolled (atezo + CnP, n&#8201;=&#8201;217; atezo + PP, n&#8201;=&#8201;211; atezo + bev&#8201;+&#8201;CP, n&#8201;=&#8201;386). The IMpower-unlike group included patients with Eastern Cooperative Oncology Group performance status &#8805;&#8201;2, autoimmune disease, or interstitial lung disease. Twelve-month OS rates (95% confidence interval [CI]) were 62.9% (55.8&#8211;69.2), 72.1% (65.2&#8211;77.9), and 68.3% (63.2&#8211;72.9) with atezo + CnP, atezo + PP, and atezo + bev&#8201;+&#8201;CP, respectively. OS hazard ratios (95% CI) in the IMpower-unlike vs. -like subgroups were 1.36 (0.91&#8211;2.05), 1.08 (0.70&#8211;1.68), and 1.49 (1.09&#8211;2.06), respectively. No new safety signals were observed. Real-world efficacy and safety for each atezolizumab combination were comparable to those in the relevant IMpower trials.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">atezolizumab</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">chemotherapy</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">lung cancer</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">non-small cell</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">observational</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2366-1070</Issn>
      <Volume>13</Volume>
      <Issue>4</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Asian Subgroup Analysis of Patients in the Phase 2 DeLLphi-301 Study of Tarlatamab for Previously Treated Small Cell Lung Cancer</ArticleTitle>
    <FirstPage LZero="delete">1041</FirstPage>
    <LastPage>1054</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Myung-Ju</FirstName>
        <LastName>Ahn</LastName>
        <Affiliation>Hematology-Oncology Department, Samsung Medical Center (SMC), Sungkyunkwan University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Byoung Chul</FirstName>
        <LastName>Cho</LastName>
        <Affiliation>Medical Oncology Department-501, ABMRC, Yonsei University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kadoaki</FirstName>
        <LastName>Ohashi</LastName>
        <Affiliation>Department of Respiratory Medicine, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroki</FirstName>
        <LastName>Izumi</LastName>
        <Affiliation>Thoracic Oncology, National Cancer Center Hospital East</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Jong-Seok</FirstName>
        <LastName>Lee</LastName>
        <Affiliation>Hematology/Oncology, Seoul National University Bundang Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ji-Youn</FirstName>
        <LastName>Han</LastName>
        <Affiliation>Center for Lung Cancer, National Cancer Center-Graduate School of Cancer Science and Policy</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Chi-Lu</FirstName>
        <LastName>Chiang</LastName>
        <Affiliation>Department of Chest Medicine, Taipei Veterans General Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shuang</FirstName>
        <LastName>Huang</LastName>
        <Affiliation>Amgen Inc.</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ali</FirstName>
        <LastName>Hamidi</LastName>
        <Affiliation>Amgen Inc.</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Sujoy</FirstName>
        <LastName>Mukherjee</LastName>
        <Affiliation>Amgen Inc.</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Krista Lin</FirstName>
        <LastName>Xu</LastName>
        <Affiliation>Amgen Asia Pacific Pte. Ltd.</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiraoki</FirstName>
        <LastName>Akamatsu</LastName>
        <Affiliation>Internal Medicine III, Wakayama Medical University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Introduction: Tarlatamab is a bispecific T-cell engager (BiTE&#174;) immunotherapy that binds delta-like ligand 3 on the surface of small cell lung cancer (SCLC) cells and CD3 on T cells, facilitating T cell-mediated cancer cell lysis. In the primary analysis of the phase 2 DeLLphi-301 study (NCT05060016), tarlatamab showed a favourable benefit-to-risk profile with durable objective responses and promising survival outcomes in patients with previously treated SCLC. Here, phase 2 data for the Asia region subgroup are presented.&lt;br&gt;
Methods: Patients with previously treated, advanced SCLC received 10 mg tarlatamab every 2 weeks. The primary endpoint was objective response rate (ORR) by blinded independent central review (RECIST version 1.1). Key secondary endpoints included duration of response (DOR), progression-free survival (PFS), overall survival (OS) and safety. The present analysis includes patients enrolled at sites in Asia.&lt;br&gt;
Results: A total of 43 patients were enrolled at sites in Asia. ORR was 46.3% (95% confidence interval [CI], 30.7&#8211;62.6) and median DOR was 7.2 months (95% CI 3.9 to not estimable). The median follow-up was 16.6 months for PFS and 21.2 months for OS. Median PFS was 5.4 months (95% CI 3.0&#8211;8.1) and median OS was 19.0 months (95% CI 11.4 to not estimable). The most common treatment-emergent adverse event (AE) was cytokine release syndrome (48.8%), and all such events were grade 1 or 2. There were no discontinuations due to treatment-related AEs.&lt;br&gt;
Conclusions: Tarlatamab demonstrated durable responses and promising survival outcomes with a manageable safety profile in this post hoc analysis of patients from Asia with previously treated SCLC.&lt;br&gt;
Trial Registration: ClinicalTrials.gov, NCT05060016.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Small cell lung cancer (SCLC)</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Tarlatamab</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">DLL3</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Bispecific T-cell engager</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Asian patients</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Wiley</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0919-8172</Issn>
      <Volume/>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Daytime Bladder Control Status in Toddlerhood Is Associated With Subsequent Bedwetting in Preschool Years: A Nationwide Cohort Study of Over 30&#8201;000 Japanese Children</ArticleTitle>
    <FirstPage LZero="delete"/>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Takatoshi</FirstName>
        <LastName>Moriwake</LastName>
        <Affiliation>Department of Urology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Naomi</FirstName>
        <LastName>Matsumoto</LastName>
        <Affiliation>Department of Epidemiology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yusuke</FirstName>
        <LastName>Tominaga</LastName>
        <Affiliation>Department of Urology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kensuke</FirstName>
        <LastName>Uraguchi</LastName>
        <Affiliation>Department of Epidemiology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomoko</FirstName>
        <LastName>Kobayashi</LastName>
        <Affiliation>Department of Urology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ichiro</FirstName>
        <LastName>Tsuboi</LastName>
        <Affiliation>Department of Urology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kasumi</FirstName>
        <LastName>Yoshinaga</LastName>
        <Affiliation>Department of Urology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomoaki</FirstName>
        <LastName>Yamanoi</LastName>
        <Affiliation>Department of Urology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tatsushi</FirstName>
        <LastName>Kawada</LastName>
        <Affiliation>Department of Urology Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University  Okayama Japan</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takuya</FirstName>
        <LastName>Sadahira</LastName>
        <Affiliation>Department of Urology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Satoshi</FirstName>
        <LastName>Katayama</LastName>
        <Affiliation>Department of Urology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takehiro</FirstName>
        <LastName>Iwata</LastName>
        <Affiliation>Department of Urology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shingo</FirstName>
        <LastName>Nishimura</LastName>
        <Affiliation>Department of Urology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kensuke</FirstName>
        <LastName>Bekku</LastName>
        <Affiliation>Department of Urology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kohei</FirstName>
        <LastName>Edamura</LastName>
        <Affiliation>Department of Urology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Soshi</FirstName>
        <LastName>Takao</LastName>
        <Affiliation>Department of Epidemiology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takashi</FirstName>
        <LastName>Yorifuji</LastName>
        <Affiliation>Department of Epidemiology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Motoo</FirstName>
        <LastName>Araki</LastName>
        <Affiliation>Department of Urology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Objectives: Nocturnal enuresis is common in early childhood. While daytime bladder control typically precedes nighttime continence, the temporal relationship between early daytime bladder control and subsequent bedwetting remains unclear. We investigated whether daytime bladder control status at age 2.5&#8201;years―as indicated by diaper use―is associated with bedwetting at age 4.5&#8201;years in a Japanese nationwide cohort.&lt;br&gt;
Methods: We analyzed data from the Japanese Longitudinal Survey of Newborns in the 21st Century (2010 cohort). Daytime bladder control was assessed at age 2.5&#8201;years through caregiver-reported diaper use, and bedwetting frequency at age 4.5&#8201;years through parental questionnaires. Modified Poisson regression estimated risk ratios (RRs), adjusting for birth-related factors, socioeconomic status, daycare attendance, and developmental milestones.&lt;br&gt;
Results: Among 32&#8201;168 children, 26&#8201;651 (82.8%) still used diapers at 2.5&#8201;years. Bedwetting prevalence at 4.5&#8201;years was 42.2%: 34.5% in children who achieved daytime bladder control at 2.5&#8201;years versus 43.9% in those still using diapers. After multivariable adjustment, incomplete daytime bladder control at 2.5&#8201;years was associated with higher bedwetting risk (adjusted RR 1.25; 95% CI, 1.20&#8211;1.31). Multinomial regression revealed dose&#8211;response relationships: odds ratios 1.41 (95% CI, 1.30&#8211;1.52) for “sometimes” and 1.58 (95% CI, 1.42&#8211;1.77) for “often” bedwetting.&lt;br&gt;
Conclusions: Daytime bladder control status at 2.5&#8201;years was associated with a 25% increased bedwetting risk at 4.5&#8201;years. This association likely reflects individual differences in bladder control maturation rather than causal effects. While daytime bladder control may serve as a developmental marker, its validity as an intervention target remains unestablished.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">bedwetting</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">cohort study</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">daytime bladder control</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">nocturnal enuresis</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>European Respiratory Society (ERS)</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2312-0541</Issn>
      <Volume>11</Volume>
      <Issue>6</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Global trends in idiopathic pulmonary fibrosis mortality rates during 2001&#8211;2022</ArticleTitle>
    <FirstPage LZero="delete">00362-2025</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Ko</FirstName>
        <LastName>Harada</LastName>
        <Affiliation>Brookdale Department of Geriatrics and Palliative Medicine, Icahn School of Medicine at Mount Sinai</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshito</FirstName>
        <LastName>Nishimura</LastName>
        <Affiliation>Division of Hematology/Oncology, Mayo Clinic</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Quynh Thi</FirstName>
        <LastName>Vu</LastName>
        <Affiliation>Department of Health Data Science, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Maki</FirstName>
        <LastName>Yamamoto</LastName>
        <Affiliation>Department of Health Data Science, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshihiro</FirstName>
        <LastName>Koyama</LastName>
        <Affiliation>Department of Health Data Science, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hideharu</FirstName>
        <LastName>Hagiya</LastName>
        <Affiliation>Department of Infectious Diseases, Okayama University Hospital</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Background Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive and ultimately fatal lung disease. Updated global mortality data, especially from underexplored countries, are limited. This study aimed to understand the current global trends in IPF-associated mortality rates.&lt;br&gt;
Methods This observational study used the World Health Organization Mortality Database to analyse data stratified by sex, age and geographic region, encompassing 64 countries between 2001 and 2022. IPF was defined according to the International Code for Diseases-10 code J84.1. Crude and age-standardised mortality rates per 100&#8201;000 individuals were calculated to estimate long-term mortality trends. Mortality rates were calculated by dividing IPF-associated deaths by the corresponding population, with age-specific rates determined for each 5-year age group. Trends in the 2001&#8211;2022 period were analysed using a locally weighted regression model, and the average annual percentage change in mortality rates between 2010 and 2022 was estimated using joinpoint regression analysis.&lt;br&gt;
Results Overall, 874&#8201;998 deaths associated with IPF were analysed. The LOESS-smoothed crude mortality rate increased from 2.10 (95% confidence interval (CI) 1.77&#8211;2.43) per 100&#8201;000 in 2001 to 3.14 (95% CI 2.71&#8211;3.57) per 100&#8201;000 by 2022. The LOESS-smoothed age-standardised mortality rates increased overall, peaking at 1.59 (95% CI 1.51&#8211;1.67) per 100&#8201;000 in 2018 and declining slightly to 1.57 (95% CI 1.35&#8211;1.79) per 100&#8201;000 in 2022. Mortality was higher among males than females; furthermore, 87.5% of deaths occurred in individuals aged &#8805;65&#8197;years. Mortality rates were highest among the American population, with a notable increase in Latin American countries.&lt;br&gt;
Conclusion IPF-associated mortality rates have increased globally, particularly in males. Significant geographical, age and sex disparities were observed, emphasising the need for targeted public health measures and improved disease management.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList/>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0300-8126</Issn>
      <Volume/>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Hospital-acquired pneumonia caused by multidrug-resistant Streptococcus pneumoniae serotype 15A</ArticleTitle>
    <FirstPage LZero="delete"/>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Hidemasa</FirstName>
        <LastName>Akazawa</LastName>
        <Affiliation>Department of Infectious Diseases, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shinnosuke</FirstName>
        <LastName>Fukushima</LastName>
        <Affiliation>Department of Infectious Diseases, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kenta</FirstName>
        <LastName>Nakamoto</LastName>
        <Affiliation>Department of Infectious Diseases, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kohei</FirstName>
        <LastName>Oguni</LastName>
        <Affiliation>Department of Infectious Diseases, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Madoka</FirstName>
        <LastName>Shimbe</LastName>
        <Affiliation>Department of Infectious Diseases, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Bin</FirstName>
        <LastName>Chang</LastName>
        <Affiliation>Department of Bacteriology I, National Institute of Infectious Diseases, Japan Institute for Health Security</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yukihiro</FirstName>
        <LastName>Akeda</LastName>
        <Affiliation>Department of Bacteriology I, National Institute of Infectious Diseases, Japan Institute for Health Security</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hideharu</FirstName>
        <LastName>Hagiya</LastName>
        <Affiliation>Department of Infectious Diseases, Okayama University Hospital</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Background Streptococcus pneumoniae remains a common cause of community-acquired pneumonia but is an infrequent pathogen in hospital-acquired pneumonia (HAP). Non-vaccine serotypes of multidrug-resistant (MDR) S. pneumoniae strains have been emerging globally, posing an increased risk of nosocomial infection.&lt;br&gt;
Case A 71 year-old man developed pneumonia on postoperative day 4 following spinal fusion surgery. Despite initial treatment with ampicillin/sulbactam, his condition deteriorated, requiring ICU admission and mechanical ventilation. Microbiological testing confirmed S. pneumoniae as a causative pathogen, and ceftriaxone was empirically administered based on the local antibiogram. However, antimicrobial susceptibility testing revealed resistant profiles to penicillin (minimum inhibitory concentration [MIC], 8 &#181;g/mL), ceftriaxone (MIC, 16 &#181;g/mL), meropenem (MIC, 1 &#181;g/mL), macrolides, and clindamycin, while demonstrating susceptibility to levofloxacin and vancomycin. The therapeutic regimen was subsequently adjusted to levofloxacin, resulting in clinical improvement. The isolate was later identified as serotype 15A, sequence type 63 (ST63).&lt;br&gt;
Conclusion This case highlights that MDR S. pneumoniae can cause early-onset HAP and may not be covered by standard empiric therapies, emphasizing the need for careful evaluation of treatment response. Continued surveillance of infections caused by vaccine-escape clones like MDR serotype 15A is essential, given their increasing clinical relevance.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Antimicrobial resistance</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Multidrug-resistant</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Nosocomial infection</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Sequence type 63</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Serotype 15A</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Streptococcus pneumoniae</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0301-486X</Issn>
      <Volume>190</Volume>
      <Issue>6</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Prognostic Value of Serum (1→3)-β-D-Glucan Levels in Patients with Candidemia Stratified by Compliance with Candida Bundle: A Multicenter Retrospective Cohort Study (2016&#8211;2023)</ArticleTitle>
    <FirstPage LZero="delete">90</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Hidemasa</FirstName>
        <LastName>Akazawa</LastName>
        <Affiliation>Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shinnosuke</FirstName>
        <LastName>Fukushima</LastName>
        <Affiliation>Department of Infectious Diseases, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshie</FirstName>
        <LastName>Higuchi</LastName>
        <Affiliation>Department of General Internal Medicine, Okayama Red Cross Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomoko</FirstName>
        <LastName>Miyoshi</LastName>
        <Affiliation>Center for Medical Education and Internationalization, Kyoto University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yasuhiro</FirstName>
        <LastName>Nakano</LastName>
        <Affiliation>Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Koji</FirstName>
        <LastName>Iio</LastName>
        <Affiliation>Microbiology Division, Clinical Laboratory, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yukinobu</FirstName>
        <LastName>Akamatsu</LastName>
        <Affiliation>Department of General Medicine, Tottori Municipal Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuto</FirstName>
        <LastName>Haruki</LastName>
        <Affiliation>Department of Pharmacy, Tsuyama Chuo Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshitaka</FirstName>
        <LastName>Iwamoto</LastName>
        <Affiliation>Department of General Medicine, NHO Okayama Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shuichi</FirstName>
        <LastName>Tanaka</LastName>
        <Affiliation>Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shun</FirstName>
        <LastName>Fujisato</LastName>
        <Affiliation>Department of Pharmacy, Okayama Rousai Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Soichiro</FirstName>
        <LastName>Ako</LastName>
        <Affiliation>Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hideharu</FirstName>
        <LastName>Hagiya</LastName>
        <Affiliation>Department of Infectious Diseases, Okayama University Hospital</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Background Candidemia is a severe systemic infection with a high mortality risk. While β-D-glucan (BDG) serves as a diagnostic biomarker, its prognostic value in candidemia, particularly in association with Candida bundle compliance, remains unclear.&lt;br&gt;
Methods In this retrospective multicenter cohort study, we evaluated 96 patients with candidemia across nine Japanese hospitals between 2016 and 2023. Candida bundle compliance was assessed using five key components: central venous catheter removal within 24 h of diagnosis, appropriate initial antifungal therapy, ophthalmologic examination, follow-up blood cultures until clearance, and antifungal therapy for at least two weeks post-clearance. Analyses stratified patients by serum BDG status (positive/negative) and compliance with the Candida bundle (high: 4&#8211;5 points; low: 0&#8211;3 points). The primary outcome was 30-day mortality, and the secondary outcome was defined as endophthalmitis incidence.&lt;br&gt;
Results Of 96 eligible patients with candidemia, 70 (72.9%) were BDG-positive and 26 (27.1%) were BDG-negative. The overall 30-day mortality was 17.7%. Among BDG-positive patients, 15 (21.4%) died, while 2 (7.7%) died in BDG-negative cohorts (p&#8201;=&#8201;0.09). Serum BDG positivity demonstrated a statistically significant association with decreased survival rates in the low bundle adherence group (p&#8201;=&#8201;0.02), whereas this correlation was not observed among patients in the high-compliance cohort (p&#8201;=&#8201;0.66). Endophthalmitis occurred in 25.0% of patients, without significant correlation to serum BDG status. C. albicans was associated with a significantly higher incidence of endophthalmitis compared with non-albicans species (45.7% vs. 8.9%).&lt;br&gt;
Conclusions Serum BDG positivity potentially correlates with worse survival in candidemia, particularly in patients with low bundle compliance. This emphasizes the importance of adherence to standardized Candida management protocols for optimizing patient outcomes.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Candidemia</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Prognosis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">β-D-glucan</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Candida bundle</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Endophthalmitis</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Elsevier BV</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2688-1152</Issn>
      <Volume>6</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Severe Intracranial Infection</ArticleTitle>
    <FirstPage LZero="delete">100026</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Shinnosuke</FirstName>
        <LastName>Fukushima</LastName>
        <Affiliation>Department of Infectious Diseases, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takumi</FirstName>
        <LastName>Fujimori</LastName>
        <Affiliation>Microbiology Division, Clinical Laboratory, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Koji</FirstName>
        <LastName>Iio</LastName>
        <Affiliation>Microbiology Division, Clinical Laboratory, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hideharu</FirstName>
        <LastName>Hagiya</LastName>
        <Affiliation>Department of Infectious Diseases, Okayama University Hospital</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract/>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">bloodstream infection</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">brain abscess</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">mixed infection</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Public Library of Science (PLoS)</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1932-6203</Issn>
      <Volume>20</Volume>
      <Issue>9</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Impact of COVID-19 on the awareness and interest in infectious disease specialization among Japanese medical students</ArticleTitle>
    <FirstPage LZero="delete">e0329451</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Naruto</FirstName>
        <LastName>Kamada</LastName>
        <Affiliation>Faculty of Medicine, Wakayama Medical University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hideharu</FirstName>
        <LastName>Hagiya</LastName>
        <Affiliation>Department of Infectious Diseases, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Satoshi</FirstName>
        <LastName>Kutsuna</LastName>
        <Affiliation>Department of Infection Control and Prevention, Graduate School of Medicine, Osaka University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Background&lt;br&gt;
The SARS-CoV-2 pandemic has highlighted the critical deficiency of infectious disease (ID) specialists, a subspecialty that remains underrepresented among Japanese medical students.&lt;br&gt;
Methods&lt;br&gt;
This nationwide cross-sectional survey was administered between April and August 2024 via an online questionnaire distributed to medical students throughout Japan. The survey assessed awareness of and interest in ID specialization, categorizing students by academic year: lower (first- and second-year students), middle (third- and fourth-year students), and upper grades (fifth- and sixth-year students).&lt;br&gt;
Results&lt;br&gt;
Of 502 respondents, data for 492 medical students were eligible, of whom 69.7% demonstrated awareness of ID specialists, with recognition rates increasing proportionally with academic progression. Regarding career aspirations, 9.8% of respondents expressed interest in pursuing ID specialization, with the highest proportion observed among upper-grade students (19.4%). Male students (14.8%) expressed greater interest in ID specialization than female students (5.2%). The pandemic positively influenced 5.5% of students to consider ID specialization as a future career, whereas only 0.6% reported a negative impact.&lt;br&gt;
Conclusions&lt;br&gt;
These findings underscore the necessity of enhanced educational initiatives to promote ID specialization among medical students, addressing current shortages and future infectious disease preparedness.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList/>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0925-5710</Issn>
      <Volume>122</Volume>
      <Issue>5</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Intravenous umbilical cord-derived mesenchymal stromal cell therapy may improve overall survival in Japanese patients with idiopathic pneumonia syndrome after hematopoietic stem cell transplantation: a multicenter, single-arm, phase II trial</ArticleTitle>
    <FirstPage LZero="delete">733</FirstPage>
    <LastPage>743</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Noriko</FirstName>
        <LastName>Doki</LastName>
        <Affiliation>Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Nobuharu</FirstName>
        <LastName>Fujii</LastName>
        <Affiliation>Department of Hematology and Oncology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shinichi</FirstName>
        <LastName>Kako</LastName>
        <Affiliation>Division of Hematology, Jichi Medical University Saitama Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Emiko</FirstName>
        <LastName>Sakaida</LastName>
        <Affiliation>Department of Hematology, Chiba University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshinobu</FirstName>
        <LastName>Kanda</LastName>
        <Affiliation>Division of Hematology, Department of Medicine, Jichi Medical University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Idiopathic pneumonia syndrome (IPS) is a serious complication of allogeneic hematopoietic stem cell transplantation (HSCT) and has a poor prognosis. Although IPS is often treated with steroids, the disease can become resistant to or dependent on steroid treatment, and there is no effective cure for patients with refractory or steroid-dependent IPS. This multicenter, open-label, single-arm, phase II clinical trial investigated the efficacy and safety of HLC-001 (allogeneic umbilical cord-derived mesenchymal stromal cells) in patients with progressive steroid-dependent or refractory IPS after HSCT. Seven male patients (all male; mean age: 43.3 years) received HLC-001 and three completed the trial. The survival rate at day 56 (primary endpoint) was 71.4% (5/7 patients; 95% confidence interval: 29.0%&#8211;96.3%) and was sustained at day 100, suggesting that HLC-001 was more effective than previously reported treatment. Three of the five patients with &#8805;&#8201;100 days of follow-up died. Five patients experienced at least one adverse drug reaction, none of which were serious. These findings indicate that HLC-001 was potentially effective and generally well tolerated in Japanese patients with steroid-dependent or refractory IPS after HSCT. Given there is no effective cure for steroid-dependent or refractory IPS, HLC-001 may be a promising treatment option and further clinical evaluation is warranted.&lt;br&gt;
Trial registration: Japan Registry of Clinical Trials identifier: jRCT2063220014.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Graft-versus-host disease</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Hematopoietic stem cell transplantation</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Idiopathic pneumonia syndrome</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Overall survival</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Umbilical cord-derived mesenchymal stromal cells</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1340-6868</Issn>
      <Volume>32</Volume>
      <Issue>6</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Clinical significance on switching CDK4/6 inhibitors among 13,284 patients with metastatic breast cancer</ArticleTitle>
    <FirstPage LZero="delete">1405</FirstPage>
    <LastPage>1416</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Takuya</FirstName>
        <LastName>Nishina</LastName>
        <Affiliation>Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Maki</FirstName>
        <LastName>Tanioka</LastName>
        <Affiliation>Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kenji</FirstName>
        <LastName>Takada</LastName>
        <Affiliation>Medical AI Project, Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takahiro</FirstName>
        <LastName>Tsukioki</LastName>
        <Affiliation>Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuko</FirstName>
        <LastName>Takahashi</LastName>
        <Affiliation>Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tadahiko</FirstName>
        <LastName>Shien</LastName>
        <Affiliation>Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shinichi</FirstName>
        <LastName>Toyooka</LastName>
        <Affiliation>Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Recent clinical trials have shown that switching to a combination therapy of a cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) and endocrine therapy (ET) prolongs progression-free survival (PFS) compared with ET monotherapy. Reports indicate that abemaciclib provides benefits regardless of the PIK3CA mutation status; however, its clinical benefits remain insufficient. This study aimed to evaluate the clinical significance of switching CDK4/6i&#8201;+&#8201;ET in a large real-world cohort. Using a medical database, we identified 13,284 patients with hormone receptor&#8211;positive/human epidermal growth factor receptor 2&#8211;negative advanced breast cancer who received CDK4/6i&#8201;+&#8201;ET between 2008 and 2022. Patients were categorized into five groups based on their first- and second-line therapy patterns. We compared the median time to discontinuation (TTD) among the groups. In patients who switched from one CDK4/6i&#8201;+&#8201;ET to another CDK4/6i&#8201;+&#8201;ET, the second-line TTD and total TTD of first- and second-line therapies (n&#8201;=&#8201;542) were significantly longer than those in patients who switched from CDK4/6i&#8201;+&#8201;ET to ET monotherapy (n&#8201;=&#8201;490) (the second-line TTD: 11.2 vs. 4.9 months, p&#8201;&lt;&#8201;0.01; total TTD: 25.1 vs. 20.5 months, p&#8201;&lt;&#8201;0.01). The order of palbociclib and abemaciclib administration did not significantly affect the second-line or total TTD in patients who switched from one CDK4/6i&#8201;+&#8201;ET to another CDK4/6i&#8201;+&#8201;ET. Switching from one CDK4/6i&#8201;+&#8201;ET to another CDK4/6i&#8201;+&#8201;ET resulted in a significantly longer TTD than switching to ET monotherapy. Considering the phase III clinical trial results of capivasertib, switching to CDK4/6i&#8201;+&#8201;ET is a viable therapeutic option regardless of the PIK3CA mutation status.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Cyclin-dependent kinase 4/6 inhibitors</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Endocrine therapy</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">HR-positive/HER2-negative advanced breast cancer </Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Progression-free survival</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Time to discontinuation</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>American Society for Microbiology</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0066-4804</Issn>
      <Volume>69</Volume>
      <Issue>12</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Genomic portrayal of emerging carbapenem-resistant El Tor variant Vibrio cholerae O1</ArticleTitle>
    <FirstPage LZero="delete">e00740-25</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Sreeja</FirstName>
        <LastName>Shaw</LastName>
        <Affiliation>ICMR-National Institute for Research in Bacterial Infections</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Agila Kumari</FirstName>
        <LastName>Pragasam</LastName>
        <Affiliation>V. Ramalingaswami Bhawan, Indian Council of Medical Research</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Goutam</FirstName>
        <LastName>Chowdhury</LastName>
        <Affiliation>ICMR-National Institute for Research in Bacterial Infections</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Prosenjit</FirstName>
        <LastName>Samanta</LastName>
        <Affiliation>ICMR-National Institute for Research in Bacterial Infections</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Deboleena</FirstName>
        <LastName>Roy</LastName>
        <Affiliation>ICMR-National Institute for Research in Bacterial Infections</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Debjani</FirstName>
        <LastName>Ghosh</LastName>
        <Affiliation>ICMR-National Institute for Research in Bacterial Infections</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Thandavarayan</FirstName>
        <LastName>Ramamurthy</LastName>
        <Affiliation>ICMR-National Institute for Research in Bacterial Infections</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Jigna</FirstName>
        <LastName>Karia</LastName>
        <Affiliation>Medical College Baroda</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Govind</FirstName>
        <LastName>Ninama</LastName>
        <Affiliation>Medical College Baroda</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shin-ichi</FirstName>
        <LastName>Miyoshi</LastName>
        <Affiliation>Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yukihiro</FirstName>
        <LastName>Akeda</LastName>
        <Affiliation>National Institute of Infectious Diseases</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hemanta</FirstName>
        <LastName>Koley</LastName>
        <Affiliation>ICMR-National Institute for Research in Bacterial Infections</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Asish Kumar</FirstName>
        <LastName>Mukhopadhyay</LastName>
        <Affiliation>ICMR-National Institute for Research in Bacterial Infections</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>The escalating prevalence of carbapenem-resistant (CR) enteric pathogens elicits significant challenges to public health management and effective antimicrobial therapy. While carbapenem resistance is rare in Vibrio cholerae O1 (VC), the recent emergence of CR strains reveals a concerning shift in their antimicrobial resistance (AMR) landscape. This study aims to characterize the resistance mechanisms in newly identified El Tor CRVC isolated from cholera patients in Gujarat, India during 2019. Fifty VC isolates were screened for major virulence-associated genes along with the determination of their antibiotic resistance profiles using Kirby-Bauer disk diffusion and MIC assays. Whole-genome sequencing (WGS) was employed to investigate the underlying mechanisms of CR. All the isolates exhibited hypervirulent Haitian alleles of major virulence genes and AMR profiles of typical multidrug resistance (MDR). Strikingly, 12% (6/50) of them were resistant to carbapenems and other antibiotics. Molecular analysis revealed that these CR isolates were clonally related and harbored a 142 kbp IncA/C type conjugative mega-plasmid with several AMR encoding genes, including blaNDM-1, that can be easily transferred to other bacterial species and confer donor AMR patterns. The plasmid’s competence for horizontal gene transfer presents a significant risk of dissemination to other enteric pathogens and thereby may complicate the treatment. This finding emphasizes the urgent need for enhanced genomic surveillance and robust antimicrobial stewardship programs aimed at curbing the spread of CRVC strains and mitigating their impact on cholera treatment and containment strategies.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">antimicrobial resistance</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Vibrio cholerae</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">blaNDM-1</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">carbapenem resistance</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">horizontal gene transfer</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">IncA/C plasmid</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1432-0851</Issn>
      <Volume>75</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Gut microbial metabolite butyrate boosts p53-expressing telomerase-specific oncolytic adenovirus efficacy by enhancing infectivity and activating MHC-I/cGAS-STING</ArticleTitle>
    <FirstPage LZero="delete">10</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Masaki</FirstName>
        <LastName>Sakamoto</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shinji</FirstName>
        <LastName>Kuroda</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tetsuya</FirstName>
        <LastName>Katayama</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yu</FirstName>
        <LastName>Mikane</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shunya</FirstName>
        <LastName>Hanzawa</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Daisuke</FirstName>
        <LastName>Kadowaki</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yusuke</FirstName>
        <LastName>Yoshida</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuki</FirstName>
        <LastName>Hamada</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryoma</FirstName>
        <LastName>Sugimoto</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Chiaki</FirstName>
        <LastName>Yagi</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masashi</FirstName>
        <LastName>Hashimoto</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Nobuhiko</FirstName>
        <LastName>Kanaya</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshihiko</FirstName>
        <LastName>Kakiuchi</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Satoru</FirstName>
        <LastName>Kikuchi</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kunitoshi</FirstName>
        <LastName>Shigeyasu</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroshi</FirstName>
        <LastName>Tazawa</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shunsuke</FirstName>
        <LastName>Kagawa</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yasuo</FirstName>
        <LastName>Urata</LastName>
        <Affiliation>Oncolys BioPharma, Inc.</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshiyoshi</FirstName>
        <LastName>Fujiwara</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>The gut microbiota plays an essential role in regulating host immunity, and its metabolites such as butyrate exert immunomodulatory effects by acting as histone deacetylase inhibitors. Oncolytic virotherapy has emerged as a promising approach for cancer treatment, and we have developed OBP-702, a telomerase-specific oncolytic adenovirus that expresses p53 and elicits strong systemic antitumor responses. In this study, the potential synergy between butyrate and OBP-702 was investigated in colorectal cancer models. Using human and murine colorectal carcinoma cell lines, butyrate was found to directly enhance the infectivity of OBP-702 by upregulating CAR and integrins, thereby promoting apoptosis and autophagy in tumor cells. In addition, butyrate indirectly boosted systemic antitumor immunity by upregulating MHC-I expression through activation of the cGAS-STING pathway and enhancing CD8&#8201;+&#8201;T cell recruitment via CXCL10 secretion. These findings were supported by in vivo experiments using CT26 subcutaneous, bilateral, and orthotopic tumor models, in which the combination of oral butyrate and intratumoral OBP-702 administration produced synergistic antitumor effects. These results highlight the therapeutic potential of integrating gut microbial metabolites with oncolytic virotherapy as a novel immunotherapeutic strategy for colorectal cancer.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Butyrate</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Oncolytic adenovirus</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">MHC-I</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">CD8 + T cells</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Cancer immunotherapy</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Tech Science Press</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1546-2226</Issn>
      <Volume>85</Volume>
      <Issue>2</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>A Spectrum Allocation and Security-Sensitive Task Offloading Algorithm in MEC Using DVS</ArticleTitle>
    <FirstPage LZero="delete">3437</FirstPage>
    <LastPage>3455</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Xianwei</FirstName>
        <LastName>Li</LastName>
        <Affiliation>School of Computer and Information Engineering, Bengbu University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Bo</FirstName>
        <LastName>Wei</LastName>
        <Affiliation>Faculty of Environmental, Life, Natural Science and Technology, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Xiaoying</FirstName>
        <LastName>Yang</LastName>
        <Affiliation>School of Information Engineering, Suzhou University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Amr</FirstName>
        <LastName>Tolba</LastName>
        <Affiliation>Computer Science and Engineering Department, College of Applied Studies, King Saud University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Zijian</FirstName>
        <LastName>Zeng</LastName>
        <Affiliation>Institute of Computer Science and Digital Innovation, UCSI University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Osama</FirstName>
        <LastName>Alfarraj</LastName>
        <Affiliation>Computer Science and Engineering Department, College of Applied Studies, King Saud University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>With the advancements of the next-generation communication networking and Internet of Things (IoT) technologies, a variety of computation-intensive applications (e.g., autonomous driving and face recognition) have emerged. The execution of these IoT applications demands a lot of computing resources. Nevertheless, terminal devices (TDs) usually do not have sufficient computing resources to process these applications. Offloading IoT applications to be processed by mobile edge computing (MEC) servers with more computing resources provides a promising way to address this issue. While a significant number of works have studied task offloading, only a few of them have considered the security issue. This study investigates the problem of spectrum allocation and security-sensitive task offloading in an MEC system. Dynamic voltage scaling (DVS) technology is applied by TDs to reduce energy consumption and computing time. To guarantee data security during task offloading, we use AES cryptographic technique. The studied problem is formulated as an optimization problem and solved by our proposed efficient offloading scheme. The simulation results show that the proposed scheme can reduce system cost while guaranteeing data security.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">IoT</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">DVS</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">MEC</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">AES</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Laser Institute of America</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1042-346X</Issn>
      <Volume>37</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>High-quality welding of copper and aluminum by angled laser irradiation and insert metals</ArticleTitle>
    <FirstPage LZero="delete">012041</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Yasuhiro</FirstName>
        <LastName>Okamoto</LastName>
        <Affiliation>Faculty of Environmental, Life, Natural Science and Technology, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuki</FirstName>
        <LastName>Yamada</LastName>
        <Affiliation>Graduate School of Environmental, Life, Natural Science and Technology, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Akira</FirstName>
        <LastName>Okada</LastName>
        <Affiliation>Faculty of Environmental, Life, Natural Science and Technology, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masaki</FirstName>
        <LastName>Miyake</LastName>
        <Affiliation>Kataoka Corporation</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takeshi</FirstName>
        <LastName>Yamamura</LastName>
        <Affiliation>Kataoka Corporation</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Katsutoshi</FirstName>
        <LastName>Nagasaki</LastName>
        <Affiliation>Kataoka Corporation</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Norio</FirstName>
        <LastName>Nishi</LastName>
        <Affiliation>Kataoka Corporation</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Copper is an important material in order to use electricity effectively, and aluminum is also an attractive material to perform lightweight construction. Laser welding of copper and aluminum is required, and there are some reports to weld copper and aluminum firmly by laser irradiation from the aluminum side. On the other hand, laser irradiation from the copper side requires high power density to generate a keyhole, which causes the strong convection of molten aluminum into copper. Thus, brittle intermetallic compounds with rich aluminum result in the deterioration of joining strength. Angled laser irradiation enables mild heat input to the aluminum side, and the combination of angled and superposed irradiation of blue and near-infrared (NIR) lasers achieved a remarkable increase of breaking strength. However, the breaking strength is still lower than the base materials. Therefore, insert materials between copper and aluminum plates were investigated by the angled irradiation of blue and NIR lasers from the copper side. The breaking strength with insert materials showed higher values in the order of titanium mesh, nickel foil, and nickel mesh, and its value with the nickel mesh was close to the tensile strength of aluminum in a cross tensile test. Further improvement of breaking strength is possible by inserting the nickel mesh between copper and aluminum plates in the case of angled irradiation of blue and NIR lasers even from the copper side.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">welding</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">copper</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">aluminum</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">insert metal</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">intermetallic compound</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">fiber laser</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">blue laser</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">angled irradiation</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Elsevier BV</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0007-8506</Issn>
      <Volume>74</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Improvement of anodic oxide film characteristics of Al-Cu alloy by refinement of IMCs with large-area electron beam irradiation</ArticleTitle>
    <FirstPage LZero="delete">263</FirstPage>
    <LastPage>267</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">T.</FirstName>
        <LastName>Shinonaga</LastName>
        <Affiliation>Faculty of Environmental, Life, Natural Science &amp; Technology, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">A.</FirstName>
        <LastName>Sebe</LastName>
        <Affiliation>Graduate School of Environmental, Life, Natural Science &amp; Technology, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">M.</FirstName>
        <LastName>Taniguchi</LastName>
        <Affiliation>Shimano Research Laboratories, R&amp;D Strategy Dept., SHIMANO INC.</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">T.</FirstName>
        <LastName>Fujii</LastName>
        <Affiliation>Shimano Research Laboratories, R&amp;D Strategy Dept., SHIMANO INC.</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">A.</FirstName>
        <LastName>Okada</LastName>
        <Affiliation>Faculty of Environmental, Life, Natural Science &amp; Technology, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Al-Cu alloy has been widely applied to automobile products due to its light weight and high strength, but pitting corrosion easily occurs due to intermetallic compounds (IMCs) in Al-Cu alloy. Anodizing process has been conventionally performed to improve the corrosion resistance of Al-Cu alloy surface. However, IMCs in Al-Cu alloy lead to defects in anodic oxide film. In this study, refinement of IMCs in Al-Cu alloy surface by large-area EB irradiation was proposed. Experimental results show that reflectance and corrosion resistance of anodic oxide film formed on Al-Cu alloy surface are improved by refinement of IMCs with the EB irradiation.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Electron beam</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">aluminum</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">anodic oxide film</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0312-5963</Issn>
      <Volume>64</Volume>
      <Issue>12</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Evaluation of Fentanyl-Emerged Adverse Events and Pharmacokinetics in Neonates: A Physiologically Based Pharmacokinetic Modeling Approach</ArticleTitle>
    <FirstPage LZero="delete">1811</FirstPage>
    <LastPage>1825</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Walaa Yousef Bassyouni</FirstName>
        <LastName>Mahdy</LastName>
        <Affiliation>Department of Pharmacy, Kobe University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuhiro</FirstName>
        <LastName>Yamamoto</LastName>
        <Affiliation>Department of Integrated Clinical and Basic Pharmaceutical Sciences, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Risa</FirstName>
        <LastName>Joji</LastName>
        <Affiliation>Department of Pharmacy, Kobe University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Mari</FirstName>
        <LastName>Hashimoto</LastName>
        <Affiliation>Department of Pharmacy, Kobe University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ruka</FirstName>
        <LastName>Nakasone</LastName>
        <Affiliation>Department of Pediatrics, Graduate School of Medicine, Kobe University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazumichi</FirstName>
        <LastName>Fujioka</LastName>
        <Affiliation>Department of Pediatrics, Graduate School of Medicine, Kobe University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kotaro</FirstName>
        <LastName>Itohara</LastName>
        <Affiliation>Department of Pharmacy, Kobe University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yumi</FirstName>
        <LastName>Kitahiro</LastName>
        <Affiliation>Department of Pharmacy, Kobe University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomohiro</FirstName>
        <LastName>Omura</LastName>
        <Affiliation>Department of Pharmacy, Kobe University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ikuko</FirstName>
        <LastName>Yano</LastName>
        <Affiliation>Department of Pharmacy, Kobe University Hospital</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Background Despite its common use for analgesia in neonatal intensive care units, the optimal dosing and safety profile of fentanyl, particularly regarding suspected fentanyl-emerged adverse events (FEAEs), such as hypotension, desaturation, and oliguria, are not well-defined.&lt;br&gt;
Objective This study aimed to develop an optimal therapeutic monitoring and dosing strategy for fentanyl for neonates. A physiologically based pharmacokinetic (PBPK) model for predicting fentanyl pharmacokinetics across various populations, including preterm and term neonates, was developed, and the relationship between predicted fentanyl exposure and FEAE incidence in neonates was assessed.&lt;br&gt;
Methods A PBPK model was developed and validated against the observed values in the literature. The model’s predictive accuracy for fentanyl pharmacokinetics and association with FEAE incidence in an external retrospective cohort of Japanese neonates was evaluated using the predicted concentrations and pharmacokinetic parameters estimated by PBPK simulation.&lt;br&gt;
Results The PBPK model exhibited reasonable predictive performance for serum fentanyl concentrations in actual neonatal patients (mean error: 9.27% [standard error: 5.06%], root mean squared error: 54.7%). The incidence of any FEAE, particularly oxygen desaturation, was associated with the fentanyl concentration-to-dose ratio, but not with some exposure parameters, such as the area under the curve and maximum concentration. The recommended reduced infusion rate allowed serum fentanyl concentrations to fall within the ranges established by the reported values and our data.&lt;br&gt;
Conclusions Our PBPK model and proposed dosing strategy may contribute to safer and more effective fentanyl use in neonates.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList/>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0718-9508</Issn>
      <Volume/>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Suppression of Na+ Uptake Via Apoplastic Flow by Chitosan in Rice</ArticleTitle>
    <FirstPage LZero="delete"/>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Maoxiang</FirstName>
        <LastName>Zhao</LastName>
        <Affiliation>Graduate School of Environmental and Life Science, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Md. Asadulla Al</FirstName>
        <LastName>Galib</LastName>
        <Affiliation>Graduate School of Environmental and Life Science, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshiyuki</FirstName>
        <LastName>Nakamura</LastName>
        <Affiliation>Graduate School of Environmental and Life Science, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshimasa</FirstName>
        <LastName>Nakamura</LastName>
        <Affiliation>Graduate School of Environmental and Life Science, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshihiko</FirstName>
        <LastName>Hirai</LastName>
        <Affiliation>Graduate School of Environmental and Life Science, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshitaka</FirstName>
        <LastName>Nakashima</LastName>
        <Affiliation/>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shintaro</FirstName>
        <LastName>Munemasa</LastName>
        <Affiliation>Graduate School of Environmental and Life Science, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Izumi C.</FirstName>
        <LastName>Mori</LastName>
        <Affiliation>Institute of Plant Science and Resources, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshiyuki</FirstName>
        <LastName>Murata</LastName>
        <Affiliation>Graduate School of Environmental and Life Science, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Purpose: Chitosan enhances tolerance to salinity in rice. Apoplastic flow plays a crucial role in the accumulation of sodium (Na+) in rice under salinity. This study investigated the effects of exogenous chitosan on apoplastic flow and Na+ uptake in NaCl-treated rice seedlings. Methods: We employed an apoplastic tracer, trisodium salt of 8-hydroxy-1,3,6-pyrenetrisulphonic acid (PTS), in order to evaluate apoplastic flow in rice (Oryza sativa L., cv. Nipponbare) seedlings that were hydroponically grown in the solution containing NaCl (0 and 25 mM), and chitosan (0 mg L−&#8201;1, 10 mg L−&#8201;1, and 50 mg L−&#8201;1). Results: Application of 25 mM NaCl significantly increased PTS uptake and Na+ content in shoots but did not affect K+ content, resulting in a lower K+/Na+ ratio although 25 mM NaCl did not affect the seedling growth. The application of chitosan suppressed Na+-enhanced PTS uptake and Na+ accumulation in shoots without affecting the K+ content, which led to a higher K+/Na+ ratio. Moreover, chitosan did not affect the reducing sugar content or electrical conductivity in the solution containing NaCl. Conclusions: These results suggest that application of chitosan suppressed Na+-enhanced apoplastic flow to reduce Na+ uptake in rice seedlings.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Rice &#183; Salinity</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Apoplastic flow</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Trisodium-8-hydroxy-1,3,6-pyrenetrisulphonic acid</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Chitosan</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Elsevier BV</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2405-8440</Issn>
      <Volume>11</Volume>
      <Issue>11</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Suppression of defect in plated film on AMed metal products by electron beam polishing</ArticleTitle>
    <FirstPage LZero="delete">e43440</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Togo</FirstName>
        <LastName>Shinonaga</LastName>
        <Affiliation>Faculty of Environmental, Life, Natural Science and Technology, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuki</FirstName>
        <LastName>Matsuda</LastName>
        <Affiliation>Graduate School of Environmental, Life, Natural Science and Technology, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Akira</FirstName>
        <LastName>Okada</LastName>
        <Affiliation>Faculty of Environmental, Life, Natural Science and Technology, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Additively manufactured (AMed) metal products with high shape accuracy can be produced by laser powder bed fusion (LPBF). However, the AMed metal products have large surface roughness due to the arrangement of bead shape. Surface irregularities such as spatter and small cavity are also generated on the surface. Furthermore, elemental composition of AMed metal products may be changed from that of original metal powder due to oxidation of surface. On the other hand, electroless plating has been applied to improvement of surface functions. However, defect is often generated in the plated film due to surface irregularities and oxidation of base material. Therefore, surface smoothing methods are required for suppression of defect in plated film.&lt;br&gt;
In this study, surface smoothing and surface repairing of AMed aluminum (Al) alloy were performed by electron beam (EB) polishing with large-area EB. After the EB polishing, electroless plating was conducted on the AMed Al alloy, and suppression of defect in plated film was proposed. Experimental results show that surface smoothing, surface repairing and removal of oxidization layer of AMed Al alloy can be done simultaneously by the EB polishing. Furthermore, the plated film without defect can be successfully formed on the EB polished Al alloy.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Additive manufacturing</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Electron beam</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Surface smoothing</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Surface repairing</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Electroless plating</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Defect</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>eLife Sciences Publications, Ltd</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2050-084X</Issn>
      <Volume>13</Volume>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Redistribution of fragmented mitochondria ensures symmetric organelle partitioning and faithful chromosome segregation in mitotic mouse zygotes</ArticleTitle>
    <FirstPage LZero="delete">RP99936</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Haruna</FirstName>
        <LastName>Gekko</LastName>
        <Affiliation>Department of Animal Science, Graduate School of Environment and Life Science, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ruri</FirstName>
        <LastName>Nomura</LastName>
        <Affiliation>Department of Animal Science, Graduate School of Environment and Life Science, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Daiki</FirstName>
        <LastName>Kuzuhara</LastName>
        <Affiliation>Reproductive Centre, Mio Fertility Clinic</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masato</FirstName>
        <LastName>Kaneyasu</LastName>
        <Affiliation>Department of Animal Science, Graduate School of Environment and Life Science, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Genpei</FirstName>
        <LastName>Koseki</LastName>
        <Affiliation>Department of Animal Science, Graduate School of Environment and Life Science, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Deepak</FirstName>
        <LastName>Adhikari</LastName>
        <Affiliation>Development and Stem Cell Program and Department of Anatomy and Developmental Biology, Monash Biomedicine Discovery Institute, Monash University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yasuyuki</FirstName>
        <LastName>Mio</LastName>
        <Affiliation>Reproductive Centre, Mio Fertility Clinic</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">John</FirstName>
        <LastName>Carroll</LastName>
        <Affiliation>Development and Stem Cell Program and Department of Anatomy and Developmental Biology, Monash Biomedicine Discovery Institute, Monash University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomohiro</FirstName>
        <LastName>Kono</LastName>
        <Affiliation>Department of Bioscience, Tokyo University of Agriculture</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroaki</FirstName>
        <LastName>Funahashi</LastName>
        <Affiliation>Department of Animal Science, Graduate School of Environment and Life Science, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takuya</FirstName>
        <LastName>Wakai</LastName>
        <Affiliation>Department of Animal Science, Graduate School of Environment and Life Science, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>In cleavage-stage embryos, preexisting organelles partition evenly into daughter blastomeres without signi&#64257;cant cell growth after symmetric cell division. The presence of mitochondrial DNA within mitochondria and its restricted replication during preimplantation development makes their inheritance particularly important. While chromosomes are precisely segregated by the mitotic spindle, the mechanisms controlling mitochondrial partitioning remain poorly understood. In this study, we investigate the mechanism by which Dynamin-related protein 1 (Drp1) controls the mitochondrial redistribution and partitioning during embryonic cleavage. Depletion of Drp1 in mouse zygotes causes marked mitochondrial aggregation, and the majority of embryos arrest at the 2 cell stage. Clumped mitochondria are located in the center of mitotic Drp1-depleted zygotes with less uniform distribution, thereby preventing their symmetric partitioning. Asymmetric mitochondrial inheritance is accompanied by functionally inequivalent blastomeres with biased ATP and endoplasmic reticulum Ca2+ levels. We also find that marked mitochondrial centration in Drp1-depleted zygotes prevents the assembly of parental chromosomes, resulting in chromosome segregation defects and binucleation. Thus, mitochondrial fragmentation mediated by Drp1 ensures proper organelle positioning and partitioning into functional daughters during the first embryonic cleavage.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList/>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>American Society for Clinical Investigation</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2379-3708</Issn>
      <Volume>10</Volume>
      <Issue>24</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Enhancement of drug delivery through fibroblast activation protein&#8211;targeted near-infrared photoimmunotherapy</ArticleTitle>
    <FirstPage LZero="delete">e195776</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Seitaro</FirstName>
        <LastName>Nishimura</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Science</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuhiro</FirstName>
        <LastName>Noma</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Science</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tasuku</FirstName>
        <LastName>Matsumoto</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Science</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yasushige</FirstName>
        <LastName>Takeda</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Science</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tatsuya</FirstName>
        <LastName>Takahashi</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Science</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hijiri</FirstName>
        <LastName>Matsumoto</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Science</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kento</FirstName>
        <LastName>Kawasaki</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Science</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hotaka</FirstName>
        <LastName>Kawai</LastName>
        <Affiliation>Department of Oral Pathology and Medicine, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Science</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomoyoshi</FirstName>
        <LastName>Kunitomo</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Science</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masaaki</FirstName>
        <LastName>Akai</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Science</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Teruki</FirstName>
        <LastName>Kobayashi</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Science</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Noriyuki</FirstName>
        <LastName>Nishiwaki</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Science</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hajime</FirstName>
        <LastName>Kashima</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Science</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takuya</FirstName>
        <LastName>Kato</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Science</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Satoru</FirstName>
        <LastName>Kikuchi</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Science</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shunsuke</FirstName>
        <LastName>Tanabe</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Science</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshiaki</FirstName>
        <LastName>Ohara</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Science</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroshi</FirstName>
        <LastName>Tazawa</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Science</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yasuhiro</FirstName>
        <LastName>Shirakawa</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Science</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Peter L.</FirstName>
        <LastName>Choyke</LastName>
        <Affiliation>Molecular Imaging Branch, Center for Cancer Research, National Cancer Institute, NIH</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hisataka</FirstName>
        <LastName>Kobayashi</LastName>
        <Affiliation>Molecular Imaging Branch, Center for Cancer Research, National Cancer Institute, NIH</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshiyoshi</FirstName>
        <LastName>Fujiwara</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Science</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>The tumor microenvironment plays a key role in cancer progression and therapy resistance, with cancer-associated fibroblasts (CAFs) contributing to desmoplasia, extracellular matrix (ECM) remodeling, and elevated interstitial fluid pressure, all of which hinder drug delivery. We investigated fibroblast activation protein&#8211;targeted (FAP-targeted) near-infrared photoimmunotherapy (NIR-PIT) as a strategy to improve drug penetration in CAF-rich tumors. In clinical esophageal cancer samples, FAP expression strongly correlated with increased collagen I, hyaluronic acid, and microvascular collapse. CAF-rich 3D spheroids demonstrated elevated ECM deposition and significantly impaired drug uptake compared with CAF-poor models. FAP-targeted NIR-PIT selectively reduced CAFs, reduced ECM components, and restored drug permeability. In vivo, FAP-targeted NIR-PIT enhanced the accumulation of panitumumab and Abraxane in CAF-rich tumors and improved antitumor efficacy when combined with chemotherapy. These findings highlight FAP-targeted NIR-PIT as a promising therapeutic approach to remodel the tumor stroma and overcome drug resistance in desmoplastic solid tumors.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList/>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1472-6831</Issn>
      <Volume>25</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Evaluation of Streptococcus mutans strains possessing genes encoding collagen-binding proteins in the Japanese population</ArticleTitle>
    <FirstPage LZero="delete">1908</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Makoto</FirstName>
        <LastName>Okuda</LastName>
        <Affiliation>Department of Pediatric Dentistry, Graduate School of Dentistry, The University of Osaka</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuto</FirstName>
        <LastName>Suehiro</LastName>
        <Affiliation>Department of Pediatric Dentistry, Graduate School of Dentistry, The University of Osaka</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Jinthana</FirstName>
        <LastName>Lapirattanakul</LastName>
        <Affiliation>Department of Oral Microbiology, Faculty of Dentistry, Mahidol University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shuhei</FirstName>
        <LastName>Naka</LastName>
        <Affiliation>Department of Pediatric Dentistry, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Michiyo</FirstName>
        <LastName>Matsumoto-Nakano</LastName>
        <Affiliation>Department of Pediatric Dentistry, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryota</FirstName>
        <LastName>Nomura</LastName>
        <Affiliation>Department of Pediatric Dentistry, Graduate School of Biomedical and Health Sciences, Hiroshima University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Rena</FirstName>
        <LastName>Okawa</LastName>
        <Affiliation>Department of Pediatric Dentistry, Graduate School of Dentistry, The University of Osaka</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuhiko</FirstName>
        <LastName>Nakano</LastName>
        <Affiliation>Department of Pediatric Dentistry, Graduate School of Dentistry, The University of Osaka</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Background Streptococcus mutans harbors collagen-binding protein genes, namely cnm and cbm, which are implicated in its virulence and pathogenicity in both oral and extraoral infections. Although both genes were initially identified in S. mutans isolated from Japanese populations, their geographical prevalence, distribution, and genetic relatedness within Japan remain largely unexplored. This study investigates the prevalence of S. mutans strains carrying cnm and cbm genes across Japan, correlates these findings with clinical data, and analyzes the genetic relatedness of cnm-positive and cnm-negative strains using multilocus sequence typing (MLST).&lt;br&gt;
Methods Dental plaque specimens were collected from 1248 individuals from eight Japanese cities (Hiroshima, Fukuoka, Nagasaki, Niigata, Okayama, Osaka, Tokushima, and Tokyo) and plated on selective medium for S. mutans isolation. S. mutans was confirmed in 523 subjects by colony morphology and PCR using species-specific primers, and the presence of the cnm and cbm genes was determined by PCR with gene-specific primers. Demographic (age, sex) and oral examination (caries prevalence, caries experience, number of teeth) data were recorded. MLST was employed to genotype selected cnm-positive and cnm-negative S. mutans strains to assess their clonal relationships.&lt;br&gt;
Results Among 523 subjects possessing S. mutans (aged 3&#8211;90 years), we detected cnm-positive strains in all cities; specifically, the prevalence ranged from 5.5% in Okayama to 25.0% in Tokushima. In contrast, cbm-positive strains were less common and undetectable in some regions. Furthermore, subjects harboring cnm-positive S. mutans were significantly older (p&#8201;=&#8201;0.002) and had higher caries prevalence and experience (p&#8201;&lt;&#8201;0.001). MLST revealed evolutionary relationships among cnm-positive strains across the cities but no discernible region-specific clustering. Clonal relationships partially reflected cnm gene distribution, particularly for exclusively cnm-positive or cnm-negative clonal complexes, but inconsistencies involving serotypes and cnm presence within some clonal complexes and sequence types were also noted.&lt;br&gt;
Conclusions The cnm-positive S. mutans strains are widely distributed throughout Japan and are associated with increased age and caries burden. Although core genome analysis revealed some clonal patterns, the non-uniform distribution of the non-core cnm gene is likely influenced by horizontal gene transfer, providing S. mutans with adaptive advantages irrespective of its core genetic background or serotype.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Collagen-binding protein gene</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">cnm gene</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">cbm gene</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Japan</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Multilocus sequence typing</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Serotype</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Streptococcus mutans</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0006-2928</Issn>
      <Volume/>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>German Chamomile (Matricaria chamomilla) Induces Cytochrome P450 Expression Through Increased BMAL1 Protein Expression in Liver Nuclei</ArticleTitle>
    <FirstPage LZero="delete"/>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Moka</FirstName>
        <LastName>Ikeda</LastName>
        <Affiliation>Division of Pharmaceutics, Faculty of Pharmaceutical Sciences, Sanyo-Onoda City University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuya</FirstName>
        <LastName>Tsurudome</LastName>
        <Affiliation>Division of Pharmaceutics, Faculty of Pharmaceutical Sciences, Sanyo-Onoda City University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Mai</FirstName>
        <LastName>Enrin</LastName>
        <Affiliation>Division of Pharmaceutics, Faculty of Pharmaceutical Sciences, Sanyo-Onoda City University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yukiyo</FirstName>
        <LastName>Wada</LastName>
        <Affiliation>Division of Pharmaceutics, Faculty of Pharmaceutical Sciences, Sanyo-Onoda City University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Michiko</FirstName>
        <LastName>Horiguchi</LastName>
        <Affiliation>Department of Regenerative and Therapeutic Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kentaro</FirstName>
        <LastName>Ushijima</LastName>
        <Affiliation>Division of Pharmaceutics, Faculty of Pharmaceutical Sciences, Sanyo-Onoda City University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>German chamomile (Matricaria chamomilla) is a medicinal herb that promotes improved digestion and reduces insomnia. Although it is widely used worldwide, the mechanism of induction of drug-metabolizing enzymes is unknown. We found that German chamomile extracts induced cytochrome P450 expression at the transcriptional stage. Cyp3a11 expression is decreased at night in wild-type mice, but German chamomile extract induced nocturnal Cyp3a11 and Cyp1a2 expression. German chamomile extract increased the nuclear protein expression of the clock gene BMAL1, which drives and abolishes the rhythm of Cyp3a11 expression. By contrast, German chamomile extract did not significantly alter clock gene expression in the suprachiasmatic nucleus (SCN). Similarly, it did not affect the mRNA expression of the clock genes in the kidneys. Because it did not induce the mRNA expression of ATP-binding cassette (ABC) transporters (Abcb1a, Abcc2, Abcc4, and Abcg2) in the kidney, German chamomile extract had no effect on the transcription of pharmacokinetics-related molecules other than CYPs. German chamomile extract promoted liver-selective nuclear transfer rhythm changes in clock genes and induced the expression of CYPs. This study may help to explain the mechanism of drug interactions associated with chronic German chamomile extract consumption.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Circadian clock</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">German chamomile</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Xenobiotic transporter</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Metabolic enzyme</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Clock gene</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2399-3642</Issn>
      <Volume>8</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>A genome-wide association study identifies the GPM6A locus associated with age at onset in ALS</ArticleTitle>
    <FirstPage LZero="delete">1720</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Ryoichi</FirstName>
        <LastName>Nakamura</LastName>
        <Affiliation>Department of Neurology, Aichi Medical University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Genki</FirstName>
        <LastName>Tohnai</LastName>
        <Affiliation>Division of ALS Research, Aichi Medical University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Naoki</FirstName>
        <LastName>Atsuta</LastName>
        <Affiliation>Department of Neurology, Aichi Medical University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yumi</FirstName>
        <LastName>Matsuda</LastName>
        <Affiliation>Public Health Informatics Unit, Department of Integrated Health Sciences, Nagoya University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Satoru</FirstName>
        <LastName>Morimoto</LastName>
        <Affiliation>Keio University Regenerative Medicine Research Center, Kawasaki</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Daisuke</FirstName>
        <LastName>Ito</LastName>
        <Affiliation>Department of Neurology, Nagoya University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masahisa</FirstName>
        <LastName>Katsuno</LastName>
        <Affiliation>Department of Neurology, Nagoya University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuishin</FirstName>
        <LastName>Izumi</LastName>
        <Affiliation>Department of Neurology, Tokushima University Graduate School of Biomedical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Mitsuya</FirstName>
        <LastName>Morita</LastName>
        <Affiliation>Division of Neurology, Department of Internal Medicine, Jichi Medical University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ikuko</FirstName>
        <LastName>Iwata</LastName>
        <Affiliation>Department of Neurology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ichiro</FirstName>
        <LastName>Yabe</LastName>
        <Affiliation>Department of Neurology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomoko</FirstName>
        <LastName>Nakazato</LastName>
        <Affiliation>Department of Neurology, Juntendo University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Nobutaka</FirstName>
        <LastName>Hattori</LastName>
        <Affiliation>Department of Neurology, Juntendo University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takehisa</FirstName>
        <LastName>Hirayama</LastName>
        <Affiliation>Department of Neurology, Toho University Faculty of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Osamu</FirstName>
        <LastName>Kano</LastName>
        <Affiliation>Department of Neurology, Toho University Faculty of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Asako</FirstName>
        <LastName>Tamura</LastName>
        <Affiliation>Department of Neurology, Mie University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Naoki</FirstName>
        <LastName>Suzuki</LastName>
        <Affiliation>Department of Neurology, Tohoku University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masashi</FirstName>
        <LastName>Aoki</LastName>
        <Affiliation>Department of Neurology, Tohoku University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazumoto</FirstName>
        <LastName>Shibuya</LastName>
        <Affiliation>Department of Neurology, Graduate School of Medicine, Chiba University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Satoshi</FirstName>
        <LastName>Kuwabara</LastName>
        <Affiliation>Department of Neurology, Graduate School of Medicine, Chiba University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masaya</FirstName>
        <LastName>Oda</LastName>
        <Affiliation>Department of Neurology, Vihara Hananosato Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Rina</FirstName>
        <LastName>Hashimoto</LastName>
        <Affiliation>Department of Neurology, NHO Higashinagoya National Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ikuko</FirstName>
        <LastName>Aiba</LastName>
        <Affiliation>Department of Neurology, NHO Higashinagoya National Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomohiko</FirstName>
        <LastName>Ishihara</LastName>
        <Affiliation>Department of Neurology, Brain Research Institute, Niigata University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Osamu</FirstName>
        <LastName>Onodera</LastName>
        <Affiliation>Department of Neurology, Brain Research Institute, Niigata University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toru</FirstName>
        <LastName>Yamashita</LastName>
        <Affiliation>Department of Neurology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroyuki</FirstName>
        <LastName>Ishiura</LastName>
        <Affiliation>Department of Neurology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kota</FirstName>
        <LastName>Bokuda</LastName>
        <Affiliation>Department of Neurology, Tokyo Metropolitan Neurological Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshio</FirstName>
        <LastName>Shimizu</LastName>
        <Affiliation>Department of Neurology, Tokyo Metropolitan Neurological Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshio</FirstName>
        <LastName>Ikeda</LastName>
        <Affiliation>Department of Neurology, Gunma University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuko</FirstName>
        <LastName>Hasegawa</LastName>
        <Affiliation>Division of Neurology, NHO Sagamihara National Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Fumiaki</FirstName>
        <LastName>Tanaka</LastName>
        <Affiliation>Department of Neurology and Stroke Medicine, Yokohama City University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takanori</FirstName>
        <LastName>Yokota</LastName>
        <Affiliation>Department of Neurology and Neurological Science, NucleoTIDE and PepTIDE Drug Discovery Center (TIDE), Institute of Science Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuaki</FirstName>
        <LastName>Kanai</LastName>
        <Affiliation>Department of Neurology, Fukushima Medical University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yu-ichi</FirstName>
        <LastName>Noto</LastName>
        <Affiliation>Department of Neurology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryuji</FirstName>
        <LastName>Kaji</LastName>
        <Affiliation>Department of Neurology, Tokushima University Graduate School of Biomedical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hirohisa</FirstName>
        <LastName>Watanabe</LastName>
        <Affiliation>Department of Neurology, Fujita Health University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomoko</FirstName>
        <LastName>Konishi</LastName>
        <Affiliation>Division of ALS Research, Aichi Medical University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Mikiko</FirstName>
        <LastName>Hasegawa</LastName>
        <Affiliation>Division of ALS Research, Aichi Medical University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hozuki</FirstName>
        <LastName>Fukaya</LastName>
        <Affiliation>Division of ALS Research, Aichi Medical University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Jun-ichi</FirstName>
        <LastName>Niwa</LastName>
        <Affiliation>Department of Neurology, Aichi Medical University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Manabu</FirstName>
        <LastName>Doyu</LastName>
        <Affiliation>Department of Neurology, Aichi Medical University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yohei</FirstName>
        <LastName>Okada</LastName>
        <Affiliation>Department of Neurology, Aichi Medical University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shiho</FirstName>
        <LastName>Nakamura</LastName>
        <Affiliation>Keio University Regenerative Medicine Research Center, Kawasaki</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Fumiko</FirstName>
        <LastName>Ozawa</LastName>
        <Affiliation>Keio University Regenerative Medicine Research Center, Kawasaki</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hideyuki</FirstName>
        <LastName>Okano</LastName>
        <Affiliation>Keio University Regenerative Medicine Research Center, Kawasaki</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masahiro</FirstName>
        <LastName>Nakatochi</LastName>
        <Affiliation>Public Health Informatics Unit, Department of Integrated Health Sciences, Nagoya University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Gen</FirstName>
        <LastName>Sobue</LastName>
        <Affiliation>Division of ALS Research, Aichi Medical University School of Medicine</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Amyotrophic lateral sclerosis (ALS) exhibits considerable clinical variability, such as differences in age at onset (AAO). Multiple factors, including genetic factors, may underlie this variability; however, the specific determinants remain unclear. To identify genes affecting AAO, we have conducted a genome-wide association study in Japanese patients with ALS (discovery cohort: n&#8201;=&#8201;1808; replication cohort: n&#8201;=&#8201;207). Here, we show that the minor A allele of rs113161727 at the ADAM29-GPM6A locus is associated with a younger AAO in the discovery cohort (effect, -4.27 years; p&#8201;=&#8201;4.60 × 10-8); this finding has been confirmed in the replication cohort (p&#8201;=&#8201;0.0068) and meta-analysis (p&#8201;=&#8201;1.08 × 10−9). Among 65 ALS patients with a SOD1 mutation, the AAO has been found to be 10.2 years younger in those with the A allele than in those without it (p&#8201;=&#8201;0.002). This variant correlates with GPM6A upregulation in iPSC-derived motor neurons, suggesting GPM6A as a candidate AAO modifier. Overall, our study highlights the impact of genetic modifiers on ALS heterogeneity and provides a potential target for delaying disease onset.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList/>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2168-8184</Issn>
      <Volume>17</Volume>
      <Issue>12</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Sequential Bilateral Central Retinal Vein Occlusion With Differential Long-Term Outcomes Following Cardiac Surgery</ArticleTitle>
    <FirstPage LZero="delete">e100045</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Toshihiko</FirstName>
        <LastName>Matsuo</LastName>
        <Affiliation>Ophthalmology, Graduate School of Interdisciplinary Science and Engineering in Health Systems, Okayama University, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Zenichi</FirstName>
        <LastName>Masuda</LastName>
        <Affiliation>Cardiovascular Surgery, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroki</FirstName>
        <LastName>Sugiyama</LastName>
        <Affiliation>Cardiovascular Medicine, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazufumi</FirstName>
        <LastName>Nakamura</LastName>
        <Affiliation>Cardiovascular Medicine and Center for Advanced Heart Failure, Okayama University Hospital</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Bilateral central retinal vein occlusion (CRVO) is rare and is associated with systemic diseases such as hypertension, diabetes, dyslipidemia, and coagulopathy. In this study, we showed that the sequential development of bilateral CRVO in an elderly patient was related to increased venous pressure in the right heart system. A 71-year-old man developed CRVO in the right eye, and one year later, he developed CRVO in the left eye. He had undergone pacemaker implantation for sick sinus syndrome 10 years earlier and had started hemodialysis three months prior for chronic renal failure, probably caused by hypertensive nephrosclerosis. The right CRVO resulted in neovascular glaucoma and loss of light perception despite intensive treatment with panretinal laser photocoagulation, intravitreal bevacizumab injection, and additional laser therapy. In contrast, the left CRVO remained at an impending stage, was treated only with panretinal laser photocoagulation, and had a favorable outcome for 11 years until his death. In retrospect, half a year after the onset of left CRVO, the patient underwent open-heart surgery to repair aortic, mitral, and tricuspid valve regurgitation through aortic valve replacement, mitral valve annuloplasty, and tricuspid valve annuloplasty, respectively. Based on the temporal sequence of events, elevated venous pressure due to right heart dysfunction may have contributed to the poor outcome of the right CRVO, whereas improvement of venous stasis after cardiac surgery may have led to the better long-term outcome of the left CRVO. Venous stasis in the right heart system should therefore be considered an underlying factor in the development of bilateral CRVO.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">aortic valve regurgitation</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">aortic valve replacement</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">bevacizumab</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">bilateral central retinal vein occlusion</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">intravitreal injection</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">mitral valve annuloplasty</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">mitral valve regurgitation</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">panretinal laser photocoagulation</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">tricuspid valve annuloplasty</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">tricuspid valve regurgitation</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Informa UK Limited</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2167-8421</Issn>
      <Volume/>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Novel in-frame duplication variant of SOD1 in a Japanese family with familial amyotrophic lateral sclerosis</ArticleTitle>
    <FirstPage LZero="delete"/>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Masanori</FirstName>
        <LastName>Nakajima</LastName>
        <Affiliation>Department of Neurology, Kyorin University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroya</FirstName>
        <LastName>Naruse</LastName>
        <Affiliation>Department of Neurology, Graduate School of Medicine, The University of Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuichi</FirstName>
        <LastName>Riku</LastName>
        <Affiliation>Department of Neuropathology, Institute for Medical Science of Aging, Aichi Medical University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kunihiro</FirstName>
        <LastName>Ueda</LastName>
        <Affiliation>Department of Neurology, Graduate School of Medicine, The University of Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takashi</FirstName>
        <LastName>Matsukawa</LastName>
        <Affiliation>Department of Neurology, Graduate School of Medicine, The University of Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Jun</FirstName>
        <LastName>Mitsui</LastName>
        <Affiliation>Department of Neurology, Graduate School of Medicine, The University of Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshitsugu</FirstName>
        <LastName>Nakamura</LastName>
        <Affiliation>Division of Neurology, Department of Internal Medicine IV, Osaka Medical and Pharmaceutical University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shimon</FirstName>
        <LastName>Ishida</LastName>
        <Affiliation>Division of Neurology, Department of Internal Medicine IV, Osaka Medical and Pharmaceutical University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takashi</FirstName>
        <LastName>Yamada</LastName>
        <Affiliation>Department of Pathology, Osaka Medical and Pharmaceutical University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Naoki</FirstName>
        <LastName>Moro</LastName>
        <Affiliation>Department of Neurology, Kyorin University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Naoki</FirstName>
        <LastName>Kotsuki</LastName>
        <Affiliation>Department of Neurology, Kyorin University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kentaro</FirstName>
        <LastName>Nagai</LastName>
        <Affiliation>Department of Neurology, Kyorin University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shin-ichi</FirstName>
        <LastName>Tokushige</LastName>
        <Affiliation>Department of Neurology, Kyorin University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ayumi</FirstName>
        <LastName>Uchibori</LastName>
        <Affiliation>Department of Neurology, Kyorin University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Chizuko</FirstName>
        <LastName>Oishi</LastName>
        <Affiliation>Department of Neurology, Kyorin University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroyuki</FirstName>
        <LastName>Yabata</LastName>
        <Affiliation>Department of Neurology, Shiga University of Medical Science</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Makoto</FirstName>
        <LastName>Urushitani</LastName>
        <Affiliation>Department of Neurology, Shiga University of Medical Science</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yasushi</FirstName>
        <LastName>Iwasaki</LastName>
        <Affiliation>Department of Neuropathology, Institute for Medical Science of Aging, Aichi Medical University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroyuki</FirstName>
        <LastName>Ishiura</LastName>
        <Affiliation>Department of Neurology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan;Department of Neurology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tatsushi</FirstName>
        <LastName>Toda</LastName>
        <Affiliation>Department of Neurology, Graduate School of Medicine, The University of Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shoji</FirstName>
        <LastName>Tsuji</LastName>
        <Affiliation>Department of Neurology, Graduate School of Medicine, The University of Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yaeko</FirstName>
        <LastName>Ichikawa</LastName>
        <Affiliation>Department of Neurology, Kyorin University School of Medicine</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Objectives: To analyze the cases of a family with a novel in-frame duplication variant (NM_000454.5:c.357_357&#8201;+&#8201;2dup, p.Val120dup) of SOD1 and a structural model of the mutated SOD1 protein. Methods: The clinical profiles of three patients in the family were analyzed, including the neuropathological findings of the proband’s mother. Genetic analyses were conducted for three patients. cDNA and in silico structural analyses were performed to evaluate the effects of duplication variants on the structure of SOD1. Results: The clinical features of the patients included predominant involvement of the lower motor neurons, asymmetric onset of motor symptoms in the lower limbs, and a relatively rapid progression of muscular weakness and respiratory insufficiency. Neuropathological findings revealed severe loss of spinal cord motor neurons, and immunohistochemistry using an anti-misfolded SOD1 antibody revealed aggregates in the spinal cord. Genetic analyses revealed a c.357_357&#8201;+&#8201;2dup at the exon 4&#8211;intron 4 boundary of SOD1 in three patients. cDNA analysis of the proband suggested the presence of a valine (p.Val120dup) duplication in the heterozygous state, and the SOD1 transcript level showed no significant differences from those of healthy controls. In silico structural analyses predicted that p.Val120dup could affect the structure of the β-barrels and copper ion binding site of SOD1, suggesting an abnormal conformation of SOD1 that is predicted to interfere with the binding of copper ions. Conclusion: We identified a novel in-frame duplication variant in the C-terminus of β7 of SOD1. This genotype&#8211;structure&#8211;phenotype study of SOD1 provides valuable insights into disease-causing mechanisms.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Familial amyotrophic lateral sclerosis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">SOD1</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">in-frame duplication</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">protein structure</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">misfolded protein</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Wiley</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2328-9503</Issn>
      <Volume/>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Dorsolateral Cervical Cord T2 Hyperintensity in KIF1C-Related Disease (Spastic Paraplegia 58): Two Long-Duration Cases</ArticleTitle>
    <FirstPage LZero="delete"/>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Akihiko</FirstName>
        <LastName>Mitsutake</LastName>
        <Affiliation>Department of Neurology, Graduate School of Medicine, The University of Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masao</FirstName>
        <LastName>Osaki</LastName>
        <Affiliation>Department of Neurology, Graduate School of Medicine, The University of Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takashi</FirstName>
        <LastName>Matsukawa</LastName>
        <Affiliation>Department of Neurology, Graduate School of Medicine, The University of Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Miho</FirstName>
        <LastName>Osako</LastName>
        <Affiliation>Department of Neurology, Tokyo Metropolitan Kita Medical and Rehabilitation Center for the Disabled</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Chisen</FirstName>
        <LastName>Takeuchi</LastName>
        <Affiliation>Department of Neurology, Tokyo Metropolitan Kita Medical and Rehabilitation Center for the Disabled</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroyuki</FirstName>
        <LastName>Ishiura</LastName>
        <Affiliation>Department of Neurology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Jun</FirstName>
        <LastName>Mitsui</LastName>
        <Affiliation>Department of Precision Medicine Neurology, Graduate School of Medicine, The University of Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryo</FirstName>
        <LastName>Kurokawa</LastName>
        <Affiliation>Department of Radiology, Graduate School of Medicine, The University of Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Harushi</FirstName>
        <LastName>Mori</LastName>
        <Affiliation>Department of Radiology, School of Medicine, Jichi Medical University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuji</FirstName>
        <LastName>Takahashi</LastName>
        <Affiliation>Department of Neurology, Graduate School of Medicine, The University of Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Jun</FirstName>
        <LastName>Goto</LastName>
        <Affiliation>Department of Neurology, Graduate School of Medicine, The University of Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shoji</FirstName>
        <LastName>Tsuji</LastName>
        <Affiliation>Institute of Medical Genomics, International University of Health and Welfare</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tatsushi</FirstName>
        <LastName>Toda</LastName>
        <Affiliation>Department of Neurology, Graduate School of Medicine, The University of Tokyo</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Pathogenic variants in KIF1C cause Spastic Paraplegia 58 (SPG58), typically presenting with cerebellar ataxia and spastic paraparesis. We report two unrelated patients with spastic paraparesis, cerebellar ataxia, and tremor. Whole-exome sequence analysis identified novel homozygous variants in the motor domain of KIF1C (NM_006612.6): c.921G&gt;A (p.Trp307Ter) and c.607C&gt;T (p.Arg203Trp). In addition to the canonical brain MRI showing leukoencephalopathy with posterior dominance and hyperintensity along the corticospinal tracts, both patients showed symmetric T2 hyperintensity confined to the lateral and dorsal columns of the cervical cord. Given the long disease durations (22 and 51&#8201;years), these findings may represent late-emerging or previously overlooked spinal cord involvement and broaden the neuroradiological spectrum of SPG58.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">cerebellar ataxia</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">hereditary spastic paraplegia</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">KIF1C</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">leukoencephalopathy</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Wiley</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1085-9489</Issn>
      <Volume>30</Volume>
      <Issue>4</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>A Case of Retinopathy&#8211;Sensory Neuropathy Syndrome With a Novel Compound Heterozygous FLVCR1 Variant</ArticleTitle>
    <FirstPage LZero="delete">e70082</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Yumiko</FirstName>
        <LastName>Nakano</LastName>
        <Affiliation>Department of Neurology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yusuke</FirstName>
        <LastName>Fukui</LastName>
        <Affiliation>Department of Neurology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kentaro</FirstName>
        <LastName>Deguchi</LastName>
        <Affiliation>Department of Neurology, Okayama City General Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Chika</FirstName>
        <LastName>Matsuoka</LastName>
        <Affiliation>Department of Neurology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomohito</FirstName>
        <LastName>Kawano</LastName>
        <Affiliation>Department of Neurology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuki</FirstName>
        <LastName>Taira</LastName>
        <Affiliation>Department of Neurology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ayaka</FirstName>
        <LastName>Matsuo</LastName>
        <Affiliation>Department of Neurology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yosuke</FirstName>
        <LastName>Osakada</LastName>
        <Affiliation>Department of Neurology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Taijun</FirstName>
        <LastName>Yunoki</LastName>
        <Affiliation>Department of Neurology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Emi</FirstName>
        <LastName>Nomura</LastName>
        <Affiliation>Department of Neurology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Mami</FirstName>
        <LastName>Takemoto</LastName>
        <Affiliation>Department of Neurology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryuta</FirstName>
        <LastName>Morihara</LastName>
        <Affiliation>Department of Neurology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toru</FirstName>
        <LastName>Yamashita</LastName>
        <Affiliation>Department of Neurology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroyuki</FirstName>
        <LastName>Ishiura</LastName>
        <Affiliation>Department of Neurology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Background and Aims: Retinopathy&#8211;sensory neuropathy syndrome (RETSNS), also known as posterior column ataxia with retinitis pigmentosa (PCARP), is a rare neurodegenerative disorder that is caused by biallelic pathogenic variants in FLVCR1. Here, we report a case of a Japanese patient with RETSNS.&lt;br&gt;
Methods: Clinical, neuroradiological, and electrophysiological findings were documented. Whole-genome sequencing was performed. Subcloning was carried out to confirm compound heterozygosity. A functional assay was performed to assess the pathogenicity of the variants.&lt;br&gt;
Results: The patient showed retinitis pigmentosa and sensory ataxia. Over the course of the disease, autonomic dysfunction has become increasingly evident. Despite consanguinity in the family, whole-genome sequencing identified two heterozygous variants in FLVCR1 (c.369T&gt;G, p.Phe123Leu and c.733A&gt;G, p.Asn245Asp). Cloning of the PCR product followed by Sanger sequencing indicated compound heterozygosity of the variants. Immunocytochemistry of HEK293FT cells transfected with plasmids containing wild-type or variant FLVCR1 cDNA demonstrated altered subcellular localization of the variant FLVCR1 proteins, characterized by reduced membrane localization.&lt;br&gt;
Interpretation: We report a novel variant in FLVCR1 causing RETSNS. The functional assay supports the pathogenicity of the variants.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">FLCVR1</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">functional analysis </Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">posterior column ataxia with retinitis pigmentosa</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">subcellular localization</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Okayama University Medical School</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0386-300X</Issn>
      <Volume>79</Volume>
      <Issue>6</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Ileus Tube-Related Intussusception: A Case Report and Review of 80 Previously Reported Cases</ArticleTitle>
    <FirstPage LZero="delete">469</FirstPage>
    <LastPage>474</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Teruyuki</FirstName>
        <LastName>Tsujii</LastName>
        <Affiliation>Department of Surgery, Matsuda Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tatsuo</FirstName>
        <LastName>Matsuda</LastName>
        <Affiliation>Department of Surgery, Matsuda Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuji</FirstName>
        <LastName>Kimura</LastName>
        <Affiliation>Department of Surgery, Matsuda Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryoichi</FirstName>
        <LastName>Katsube</LastName>
        <Affiliation>Department of Surgery, Matsuda Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hironori</FirstName>
        <LastName>Iwadou</LastName>
        <Affiliation>Department of Surgery, Matsuda Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Sadami</FirstName>
        <LastName>Funabiki</LastName>
        <Affiliation>Department of Surgery, Matsuda Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yasuaki</FirstName>
        <LastName>Kamikawa</LastName>
        <Affiliation>Department of Surgery, Matsuda Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tadakazu</FirstName>
        <LastName>Matsuda</LastName>
        <Affiliation>Department of Surgery, Matsuda Hospital</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType>Case Report</PublicationType>
    <ArticleIdList>
      <ArticleId IdType="doi">10.18926/AMO/69851</ArticleId>
    </ArticleIdList>
    <Abstract>We report a rare case of ileus tube-related intussusception in an adult. A 56-year-old man with adhesive bowel obstruction was treated with a nasointestinal ileus tube. Although his condition initially improved, persistent abdominal pain led to the diagnosis of intussusception via CT imaging. Manual repositioning of the tube resolved the intussusception without the need for bowel resection. A review of 80 previously reported cases of ileus tube-associated intussusception (total 81 cases, 95 lesions) highlighted the timing of onset, treatment strategies, and precautions. Early detection and diagnosis are crucial to prevent severe complications and preserve bowel function.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">nasointestinal ileus tube</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">intussusception</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">small bowel obstruction</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">enterectomy</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">conservative treatment</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Okayama University Medical School</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0386-300X</Issn>
      <Volume>79</Volume>
      <Issue>6</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Exacerbation of Proteinuria in a Patient with Beh&#231;et’s Disease and IgA Nephropathy Following Colchicine Discontinuation</ArticleTitle>
    <FirstPage LZero="delete">457</FirstPage>
    <LastPage>461</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Tomohiko</FirstName>
        <LastName>Asakawa</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Faculty of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Haruhito A.</FirstName>
        <LastName>Uchida</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Faculty of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yu</FirstName>
        <LastName>Katayama</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Faculty of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshimasa</FirstName>
        <LastName>Sakurabu</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Faculty of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Katsuyoshi</FirstName>
        <LastName>Katayama</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Faculty of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yasuhiro</FirstName>
        <LastName>Onishi</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Faculty of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Natsumi</FirstName>
        <LastName>Matsuoka-Uchiyama</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Faculty of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hidemi</FirstName>
        <LastName>Takeuchi</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Faculty of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Keiko</FirstName>
        <LastName>Tanaka</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Faculty of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kenji</FirstName>
        <LastName>Tsuji</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Faculty of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryoko</FirstName>
        <LastName>Umebayashi</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Faculty of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Rika</FirstName>
        <LastName>Takemoto</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Faculty of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Jun</FirstName>
        <LastName>Wada</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Faculty of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType>Case Report</PublicationType>
    <ArticleIdList>
      <ArticleId IdType="doi">10.18926/AMO/69849</ArticleId>
    </ArticleIdList>
    <Abstract>This case involves a 23-year-old male who was diagnosed with Beh&#231;et’s disease 5 years ago and managed with colchicine. Two months ago, he underwent renal biopsy due to abnormal urinalysis and kidney dysfunction, leading to a diagnosis of IgA nephropathy. He subsequently underwent tonsillectomy followed by glucocorticoid pulse therapy. However, after the tonsillectomy, discontinuing colchicine led to increased proteinuria, despite the glucocorticoid pulse therapy. Upon reintroducing colchicine, urinary protein excretion decreased, achieving incomplete remission. These findings suggest that colchicine may be effective in decreasing proteinuria in patients with Beh&#231;et’s disease complicated by IgA nephropathy.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Beh&#231;et’s disease</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">IgA nephropathy</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">colchicine</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Okayama University Medical School</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0386-300X</Issn>
      <Volume>79</Volume>
      <Issue>6</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>COVID-19 and the Risks of Migraine and Headache: A Mendelian Randomization Study</ArticleTitle>
    <FirstPage LZero="delete">413</FirstPage>
    <LastPage>419</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Zhiyun</FirstName>
        <LastName>Jiang</LastName>
        <Affiliation>Department of Clinical Laboratory, The First Affiliated Hospital of Zhengzhou University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ying</FirstName>
        <LastName>Xi</LastName>
        <Affiliation>Department of Clinical Laboratory, The First Affiliated Hospital of Zhengzhou University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType>Original Article</PublicationType>
    <ArticleIdList>
      <ArticleId IdType="doi">10.18926/AMO/69843</ArticleId>
    </ArticleIdList>
    <Abstract>Several observational studies suggested that migraine headache attacks were associated with coronavirus disease 2019 (COVID-19). We investigated genetic causal links between COVID-19 phenotypes and the development of headache and migraine, including migraine with aura (MA) and migraine without aura (MO). We conducted a two-sample Mendelian randomization (MR) analysis to estimate the genetic association in European populations. The inverse-variance weighted (IVW) method was used as the main approach in the MR analyses, together with weighted median and MR-Egger methods. We also performed a series of sensitivity tests to assess the robustness of the MR results. The MR results demonstrated that COVID-19 severity, hospitalization, and susceptibility had no causal effect on the risks of headache, migraine, MA, or MO. No horizontal pleiotropy was detected, and the results were robust as supported by the sensitivity analysis findings. Our analyses identified no casual effect of COVID-19 severity, hospitalization, or susceptibility on the risks of headache or migraine in European populations.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">headache</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">migraine</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Mendelian randomization</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">COVID-19</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>MDPI AG</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2076-3921</Issn>
      <Volume>14</Volume>
      <Issue>9</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Clinical Evaluation of Oxidative Stress Markers in Patients with Long COVID During the Omicron Phase in Japan</ArticleTitle>
    <FirstPage LZero="delete">1068</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Osamu</FirstName>
        <LastName>Mese</LastName>
        <Affiliation>Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuki</FirstName>
        <LastName>Otsuka</LastName>
        <Affiliation>Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yasue</FirstName>
        <LastName>Sakurada</LastName>
        <Affiliation>Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuki</FirstName>
        <LastName>Tokumasu</LastName>
        <Affiliation>Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshiaki</FirstName>
        <LastName>Soejima</LastName>
        <Affiliation>Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Satoru</FirstName>
        <LastName>Morita</LastName>
        <Affiliation>Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yasuhiro</FirstName>
        <LastName>Nakano</LastName>
        <Affiliation>Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroyuki</FirstName>
        <LastName>Honda</LastName>
        <Affiliation>Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Akiko</FirstName>
        <LastName>Eguchi</LastName>
        <Affiliation>Biobank Center, Mie University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Sanae</FirstName>
        <LastName>Fukuda</LastName>
        <Affiliation>Department of Health Welfare Sciences, Kansai University of Welfare Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Junzo</FirstName>
        <LastName>Nojima</LastName>
        <Affiliation>Department of Laboratory Medicine, Yamaguchi University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Fumio</FirstName>
        <LastName>Otsuka</LastName>
        <Affiliation>Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>To characterize changes in markers of oxidative stress for the clinical evaluation of patients with long COVID, we assessed oxidative stress and antioxidant activity based on serum samples from patients who visited our clinic between May and November 2024. Seventy-seven patients with long COVID (41 [53%] females and 36 [47%] males; median age, 44 years) were included. Median [interquartile range] serum levels of diacron-reactive oxygen metabolites (d-ROM; CARR Unit), biological antioxidant potential (BAP; μmol/L), and oxidative stress index (OSI) were 533.8 [454.9&#8211;627.6], 2385.8 [2169.2&#8211;2558.1] and 2.0 [1.7&#8211;2.5], respectively. Levels of d-ROMs (579.8 vs. 462.2) and OSI (2.3 vs. 1.8), but not BAP (2403.4 vs. 2352.6), were significantly higher in females than in males. OSI levels positively correlated with age and body mass index, whereas BAP levels negatively correlated with these parameters. d-ROM and OSI levels were significantly associated with inflammatory markers, including C-reactive protein (CRP) and fibrinogen, whereas BAP levels were inversely correlated with CRP and ferritin levels. Notably, serum free thyroxine levels were negatively correlated with d-ROMs and OSI, whereas cortisol levels were positively correlated with d-ROMs. Among long COVID symptoms, patients reporting brain fog exhibited significantly higher OSI levels (2.2 vs. 1.8), particularly among females (d-ROMs: 625.6 vs. 513.0; OSI: 2.4 vs. 2.0). The optimal OSI cut-off values were determined to be 1.32 for distinguishing long COVID from healthy controls and 1.92 for identifying brain fog among patients with long COVID. These findings suggest that oxidative stress markers may serve as indicators for the presence or prediction of psycho-neurological symptoms associated with long COVID in a gender-dependent manner.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">biological antioxidant potential (BAP)</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Coronavirus disease 2019 (COVID-19)</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">diacron-reactive oxygen metabolites (d-ROM)</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Long COVID</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">oxidative stress index (OSI)</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>MDPI AG</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2077-0383</Issn>
      <Volume>14</Volume>
      <Issue>14</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Symptomatic Trends and Time to Recovery for Long COVID Patients Infected During the Omicron Phase</ArticleTitle>
    <FirstPage LZero="delete">4918</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Hiroshi</FirstName>
        <LastName>Akiyama</LastName>
        <Affiliation>Department of General Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yasue</FirstName>
        <LastName>Sakurada</LastName>
        <Affiliation>Department of General Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroyuki</FirstName>
        <LastName>Honda</LastName>
        <Affiliation>Department of General Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yui</FirstName>
        <LastName>Matsuda</LastName>
        <Affiliation>Department of General Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuki</FirstName>
        <LastName>Otsuka</LastName>
        <Affiliation>Department of General Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuki</FirstName>
        <LastName>Tokumasu</LastName>
        <Affiliation>Department of General Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yasuhiro</FirstName>
        <LastName>Nakano</LastName>
        <Affiliation>Department of General Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryosuke</FirstName>
        <LastName>Takase</LastName>
        <Affiliation>Department of General Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Daisuke</FirstName>
        <LastName>Omura</LastName>
        <Affiliation>Department of General Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Keigo</FirstName>
        <LastName>Ueda</LastName>
        <Affiliation>Department of General Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Fumio</FirstName>
        <LastName>Otsuka</LastName>
        <Affiliation>Department of General Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Background: Since the pathophysiology of long COVID is not yet fully understood, there are no specific methods for its treatment; however, its individual symptoms can currently be treated. Long COVID is characterized by symptoms that persist at least 2 to 3 months after contracting COVID-19, although it is difficult to predict how long such symptoms may persist. Methods: In the present study, 774 patients who first visited our outpatient clinic during the Omicron period from February 2022 to October 2024 were divided into two groups: the early recovery (ER) group (370 cases; 47.8%), who recovered in less than 180 days (median 33 days), and the persistent-symptom (PS) group (404 cases; 52.2%), who had symptoms that persisted for more than 180 days (median 437 days). The differences in clinical characteristics between these two groups were evaluated. Results: Although the median age of the two groups did not significantly differ (40 and 42 in ER and PS groups, respectively), the ratio of female patients was significantly higher in the PS group than the ER group (59.4% vs. 47.3%). There were no significant differences between the two groups in terms of the period after infection, habits, BMI, severity of COVID-19, and vaccination history. Notably, at the first visit, female patients in the PS group had a significantly higher rate of complaints of fatigue, insomnia, memory disturbance, and paresthesia, while male patients in the PS group showed significantly higher rates of fatigue and headache complaints. Patients with more than three symptoms at the first visit were predominant in the PS groups in both genders. Notably, one to two symptoms were predominant in the male ER group, while two to three symptoms were mostly reported in the female PS group. Moreover, the patients in the PS group had significantly higher scores for physical and mental fatigue and for depressive symptoms. Conclusions: Collectively, these results suggest that long-lasting long COVID is related to the number of symptoms and presents gender-dependent differences.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">fatigue</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">headache</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">insomnia</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">long COVID</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Omicron variants</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">recovery</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Wiley</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2189-7948</Issn>
      <Volume>26</Volume>
      <Issue>4</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Video review by utilizing asynchronous video communication platform</ArticleTitle>
    <FirstPage LZero="delete">375</FirstPage>
    <LastPage>378</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Yuki</FirstName>
        <LastName>Otsuka</LastName>
        <Affiliation>Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Eiko</FirstName>
        <LastName>Mitsuda</LastName>
        <Affiliation>Kato &amp; Namiki-dori Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yukichika</FirstName>
        <LastName>Yamamoto</LastName>
        <Affiliation>Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Atsushi</FirstName>
        <LastName>Kato</LastName>
        <Affiliation>Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Mano</FirstName>
        <LastName>Soshi</LastName>
        <Affiliation>BonBon, Inc</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masaya</FirstName>
        <LastName>Higuchi</LastName>
        <Affiliation>Harvard Medical School</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Mikako</FirstName>
        <LastName>Obika</LastName>
        <Affiliation>Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Fumio</FirstName>
        <LastName>Otsuka</LastName>
        <Affiliation>Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tadayuki</FirstName>
        <LastName>Hashimoto</LastName>
        <Affiliation>Department of Emergency Medicine, Brigham and Women's Hospital</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Background: Video review is widely recognized as an effective method for teaching communication; however, it can increase educators' workload and learners' stress.&lt;br&gt;
Methods: We utilized Tsucom, an online platform developed by BonBon, Inc., which enables asynchronous video communication instead of traditional styles. An 11-min and 42-s consultation video from a fifth-year resident was uploaded, and 10 physicians provided 30 text-based feedback.&lt;br&gt;
Results: In this pilot survey, the utility and ease of use were rated 4.4 and 4.1 out of 5, respectively.&lt;br&gt;
Conclusions: While asynchronous online video reviews provided flexibility and greater participation, challenges remain, and further trials and evaluations were deemed necessary.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">feedback</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">general medicine</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">video review</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Wiley</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0031-9317</Issn>
      <Volume>177</Volume>
      <Issue>4</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Comparative Transcriptome Reveals ART1-Dependent Regulatory Pathways for Fe Toxicity Response in Rice Roots</ArticleTitle>
    <FirstPage LZero="delete">e70398</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Yoshiaki</FirstName>
        <LastName>Ueda</LastName>
        <Affiliation>Crop, Livestock and Environment Division, Japan International Research Center for Agricultural Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Naoki</FirstName>
        <LastName>Yamaji</LastName>
        <Affiliation>Institute of Plant Science and Resources, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Matthias</FirstName>
        <LastName>Wissuwa</LastName>
        <Affiliation>Crop, Livestock and Environment Division, Japan International Research Center for Agricultural Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Iron (Fe) is an essential element for plants, but an excess supply can have detrimental effects. Fe toxicity induces complex physiological and genetic responses, and due to this complexity, the knowledge of transcriptional regulatory mechanisms under Fe toxicity is very limited. Previous studies suggested that plant responses to excess Fe involve oxidative stress caused by reactive oxygen species (ROS), which itself causes transcriptional changes. We hypothesized that dissecting these complex responses could lead to the identification of a novel factor and conducted a comparative transcriptome analysis using roots of rice plants exposed to nutrient solutions containing 1 or 5&#8201;mM of hydrogen peroxide (a major form of ROS) or 300&#8201;mg&#8201;L−1 of Fe (as FeSO4). Genes induced by hydrogen peroxide overlapped with 62%, 49%, and 30% of Fe toxicity-upregulated genes at 3&#8201;h, 1&#8201;day, and 3&#8201;days following treatment initiation. Subsequent gene co-expression analyses classified genes into 21 groups with varying responsiveness to ROS and Fe toxicity. Genes in group 15 were specifically upregulated by Fe toxicity and overlapped significantly with aluminum (Al)-inducible genes and target genes of the Zn-finger transcription factor, ART1, which regulates Al response in rice roots. Additional experiments using the art1 knock-out mutant demonstrated that ART1 is crucial for upregulating genes such as STAR2 and FRDL4 in response to Fe toxicity. This study reveals the contribution of ART1-dependent regulatory pathways in rice roots under Fe toxicity.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">ART1</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">gene co-expression analysis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">iron toxicity</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">reactive oxygen species</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">rice</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1341-9625</Issn>
      <Volume>30</Volume>
      <Issue>8</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Phase-Ib dose-finding and pharmacokinetic trial of metformin combined with nivolumab for refractory/recurrent solid tumors</ArticleTitle>
    <FirstPage LZero="delete">1537</FirstPage>
    <LastPage>1544</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Toshio</FirstName>
        <LastName>Kubo</LastName>
        <Affiliation>Department of Allergy and Respiratory Medicine, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hironari</FirstName>
        <LastName>Kato</LastName>
        <Affiliation>Department of Gastroenterology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shigeru</FirstName>
        <LastName>Horiguchi</LastName>
        <Affiliation>Department of Gastroenterology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshiyuki</FirstName>
        <LastName>Kozuki</LastName>
        <Affiliation>Department of Thoracic Oncology and Medicine, NHO Shikoku Cancer Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Akinori</FirstName>
        <LastName>Asagi</LastName>
        <Affiliation>Department of Gastrointestinal Medical Oncology, NHO Shikoku Cancer Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Michihiro</FirstName>
        <LastName>Yoshida</LastName>
        <Affiliation>Center for Innovative Clinical Medicine, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Heiichiro</FirstName>
        <LastName>Udono</LastName>
        <Affiliation>Department of Immunology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Katsuyuki</FirstName>
        <LastName>Kiura</LastName>
        <Affiliation>Department of Allergy and Respiratory Medicine, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Katsuyuki</FirstName>
        <LastName>Hotta</LastName>
        <Affiliation>Department of Allergy and Respiratory Medicine, Okayama University Hospital</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Background Our previous findings showed that the addition of metformin to nivolumab resulted in remarkable tumor regression and increased the number of tumor-infiltrating T cells in mouse models. Therefore, we conducted a phase Ib study using combination therapy with nivolumab and metformin in patients with refractory/recurrent solid tumors.&lt;br&gt;
Methods This study consisted of two parts: 1, evaluating the maximum tolerated dose (MTD), safety, pharmacokinetics in solid tumors, and 2, principally investigating the safety at the recommended dose limited to thoracic and pancreatic cancers. Metformin and nivolumab were administered orally at doses of 750&#8211;2,250 mg/day and biweekly at a fixed intravenous dose of 3 mg/kg, respectively. Dose-limiting toxicity was evaluated within the first 4 weeks. Both metformin and nivolumab were continued until disease progression or discontinued because of toxicity.&lt;br&gt;
Results In total, 17 and 24 patients were enrolled in parts 1 and 2, respectively. One patient experienced increased pancreatic enzyme levels (grade 4) and lactic acidosis (grade 3). No Grade 5 adverse events were observed. MTD was not reached up to 2,250 mg/day of metformin, 2,250 mg/day was selected for part 2. An objective response was observed in 4 of 41 patients. One-year progression-free and overall survival rates were 9.8% and 56.8%, respectively. Two patients remained alive without disease progression for more than three years.&lt;br&gt;
Conclusions Nivolumab and metformin combination therapy was well-tolerated and showed preliminary signals of efficacy in a subset of patients. Further verification of the underlying mechanism in cases where treatment is effective is required.&lt;br&gt;
Trial registration numbers UMIN registration number 000028405 https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000031915.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Pancreatic cancer</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Thoracic tumors</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Phase Ib</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Anti-PD-1 antibody</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Nivolumab</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Metformin</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2399-3642</Issn>
      <Volume>8</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Single-cell and spatial transcriptomic characterization of pulmonary pleomorphic carcinoma</ArticleTitle>
    <FirstPage LZero="delete">1773</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Atsushi</FirstName>
        <LastName>Matsuoka</LastName>
        <Affiliation>Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuhiko</FirstName>
        <LastName>Shien</LastName>
        <Affiliation>Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shuta</FirstName>
        <LastName>Tomida</LastName>
        <Affiliation/>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masayoshi</FirstName>
        <LastName>Ohki</LastName>
        <Affiliation>Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuya</FirstName>
        <LastName>Hisamatsu</LastName>
        <Affiliation>Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryota</FirstName>
        <LastName>Fujiwara</LastName>
        <Affiliation>Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kosei</FirstName>
        <LastName>Ishimura</LastName>
        <Affiliation>Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryunosuke</FirstName>
        <LastName>Fujii</LastName>
        <Affiliation>Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomoaki</FirstName>
        <LastName>Higashihara</LastName>
        <Affiliation>Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Naohiro</FirstName>
        <LastName>Hayashi</LastName>
        <Affiliation>Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuhiro</FirstName>
        <LastName>Okada</LastName>
        <Affiliation>Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryo</FirstName>
        <LastName>Yoshichika</LastName>
        <Affiliation>Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Fumiaki</FirstName>
        <LastName>Mukohara</LastName>
        <Affiliation>Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Mao</FirstName>
        <LastName>Yoshikawa</LastName>
        <Affiliation>Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuma</FirstName>
        <LastName>Fukumoto</LastName>
        <Affiliation>Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ken</FirstName>
        <LastName>Suzawa</LastName>
        <Affiliation>Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yasuaki</FirstName>
        <LastName>Tomioka</LastName>
        <Affiliation>Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shin</FirstName>
        <LastName>Tanaka</LastName>
        <Affiliation>Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kentaroh</FirstName>
        <LastName>Miyoshi</LastName>
        <Affiliation>Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Mikio</FirstName>
        <LastName>Okazaki</LastName>
        <Affiliation>Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Seiichiro</FirstName>
        <LastName>Sugimoto</LastName>
        <Affiliation>Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yusuke</FirstName>
        <LastName>Otani</LastName>
        <Affiliation>Department of Pathology, Beth Israel Deaconess Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Atsushi</FirstName>
        <LastName>Tanaka</LastName>
        <Affiliation>Department of Pathology, Beth Israel Deaconess Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hirofumi</FirstName>
        <LastName>Inoue</LastName>
        <Affiliation>Center for Comprehensive Genomic Medicine, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yosuke</FirstName>
        <LastName>Togashi</LastName>
        <Affiliation>Department of Tumor Microenvironment, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hidetaka</FirstName>
        <LastName>Yamamoto</LastName>
        <Affiliation>Department of Pathology and Oncology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Daisuke</FirstName>
        <LastName>Ennishi</LastName>
        <Affiliation>Center for Comprehensive Genomic Medicine, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shinichi</FirstName>
        <LastName>Toyooka</LastName>
        <Affiliation>Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Pulmonary pleomorphic carcinoma (PPC) is a rare subtype of lung cancer that comprises both epithelial and sarcomatoid components. The molecular basis of PPC, including the cellular dynamics of its components, remains largely unknown. To elucidate potential therapeutic targets for PPC, we perform a multi-omics analysis incorporating digital spatial profiling and single-cell RNA sequencing (scRNA-seq). PPC exhibits diverse driver gene alterations, including MET exon 14 skipping mutation (METex14) and ALK fusion. In spatial transcriptomics, MET gene and protein are overexpressed exclusively within the epithelial component and not in the sarcomatoid component, even in patients harboring METex14. Epithelial-mesenchymal transition (EMT)-related transcriptional changes, along with extracellular matrix (ECM) remodeling between the epithelial and sarcomatoid components, are observed. scRNA-seq identifies cell populations within the epithelial component that contribute to the malignant transformation and differentiation of the sarcomatoid component. They are characterized by an intermediate EMT state with ECM remodeling signature, suggesting their potential as novel therapeutic targets for PPC.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList/>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2041-1723</Issn>
      <Volume>16</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Efficient and stable n-type sulfide overall water splitting with separated hydrogen production</ArticleTitle>
    <FirstPage LZero="delete">8786</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Haolin</FirstName>
        <LastName>Luo</LastName>
        <Affiliation>Research Center for Combustion and Environment Technology, Shanghai Jiao Tong University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Zhixi</FirstName>
        <LastName>Liu</LastName>
        <Affiliation>Research Center for Combustion and Environment Technology, Shanghai Jiao Tong University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Haifeng</FirstName>
        <LastName>Lv</LastName>
        <Affiliation>State Key Laboratory of Precision and Intelligent Chemistry, School of Chemistry and Material Sciences, and Collaborative Innovation Center of Chemistry for Energy Materials (iChEM), University of Science and Technology of China</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Junie Jhon M.</FirstName>
        <LastName>Vequizo</LastName>
        <Affiliation>Institute of Aqua Regeneration, Shinshu University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Mengting</FirstName>
        <LastName>Zheng</LastName>
        <Affiliation>College of Chemical and Biological Engineering, Zhejiang University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Feng</FirstName>
        <LastName>Han</LastName>
        <Affiliation>Research Center for Combustion and Environment Technology, Shanghai Jiao Tong University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Zhen</FirstName>
        <LastName>Ye</LastName>
        <Affiliation>Research Center for Combustion and Environment Technology, Shanghai Jiao Tong University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Akira</FirstName>
        <LastName>Yamakata</LastName>
        <Affiliation>Faculty of Natural Science and Technology, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Wenfeng</FirstName>
        <LastName>Shangguan</LastName>
        <Affiliation>Research Center for Combustion and Environment Technology, Shanghai Jiao Tong University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Adam F.</FirstName>
        <LastName>Lee</LastName>
        <Affiliation>Centre for Catalysis and Clean Energy, School of Environment and Science, Griffith University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Xiaojun</FirstName>
        <LastName>Wu</LastName>
        <Affiliation>State Key Laboratory of Precision and Intelligent Chemistry, School of Chemistry and Material Sciences, and Collaborative Innovation Center of Chemistry for Energy Materials (iChEM), University of Science and Technology of China</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Domen</FirstName>
        <LastName>Kazunari</LastName>
        <Affiliation>Institute of Aqua Regeneration, Shinshu University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Jun</FirstName>
        <LastName>Lu</LastName>
        <Affiliation>College of Chemical and Biological Engineering, Zhejiang University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Zhi</FirstName>
        <LastName>Jiang</LastName>
        <Affiliation>Research Center for Combustion and Environment Technology, Shanghai Jiao Tong University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>N-type sulfide semiconductors are promising photocatalysts due to their broad visible-light absorption, facile synthesis and chemical diversity. However, photocorrosion and limited electron transport in one-step excitation and solid-state Z-scheme systems hinder efficient overall water splitting. Liquid-phase Z-schemes offer a viable alternative, but sluggish mediator kinetics and interfacial side reactions impede their construction. Here we report a stable Z-scheme system integrating n-type CdS and BiVO&#8324; with a [Fe(CN)&#8326;]&#179;&#8315;/[Fe(CN)&#8326;]&#8308;&#8315; mediator, achieving 10.2% apparent quantum yield at 450&#8201;nm with stoichiometric H&#8322;/O&#8322; evolution. High activity reflects synergies between Pt@CrOx and Co3O4 cocatalysts on CdS, and cobalt-directed facet asymmetry in BiVO&#8324;, resulting in matched kinetics for hydrogen and oxygen evolution in a reversible mediator solution. Stability is dramatically improved through coating CdS and BiVO4 with different oxides to inhibit Fe4[Fe(CN)6]3 precipitation and deactivation by a hitherto unrecognized mechanism. Separate hydrogen and oxygen production is also demonstrated in a two-compartment reactor under visible light and ambient conditions. This work unlocks the long-sought potential of n-type sulfides for efficient, durable and safe solar-driven hydrogen production.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList/>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>British Editorial Society of Bone &amp; Joint Surgery</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2633-1462</Issn>
      <Volume>6</Volume>
      <Issue>8</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Long-term functional and quality of life outcomes after cementless minimally invasive extendable endoprosthesis replacement in skeletally immature patients with bone sarcomas at the lower limb a Japanese Musculoskeletal Oncology Group (JMOG) study</ArticleTitle>
    <FirstPage LZero="delete">954</FirstPage>
    <LastPage>963</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Yusuke</FirstName>
        <LastName>Tsuda</LastName>
        <Affiliation>Department of Orthopaedic Surgery, The University of Tokyo Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshihiro</FirstName>
        <LastName>Nishida</LastName>
        <Affiliation>Department of Rehabilitation, Nagoya University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Akio</FirstName>
        <LastName>Sakamoto</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Graduate School of Medicine, Kyoto University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Koichi</FirstName>
        <LastName>Ogura</LastName>
        <Affiliation>Department of Musculoskeletal Oncology and Rehabilitation, National Cancer Center Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomohiro</FirstName>
        <LastName>Fujiwara</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tetsuya</FirstName>
        <LastName>Sekita</LastName>
        <Affiliation>Department of Musculoskeletal Oncology and Rehabilitation, National Cancer Center Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hirotaka</FirstName>
        <LastName>Kawano</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Teikyo University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroshi</FirstName>
        <LastName>Kobayashi</LastName>
        <Affiliation>Department of Orthopaedic Surgery, The University of Tokyo Hospital</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Aims&lt;br&gt;
Extendable endoprostheses are utilized to reconstruct segmental defects following resection of bone sarcomas in skeletally immature children. However, there remains a paucity of data regarding long-term functional and quality of life outcomes.&lt;br&gt;
Methods&lt;br&gt;
We conducted a retrospective, multicentre study and reviewed 45 children who underwent cementless minimally invasive extendable endoprosthetic replacement. Anatomical sites included the distal femur (n = 29), proximal femur (n = 4), proximal tibia (n = 11), and total femur (n = 1). The mean follow-up period was 12 years. The mean age at extendable endoprosthetic replacement was ten years (5 to 15). Most patients (96%, 43/45) had reached skeletal maturity at the final follow-up.&lt;br&gt;
Results&lt;br&gt;
The ten-year endoprosthetic failure-free survival rate was 60%. Of the 45 patients, 25 (56%) had 42 complications which were frequently related to structural failure (45%, 19/42), with extension mechanism jamming being the most common (n = 7, 17%). Excluding lengthening procedures, 20 patients (44%) underwent additional surgery with a mean of two surgeries per patient. The mean limb-length discrepancy at the final follow-up was 2.3 cm. Limb salvage was achieved in 44 (98%) patients. The mean Musculoskeletal Tumor Society (MSTS) scores, Toronto Extremity Salvage Score (TESS), and EuroQol five-dimension five-level questionnaire (EQ-5D-5L) were 78%, 92%, and 92% at the last follow-up, respectively. Multiple additional surgeries (&#8805; 2 times) for complications were associated with worse MSTS scores compared with those without multiple additional surgeries (p = 0.009). Moreover, limb-length discrepancy &gt; 3 cm showed significantly worse MSTS scores compared with those &#8804; 3 cm (p = 0.019).&lt;br&gt;
Conclusion&lt;br&gt;
Extendable endoprostheses were associated with a high complication rate and need for additional surgeries over time, especially for structural-related complications. Despite this, successful limb salvage with reasonable function/quality of life and small limb-length discrepancy were achievable in the long term. Patients’ function in the long term depended on the experience of postoperative complications and limb-length discrepancy.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList/>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1479-5876</Issn>
      <Volume>23</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Tumor marker&#8211;guided precision BNCT for CA19-9&#8211;positive cancers: a new paradigm in molecularly targeted chemoradiation therapy</ArticleTitle>
    <FirstPage LZero="delete">1387</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Noriyuki</FirstName>
        <LastName>Kanehira</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Fuminori</FirstName>
        <LastName>Teraishi</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomoyuki</FirstName>
        <LastName>Tajima</LastName>
        <Affiliation>Graduate School of Environmental, Life, Natural Science and Technology, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tatsunori</FirstName>
        <LastName>Osone</LastName>
        <Affiliation>Department of Regenerative Science, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuyoshi</FirstName>
        <LastName>Gotoh</LastName>
        <Affiliation>Department of Medical Laboratory Science, Okayama University Graduate School of Health Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takuya</FirstName>
        <LastName>Fujimoto</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshinori</FirstName>
        <LastName>Sakurai</LastName>
        <Affiliation>Institute for Integrated Radiation and Nuclear Science, Kyoto University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Natsuko</FirstName>
        <LastName>Kondo</LastName>
        <Affiliation>Institute for Integrated Radiation and Nuclear Science, Kyoto University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Narikazu</FirstName>
        <LastName>Nagahisa</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kaoru</FirstName>
        <LastName>Kamei</LastName>
        <Affiliation>Graduate School of Environmental, Life, Natural Science and Technology, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Taiga</FirstName>
        <LastName>Fujita</LastName>
        <Affiliation>Graduate School of Environmental, Life, Natural Science and Technology, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Akira</FirstName>
        <LastName>Morihara</LastName>
        <Affiliation>Graduate School of Environmental, Life Science, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yutaka</FirstName>
        <LastName>Takaguchi</LastName>
        <Affiliation>Faculty of Sustainable Design, Department of Material Design and Engineering, University of Toyama</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Mizuki</FirstName>
        <LastName>Kitamatsu</LastName>
        <Affiliation>Department of Applied Chemistry, Kindai University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takeshi</FirstName>
        <LastName>Takarada</LastName>
        <Affiliation>Department of Regenerative Science, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kunitoshi</FirstName>
        <LastName>Shigeyasu</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Minoru</FirstName>
        <LastName>Suzuki</LastName>
        <Affiliation>Institute for Integrated Radiation and Nuclear Science, Kyoto University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshiyoshi</FirstName>
        <LastName>Fujiwara</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroyuki</FirstName>
        <LastName>Michiue</LastName>
        <Affiliation>Neutron Therapy Research Center, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Background: Boron neutron capture therapy (BNCT) is a molecularly targeted chemoradiation modality that relies on boron delivery agents such as p-borophenylalanine (BPA), which require LAT1 (L-type amino acid transporter 1) for tumor uptake. However, the limited efficacy of BPA in LAT1-low tumors restricts its therapeutic scope. To address this limitation, we developed a tumor marker&#8211;guided BNCT strategy targeting cancers overexpressing the clinically validated glycan biomarker CA19-9.&lt;br&gt;
Methods: We conducted transcriptomic analyses using The Cancer Genome Atlas (TCGA) datasets to identify LAT1-low cancers with high CA19-9 expression. These analyses revealed elevated expression of fucosyltransferase 3 (FUT3), which underlies CA19-9 biosynthesis, in pancreatic, biliary, and ovarian malignancies. Based on this, we synthesized a novel boron compound, fucose-BSH, designed to selectively accumulate in CA19-9&#8211;positive tumors. We evaluated its physicochemical properties, pharmacokinetics, biodistribution, and antitumor efficacy in cell lines and xenograft models, comparing its performance to that of BPA.&lt;br&gt;
Results: Fucose-BSH demonstrated significantly greater boron uptake in CA19-9&#8211;positive cell lines (AsPC-1, Panc 04.03, HuCCT-1, HSKTC, OVISE) compared to CA19-9&#8211;negative PANC-1. In HuCCT-1 xenografts, boron accumulation reached 36.2 ppm with a tumor/normal tissue ratio of 2.1, outperforming BPA. Upon neutron irradiation, fucose-BSH&#8211;mediated BNCT achieved&#8201;&gt;&#8201;80% tumor growth inhibition. Notably, fucose-BSH retained therapeutic efficacy in LAT1-deficient models where BPA was ineffective, confirming LAT1-independent targeting.&lt;br&gt;
Conclusions: This study establishes a novel precision BNCT approach by leveraging CA19-9 as a tumor-selective glycan marker for boron delivery. Fucose-BSH offers a promising platform for expanding BNCT to previously inaccessible LAT1-low malignancies, including pancreatic, biliary, and ovarian cancers. These findings provide a clinically actionable strategy for tumor marker&#8211;driven chemoradiation and lay the foundation for translational application in BNCT. This strategy has the potential to support companion diagnostic development and precision stratification in ongoing and future BNCT clinical trials.&lt;br&gt;
Translational Relevance: Malignancies with elevated CA19-9 expression, such as pancreatic, biliary, and ovarian cancers, are associated with poor prognosis and limited response to current therapies. This study presents a tumor marker&#8211;guided strategy for boron neutron capture therapy (BNCT) by leveraging CA19-9 glycan biology to enable selective tumor targeting via fucose-BSH, a novel boron compound. Through transcriptomic data mining and preclinical validation, fucose-BSH demonstrated LAT1-independent boron delivery, potent BNCT-mediated cytotoxicity, and tumor-specific accumulation in CA19-9&#8211;positive models. These findings support a precision chemoradiation approach that addresses a critical gap in BNCT applicability, offering a clinically actionable pathway for patient stratification and therapeutic development in CA19-9&#8211;expressing cancers.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Boron neutron capture therapy (BNCT)</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Precision BNCT</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Fucose-conjugated medicine</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">CA19-9</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Drug discovery</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0944-1174</Issn>
      <Volume>60</Volume>
      <Issue>12</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Combination chemotherapy for older patients with unresectable biliary tract cancer: a prospective observational study using propensity-score matched analysis (JON2104-B)</ArticleTitle>
    <FirstPage LZero="delete">1584</FirstPage>
    <LastPage>1595</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Satoshi</FirstName>
        <LastName>Kobayashi</LastName>
        <Affiliation>Department of Gastroenterology, Kanagawa Cancer Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kohei</FirstName>
        <LastName>Nakachi</LastName>
        <Affiliation>Department of Medical Oncology, Tochigi Cancer Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kouji</FirstName>
        <LastName>Yamamoto</LastName>
        <Affiliation>Department of Biostatistics, Yokohama City University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Makoto</FirstName>
        <LastName>Ueno</LastName>
        <Affiliation>Department of Gastroenterology, Kanagawa Cancer Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuta</FirstName>
        <LastName>Maruki</LastName>
        <Affiliation/>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kenji</FirstName>
        <LastName>Ikezawa</LastName>
        <Affiliation>Department of Hepatobiliary and Pancreatic Oncology, Osaka International Cancer Institute</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takeshi</FirstName>
        <LastName>Terashima</LastName>
        <Affiliation>Department of Gastroenterology, Kanazawa University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Satoshi</FirstName>
        <LastName>Shimizu</LastName>
        <Affiliation>Department of Gastroenterology, Kanazawa University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kotoe</FirstName>
        <LastName>Oshima</LastName>
        <Affiliation>Division of Gastrointestinal Oncology, Shizuoka Cancer Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kunihiro</FirstName>
        <LastName>Tsuji</LastName>
        <Affiliation>Department of Gastroenterology, Ishikawa Prefectural Central Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshiharu</FirstName>
        <LastName>Masaki</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Sapporo Medical University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hidetaka</FirstName>
        <LastName>Tsumura</LastName>
        <Affiliation>Department of Gastroenterological Oncology, Hyogo Cancer Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Taro</FirstName>
        <LastName>Shibuki</LastName>
        <Affiliation>Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masato</FirstName>
        <LastName>Ozaka</LastName>
        <Affiliation>Hepato-Biliary-Pancreatic Medicine Department, Cancer Institute Hospital of Japanese Foundation for Cancer Research</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Naohiro</FirstName>
        <LastName>Okano</LastName>
        <Affiliation>Department of Medical Oncology, Kyorin University Faculty of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yukiyasu</FirstName>
        <LastName>Okamura</LastName>
        <Affiliation>Division of Digestive Surgery, Department of Surgery, Nihon University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kumiko</FirstName>
        <LastName>Umemoto</LastName>
        <Affiliation>Department of Clinical Oncology, St. Marianna University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tatsunori</FirstName>
        <LastName>Satoh</LastName>
        <Affiliation>Department of Gastroenterology, Shizuoka General Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yasushi</FirstName>
        <LastName>Kojima</LastName>
        <Affiliation>Department of Gastroenterology, National Center for Global Health and Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuhiko</FirstName>
        <LastName>Shioji</LastName>
        <Affiliation>Department of Gastroenterology, Niigata Cancer Center Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroko</FirstName>
        <LastName>Nebiki</LastName>
        <Affiliation>Department of Gastroenterology, Osaka City General Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshifumi</FirstName>
        <LastName>Doi</LastName>
        <Affiliation>Department of Molecular Gastroenterology and Hepatology, Kyoto Prefectural University of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Atsushi</FirstName>
        <LastName>Naganuma</LastName>
        <Affiliation>Department of Gastroenterology, National Hospital Organization Takasaki General Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shigeki</FirstName>
        <LastName>Kataoka</LastName>
        <Affiliation>Department of Clinical Oncology, Graduate School of Medicine Faculty of Medicine, Kyoto University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Emiri</FirstName>
        <LastName>Kita</LastName>
        <Affiliation>Department of Gastroenterology, Chiba Cancer Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroyuki</FirstName>
        <LastName>Asama</LastName>
        <Affiliation>Department of Gastroenterology, Fukushima Medical University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kaoru</FirstName>
        <LastName>Tsuchiya</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Musashino Red Cross Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Michiaki</FirstName>
        <LastName>Unno</LastName>
        <Affiliation>Department of Surgery, Tohoku University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Reiko</FirstName>
        <LastName>Ashida</LastName>
        <Affiliation>Second Department of Internal Medicine, Wakayama Medical University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuyuki</FirstName>
        <LastName>Matsumoto</LastName>
        <Affiliation>Department of Gastroenterology, Okayama University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Izumi</FirstName>
        <LastName>Ohno</LastName>
        <Affiliation>Department of Gastroenterology, Chiba University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takao</FirstName>
        <LastName>Itoi</LastName>
        <Affiliation>Department of Gastroenterology, Tokyo Medical University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuji</FirstName>
        <LastName>Negoro</LastName>
        <Affiliation>Department of Oncologial Medicine, Kochi Health Sciences Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yasunari</FirstName>
        <LastName>Sakamoto</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, International University of Health and Welfare Atami Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shiho</FirstName>
        <LastName>Arima</LastName>
        <Affiliation>Digestive and Lifestyle Diseases, Kagoshima University Graduate School of Medical and Dental Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Akinori</FirstName>
        <LastName>Asagi</LastName>
        <Affiliation>Department of Gastroenterology, National Hospital Organization Shikoku Cancer Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroyuki</FirstName>
        <LastName>Okuyama</LastName>
        <Affiliation>Department of Medical Oncology, Kagawa University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshito</FirstName>
        <LastName>Komatsu</LastName>
        <Affiliation>Department of Cancer Chemotherapy, Hokkaido University Hospital Cancer Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Noritoshi</FirstName>
        <LastName>Kobayashi</LastName>
        <Affiliation>Department of Oncology, School of Medicine Graduate School of Medicine, Yokohama City University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroaki</FirstName>
        <LastName>Nagano</LastName>
        <Affiliation>Department of Gastroenterological, Breast and Endocrine Surgery, Yamaguchi University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Junji</FirstName>
        <LastName>Furuse</LastName>
        <Affiliation>Department of Gastroenterology, Kanagawa Cancer Center</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Background: Systemic chemotherapy with gemcitabine plus S-1 (GEM&#8201;+&#8201;S-1), GEM&#8201;+&#8201;CDDP plus S-1 (GEM&#8201;+&#8201;CDDP&#8201;+&#8201;S-1), or gemcitabine plus cisplatin (GEM&#8201;+&#8201;CDDP) is standard treatment for advanced biliary tract cancer (aBTC). We aimed to evaluate the efficacy and safety of combination chemotherapy in older patients with aBTC.&lt;br&gt;
Methods: This multicenter prospective observational study (JON2104-B, UMIN000045156) included patients aged&#8201;&#8805;&#8201;70 years with aBTC. Inverse-probability weighting propensity-score analyses (IPW) were used to compare overall survival (OS) as the primary endpoint and progression-free survival (PFS) across treatment groups.&lt;br&gt;
Results: This study included 305 patients between August 2021 and January 2023. Of them, 75, 131, 26, 52, and 10 received GEM&#8201;+&#8201;CDDP&#8201;+&#8201;S-1, GEM&#8201;+&#8201;CDDP, GEM&#8201;+&#8201;S-1, gemcitabine, and S-1; their median ages were 74, 75, 77.5, 80, and 80 years, and approximately 24%, 16.8%, 23.1%, 9.6%, and 0% had G-8 scores of&#8201;&gt;&#8201;14, respectively. GEM&#8201;+&#8201;CDDP had a safety profile comparable to that of GEM&#8201;+&#8201;CDDP&#8201;+&#8201;S-1 but was more toxic than gemcitabine. Per IPW, the hazard ratio (HR) for GEM&#8201;+&#8201;CDDP&#8201;+&#8201;S-1 versus GEM&#8201;+&#8201;CDDP was 0.80 for OS (95% confidence interval [CI], 0.55&#8211;1.17) and 0.55 for PFS (95% CI 0.38&#8211;0.80). The HR for GEM&#8201;+&#8201;CDDP versus gemcitabine was 0.74 for OS (95% CI 0.42&#8211;1.29) and 0.79 for PFS (95% CI 0.42&#8211;1.49).&lt;br&gt;
Conclusions: GEM&#8201;+&#8201;CDDP&#8201;+&#8201;S-1 was associated with longer PFS without additional toxicity than GEM&#8201;+&#8201;CDDP for fit older patients. However, the OS for both were not statistically different. The efficacies of GEM&#8201;+&#8201;CDDP and gemcitabine for vulnerable older patients did not also differ significantly. These findings highlight the importance of vulnerability in patients with aBTC.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Biliary tract cancer</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Unresectable</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Chemotherapy</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Older</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Survival</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Wiley</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0915-5635</Issn>
      <Volume/>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>EUS-Guided Versus Percutaneous Transhepatic Drainage of Liver Abscesses: A Multicenter Endohepatology Study in Western Japan (EPIC-LA Study)</ArticleTitle>
    <FirstPage LZero="delete"/>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Takeshi</FirstName>
        <LastName>Ogura</LastName>
        <Affiliation>Pancreatobiliary Advanced Medical Center, Osaka Medical and Pharmaceutical University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Taira</FirstName>
        <LastName>Kuroda</LastName>
        <Affiliation>Gastroenterology Center, Ehime Prefectural Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takanori</FirstName>
        <LastName>Matsuura</LastName>
        <Affiliation>Division of Gastroenterology, Department of Internal Medicine, Kobe University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Jun</FirstName>
        <LastName>Kitadai</LastName>
        <Affiliation>Division of Gastroenterology, Department of Internal Medicine, Kobe University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Koh</FirstName>
        <LastName>Kitagawa</LastName>
        <Affiliation>Department of Gastroenterology, Nara Medical University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masahiro</FirstName>
        <LastName>Itonaga</LastName>
        <Affiliation>Second Department of Internal Medicine, Wakayama Medical University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kotaro</FirstName>
        <LastName>Takeshita</LastName>
        <Affiliation>Department of Gastroenterology, Tane General Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomoaki</FirstName>
        <LastName>Matsumori</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Kyoto University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomoya</FirstName>
        <LastName>Emori</LastName>
        <Affiliation>Department of Gastroenterology, Wakayama Rosai Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Mamoru</FirstName>
        <LastName>Takenaka</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine Graduate School of Medical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hajime</FirstName>
        <LastName>Imai</LastName>
        <Affiliation>Department of Gastroenterology, Okanami General Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Koichiro</FirstName>
        <LastName>Mandai</LastName>
        <Affiliation>Department of Gastroenterology, Kyoto Second Red Cross Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shuhei</FirstName>
        <LastName>Shintani</LastName>
        <Affiliation>Department of Gastroenterology, Shiga University of Medical Science</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Nao</FirstName>
        <LastName>Fujimori</LastName>
        <Affiliation>Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hideyuki</FirstName>
        <LastName>Shiomi</LastName>
        <Affiliation>Division of Hepatobiliary and Pancreatic Diseases, Department of Gastroenterology, Hyogo Medical University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masanori</FirstName>
        <LastName>Asada</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Japanese Red Cross Osaka Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryota</FirstName>
        <LastName>Sagami</LastName>
        <Affiliation>Department of Gastroenterology, Faculty of Medicine, Oita University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hirotsugu</FirstName>
        <LastName>Maruyama</LastName>
        <Affiliation>Department of Gastroenterology, Graduate School of Medicine, Osaka Metropolitan University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tsukasa</FirstName>
        <LastName>Ikeura</LastName>
        <Affiliation>Division of Gastroenterology and Hepatology, Kansai Medical University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masaaki</FirstName>
        <LastName>Shimatani</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Kansai Medical University Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hidefumi</FirstName>
        <LastName>Nishikiori</LastName>
        <Affiliation>Department of Gastroenterology, Oita San-ai Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuyuki</FirstName>
        <LastName>Matsumoto</LastName>
        <Affiliation>Department of Endoscopy, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masahito</FirstName>
        <LastName>Kokubu</LastName>
        <Affiliation>Department of Gastroenterology and Metabology, Ehime University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hideki</FirstName>
        <LastName>Kamada</LastName>
        <Affiliation>Department of Gastroenterology and Neurology, Faculty of Medicine, Kagawa University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yusuke</FirstName>
        <LastName>Ishida</LastName>
        <Affiliation>Department of Gastroenterology and Medicine, Faculty of Medicine, Fukuoka University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Akitoshi</FirstName>
        <LastName>Hakoda</LastName>
        <Affiliation>2nd Department of Internal Medicine, Osaka Medical and Pharmaceutical University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masayuki</FirstName>
        <LastName>Kitano</LastName>
        <Affiliation>Second Department of Internal Medicine, Wakayama Medical University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Objective: Percutaneous transhepatic liver abscess drainage (PTAD) and endoscopic ultrasound-guided liver abscess drainage (EUS-LAD) have several limitations. Recently, because of technical improvements in echoendoscope maneuvers, EUS-guided access for the right hepatic lobe has been reported. The aim of this multicenter, retrospective study was to compare clinical outcomes of PTAD and EUS-LAD including the right hepatic lobe in West Japan.&lt;br&gt;
Method: This retrospective, multicenter study included consecutive patients with liver abscesses between January 2019 and November 2024. The primary outcome in this study was the clinical success rate compared between EUS-LAD and PTAD.&lt;br&gt;
Results: During the study period, 1012 consecutive patients developed liver abscesses. Of them, 734 patients were excluded, 43 underwent EUS-LAD and 235 patients underwent PTAD. After propensity score-matched analysis, the clinical success rate was significantly higher in the EUS-LAD group (97.7%, 42/43) than in the PTAD group (79.1%, 34/43) (p&#8201;=&#8201;0.007). After a propensity score-matched analysis, 25 patients were included in each group. The clinical success rate was significantly higher in the EUS-LAD group (100%, 25/25) than in the PTAD group (84%, 21/25) (p&#8201;=&#8201;0.037). Adverse events were also significantly higher in the PTAD group (16%, 5/25) than in the EUS-LAD group (p&#8201;=&#8201;0.025). In addition, the median length of hospital stay was significantly shorter in the EUS-LAD group (15&#8201;days) than in the PTAD group (22&#8201;days) (p&#8201;=&#8201;0.005).&lt;br&gt;
Conclusions: EUS-LAD using a metal stent might be one of the options, but further randomized, controlled trials are needed.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">drainage</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">endoscopic ultrasound-guided liver abscess drainage</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">EUS</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">liver abscess</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">percutaneous transhepatic liver abscess drainage</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0944-1174</Issn>
      <Volume/>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Mortality and cancer risk in patients with chronic pancreatitis in japan: insights into the importance of surveillance for pancreatic cancer</ArticleTitle>
    <FirstPage LZero="delete"/>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Ryotaro</FirstName>
        <LastName>Matsumoto</LastName>
        <Affiliation>Division of Gastroenterology, Tohoku University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuhiro</FirstName>
        <LastName>Kikuta</LastName>
        <Affiliation>Division of Gastroenterology, Tohoku University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tetsuya</FirstName>
        <LastName>Takikawa</LastName>
        <Affiliation>Division of Gastroenterology, Tohoku University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yousuke</FirstName>
        <LastName>Nakai</LastName>
        <Affiliation>Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Mamoru</FirstName>
        <LastName>Takenaka</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kentaro</FirstName>
        <LastName>Oki</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Kurashiki Central Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Eizaburo</FirstName>
        <LastName>Ohno</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Fujita Health University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ken</FirstName>
        <LastName>Ito</LastName>
        <Affiliation>Division of Gastroenterology and Hepatology, Toho University Omori Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Nao</FirstName>
        <LastName>Fujimori</LastName>
        <Affiliation>Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Akio</FirstName>
        <LastName>Katanuma</LastName>
        <Affiliation>Center for Gastroenterology, Teine-Keijinkai Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Atsuhiro</FirstName>
        <LastName>Masuda</LastName>
        <Affiliation>Division of Gastroenterology, Department of Internal Medicine, Kobe University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yasuki</FirstName>
        <LastName>Hori</LastName>
        <Affiliation>Department of Gastroenterology and Metabolism, Nagoya City University Graduate School of Medical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tsukasa</FirstName>
        <LastName>Ikeura</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Kansai Medical University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Rei</FirstName>
        <LastName>Suzuki</LastName>
        <Affiliation>Department of Gastroenterology, Fukushima Medical University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Satoshi</FirstName>
        <LastName>Yamamoto</LastName>
        <Affiliation>Department of Gastroenterology, Fujita Health University Bantane Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshio</FirstName>
        <LastName>Sogame</LastName>
        <Affiliation>Department of Molecular Gastroenterology and Hepatology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroki</FirstName>
        <LastName>Kawashima</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Nagoya University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tetsuhide</FirstName>
        <LastName>Ito</LastName>
        <Affiliation>Neuroendocrine Tumor Centre, Fukuoka Sanno Hospital, International University of Health and Welfare</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kosuke</FirstName>
        <LastName>Okuwaki</LastName>
        <Affiliation>Department of Gastroenterology, Kitasato University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takao</FirstName>
        <LastName>Itoi</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Tokyo Medical University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yukiko</FirstName>
        <LastName>Takayama</LastName>
        <Affiliation>Department of Internal Medicine, Institute of Gastroenterology, Tokyo Women’s Medical University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Akira</FirstName>
        <LastName>Nakamura</LastName>
        <Affiliation>Department of Medicine, Division of Gastroenterology and Hepatology, Shinshu University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shuji</FirstName>
        <LastName>Terai</LastName>
        <Affiliation>Division of Gastroenterology and Hepatology, Graduate School of Medical and Dental Sciences, Niigata University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuyuki</FirstName>
        <LastName>Matsumoto</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masaki</FirstName>
        <LastName>Kuwatani</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Hokkaido University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masashi</FirstName>
        <LastName>Kishiwada</LastName>
        <Affiliation>Department of Hepatobiliary Pancreatic and Transplant Surgery, Mie University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Minoru</FirstName>
        <LastName>Shigekawa</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, The University of Osaka Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomoaki</FirstName>
        <LastName>Matsumori</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Kyoto University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Osamu</FirstName>
        <LastName>Inatomi</LastName>
        <Affiliation>Department of Medicine, Shiga University of Medical Science</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Waku</FirstName>
        <LastName>Hatta</LastName>
        <Affiliation>Division of Gastroenterology, Tohoku University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Atsushi</FirstName>
        <LastName>Irisawa</LastName>
        <Affiliation>Department of Gastroenterology, Dokkyo Medical University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Michiaki</FirstName>
        <LastName>Unno</LastName>
        <Affiliation>Department of Surgery, Tohoku University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshifumi</FirstName>
        <LastName>Takeyama</LastName>
        <Affiliation>Department of Surgery, Kindai University Faculty of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Atsushi</FirstName>
        <LastName>Masamune</LastName>
        <Affiliation>Division of Gastroenterology, Tohoku University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N"/>
        <LastName>Japan Pancreatitis Study Group for Chronic Pancreatitis</LastName>
        <Affiliation/>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Background/Objective: Since the 2010s, Japan’s national health insurance system has covered key management for chronic pancreatitis (CP), including pancreatic enzyme replacement therapy. These therapies are expected to improve long-term prognosis; however, recent data are lacking. This study aimed to clarify the updated cancer risk and mortality among patients with CP in Japan.&lt;br&gt;
Methods: We conducted a multicenter, retrospective cohort study on 1,110 patients with CP treated at 28 institutions in 2011. Standardized incidence ratios (SIRs) and standardized mortality ratios (SMRs) were calculated for comorbidities. Factors associated with the development of malignancy and overall survival were analyzed.&lt;br&gt;
Results: Patients with CP had an elevated SIR of 1.62 (95% confidence interval [CI], 1.43&#8211;1.83) for malignancy, with the highest risk observed for pancreatic cancer (SIR&#8201;=&#8201;6.44 [95% CI, 4.64&#8211;8.90]). During follow-up, 143 patients (12.9%) died, most frequently from malignancy (47.5%). The SMR was elevated in all patients with CP (SMR&#8201;=&#8201;1.20 [95% CI, 1.01&#8211;1.42]) and in those with alcohol-related CP (SMR&#8201;=&#8201;1.49 [95% CI, 1.23&#8211;1.81]) but not in those with alcohol-unrelated CP. Pancreatic cancer was identified as the strongest factor associated with overall survival (hazard ratio, 48.92 in multivariate analysis). Overall survival of the patients with pancreatic cancer was significantly longer in those who underwent regular examinations for CP at least every three months (P&#8201;=&#8201;0.011).&lt;br&gt;
Conclusions: Patients with alcohol-related CP have higher mortality than the general population in Japan. Pancreatic cancer remains a crucial prognostic factor in patients with CP. Regular surveillance for pancreatic cancer is important to improve their prognosis.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Alcohol</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Chronic pancreatitis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Pancreatic cancer</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Pancreatitis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Smoking</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>American Society of Clinical Oncology (ASCO)</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0732-183X</Issn>
      <Volume/>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Amivantamab Plus Lazertinib in Atypical EGFR-Mutated Advanced Non&#8211;Small Cell Lung Cancer: Results From CHRYSALIS-2</ArticleTitle>
    <FirstPage LZero="delete">JCO-24-02835</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Pascale</FirstName>
        <LastName>Tomasini</LastName>
        <Affiliation>Aix Marseille University - CNRS, INSERM, CRCM; CEPCM - AP-HM H&#244;pital de La Timone</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yongsheng</FirstName>
        <LastName>Wang</LastName>
        <Affiliation>Division of Thoracic Tumor Multimodality Treatment, Cancer Center and Clinical Trial Center, West China Hospital, Sichuan University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yongsheng</FirstName>
        <LastName>Li</LastName>
        <Affiliation>Chongqing University Cancer Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Enriqueta</FirstName>
        <LastName>Felip</LastName>
        <Affiliation>Medical Oncology Service, Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron Barcelona Hospital Campus, Universitat Aut&#242;noma de Barcelona</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Lin</FirstName>
        <LastName>Wu</LastName>
        <Affiliation>Department of Thoracic Medical Oncology, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Jiuwei</FirstName>
        <LastName>Cui</LastName>
        <Affiliation>The First Hospital of Jilin University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Benjamin</FirstName>
        <LastName>Besse</LastName>
        <Affiliation>Paris-Saclay University, Institut Gustave Roussy</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Alexander I.</FirstName>
        <LastName>Spira</LastName>
        <Affiliation>Virginia Cancer Specialists</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Joel W.</FirstName>
        <LastName>Neal</LastName>
        <Affiliation>Stanford Cancer Institute, Stanford University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Koichi</FirstName>
        <LastName>Goto</LastName>
        <Affiliation>National Cancer Center Hospital East</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Christina S.</FirstName>
        <LastName>Baik</LastName>
        <Affiliation>University of Washington Fred Hutchinson Cancer Research Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Melina E.</FirstName>
        <LastName>Marmarelis</LastName>
        <Affiliation>Perelman School of Medicine, University of Pennsylvania</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Eiki</FirstName>
        <LastName>Ichihara</LastName>
        <Affiliation>Center for Clinical Oncology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yiping</FirstName>
        <LastName>Zhang</LastName>
        <Affiliation>Zhejiang Cancer Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Jong-Seok</FirstName>
        <LastName>Lee</LastName>
        <Affiliation>Seoul National University College of Medicine and Seoul National University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Se-Hoon</FirstName>
        <LastName>Lee</LastName>
        <Affiliation>Samsung Medical Center, Sungkyunkwan University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">James Chih-Hsin</FirstName>
        <LastName>Yang</LastName>
        <Affiliation>National Taiwan University Cancer Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Sebastian</FirstName>
        <LastName>Michels</LastName>
        <Affiliation>Department I for Internal Medicine, Faculty of Medicine and University Hospital Cologne, Lung Cancer Group Cologne, Center for Integrated Oncology Aachen K&#246;ln Bonn D&#252;sseldorf, University of Cologne</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Zacharias</FirstName>
        <LastName>Anastasiou</LastName>
        <Affiliation>Johnson &amp; Johnson</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Joshua C.</FirstName>
        <LastName>Curtin</LastName>
        <Affiliation>Johnson &amp; Johnson</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Xuesong</FirstName>
        <LastName>Lyu</LastName>
        <Affiliation>Johnson &amp; Johnson</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Janine</FirstName>
        <LastName>Mahoney</LastName>
        <Affiliation>Johnson &amp; Johnson</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Levon</FirstName>
        <LastName>Demirdjian</LastName>
        <Affiliation>Johnson &amp; Johnson</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Craig S.</FirstName>
        <LastName>Meyer</LastName>
        <Affiliation>Johnson &amp; Johnson</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Youyi</FirstName>
        <LastName>Zhang</LastName>
        <Affiliation>Johnson &amp; Johnson</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Isabelle</FirstName>
        <LastName>Leconte</LastName>
        <Affiliation>Johnson &amp; Johnson</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Patricia</FirstName>
        <LastName>Lorenzini</LastName>
        <Affiliation>Johnson &amp; Johnson</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Roland E.</FirstName>
        <LastName>Knoblauch</LastName>
        <Affiliation>Johnson &amp; Johnson</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Leonardo</FirstName>
        <LastName>Trani</LastName>
        <Affiliation>Johnson &amp; Johnson</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Mahadi</FirstName>
        <LastName>Baig</LastName>
        <Affiliation>Johnson &amp; Johnson</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Joshua M.</FirstName>
        <LastName>Bauml</LastName>
        <Affiliation>Johnson &amp; Johnson</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Byoung Chul</FirstName>
        <LastName>Cho</LastName>
        <Affiliation>Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Purpose For patients with advanced non&#8211;small cell lung cancer (NSCLC) harboring atypical epidermal growth factor receptor (EGFR) mutations (eg, S768I, L861Q, G719X), efficacy of current treatment options is limited.&lt;br&gt;
Patients and Methods CHRYSALIS-2 Cohort C enrolled participants with NSCLC harboring atypical EGFR mutations (G719X, S768I, L861Q, etc) and &#8804;2 previous lines of therapy. Participants were treatment-na&#239;ve or previously received first- or second-generation EGFR tyrosine kinase inhibitors. Coexisting exon 20 insertions, exon 19 deletions, or exon 21 L858R mutations were exclusionary. Participants received 1,050 mg (1,400 mg if &#8805;80 kg) intravenous amivantamab once weekly for the first 4 weeks and then once every 2 weeks plus 240 mg oral lazertinib once daily. The primary end point was investigator-assessed objective response rate (ORR).&lt;br&gt;
Results As of January 12, 2024, 105 participants received amivantamab-lazertinib. Most common atypical mutations were G719X (56%), L861X (26%), and S768I (23%), including single and compound mutations. In the overall population (median follow-up: 16.1 months), the ORR was 52% (95% CI, 42 to 62). The median duration of response (mDoR) was 14.1 months (95% CI, 9.5 to 26.2). The median progression-free survival (mPFS) was 11.1 months (95% CI, 7.8 to 17.8); median overall survival (mOS) was not estimable (NE; 95% CI, 22.8 to NE). Adverse events were consistent with previous studies and primarily grade 1 and 2. Among treatment-na&#239;ve participants, the ORR was 57% (95% CI, 42 to 71). The mPFS was 19.5 months (95% CI, 11.2 to NE), the mDoR was 20.7 months (95% CI, 9.9 to NE), and mOS was NE (95% CI, 26.3 to NE). Solitary or compound EGFR mutations had no major impact on ORR. The ORR in participants with P-loop and αC-helix compressing, classical-like, and T790M-like mutations was 45% (n = 38), 64% (n = 14), and 67% (n = 3), respectively.&lt;br&gt;
Conclusion In participants with atypical EGFR-mutated advanced NSCLC, amivantamab-lazertinib demonstrated clinically meaningful antitumor activity with no new safety signals.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList/>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Wiley</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1341-8076</Issn>
      <Volume>51</Volume>
      <Issue>11</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>The Short‐Term Impacts of Japan's 2024 Physician Working‐Hour Limits on Labor Conditions, Self‐Directed Professional Development, and Happiness Among Obstetrician‐Gynecologists</ArticleTitle>
    <FirstPage LZero="delete">e70112</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Yuto</FirstName>
        <LastName>Maeda</LastName>
        <Affiliation>Department of Public Health, Institute of Science Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Satoru</FirstName>
        <LastName>Nakagawa</LastName>
        <Affiliation>Department of Obstetrics and Gynecology, Osaka University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kentaro</FirstName>
        <LastName>Nakanishi</LastName>
        <Affiliation>Department of Obstetrics and Gynecology, Asahikawa Medical University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Eri</FirstName>
        <LastName>Inoue</LastName>
        <Affiliation>Aiiku Maternal and Child Health Center, Aiiku Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Daisuke</FirstName>
        <LastName>Inoue</LastName>
        <Affiliation>Department of Obstetrics and Gynecology, University of Fukui</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Saki</FirstName>
        <LastName>Kido</LastName>
        <Affiliation>Department of Obstetrics and Gynecology, Graduate School of Medical Sciences, Kyushu University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Michiko</FirstName>
        <LastName>Kido</LastName>
        <Affiliation>Department of Obstetrics and Gynecology, Japanese Red Cross Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kaori</FirstName>
        <LastName>Koga</LastName>
        <Affiliation>Department of Obstetrics and Gynecology, Reproductive Medicine Chiba University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shunji</FirstName>
        <LastName>Suzuki</LastName>
        <Affiliation>Department of Obstetrics and Gynecology, Nippon Medical School</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yukio</FirstName>
        <LastName>Suzuki</LastName>
        <Affiliation>Department of Gynecology, Kanagawa Cancer Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Junko</FirstName>
        <LastName>Haraga</LastName>
        <Affiliation>Department of Obstetrics and Gynecology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hisashi</FirstName>
        <LastName>Masuyama</LastName>
        <Affiliation>Department of Obstetrics and Gynecology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Eiko</FirstName>
        <LastName>Yamamoto</LastName>
        <Affiliation>Department of Healthcare Administration, Nagoya University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takeshi</FirstName>
        <LastName>Umazume</LastName>
        <Affiliation>Department of Obstetrics and Gynecology, Hokkaido University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshihito</FirstName>
        <LastName>Yokoyama</LastName>
        <Affiliation>Department of Obstetrics and Gynecology, Hirosaki University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Akira</FirstName>
        <LastName>Iwase</LastName>
        <Affiliation>Department of Obstetrics and Gynecology, Gunma University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomoaki</FirstName>
        <LastName>Ikeda</LastName>
        <Affiliation>Saiseikai Matsusaka General Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshio</FirstName>
        <LastName>Yoshida</LastName>
        <Affiliation>Department of Obstetrics and Gynecology, University of Fukui</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshiki</FirstName>
        <LastName>Kudo</LastName>
        <Affiliation>Department of Obstetrics and Gynecology, Hiroshima University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takashi</FirstName>
        <LastName>Sugiyama</LastName>
        <Affiliation>Department of Obstetrics and Gynecology, Ehime University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kiyonori</FirstName>
        <LastName>Miura</LastName>
        <Affiliation>Department of Obstetrics and Gynecology, Nagasaki University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hideaki</FirstName>
        <LastName>Yahata</LastName>
        <Affiliation>Department of Obstetrics and Gynecology, Graduate School of Medical Sciences, Kyushu University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Nobuya</FirstName>
        <LastName>Unno</LastName>
        <Affiliation>Center for Perinatal Medicine, JCHO Sagamino Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kentaro</FirstName>
        <LastName>Kurasawa</LastName>
        <Affiliation>Department of Obstetrics and Gynecology, Yokohama City University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takahide</FirstName>
        <LastName>Maenaka</LastName>
        <Affiliation>Department of Obstetrics and Gynecology, Higashiosaka City Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Etsuko</FirstName>
        <LastName>Miyagi</LastName>
        <Affiliation>Department of Obstetrics and Gynecology, Yokohama City University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kiyoko</FirstName>
        <LastName>Kato</LastName>
        <Affiliation>Department of Obstetrics and Gynecology, Graduate School of Medical Sciences, Kyushu University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yasuhito</FirstName>
        <LastName>Kato</LastName>
        <Affiliation>Department of Obstetrics and Gynecology, Asahikawa Medical University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Objective: To examine the short-term impacts of Japan's newly implemented physician working-hour limits (April 2024) on working conditions, self-directed professional development (SDPD), defined as activities undertaken outside working hours to enhance one's professional skills, and work-related happiness among obstetrician-gynecologists (OB-GYNs).&lt;br&gt;
Methods: An online survey was conducted between July 8 and July 31, 2024, targeting 867 Japan Society of Obstetrics and Gynecology members. Five hundred and fourteen full-time practitioners who had not changed workplaces around April 2024 and had no missing data were analyzed. Participants were stratified by regulation levels (A, B, C, discretionary labor system, those who don't know their own level), and their working hours, anticipated income, SDPD satisfaction, and happiness (0&#8211;10 scale) were assessed. We used multivariate linear regression to evaluate the influence of labor condition changes on happiness and explored interactions involving unpaid overtime, income changes, and SDPD satisfaction.&lt;br&gt;
Results: Compared with level A (up to 960&#8201;h of overtime per year), participants at levels B and C (up to 1860&#8201;h of overtime per year) reported significantly lower happiness (p&#8201;&lt;&#8201;0.001). Most respondents observed no major shifts in working conditions since March 2024, yet about 40% did not record SDPD hours that meet the working hour requirement as official work time. Adjusted analyses revealed that decreased income and unsatisfactory SDPD significantly lowered happiness, whereas higher SDPD satisfaction increased it (β: −0.64 [−1.07, −0.21], −0.98 [−1.46, −0.50], and 0.90 [0.44, 1.35], respectively). Subgroup analysis indicated that rising unpaid overtime further reduced happiness among those dissatisfied with SDPD (−1.43 [−2.41, −0.45]).&lt;br&gt;
Conclusions: The new working-hour limits had minimal impact on labor conditions in the short run. However, satisfaction with SDPD was positively associated with happiness, whereas anticipated decreases in income were correlated with lower happiness.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">gynecologists</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">happiness</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">obstetrician</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">work style reform</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">working-hour limits</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0941-4355</Issn>
      <Volume>33</Volume>
      <Issue>12</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Factors associated with period of sick leave after gynecologic cancer treatment: a prospective cohort study</ArticleTitle>
    <FirstPage LZero="delete">1087</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Yoshinori</FirstName>
        <LastName>Tani</LastName>
        <Affiliation>Department of Obstetrics and Gynecology, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Keiichiro</FirstName>
        <LastName>Nakamura</LastName>
        <Affiliation>Department of Obstetrics and Gynecology, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hanako</FirstName>
        <LastName>Sugihara</LastName>
        <Affiliation>Department of Obstetrics and Gynecology, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shinsuke</FirstName>
        <LastName>Shirakawa</LastName>
        <Affiliation>Department of Obstetrics and Gynecology, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hirofumi</FirstName>
        <LastName>Matsuoka</LastName>
        <Affiliation>Department of Obstetrics and Gynecology, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Naoyuki</FirstName>
        <LastName>Ida</LastName>
        <Affiliation>Department of Obstetrics and Gynecology, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Junko</FirstName>
        <LastName>Haraga</LastName>
        <Affiliation>Department of Obstetrics and Gynecology, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Chikako</FirstName>
        <LastName>Ogawa</LastName>
        <Affiliation>Department of Obstetrics and Gynecology, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Eriko</FirstName>
        <LastName>Eto</LastName>
        <Affiliation>Department of Obstetrics and Gynecology, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shoji</FirstName>
        <LastName>Nagao</LastName>
        <Affiliation>Department of Obstetrics and Gynecology, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hisashi</FirstName>
        <LastName>Masuyama</LastName>
        <Affiliation>Department of Obstetrics and Gynecology, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Purpose Gynecologic cancer is one of the most common malignancies in working-age women. This study aimed to investigate factors associated with period of sick leave after gynecologic cancer treatment in Japan.&lt;br&gt;
Methods A prospective cohort study on period of sick leave was conducted among 207 cancer survivors who returned to work at the same workplace. Questionnaires were randomly distributed to patients aged under 65 years and more than one-year post-treatment. Clinical information was extracted from medical records, and the factors influencing the period of sick leave were analyzed using the Mann&#8211;Whitney U test and logistic regression analysis.&lt;br&gt;
Results Surgery plus more than six courses of chemotherapy (number (n)&#8201;=&#8201;41, 166.02&#8201;±&#8201;146.84 days) led to a significantly longer period of sick leave than surgery without lymph node dissection (n&#8201;=&#8201;64, 31.15&#8201;±&#8201;30.47 days), surgery with lymph node dissection (n&#8201;=&#8201;41, 55.56&#8201;±&#8201;85.90 days), surgery plus less than six courses of chemotherapy (n&#8201;=&#8201;21, 72.42&#8201;±&#8201;56.07 days), and radiotherapy alone (n&#8201;=&#8201;21, 58.85&#8201;±&#8201;84.24 days) (OR: 2.63, 2.95, 2.67, and 2.08; 95% CI: 7.71&#8211;54.59, 18.17&#8211;92.94, 18.22&#8211;126.63, and 2.38&#8211;115.33; p&#8201;=&#8201;0.009, p&#8201;=&#8201;0.004, p&#8201;=&#8201;0.009, and p&#8201;=&#8201;0.041). gynecologic cancer survivors who experienced adverse effects after treatment had a significantly longer period of sick leave (OR: 8.50; CI: 52.98&#8211;84.98; p&#8201;&lt;&#8201;0.001). In univariate and multivariate analyses, patients who received surgery plus more than six courses of chemotherapy were most involved in long period of sick leave than other factors (OR: 11.20, and 16.997; CI: 4.86&#8211;25.08, and 5.51&#8211;52.35; p&#8201;&lt;&#8201;0.001, and p&#8201;&lt;&#8201;0.001).&lt;br&gt;
Conclusion Patients with gynecologic cancer requiring long-term treatment required the most time to return to work.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Period of sick leave</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Surgery plus chemotherapy</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Six or more cycles of chemotherapy</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Gynecologic cancer survivors</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Wiley</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1616-301X</Issn>
      <Volume/>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>A Biologically-Architected Wear and Damage-Resistant Nanoparticle Coating From the Radular Teeth of Cryptochiton stelleri</ArticleTitle>
    <FirstPage LZero="delete">e21664</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Taifeng</FirstName>
        <LastName>Wang</LastName>
        <Affiliation>Department of Materials Science and Engineering, University of California</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yu</FirstName>
        <LastName>Chen</LastName>
        <Affiliation>Lyles School of Civil and Construction Engineering, Purdue University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ezra</FirstName>
        <LastName>Sarmiento</LastName>
        <Affiliation>Department of Materials Science and Engineering, University of California</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Taige</FirstName>
        <LastName>Hao</LastName>
        <Affiliation>Materials and Manufacturing Technologies Program, University of California</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Atsushi</FirstName>
        <LastName>Arakaki</LastName>
        <Affiliation>Division of Biotechnology and Life Science, Institute of Engineering, Tokyo University of Agriculture and Technology </Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Michiko</FirstName>
        <LastName>Nemoto</LastName>
        <Affiliation>Graduate School of Environmental and Life Science, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Pablo</FirstName>
        <LastName>Zavattieri</LastName>
        <Affiliation>Lyles School of Civil and Construction Engineering, Purdue University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">David</FirstName>
        <LastName>Kisailus</LastName>
        <Affiliation>Department of Materials Science and Engineering, University of California</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Nature utilizes simple building blocks to construct mechanically robust materials that demonstrate superior performance under extreme conditions. These exquisite structures result from the controlled synthesis and hierarchical assembly of nanoscale organic and mineral components that have provided critical evolutionary advantages to ensure survival. One such example is the ultrahard radular teeth found in mollusks, which are used to scrape against rock to feed on algae. Here, it is reported that the leading edges of these teeth consist of a wear-resistant coating that is comprised of densely packed &#8776;65 nm magnetic nanoparticles integrated within an organic matrix of chitin and protein. These mesocrystalline magnetite-based structures are assembled from smaller, highly aligned nanocrystals with inter/intracrystalline organics introduced during the crystallization process. Nanomechanical testing reveals that this multi-scale, nano-architected coating has a combination of increased hardness and a slight decrease in modulus versus geologic magnetite provides the surface of the chiton tooth with superior abrasion resistance. The mesocrystalline structures fracture at primary domain interfaces, corroborated by computational models, providing significant toughening to the tooth under extreme contact stresses. The design features revealed provide insight for the design and fabrication of next-generation advanced wear- and impact-resistant coatings for tooling, machinery, wind turbines, armor, etc.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">biomineralization</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">coatings</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">damage tolerance</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">magnetite</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">mesocrystals</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Public Library of Science</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1932-6203</Issn>
      <Volume>20</Volume>
      <Issue>8</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Risk stratification for the prediction of skeletal-related events in patients with castration-resistant prostate cancer with bone metastases</ArticleTitle>
    <FirstPage LZero="delete">e0328792</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Masanori</FirstName>
        <LastName>Hamada</LastName>
        <Affiliation/>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Eiji</FirstName>
        <LastName>Nakata</LastName>
        <Affiliation/>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryuichi</FirstName>
        <LastName>Nakahara</LastName>
        <Affiliation/>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shinsuke</FirstName>
        <LastName>Sugihara</LastName>
        <Affiliation/>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Haruyoshi</FirstName>
        <LastName>Katayama</LastName>
        <Affiliation/>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takuto</FirstName>
        <LastName>Itano</LastName>
        <Affiliation/>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomohiro</FirstName>
        <LastName>Inoue</LastName>
        <Affiliation/>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shota</FirstName>
        <LastName>Takihira</LastName>
        <Affiliation/>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshiteru</FirstName>
        <LastName>Akezaki</LastName>
        <Affiliation/>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshifumi</FirstName>
        <LastName>Ozaki</LastName>
        <Affiliation/>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Skeletal-related events (SREs) are common in patients with bone metastases from castration-resistant prostate cancer (CRPC). Despite advances in prostate cancer treatment, clinically validated predictive models for SREs in CRPC patients with bone metastases remain elusive. This gap in prognostic tools hinders optimal patient management and treatment planning for this high-risk population. This study aimed to develop a prediction model for SRE by investigating potential risk factors and classifying them into different groups. This model can be used to identify patients at high risk of SREs who need close follow-up. Between 2004 and 2013, 68 male patients with bone metastases from CRPC who were treated at our institute were evaluated for survival without SREs and survival without SREs of the spinal cord. The study analyzed clinical data at enrollment to identify risk factors for initial and spinal SREs. Multivariate analysis revealed that a high count of metastatic vertebrae, along with visceral or lymph node metastases, were significant risk factors. Patients were categorized into four subgroups based on the number of vertebral metastases and presence of visceral or lymph node metastases: 1) extensive vertebral and both types of metastases, 2) extensive vertebral without additional metastases, 3) some vertebral with other metastases, 4) some vertebral without additional metastases. The first SRE and spinal SRE occurred significantly sooner in the first subgroup compared to others. Incidence rates at 12 months for the first SRE were 56%, 40%, 27%, and 5%, and for the first spinal SRE were 47%, 40%, 27%, and 0% respectively. Patients with extensive vertebral and additional metastases require vigilant monitoring to mitigate SREs.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList/>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2045-2322</Issn>
      <Volume>15</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Association between gestational age and child health and neurodevelopment in twins from a nationwide longitudinal survey in Japan</ArticleTitle>
    <FirstPage LZero="delete">40608</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Kei</FirstName>
        <LastName>Tamai</LastName>
        <Affiliation>Department of Epidemiology, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Naomi</FirstName>
        <LastName>Matsumoto</LastName>
        <Affiliation>Department of Epidemiology, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Akihito</FirstName>
        <LastName>Takeuchi</LastName>
        <Affiliation>Division of Neonatology, NHO Okayama Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Makoto</FirstName>
        <LastName>Nakamura</LastName>
        <Affiliation>Division of Neonatology, NHO Okayama Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Misao</FirstName>
        <LastName>Kageyama</LastName>
        <Affiliation>Division of Neonatology, NHO Okayama Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takashi</FirstName>
        <LastName>Yorifuji</LastName>
        <Affiliation>Department of Epidemiology, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Despite previous research, evidence on the relationship between gestational age and long-term health and neurodevelopmental outcomes among twins remains limited. Using data from the Longitudinal Survey of Babies in the 21st Century, we analyzed 549 twins born in Japan in 2010. The twins were grouped by gestational age: &lt;32 weeks (very preterm), 32&#8211;36 weeks (moderately and late preterm), and 37&#8211;38 weeks (early term). The health status was evaluated by hospitalization between 0.5 and 5.5 years, and behavioral development was assessed using questionnaires at 2.5 and 5.5 years. Binomial log-linear regression with generalized estimating equations accounted for within-pair correlations and adjusted for child and parental variables. Moderately and late preterm children showed a higher risk of all-cause hospitalization during infancy than early-term children (adjusted risk ratio, 1.7; 95% CI, 1.0&#8211;2.6). Very preterm children showed a higher point estimate of the risk ratio, but a wide CI (risk ratio, 2.3; 95% CI, 0.8&#8211;6.8). Behavioral delays were more common in preterm groups at 2.5 years but not at 5.5 years. Preterm twins have a higher risk of hospitalization during infancy and developmental delay at 2.5 years than early-term twins. These risks show an increasing trend as gestational age decreases.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Behavioral development</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Child health</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Early term</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Gestational age</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Hospitalization</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Multiple births</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2168-8184</Issn>
      <Volume>17</Volume>
      <Issue>10</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Association of Use of GRADE, Protocol Registration, and Journal Impact Factor With Reporting and Methodological Quality of Systematic Reviews Published in Rehabilitation Journals: A Meta-Epidemiological Study</ArticleTitle>
    <FirstPage LZero="delete">e95695</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Takahiro</FirstName>
        <LastName>Tsuge</LastName>
        <Affiliation>Department of Epidemiology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Norio</FirstName>
        <LastName>Yamamoto</LastName>
        <Affiliation>Systematic Reviewers, Scientific Research WorkS Peer Support Group (SRWS-PSG)</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yosuke</FirstName>
        <LastName>Tomita</LastName>
        <Affiliation>Physical Therapy, Faculty of Health Care, Takasaki University of Health and Welfare</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Akikazu</FirstName>
        <LastName>Hagiyama</LastName>
        <Affiliation>Department of Epidemiology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Daijo</FirstName>
        <LastName>Shiratsuchi</LastName>
        <Affiliation>Physical Therapy, School of Health Sciences, Faculty of Medicine, Kagoshima University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masatsugu</FirstName>
        <LastName>Okamura</LastName>
        <Affiliation>Systematic Reviewers, Scientific Research WorkS Peer Support Group (SRWS-PSG)</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takao</FirstName>
        <LastName>Kaneko</LastName>
        <Affiliation>Rehabilitation, Yamagata Prefectural Central Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kosuke</FirstName>
        <LastName>Suzuki</LastName>
        <Affiliation>Rehabilitation, Yamagata Saisei Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuki</FirstName>
        <LastName>Nakashima</LastName>
        <Affiliation>Systematic Reviewers, Scientific Research WorkS Peer Support Group (SRWS-PSG)</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shunsuke</FirstName>
        <LastName>Taito</LastName>
        <Affiliation>Systematic Reviewers, Scientific Research WorkS Peer Support Group (SRWS-PSG)</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takashi</FirstName>
        <LastName>Yorifuji</LastName>
        <Affiliation>Department of Epidemiology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>This study aimed to identify factors associated with the reporting and methodological quality of systematic reviews (SRs) published in rehabilitation journals. We conducted a meta-epidemiological study as a secondary analysis of a previous study. The study protocol was registered in the Open Science Framework. We analyzed 219 SRs from rehabilitation journals published since 2020. We assessed reporting quality using the Preferred Reporting Items for Systematic reviews and Meta-Analysis (PRISMA) 2020 and methodological quality using A MeaSurement Tool to Assess systematic Reviews (AMSTAR) 2. Multiple linear regression and Spearman's correlation were used to identify factors associated with quality, including Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach and the Journal Impact Factor (JIF). Multivariate analysis revealed PRISMA 2020 adherence was significantly associated with use of GRADE (β = 4.33; 95% confidence interval (CI): 3.24-5.42), protocol registration (β = 3.40; 95% CI: 2.32-4.47), and the JIF (2023) (β = 0.69; 95% CI: 0.42-0.95). AMSTAR 2 adherence was also significantly associated with use of GRADE (β = 2.52; 95% CI: 1.88-3.17), protocol registration (β = 2.07; 95% CI: 1.44-2.70), and the JIF (2023) (β = 0.29; 95% CI: 0.14-0.45). Weak positive correlations were observed between the JIF (2023) and both PRISMA 2020 and AMSTAR 2 adherence (ρ = 0.27 and ρ = 0.22, respectively; both P &lt; 0.01). It should be noted that these findings reflect associations and do not imply causality. To enhance the quality of SRs in rehabilitation, researchers should prioritize adherence to PRISMA 2020, particularly the use of GRADE and protocol registration, which this study identified as key associated factors.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">citation</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">grade</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">journal impact factor</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">methodological and reporting quality</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">prisma</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>American Society for Microbiology</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2379-5042</Issn>
      <Volume/>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Analysis of the drug target of the anti-tuberculosis compound OCT313: phosphotransacetylase is a potential drug target for anti-mycobacterial agents</ArticleTitle>
    <FirstPage LZero="delete">e00463-25</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Takemasa</FirstName>
        <LastName>Takii</LastName>
        <Affiliation>Department of Mycobacterium Reference and Research, the Research Institute of Tuberculosis, Japan Anti-Tuberculosis Association</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomohiro</FirstName>
        <LastName>Hasegawa</LastName>
        <Affiliation>Department of Hygienic Chemistry, Graduate School of Pharmaceutical Sciences, Nagoya City University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Saotomo</FirstName>
        <LastName>Itoh</LastName>
        <Affiliation>Department of Hygienic Chemistry, Graduate School of Pharmaceutical Sciences, Nagoya City University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shinji</FirstName>
        <LastName>Maeda</LastName>
        <Affiliation>Graduate School of Pharmaceutical Sciences, Hokkaido University of Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takayuki</FirstName>
        <LastName>Wada</LastName>
        <Affiliation>Department of Microbiology, Graduate School of Human Life and Ecology, Osaka Metropolitan University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yasuhiro</FirstName>
        <LastName>Horita</LastName>
        <Affiliation>Department of Clinical Pharmaceutics, Graduate School of Medical Sciences, Nagoya City University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Akihito</FirstName>
        <LastName>Nishiyama</LastName>
        <Affiliation>Department of Bacteriology, Niigata University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Sohkichi</FirstName>
        <LastName>Matsumoto</LastName>
        <Affiliation>Department of Bacteriology, Niigata University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Naoya</FirstName>
        <LastName>Ohara</LastName>
        <Affiliation>Department of Oral Microbiology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Aoi</FirstName>
        <LastName>Kimishima</LastName>
        <Affiliation>Laboratory of Applied Microbial Chemistry, &#332;mura Satoshi Memorial Institute, Kitasato University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yukihiro</FirstName>
        <LastName>Asami</LastName>
        <Affiliation>Laboratory of Applied Microbial Chemistry, &#332;mura Satoshi Memorial Institute, Kitasato University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shigeaki</FirstName>
        <LastName>Hida</LastName>
        <Affiliation>Department of Hygienic Chemistry, Graduate School of Pharmaceutical Sciences, Nagoya City University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kikuo</FirstName>
        <LastName>Onozaki</LastName>
        <Affiliation>Department of Hygienic Chemistry, Graduate School of Pharmaceutical Sciences, Nagoya City University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Tuberculosis (TB) is one of the most common infectious diseases caused by bacteria worldwide. The increasing prevalence of multidrug-resistant TB (MDR-TB) and latent TB infection (LTBI) has intensified the global TB burden. Therefore, the development of new drugs for MDR-TB and LTBI is urgently required. We have reported that the derivative of dithiocarbamate sugar derivative, 2-acetamido-2-deoxy-β-D-glucopyranosyl N,N-dimethyldithiocarbamate (OCT313), exhibits anti-mycobacterial activity against MDR-MTB. Here, we identified the target of OCT313. In experimentally generated OCT313-resistant bacteria, adenine at position 1,092 in the metabolic enzyme phosphotransacetylase (PTA) gene was replaced with cytosine. This mutation is a nonsynonymous mutation that converts methionine to leucine at position 365 in the PTA protein. OCT313 inhibited the enzymatic activity of recombinant wild-type PTA, but not of the mutant PTA (M365L). PTA is an enzyme that produces acetyl-coenzyme A (acetyl-CoA) from acetyl phosphate and CoA and is involved in metabolic pathways; therefore, it was expected to also be active against dormant Mycobacterium tuberculosis bacilli. OCT313 exhibits antibacterial activity in the Wayne model of dormancy using Mycobacterium bovis BCG, and overexpression of PTA in OCT313-resistant bacilli restored sensitivity to OCT313. Collectively, the target of OCT313 is PTA, and OCT313 is a promising antimicrobial candidate for MDR-TB and LTBI.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">phosphotransacetylase</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">acetyl coenzyme A</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">dithiocarbamate</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">N-acetyl glucosamine</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">anti-mycobacterial agents</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">latent tuberculosis infection</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2045-2322</Issn>
      <Volume>15</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Long intervals between repetitive concussions reduce risk of cognitive impairment and limit microglial activation, astrogliosis, and tauopathy in adolescent rats</ArticleTitle>
    <FirstPage LZero="delete">40522</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Yuichi</FirstName>
        <LastName>Hirata</LastName>
        <Affiliation>Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kyohei</FirstName>
        <LastName>Kin</LastName>
        <Affiliation>Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takayuki</FirstName>
        <LastName>Nagase</LastName>
        <Affiliation>Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tatsuya</FirstName>
        <LastName>Sasaki</LastName>
        <Affiliation>Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Susumu</FirstName>
        <LastName>Sasada</LastName>
        <Affiliation>Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Chiaki</FirstName>
        <LastName>Sugahara</LastName>
        <Affiliation>Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takahiro</FirstName>
        <LastName>Hirayama</LastName>
        <Affiliation>Department of Emergency, Critical Care, and Disaster Medicine, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Koji</FirstName>
        <LastName>Kawai</LastName>
        <Affiliation>Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shun</FirstName>
        <LastName>Tanimoto</LastName>
        <Affiliation>Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hayato</FirstName>
        <LastName>Miyake</LastName>
        <Affiliation>Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomoya</FirstName>
        <LastName>Saijo</LastName>
        <Affiliation>Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiromichi</FirstName>
        <LastName>Naito</LastName>
        <Affiliation>Department of Emergency, Critical Care, and Disaster Medicine, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kaori</FirstName>
        <LastName>Masai</LastName>
        <Affiliation>Department of Medical Neurobiology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takao</FirstName>
        <LastName>Yasuhara</LastName>
        <Affiliation>Yasuhara Clinic</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shota</FirstName>
        <LastName>Tanaka</LastName>
        <Affiliation>Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University Hospital</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Although previous studies have demonstrated the effects of concussions do not accumulate as the time interval between injuries increases, little is known about the relationship between this interval and the effects of repetitive concussions. The objective of this study is to explore the relationship between the time interval and changes in behavior and histology following repetitive concussions. Male adolescent rats received concussions by weight drop and were randomly assigned to one of five experimental groups, receiving concussions three times either daily, every other day, once per week, once every 2 weeks, or receiving sham procedures. Only rats that received daily concussions exhibited cognitive impairment, while the other groups did not. No groups showed motor or anxiety-like impairments. Histological analysis revealed accumulation of microglia, as well as astrogliosis, in the prefrontal cortex, corpus callosum, dentate gyrus, and cornu Ammonis 1 region of the hippocampus in rats subjected to daily concussions. Accumulation of phosphorylated tau was also observed in the prefrontal cortex and cornu Ammonis 1. Longer intervals between concussions may reduce the risk of cognitive impairment and limit microglial activation, astrogliosis, and phosphorylated tau accumulation. These findings may help guide decisions on the appropriate timing for return to play in humans.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Concussion</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Return to play</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Sports-related head injury</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Microglia</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Astrocyte</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Tauopathy</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1478-6362</Issn>
      <Volume>27</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Does perioperative discontinuation of anti-rheumatic drugs increase postoperative complications in orthopedic surgery for rheumatoid arthritis?</ArticleTitle>
    <FirstPage LZero="delete">219</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Hiromu</FirstName>
        <LastName>Ito</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Kurashiki Central Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hajime</FirstName>
        <LastName>Ishikawa</LastName>
        <Affiliation>Department of Rheumatology, Niigata Rheumatic Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shigeyoshi</FirstName>
        <LastName>Tsuji</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Osaka Minami Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masanori</FirstName>
        <LastName>Nakayama</LastName>
        <Affiliation>Department of Orthopaedic Surgery, International University of Health and Welfare</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Keiichiro</FirstName>
        <LastName>Nishida</LastName>
        <Affiliation>Locomotive Pain Center, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takeshi</FirstName>
        <LastName>Mochizuki</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Kamagaya General Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kosuke</FirstName>
        <LastName>Ebina</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Osaka University Faculty of Medicine Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshihisa</FirstName>
        <LastName>Kojima</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Nagoya University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takumi</FirstName>
        <LastName>Matsumoto</LastName>
        <Affiliation>Department of Orthopaedic Surgery, University of Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ayako</FirstName>
        <LastName>Kubota</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Toho University Omori Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Arata</FirstName>
        <LastName>Nakajima</LastName>
        <Affiliation>Department of Orthopaedic Surgery and Rehabilitation, Toho University Sakura Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Atsushi</FirstName>
        <LastName>Kaneko</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Nagoya Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Isao</FirstName>
        <LastName>Matsushita</LastName>
        <Affiliation>Department of Rehabilitation Medicine, Kanazawa Medical University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryota</FirstName>
        <LastName>Hara</LastName>
        <Affiliation>The Center for Rheumatic Diseases, Nara Medical University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Koji</FirstName>
        <LastName>Sakuraba</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Kyushu Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yukio</FirstName>
        <LastName>Akasaki</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Kyushu University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tsukasa</FirstName>
        <LastName>Matsubara</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Matsubara Mayflower Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuichi</FirstName>
        <LastName>Mochida</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Yokohama City University Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Katsuaki</FirstName>
        <LastName>Kanbe</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Nippori Orthopaedics and Rheumatic Clinic</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Natsuko</FirstName>
        <LastName>Nakagawa</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Kakogawa Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Koichi</FirstName>
        <LastName>Murata</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Kyoto University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shigeki</FirstName>
        <LastName>Momohara</LastName>
        <Affiliation>Endowed Course for Advanced Therapy for Musculoskeletal Disorders, Keio University School of Medicine</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Objective This study aimed to investigate whether discontinuation of biological or targeted synthetic antirheumatic disease-modifying drugs (bDMARDs or tsDMARDs) influences the incidence of postoperative complications in patients with rheumatoid arthritis (RA) undergoing orthopedic surgery.&lt;br&gt;
Methods A retrospective multicenter cohort study including patients receiving bDMARDs or tsDMARDs who underwent orthopedic surgery was conducted. Data collected encompassed the duration of drug discontinuation and postoperative adverse events, such as delayed wound healing, surgical site infection (SSI), disease flare-ups, and mortality. The association between drug discontinuation and these outcomes was analyzed. Multivariate analyses were conducted to identify potential risk factors for these events.&lt;br&gt;
Results A total of 2,060 cases were initially enrolled. After applying inclusion and exclusion criteria, data from 1,953 patients were analyzed. No significant differences were observed between the groups regarding delayed wound healing, SSI, or mortality. However, the incidence of disease flare-ups was substantially higher in the drug discontinuation group and in the interleukin (IL)-6 inhibitor group. Multivariate analysis identified that tumor necrosis factor α and IL-6 inhibitor use was associated with a higher risk of delayed wound healing relative to T-cell function modifiers.&lt;br&gt;
Conclusion In orthopedic surgery for patients with RA, maintaining the standard or the half of administration interval of bDMARD appears safe in the preoperative period. However, the drug discontinuation may increase the risk of postoperative flare-ups, particularly with IL-6 inhibitors. In addition, T-cell function modifiers may be associated with a lower risk of delayed wound healing, suggesting their safety profile in this context.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Rheumatoid arthritis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Orthopaedic surgery</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">DMARD</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Perioperative complications</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Wiley</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0305-182X</Issn>
      <Volume/>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Is Pain Intensity Related to Psychosocial Factors in Chronic Non‐Nociceptive Orofacial Pain Patients?</ArticleTitle>
    <FirstPage LZero="delete"/>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Akiko</FirstName>
        <LastName>Kawase</LastName>
        <Affiliation>Department of Dental Anesthesiology and Special Care Dentistry, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hitoshi</FirstName>
        <LastName>Higuchi</LastName>
        <Affiliation>Department of Dental Anesthesiology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Fumika</FirstName>
        <LastName>Hashimoto</LastName>
        <Affiliation>Department of Dental Anesthesiology and Special Care Dentistry, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Saki</FirstName>
        <LastName>Miyake</LastName>
        <Affiliation>Department of Dental Anesthesiology and Special Care Dentistry, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yukiko</FirstName>
        <LastName>Nishioka</LastName>
        <Affiliation>Department of Dental Anesthesiology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Midori</FirstName>
        <LastName>Inoue</LastName>
        <Affiliation>Department of Dental Anesthesiology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hitomi</FirstName>
        <LastName>Ujita</LastName>
        <Affiliation>Department of Dental Anesthesiology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Aki</FirstName>
        <LastName>Kawauchi</LastName>
        <Affiliation>Department of Dental Anesthesiology, Graduate School of Medical and Dental Sciences, Institute of Science Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shigeru</FirstName>
        <LastName>Maeda</LastName>
        <Affiliation>Department of Dental Anesthesiology, Graduate School of Medical and Dental Sciences, Institute of Science Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takuya</FirstName>
        <LastName>Miyawaki</LastName>
        <Affiliation>Department of Dental Anesthesiology and Special Care Dentistry, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Background: In order to understand the psychological aspects of chronic pain, it is important to consider the relationships between pain and psychosocial factors in patients with chronic pain. While psychosocial factors are known to affect pain intensity in temporomandibular disorders, few studies have evaluated them in patients with other types of chronic orofacial pain.&lt;br&gt;
Objective: The purpose of the present study was to evaluate the relationships between pain intensity and patient characteristics, diagnostic categories and psychosocial factors in chronic non-nociceptive orofacial pain patients.&lt;br&gt;
Methods: In a retrospective, cross-sectional study, we collected information from the medical records of 123 patients with chronic non-nociceptive orofacial pain. Pain intensity was measured using the Brief Pain Inventory (BPI) total score. Analysis of the correlations among the variables revealed several strong correlations. Principal component analysis identified two components: the psychological distress and self-efficacy/quality of life (QOL) components. Multiple linear regression analyses of the overall study population and each ICOP pain category were also performed.&lt;br&gt;
Results: In the overall sample, higher BPI scores were significantly associated with a greater psychological distress component and lower self-efficacy/QOL component. The pain category was not a significant predictor of the BPI score. In the subgroup analyses, both components were significant predictors of the BPI score in myofascial orofacial pain; whereas, only the self-efficacy/QOL component was in idiopathic orofacial pain.&lt;br&gt;
Conclusion: The results indicated that pain intensity in chronic non-nociceptive orofacial pain is related to the self-efficacy/QOL psychosocial factor component. These findings suggest that assessing psychosocial factors may be clinically important for the diagnosis and treatment of chronic orofacial pain.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">chronic pain</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">International Classification of Orofacial Pain</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">orofacial pain</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">psychological distress component</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">psychosocial factors</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">self-efficacy/ QOL component</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2050-6511</Issn>
      <Volume>26</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>PEGylation of liposome-encapsulated midazolam does not improve the bioavailability of midazolam when administered orally</ArticleTitle>
    <FirstPage LZero="delete">166</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Yukiko</FirstName>
        <LastName>Nishioka</LastName>
        <Affiliation>Department of Dental Anesthesiology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yanyin</FirstName>
        <LastName>Lu</LastName>
        <Affiliation>Department of Dental Anesthesiology and Special Care Dentistry, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hitoshi</FirstName>
        <LastName>Higuchi</LastName>
        <Affiliation>Department of Dental Anesthesiology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Saki</FirstName>
        <LastName>Miyake</LastName>
        <Affiliation>Department of Dental Anesthesiology and Special Care Dentistry, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Maki</FirstName>
        <LastName>Fujimoto</LastName>
        <Affiliation>Department of Dental Anesthesiology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Midori</FirstName>
        <LastName>Hamaoka-Inoue</LastName>
        <Affiliation>Department of Dental Anesthesiology and Special Care Dentistry, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroshi</FirstName>
        <LastName>Tanimura</LastName>
        <Affiliation>Department of Dental Anesthesiology and Special Care Dentistry, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hitomi</FirstName>
        <LastName>Ujita</LastName>
        <Affiliation>Department of Dental Anesthesiology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shigeru</FirstName>
        <LastName>Maeda</LastName>
        <Affiliation>Department of Dental Anesthesiology and Special Care Dentistry, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takuya</FirstName>
        <LastName>Miyawaki</LastName>
        <Affiliation>Department of Dental Anesthesiology and Special Care Dentistry, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Background Liposomes are closed vesicles made of the same phospholipid bilayer as biological membranes and are capable of containing drugs, and so they have been investigated as useful drug carriers for drug delivery. We previously developed liposome-encapsulated midazolam (LE-midazolam) for oral administration, but midazolam is metabolized in the liver, and for clinical use the encapsulation of the liposomes needed to be improved to increase the bioavailability of midazolam. The surfaces of pharmaceutical liposomes are generally coated with polyethylene glycol (PEGylation) because it prevents their capture by phagocytes and helps them to avoid the reticuloendothelial system. Therefore, we considered that PEGylation could reduce the metabolism of orally administered encapsulated midazolam in the liver.&lt;br&gt;
Methods Midazolam solution, LE-midazolam solution, and PEGylated liposome-encapsulated midazolam (PEG-LE-midazolam) solution were prepared, and the characteristics of the liposomes in these solutions were evaluated. Furthermore, these solutions were orally administered to rabbits, and the resultant plasma midazolam concentrations were measured. The effects of the PEGylation of LE-midazolam on the plasma concentration and bioavailability of orally administered midazolam were also evaluated.&lt;br&gt;
Results The PEG-LE-midazolam solution contained a higher percentage of larger liposomes than the LE-midazolam solution. The area under the concentration-time curve (AUC) of the LE-midazolam solution was significantly higher than that of the midazolam solution, but there was no difference between the AUC values of the PEG-LE-midazolam and midazolam solutions.&lt;br&gt;
Conclusions These findings suggest that liposome encapsulation may reduce the first-pass effect following oral administration, but PEGylation is not expected to improve the bioavailability of orally administered midazolam.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">PEGylation</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Liposome</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Midazolam</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Oral administration</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Bioavailability</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0944-1174</Issn>
      <Volume>60</Volume>
      <Issue>5</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Diagnostic accuracy and cut-off values of serum leucine-rich alpha-2 glycoprotein for Crohn’s disease activity in the small bowel</ArticleTitle>
    <FirstPage LZero="delete">573</FirstPage>
    <LastPage>582</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Muneyori</FirstName>
        <LastName>Okita</LastName>
        <Affiliation>Department of Biostatistics, Nagoya University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kento</FirstName>
        <LastName>Takenaka</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Institute of Science Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Fumihito</FirstName>
        <LastName>Hirai</LastName>
        <Affiliation>Department of Gastroenterology and Medicine, Fukuoka University Faculty of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shinya</FirstName>
        <LastName>Ashizuka</LastName>
        <Affiliation>Department of Gastroenterology and Medicine, Fukuoka University Faculty of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hideki</FirstName>
        <LastName>Iijima</LastName>
        <Affiliation>Osaka International Medical &amp; Science Center, Osaka Keisatsu Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shigeki</FirstName>
        <LastName>Bamba</LastName>
        <Affiliation>Department of Fundamental Nursing, Shiga University of Medical Science</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshimitsu</FirstName>
        <LastName>Fujii</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Institute of Science Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kenji</FirstName>
        <LastName>Watanabe</LastName>
        <Affiliation>Department of Internal Medicine for Inflammatory Bowel Disease, Toyama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yosuke</FirstName>
        <LastName>Shimodaira</LastName>
        <Affiliation>Department of Gastroenterology and Neurology, Akita University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hisashi</FirstName>
        <LastName>Shiga</LastName>
        <Affiliation>Division of Gastroenterology, Tohoku University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Sakiko</FirstName>
        <LastName>Hiraoka</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshihiro</FirstName>
        <LastName>Inokuchi</LastName>
        <Affiliation>Research Center for Intestinal Health Science, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takeshi</FirstName>
        <LastName>Yamamura</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Nagoya University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryo</FirstName>
        <LastName>Emoto</LastName>
        <Affiliation>Department of Biostatistics, Nagoya University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shigeyuki</FirstName>
        <LastName>Matsui</LastName>
        <Affiliation>Department of Biostatistics, Nagoya University Graduate School of Medicine</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Background Small bowel (SB) lesions in Crohn’s disease (CD) are often asymptomatic despite being highly active. Fecal calprotectin (FC) is the most widely used biomarker of CD activity, but its drawbacks include a large intra-individual sample variability and the burden of collecting stool samples. Meanwhile, serum leucine-rich alpha-2 glycoprotein (LRG) has recently attracted attention as a biomarker that can address the limitations of FC. This study determined the diagnostic accuracy of LRG and its cut-off values for diagnosing CD activity in SB.&lt;br&gt;
Methods This was a retrospective, multi-center study of CD patients undergoing retrograde balloon-assisted endoscopy. For ileal- and ileocolonic-type patients with a colon SES-CD score of 0, we estimated the receiver operating characteristic curve of LRG and determined the cut-off value to achieve a target sensitivity level of 80%.&lt;br&gt;
Results Among 285 patients with SB lesions, LRG had an area under the curve (AUC) of 0.72 (95% CI 0.67&#8211;0.78) with a sensitivity of 80.2% and specificity of 47.2% for a cut-off value of 10.5 when diagnosing endoscopic remission (modified SES-CD&#8201;&#8804;&#8201;3), while it had an AUC of 0.72 (95% CI 0.65&#8211;0.78) with a sensitivity of 81.2% and specificity of 46.2% for a cut-off value of 10.1 when diagnosing complete ulcer healing (modified SES-CD&#8201;&#8804;&#8201;1).&lt;br&gt;
Conclusion LRG was effective for diagnosing CD activity in SB, specifically with cut-off values of 10.5 and 10.1 for endoscopic remission and complete ulcer healing, respectively. A future prospective validation study will assess its clinical utility.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">LRG</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Biomarker</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Crohn’s disease</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1865-7257</Issn>
      <Volume/>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Avoiding splenectomy in splenic sclerosing angiomatoid nodular transformation through endoscopic ultrasound-guided tissue acquisition: a 36-month follow-up case report</ArticleTitle>
    <FirstPage LZero="delete"/>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Takaki</FirstName>
        <LastName>Okuyama</LastName>
        <Affiliation>Department of Internal Medicine, Tsuyama Chuo Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuyuki</FirstName>
        <LastName>Matsumoto</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kosaku</FirstName>
        <LastName>Morimoto</LastName>
        <Affiliation>Department of Internal Medicine, Tsuyama Chuo Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shogo</FirstName>
        <LastName>Kimura</LastName>
        <Affiliation>Department of Internal Medicine, Tsuyama Chuo Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takayoshi</FirstName>
        <LastName>Miyake</LastName>
        <Affiliation>Department of Pathology, Tsuyama Chuo Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takuya</FirstName>
        <LastName>Satomi</LastName>
        <Affiliation>Department of Internal Medicine, Tsuyama Chuo Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kensuke</FirstName>
        <LastName>Takei</LastName>
        <Affiliation>Department of Internal Medicine, Tsuyama Chuo Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shogo</FirstName>
        <LastName>Inoue</LastName>
        <Affiliation>Department of Internal Medicine, Tsuyama Chuo Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryuta</FirstName>
        <LastName>Takenaka</LastName>
        <Affiliation>Department of Internal Medicine, Tsuyama Chuo Hospital</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>A 48-mm splenic mass was incidentally discovered in a 78-year-old man upon computed tomography. Follow-up imaging at 12 months revealed enlargement to 60 mm, prompting endoscopic ultrasound-guided tissue acquisition with a 22-gauge needle. Histopathological analysis confirmed that it was a sclerosing angiomatoid nodular transformation. The patient was asymptomatic and had no hematologic abnormalities; therefore, splenectomy was not performed. After biopsy, the lesion regressed from 60 mm to 46 mm, possibly owing to hematoma formation or vascular disruption, and remained stable during 36 months of follow-up. Although splenectomy has been performed in most reported cases of sclerosing angiomatoid nodular transformation because of diagnostic uncertainty, a few recent reports have demonstrated that sclerosing angiomatoid nodular transformation can be diagnosed by endoscopic ultrasound-guided tissue acquisition, thereby avoiding splenectomy. This case highlights the diagnostic utility of endoscopic ultrasound-guided tissue acquisition and supports spleen-preserving management for biopsy-proven sclerosing angiomatoid nodular transformation.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Sclerosing angiomatoid nodular transformation</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Spleen</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Endoscopic ultrasound-guided tissue acquisition</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Conservative management</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Biopsy</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1433-7398</Issn>
      <Volume/>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>A rare case of supratentorial ependymosarcoma harboring ZFTA::RELA fusion</ArticleTitle>
    <FirstPage LZero="delete"/>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Yuji</FirstName>
        <LastName>Matsumoto</LastName>
        <Affiliation>Department of Neurological Surgery, Dentistry, and Pharmaceutical Sciences, Okayama University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yasuki</FirstName>
        <LastName>Suruga</LastName>
        <Affiliation>Department of Neurological Surgery, Dentistry, and Pharmaceutical Sciences, Okayama University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kaishi</FirstName>
        <LastName>Satomi</LastName>
        <Affiliation>Department of Pathology, Faculty of Medicine, Kyorin University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yohei</FirstName>
        <LastName>Inoue</LastName>
        <Affiliation>Department of Neurological Surgery, Dentistry, and Pharmaceutical Sciences, Okayama University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yasuhiko</FirstName>
        <LastName>Hattori</LastName>
        <Affiliation>Department of Neurological Surgery, Dentistry, and Pharmaceutical Sciences, Okayama University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Joji</FirstName>
        <LastName>Ishida</LastName>
        <Affiliation>Department of Neurological Surgery, Dentistry, and Pharmaceutical Sciences, Okayama University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuhiko</FirstName>
        <LastName>Kurozumi</LastName>
        <Affiliation>Department of Neurosurgery, Hamamatsu University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Sumihito</FirstName>
        <LastName>Nobusawa</LastName>
        <Affiliation>Department of Human Pathology, Gunma University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Junko</FirstName>
        <LastName>Hirato</LastName>
        <Affiliation>Department of Pathology, Public Tomioka General Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takehiro</FirstName>
        <LastName>Tanaka</LastName>
        <Affiliation>Department of Pathology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroyuki</FirstName>
        <LastName>Yanai</LastName>
        <Affiliation>Department of Pathology, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kana</FirstName>
        <LastName>Washio</LastName>
        <Affiliation>Department of Pediatrics, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Koichi</FirstName>
        <LastName>Ichimura</LastName>
        <Affiliation>Department of Pathology, Faculty of Medicine, Kyorin University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomotsugu</FirstName>
        <LastName>Ichikawa</LastName>
        <Affiliation>Department of Neurosurgery, Kagawa Prefectural Central Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshihiro</FirstName>
        <LastName>Otani</LastName>
        <Affiliation>Department of Neurological Surgery, Dentistry, and Pharmaceutical Sciences, Okayama University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shota</FirstName>
        <LastName>Tanaka</LastName>
        <Affiliation>Department of Neurological Surgery, Dentistry, and Pharmaceutical Sciences, Okayama University Graduate School of Medicine</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Ependymosarcoma is an exceedingly rare variant of ependymoma characterized by a mixture of ependymomatous and sarcomatous components. We report a case of supratentorial ependymosarcoma harboring a ZFTA::RELA fusion in a 10-year-old girl. Histologically, the tumor comprised an ependymomatous component resembling clear cell ependymoma and a sarcomatous component. ZFTA::RELA fusion was confirmed in both components. Genome-wide methylation profiling classified both components as supratentorial ependymoma, ZFTA fusion&#8211;positive by the German Cancer Research Center (DKFZ) CNS tumor classifier v12b8. However, their copy number alteration profiles were distinct. The ependymomatous component exhibited a gain of chromosome 1q and a loss of chromosomes 1p, 9, and 19q, while the sarcomatous component showed a loss of chromosome 14. These findings suggest that both components may have differentiated from a common precursor despite their distinct morphologies. The patient underwent gross total resection followed by adjuvant chemoradiotherapy and remains recurrence-free eight years post-treatment. Further investigation of additional cases is warranted to better understand the pathogenesis of this rare tumor.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Ependymoma</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Ependymosarcoma</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">ZFTA</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">RELA</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Methylation profiling</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Wiley</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0041-1132</Issn>
      <Volume>65</Volume>
      <Issue>9</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Novel method for autologous peripheral blood stem cell harvest using highly concentrated sodium citrate solution replacing acid citrate dextrose solution A</ArticleTitle>
    <FirstPage LZero="delete">1662</FirstPage>
    <LastPage>1672</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Wataru</FirstName>
        <LastName>Kitamura</LastName>
        <Affiliation>Department of Hematology and Oncology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Keiko</FirstName>
        <LastName>Fujii</LastName>
        <Affiliation>Department of Hematology and Oncology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masaya</FirstName>
        <LastName>Abe</LastName>
        <Affiliation>Department of Hematology and Oncology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuhiro</FirstName>
        <LastName>Ikeuchi</LastName>
        <Affiliation>Department of Hematology and Oncology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Joji</FirstName>
        <LastName>Shimono</LastName>
        <Affiliation>Department of Hematology and Oncology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kana</FirstName>
        <LastName>Washio</LastName>
        <Affiliation>Department of Pediatrics, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Fumio</FirstName>
        <LastName>Otsuka</LastName>
        <Affiliation>Division of Clinical Laboratory, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshinobu</FirstName>
        <LastName>Maeda</LastName>
        <Affiliation>Department of Hematology and Oncology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Nobuharu</FirstName>
        <LastName>Fujii</LastName>
        <Affiliation>Department of Hematology and Oncology, Okayama University Hospital</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Background: As the processed blood volume increases, a larger amount of anticoagulant (AC) is required, which leads to a serious issue of fluid dilution in large-volume leukocytapheresis (defined as &#8805;3-fold total blood volume). We previously reported a novel method for allogeneic peripheral blood stem cell harvest (PBSCH) using highly concentrated sodium citrate (HSC; 5.32%), which shortened the procedure time and reduced the need for an AC solution without heparin. In this study, we extended this novel method to autologous PBSCH (auto-PBSCH) and compared it with patients who received auto-PBSCH using normal concentrated sodium citrate (NSC; 2.2%).&lt;br&gt;
Study Design and Methods: We retrospectively analyzed consecutive auto-PBSCH data obtained using the Spectra Optia continuous mononuclear cell collection mode between May 2017 and May 2025 at our institution.&lt;br&gt;
Results: Leukocytapheresis was performed using NSC in 36 patients and HSC in 22. In the HSC group, patients tended to be younger, had significantly lower body weight, and had significantly fewer hematopoietic tumors as primary diseases compared to the NSC group. After propensity score-matched cohort adjusted for patient background, the total amount of AC solution was significantly lower (694 [range, 77&#8211;1648] vs. 298&#8201;mL [range, 64&#8211;797], p&#8201;=&#8201;.02), and procedure time was significantly shorter (224 [range, 117&#8211;395] vs. 181&#8201;min [range, 103&#8211;309], p&#8201;=&#8201;.048) in the HSC group. Furthermore, the loss rates of magnesium and potassium were lower in the HSC group.&lt;br&gt;
Conclusion: This novel leukocytapheresis method demonstrated the efficacy and safety in auto-PBSCH, while minimizing the patient burden.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">acid citrate dextrose solution A</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">anticoagulant</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">autologous</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">highly concentrated sodium citrate</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">peripheral blood stem cell</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2168-8184</Issn>
      <Volume>17</Volume>
      <Issue>10</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Risk Stratification for the Prediction of Skeletal-Related Events in Patients With Bone Metastases From Non-small Cell Lung Cancer</ArticleTitle>
    <FirstPage LZero="delete">e95808</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Yoshihiro</FirstName>
        <LastName>Sakamoto</LastName>
        <Affiliation>Department of Orthopedic Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Eiji</FirstName>
        <LastName>Nakata</LastName>
        <Affiliation>Department of Orthopedic Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masanori</FirstName>
        <LastName>Hamada</LastName>
        <Affiliation>Department of Orthopedic Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshimi</FirstName>
        <LastName>Katayama</LastName>
        <Affiliation>Department of Orthopedic Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shinsuke</FirstName>
        <LastName>Sugihara</LastName>
        <Affiliation>Department of Orthopedic Surgery, Shikoku Cancer Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshifumi</FirstName>
        <LastName>Ozaki</LastName>
        <Affiliation>Department of Orthopedic Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Skeletal-related events (SREs) frequently occur in patients with bone metastases from non-small cell lung cancer (NSCLC). This study aimed to identify risk factors for SREs in patients with NSCLC. Based on these factors, we also aimed to stratify patients into subgroups to facilitate the assessment of SRE risk. This retrospective analysis used medical records of 139 patients with NSCLC bone metastases who received treatment at our institution between 2011 and 2014. The incidence of SREs was assessed, and SRE-free survival was analyzed using the Kaplan-Meier method. Clinical information collected at registration was assessed to identify factors associated with the onset of SREs within six months. Univariate analysis was performed using Fisher’s exact test, and multivariate analysis was performed using Cox regression. Of the 139 patients, 36 (26%) developed SREs after registration. The SRE-free survival rates were 80% and 64% at 6 and 12 months, respectively. The univariate and multivariate analyses revealed that the absence of epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) rearrangement (hazard ratio (HR): 4.51, 95% confidence interval (CI): 1.32-15.7, p = 0.017) and a lactate dehydrogenase (LDH) level &#8805;400 U/L (HR: 8.08, 95% CI: 1.78-36.6, p = 0.0067) were risk factors for SRE presentation within six months. Patients were classified into the following three subgroups: with EGFR mutation or ALK rearrangement and LDH level &lt;400 U/L; without EGFR mutation or ALK rearrangement and LDH level &lt;400 U/L; with/without EGFR mutation or ALK rearrangement and LDH level &#8805;400 U/L. The corresponding six-month SRE-free survival rates were 92%, 69%, and 34%, respectively, showing significant differences (p &lt; 0.001). Close monitoring is recommended for patients with LDH levels &#8805;400 U/L in daily clinical practice, particularly with the help of the proficiency of orthopedic and radiological experts, to prevent complications such as pathological fractures and paraplegia.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">anaplastic lymphoma kinase</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">bone metastases</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">epidermal growth factor receptor-tyrosine kinase</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">lactate dehydrogenase</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">non-small cell lung cancer</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">skeletal related events</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2168-8184</Issn>
      <Volume>17</Volume>
      <Issue>8</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Conversion to Hip Arthroplasty After Internal Fixation Failure in an Intertrochanteric Femoral Fracture: A Case Report</ArticleTitle>
    <FirstPage LZero="delete">e90112</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Shiro</FirstName>
        <LastName>Fukuoka</LastName>
        <Affiliation>Department of Orthopedics, Kagawa Prefectural Central Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomoo</FirstName>
        <LastName>Inoue</LastName>
        <Affiliation>Department of Orthopedics, Kagawa Prefectural Central Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Motoki</FirstName>
        <LastName>Takahashi</LastName>
        <Affiliation>Department of Orthopedics, Kagawa Prefectural Central Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Keisuke</FirstName>
        <LastName>Kawasaki</LastName>
        <Affiliation>Department of Orthopedic Surgery, Kagawa Prefectural Central Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshifumi</FirstName>
        <LastName>Ozaki</LastName>
        <Affiliation>Department of Orthopedic Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Science</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Intertrochanteric femoral fractures are mainly managed by internal fixation. However, failures such as over-telescoping, cut-out, nonunion, or implant failure can occur, especially in osteoporotic elderly patients. We report the case of a patient in whom we performed artificial hip replacement surgery after fixation failure following internal fixation of an intertrochanteric femoral fracture. We report the case of an 85-year-old woman who sustained a left intertrochanteric femoral fracture treated with a dynamic hip screw (DHS). One week postoperatively, radiographs revealed over-telescoping of the lag screw. The patient did not complain of pain, but she underwent conversion to cemented bipolar hemiarthroplasty under general anesthesia. One possible cause of over-telescoping of the lag screw after surgery was that the longitudinal fracture line in the calcar of the proximal bone fragment, as seen in the initial CT image, may have extended horizontally at the neck level. During surgery, a fracture at the same site caused the anterior medial fragment to fail, resulting in a coronal shear fracture and fixation failure. When a longitudinal fracture line is observed in the calcar of the proximal fragment, it is necessary to keep in mind that it may extend horizontally at the neck level.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">arthroplasty</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">coronal shear fracture</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">double jaws sign</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">fixation failure</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">intertrochanteric femoral fracture</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2168-8184</Issn>
      <Volume>17</Volume>
      <Issue>6</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Clinical Outcomes and Biomechanical Evaluation of the Cement-Catching Screw Technique for Osteoporotic Vertebral Fractures</ArticleTitle>
    <FirstPage LZero="delete">e85955</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Hisakazu</FirstName>
        <LastName>Shitozawa</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Science of Functional Recovery and Reconstruction, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Haruo</FirstName>
        <LastName>Misawa</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Ryusou Orthopaedic Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshiaki</FirstName>
        <LastName>Oda</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryoji</FirstName>
        <LastName>Joko</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Japanese Red Cross Okayama Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masaya</FirstName>
        <LastName>Takahashi</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Japanese Red Cross Okayama Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Koji</FirstName>
        <LastName>Uotani</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yasuyuki</FirstName>
        <LastName>Shiozaki</LastName>
        <Affiliation>Department of Orthopaedic surgery, Mitoyo General Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomoko</FirstName>
        <LastName>Tetsunaga</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kensuke</FirstName>
        <LastName>Shinohara</LastName>
        <Affiliation>Department of Sports Medicine, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryo</FirstName>
        <LastName>Nakamichi</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masataka</FirstName>
        <LastName>Ueda</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Science of Functional Recovery and Reconstruction, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryo</FirstName>
        <LastName>Takatori</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Science of Functional Recovery and Reconstruction, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazutaka</FirstName>
        <LastName>Yamashita</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Science of Functional Recovery and Reconstruction, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshifumi</FirstName>
        <LastName>Ozaki</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Objectives: We developed a cement-catching screw (CCS) technique for pedicle screw insertion into hardened cement, connecting anterior and posterior vertebral elements during balloon kyphoplasty (BKP) for osteoporotic vertebral fractures (OVFs). This study reports the CCS technique, clinical outcomes, and biomechanical properties.&lt;br&gt;
Methods: This retrospective study included 59 patients (20 men, 39 women; mean age, 77.4 ± 8.7 years) who underwent BKP with one-above-one-below posterior fixation for OVFs between 2020 and 2023. Patients were divided into CCS (−) (without intermediate screws, n = 28) and CCS (+) (with intermediate CCSs, n = 31) groups. Clinical and radiographic outcomes, including activities of daily living, vertebral wedge angle (VWA), surgical level Cobb angle (CA), anterior vertebral body height (AVBH), screw loosening, pullout, and adjacent vertebral fractures, were evaluated preoperatively, postoperatively, and at the final follow-up (&#8805;6 months). Biomechanical pullout strength was assessed at different insertion depths (5, 10, and 15 mm) using polymethylmethacrylate cement.&lt;br&gt;
Results: No significant differences were observed between groups in age, sex, follow-up duration, or blood loss; however, the operation time was significantly longer in the CCS (+) group than in the CCS (−) group (P &lt; 0.0001). Radiographic outcomes showed no significant differences in the VWA, CA, AVBH, adjacent vertebral fracture rates, and reoperation rates. However, the incidence of adjacent pedicle screws loosening and pullout was significantly higher in the CCS (−) group than in the CCS (+) group (P = 0.046 and 0.0084, respectively). The correction loss of the CA was significantly lower in the CCS (+) group (CCS (−), 5.6° ± 4.8°; CCS (+), 3.5° ± 4.8°, P = 0.023). The biomechanical test revealed pullout strengths of 683 ± 164, 2231 ± 208, and 3477 ± 393 N for insertion depths of 5, 10, and 15 mm, respectively, with significant increases by depth (P = 0.003 and 0.009).&lt;br&gt;
Conclusions: The CCS technique improves anterior-posterior vertebral body stability, enhances fixation strength, and contributes to better surgical outcomes in OVFs treatment.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">balloon kyphoplasty</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">cement-catching screw</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">intermediate screws</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">osteoporotic vertebral fractures</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">pullout strength</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2168-8184</Issn>
      <Volume>17</Volume>
      <Issue>3</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>A Case of Charcot Spine Arthropathy at the Lumbosacral Level in a Patient With Ankylosis of the Spine</ArticleTitle>
    <FirstPage LZero="delete">e80656</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Yoshiaki</FirstName>
        <LastName>Oda</LastName>
        <Affiliation>Department of Orthopedic Surgery, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Koji</FirstName>
        <LastName>Uotani</LastName>
        <Affiliation>Department of Musculoskeletal Traumatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomoko</FirstName>
        <LastName>Tetsunaga</LastName>
        <Affiliation>Department of Orthopedic Surgery, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kensuke</FirstName>
        <LastName>Shinohara</LastName>
        <Affiliation>Department of Orthopedic Surgery, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshifumi</FirstName>
        <LastName>Ozaki</LastName>
        <Affiliation>Department of Orthopedic Surgery, Faculty of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Charcot spinal arthropathy, a rare refractory progressive disease, is characterized by symptoms such as pain, deformity, and neurological impairment, which can significantly reduce functional ability, quality of life, and life expectancy. We report a case of Charcot spine at the L5/S1 level with long segment ankylosis to the L5 vertebra. We first performed thorough debridement via a posterior approach. We used antibiotic-containing cement as a spacer to fill the dead space, facilitating the second surgery approach. In the second surgery, transdiscal screws, which have a low profile and strong force, were used as anchors, and bulk bone harvested from both iliac bones was grafted to the intervertebral space. The lumbosacral alignment was kyphotic, and the patient could sit and move independently. Disimpaction was impossible, and a stoma had to be created.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">ankylosing spine</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">charcot spine</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">charcot spine arthropathy</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">lumbosacral segment</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">paraplegia</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">transdiscal screw</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2168-8184</Issn>
      <Volume>17</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Mid-term Clinical and Radiographic Outcomes of the Actis Total Hip System: A Retrospective Study</ArticleTitle>
    <FirstPage LZero="delete">e77632</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Yasutaka</FirstName>
        <LastName>Masada</LastName>
        <Affiliation>Department of Medical Materials for Musculoskeletal Reconstruction, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomonori</FirstName>
        <LastName>Tetsunaga</LastName>
        <Affiliation>Department of Musculoskeletal Health Promotion, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuki</FirstName>
        <LastName>Yamada</LastName>
        <Affiliation>Department of Medical Materials for Musculoskeletal Reconstruction, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takashi</FirstName>
        <LastName>Koura</LastName>
        <Affiliation>Department of Medical Materials for Musculoskeletal Reconstruction, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomohiro</FirstName>
        <LastName>Inoue</LastName>
        <Affiliation>Department of Medical Materials for Musculoskeletal Reconstruction, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryuichiro</FirstName>
        <LastName>Okuda</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomoko</FirstName>
        <LastName>Tetsunaga</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yusuke</FirstName>
        <LastName>Yokoyama</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuki</FirstName>
        <LastName>Okazaki</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshifumi</FirstName>
        <LastName>Ozaki</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Introduction&lt;br&gt;
Implant technology for total hip arthroplasty (THA) was developed to improve hip function and patient satisfaction. Actis (DePuy Synthes, Warsaw, IN, USA) is a short fit-and-fill titanium stem, with a medial-collared and triple-taper (MCTT) geometry, that is fully coated with hydroxyapatite (HA). We evaluated the radiographic and clinical outcomes of the Actis Total Hip System during a mean follow-up of five years.&lt;br&gt;
Patients and methods&lt;br&gt;
We retrospectively analyzed data from 80 patients (14 male and 66 female, mean age: 65 ± 8.4 years) who underwent primary THA using Actis stems (anterolateral approach, 60 hips; posterior approach, 20 hips). Radiographs were obtained postoperatively and at the time of the final examination. Radiographic assessments included the alignment of the femoral stem, spot welds, stress shielding, cortical hypertrophy, subsidence (&gt;2 mm), radiolucent line, pedestal formation, Dorr type, canal fill ratio (CFR), and stem fixation. Clinical evaluation included the Japanese Orthopaedic Association Hip-Disease Evaluation Questionnaire (JHEQ) and Harris Hip Score (HHS).&lt;br&gt;
Results&lt;br&gt;
The mean follow-up period was 64.0 ± 6.0 months. No significant differences were observed in the alignment of the femoral components between approaches. Of the 80 hips, 53 (66.3%) showed radiographic signs of stem osseointegration, predominantly in the mid-distal region of the stem at the final follow-up. Multiple logistic regression analysis revealed that younger age and a higher CFR (20 mm proximal to the lesser trochanter) were associated with the presence of spot welds. Mild stress shielding occurred in 25 hips (31.3%), and no patient experienced severe stress shielding. All stems were fixed by bone on growth. The JHEQ and HHS significantly improved at the final assessment.&lt;br&gt;
Conclusion&lt;br&gt;
At the five-year follow-up, patients who received the Actis Total Hip System during THA had good radiographic and clinical outcomes.&lt;br&gt;</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">actis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">hydroxyapatite</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">mid-term outcome</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">spot welds</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">stem</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">total hip arthroplasty</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1434-3916</Issn>
      <Volume>145</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Changes in the anatomical positions of the femoral nerve and artery in the lateral and supine positions: a multicenter retrospective study</ArticleTitle>
    <FirstPage LZero="delete">373</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Ryuichiro</FirstName>
        <LastName>Okuda</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomonori</FirstName>
        <LastName>Tetsunaga</LastName>
        <Affiliation>Department of Musculoskeletal Health Promotion, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuki</FirstName>
        <LastName>Yamada</LastName>
        <Affiliation>Department of Medical Materials for Musculoskeletal Reconstruction, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomoko</FirstName>
        <LastName>Tetsunaga</LastName>
        <Affiliation>Department of Sports Medicine, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takashi</FirstName>
        <LastName>Koura</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomohiro</FirstName>
        <LastName>Inoue</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yasutaka</FirstName>
        <LastName>Masada</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tetsuya</FirstName>
        <LastName>Yamamoto</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shin</FirstName>
        <LastName>Matsumoto</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hisanori</FirstName>
        <LastName>Ikuma</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Kagawa Prefectural Central Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tadashi</FirstName>
        <LastName>Komatsubara</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Okayama Rosai Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuki</FirstName>
        <LastName>Okazaki</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshifumi</FirstName>
        <LastName>Ozaki</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Introduction Femoral nerve palsy and femoral artery injury are serious complications of total hip arthroplasty. However, few studies have compared the anatomical positions of these structures in different patient positions. This study aimed to compare the anatomical positions of the femoral nerve and artery in the lateral and supine positions.&lt;br&gt;
Materials and methods This multicenter retrospective study included 111 patients who underwent lateral and supine computed tomography (CT) from 2016 to 2023. CT images were reconstructed in the anterior pelvic plane. The horizontal distance from the anterior margin of the acetabulum to the femoral nerve (Distance N) and femoral artery (Distance A) was measured. The difference in Distance N between the two positions (ΔLateral&#8211;supine Distance N) was calculated by subtracting the supine value from the lateral value.&lt;br&gt;
Results The average Distance N was 26.5&#8201;±&#8201;5.1 mm in the lateral position and 21.1&#8201;±&#8201;4.4 mm in the supine position, with the nerve located significantly closer to the acetabulum in the supine position (P&#8201;&lt;&#8201;0.001). Similarly, the average Distance A was 26.8&#8201;±&#8201;5.4 mm in the lateral position and 20.4&#8201;±&#8201;4.9 mm in the supine position (P&#8201;&lt;&#8201;0.001). Multiple regression analysis showed that Distance N in the lateral position was significantly shorter in female patients and those with low body weight. In addition, low body weight correlated with a smaller ΔLateral&#8211;supine Distance N.&lt;br&gt;
Conclusions The femoral nerve and artery are located closer to the anterior margin of the acetabulum in the supine position than in the lateral position. Low body weight was an independent predictor of shorter Distance N in both positions and a smaller ΔLateral&#8211;supine Distance N. These findings underscore the importance of considering patient positioning during total hip arthroplasty, particularly in patients with low body weight, to reduce neurovascular risks.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Total hip arthroplasty</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Femoral artery</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Femoral nerve</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Computed tomography</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Lateral position</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Supine position</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName/>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn/>
      <Volume/>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Vesicular Glutamate Transporter 3 Is Involved in Glutamatergic Signalling in Podocytes</ArticleTitle>
    <FirstPage LZero="delete"/>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Naoko</FirstName>
        <LastName>NISHII</LastName>
        <Affiliation>Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract/>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList/>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName/>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn/>
      <Volume/>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Improving Diagnostic Performance for Head and Neck Tumors with Simple Diffusion Kurtosis Imaging and Machine Learning Bi-Parameter Analysis</ArticleTitle>
    <FirstPage LZero="delete"/>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Suzuka</FirstName>
        <LastName>YOSHIDA</LastName>
        <Affiliation>Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract/>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList/>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName/>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn/>
      <Volume/>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Gingipain regulates isoform switches of PD-L1 in macrophages infected with Porphyromonas gingivalis</ArticleTitle>
    <FirstPage LZero="delete"/>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">YILIN</FirstName>
        <LastName>ZHENG</LastName>
        <Affiliation>Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract/>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList/>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName/>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn/>
      <Volume/>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Effects of Aged Garlic Extract on Experimental Periodontitis in Mice.</ArticleTitle>
    <FirstPage LZero="delete"/>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">CANYAN</FirstName>
        <LastName>KUANG</LastName>
        <Affiliation>Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract/>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList/>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName/>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn/>
      <Volume/>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Importance of Blood Glucose Measurement for Predicting the Prognosis of Long COVID：A Retrospective Study in Japan</ArticleTitle>
    <FirstPage LZero="delete"/>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Sho</FirstName>
        <LastName>YOKOYAMA</LastName>
        <Affiliation>Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract/>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList/>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName/>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn/>
      <Volume/>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Trends in childhood obesity in Japan: A nationwide observational study from 2012 to 2021</ArticleTitle>
    <FirstPage LZero="delete"/>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Shintaro</FirstName>
        <LastName>FUJIWARA</LastName>
        <Affiliation>Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract/>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList/>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName/>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn/>
      <Volume/>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Examination of yield, bacteriolytic activity and cold storage of linker deletion mutants based on endolysin S6_ORF93 derived from Staphylococcus giant bacteriophage S6</ArticleTitle>
    <FirstPage LZero="delete"/>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Sosuke</FirstName>
        <LastName>MUNETOMO</LastName>
        <Affiliation>Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract/>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList/>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName/>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn/>
      <Volume/>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Tumor microvessels with specific morphology as a prognostic factor in esophageal squamous cell carcinoma</ArticleTitle>
    <FirstPage LZero="delete"/>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N"/>
        <LastName>HNIN THIDA TUN</LastName>
        <Affiliation>Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract/>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList/>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName/>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn/>
      <Volume/>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>TRPV2 mediates stress resilience in mouse cardiomyocytes</ArticleTitle>
    <FirstPage LZero="delete"/>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">YUBING</FirstName>
        <LastName>DONG</LastName>
        <Affiliation>Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract/>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList/>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName/>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn/>
      <Volume/>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Novel extracellular role of REIC/Dkk-3 protein in PD-L1 regulation in cancer cells</ArticleTitle>
    <FirstPage LZero="delete"/>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Yuma</FirstName>
        <LastName>GOHARA</LastName>
        <Affiliation>Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract/>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList/>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName/>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn/>
      <Volume/>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Cancer&#8209;associated fibroblasts promote pro&#8209;tumor functions of neutrophils in pancreatic cancer via IL&#8209;8: potential suppression by pirfenidon</ArticleTitle>
    <FirstPage LZero="delete"/>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Tomohiko</FirstName>
        <LastName>YAGI</LastName>
        <Affiliation>Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract/>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList/>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName/>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn/>
      <Volume/>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>ADAR1-high tumor-associated macrophages induce drug resistance and are therapeutic targets in colorectal cancer</ArticleTitle>
    <FirstPage LZero="delete"/>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Hibiki</FirstName>
        <LastName>OTSUKI (UMEDA)</LastName>
        <Affiliation>Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract/>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList/>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName/>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn/>
      <Volume/>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Outcomes of ultra-high-pressure balloon angioplasty for congenital heart disease in single-center experience</ArticleTitle>
    <FirstPage LZero="delete"/>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Maiko</FirstName>
        <LastName>KONDO</LastName>
        <Affiliation>Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract/>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList/>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName/>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn/>
      <Volume/>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>HIF‐PH inhibitors induce pseudohypoxia in T cells and suppress the growth of microsatellite stable colorectal cancer by enhancing antitumor immune responses</ArticleTitle>
    <FirstPage LZero="delete"/>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">YUEHUA</FirstName>
        <LastName>CHEN</LastName>
        <Affiliation>Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract/>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList/>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName/>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn/>
      <Volume/>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Novel treatment strategy targeting interleukin-6 induced by cancer associated fibroblasts for peritoneal metastasis of gastric cancer</ArticleTitle>
    <FirstPage LZero="delete"/>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Ema</FirstName>
        <LastName>MITSUI</LastName>
        <Affiliation>Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract/>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList/>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName/>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn/>
      <Volume/>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>The Association of Postprandial Triglyceride Variability with Renal Dysfunction and Microalbuminuria in Patients with Type 2 Diabetic Mellitus: A Retrospective and Observational Study</ArticleTitle>
    <FirstPage LZero="delete"/>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Natsumi</FirstName>
        <LastName>UCHIYAMA</LastName>
        <Affiliation>Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract/>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList/>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName/>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn/>
      <Volume/>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Role of galectin-9 in the development of gestational diabetes mellitus </ArticleTitle>
    <FirstPage LZero="delete"/>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N"/>
        <LastName>ALBUAYJAN HAYA HAMED H</LastName>
        <Affiliation>Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract/>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList/>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName/>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn/>
      <Volume/>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Efficient diagnosis for endoscopic remission in Crohn’s diseases by the combination of three non-invasive markers</ArticleTitle>
    <FirstPage LZero="delete"/>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Kensuke</FirstName>
        <LastName>TAKEI</LastName>
        <Affiliation>Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract/>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList/>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName/>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn/>
      <Volume/>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Osteosarcoma cell&#8211;derived CCL2 facilitates lung metastasis via accumulation of tumor-associated macrophages</ArticleTitle>
    <FirstPage LZero="delete"/>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Hiroya</FirstName>
        <LastName>KONDO</LastName>
        <Affiliation>Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract/>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList/>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName/>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn/>
      <Volume/>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>LRP4 and Agrin Are Modulated by Cartilage Degeneration and Involved in β-Catenin Signaling in Human Articular Chondrocytes</ArticleTitle>
    <FirstPage LZero="delete"/>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Shuichi</FirstName>
        <LastName>NANIWA</LastName>
        <Affiliation>Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract/>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList/>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName/>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn/>
      <Volume/>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Maternal smoking during infancy increases the risk of allergic disease in children: a nationwide longitudinal survey in Japan</ArticleTitle>
    <FirstPage LZero="delete"/>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Kenji</FirstName>
        <LastName>SHIGEHARA</LastName>
        <Affiliation>Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract/>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList/>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName/>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn/>
      <Volume/>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Avoidant/restrictive food intake disorder prognosis and its relation with autism spectrum disorder in Japanese children</ArticleTitle>
    <FirstPage LZero="delete"/>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Chie</FirstName>
        <LastName>TANAKA</LastName>
        <Affiliation>Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract/>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList/>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName/>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn/>
      <Volume/>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Spatiotemporal expression pattern of dyslexia susceptibility 1 candidate 1 (DYX1C1) during rat cerebral cortex development</ArticleTitle>
    <FirstPage LZero="delete"/>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Kazumasa</FirstName>
        <LastName>ZENSHO</LastName>
        <Affiliation>Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract/>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList/>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>MDPI AG</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2072-6694</Issn>
      <Volume>17</Volume>
      <Issue>19</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Utility of Same-Modality, Cross-Domain Transfer Learning for Malignant Bone Tumor Detection on Radiographs: A Multi-Faceted Performance Comparison with a Scratch-Trained Model</ArticleTitle>
    <FirstPage LZero="delete">3144</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Joe</FirstName>
        <LastName>Hasei</LastName>
        <Affiliation>Department of Medical Informatics and Clinical Support Technology Development, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryuichi</FirstName>
        <LastName>Nakahara</LastName>
        <Affiliation>Science of Functional Recovery and Reconstruction, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yujiro</FirstName>
        <LastName>Otsuka</LastName>
        <Affiliation>Department of Radiology, Juntendo University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Koichi</FirstName>
        <LastName>Takeuchi</LastName>
        <Affiliation>Graduate School of Environmental, Life Natural Science and Technology, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yusuke</FirstName>
        <LastName>Nakamura</LastName>
        <Affiliation>Plusman LCC</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kunihiro</FirstName>
        <LastName>Ikuta</LastName>
        <Affiliation>Department of Orthopedic Surgery, Graduate School of Medicine, Nagoya University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shuhei</FirstName>
        <LastName>Osaki</LastName>
        <Affiliation>Department of Musculoskeletal Oncology and Rehabilitation, National Cancer Center Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hironari</FirstName>
        <LastName>Tamiya</LastName>
        <Affiliation>Department of Musculoskeletal Oncology Service, Osaka International Cancer Institute,</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shinji</FirstName>
        <LastName>Miwa</LastName>
        <Affiliation>Department of Orthopedic Surgery, Graduate School of Medical Sciences, Kanazawa University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shusa</FirstName>
        <LastName>Ohshika</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Hirosaki University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shunji</FirstName>
        <LastName>Nishimura</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Kindai University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Naoaki</FirstName>
        <LastName>Kahara</LastName>
        <Affiliation>Department of Orthopedic Surgery, Mizushima Central Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Aki</FirstName>
        <LastName>Yoshida</LastName>
        <Affiliation>Science of Functional Recovery and Reconstruction, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroya</FirstName>
        <LastName>Kondo</LastName>
        <Affiliation>Science of Functional Recovery and Reconstruction, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomohiro</FirstName>
        <LastName>Fujiwara</LastName>
        <Affiliation>Science of Functional Recovery and Reconstruction, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshiyuki</FirstName>
        <LastName>Kunisada</LastName>
        <Affiliation>Science of Functional Recovery and Reconstruction, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshifumi</FirstName>
        <LastName>Ozaki</LastName>
        <Affiliation>Science of Functional Recovery and Reconstruction, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Background/Objectives: Developing high-performance artificial intelligence (AI) models for rare diseases like malignant bone tumors is limited by scarce annotated data. This study evaluates same-modality cross-domain transfer learning by comparing an AI model pretrained on chest radiographs with a model trained from scratch for detecting malignant bone tumors on knee radiographs. Methods: Two YOLOv5-based detectors differed only in initialization (transfer vs. scratch). Both were trained/validated on institutional data and tested on an independent external set of 743 radiographs (268 malignant, 475 normal). The primary outcome was AUC; prespecified operating points were high-sensitivity (&#8805;0.90), high-specificity (&#8805;0.90), and Youden-optimal. Secondary analyses included PR/F1, calibration (Brier, slope), and decision curve analysis (DCA). Results: AUC was similar (YOLO-TL 0.954 [95% CI 0.937&#8211;0.970] vs. YOLO-SC 0.961 [0.948&#8211;0.973]; DeLong p = 0.53). At the high-sensitivity point (both sensitivity = 0.903), YOLO-TL achieved higher specificity (0.903 vs. 0.867; McNemar p = 0.037) and PPV (0.840 vs. 0.793; bootstrap p = 0.030), reducing ~17 false positives among 475 negatives. At the high-specificity point (~0.902&#8211;0.903 for both), YOLO-TL showed higher sensitivity (0.798 vs. 0.764; p = 0.0077). At the Youden-optimal point, sensitivity favored YOLO-TL (0.914 vs. 0.892; p = 0.041) with a non-significant specificity difference. Conclusions: Transfer learning may not improve overall AUC but can enhance practical performance at clinically crucial thresholds. By maintaining high detection rates while reducing false positives, the transfer learning model offers superior clinical utility. Same-modality cross-domain transfer learning is an efficient strategy for developing robust AI systems for rare diseases, supporting tools more readily acceptable in real-world screening workflows.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">malignant bone tumors</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">artificial intelligence</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">transfer learning</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">YOLO</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">radiographs</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">cross-domain learning</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">diagnostic imaging</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2168-8184</Issn>
      <Volume>17</Volume>
      <Issue>4</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Subcutaneous and Periorbital Emphysema Following a Dental Procedure</ArticleTitle>
    <FirstPage LZero="delete">e83089</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Takafumi</FirstName>
        <LastName>Obara</LastName>
        <Affiliation>Department of Emergency, Critical Care and Disaster Medicine, Faculty of Medicine, Dentistry and Pharmaceutical Sciences Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tsuyoshi</FirstName>
        <LastName>Nojima</LastName>
        <Affiliation>Department of Emergency, Critical Care and Disaster Medicine, Faculty of Medicine, Dentistry and Pharmaceutical Sciences Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuki</FirstName>
        <LastName>Nakatsuji</LastName>
        <Affiliation>Department of Oral and Maxillofacial Reconstructive Surgery, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takashi</FirstName>
        <LastName>Hongo</LastName>
        <Affiliation>Department of Emergency, Critical Care and Disaster Medicine, Faculty of Medicine, Dentistry and Pharmaceutical Sciences Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tetsuya</FirstName>
        <LastName>Yumoto</LastName>
        <Affiliation>Department of Emergency, Critical Care and Disaster Medicine, Faculty of Medicine, Dentistry and Pharmaceutical Sciences Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Atsunori</FirstName>
        <LastName>Nakao</LastName>
        <Affiliation>Department of Emergency, Critical Care and Disaster Medicine, Faculty of Medicine, Dentistry and Pharmaceutical Sciences Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Subcutaneous emphysema following dental procedures is rare. We present the case of a young, healthy woman who was transferred from a dental clinic to our emergency department due to sudden swelling of the left orbit immediately after a dental procedure involving the use of the dental air and water syringe. The diagnosis of subcutaneous facial emphysema was made based on the patient's history, physical examination, and computed tomography imaging. The patient received prophylactic amoxicillin, and the lesion resolved completely in one week. Prompt clinical suspicion and a thorough evaluation of the signs and symptoms, including a detailed clinical history, are crucial for diagnosing subcutaneous emphysema following a dental procedure.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">air pressure</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">antibiotic prophylaxis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">dental procedures</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">operative</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">subcutaneous emphysema</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1869-6953</Issn>
      <Volume>16</Volume>
      <Issue>12</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>A Multicenter, Prospective, Observational, and Single-Arm Interventional Study of Mirogabalin in Diabetic Peripheral Neuropathic Pain: Rationale and Design of Dia-NeP</ArticleTitle>
    <FirstPage LZero="delete">2351</FirstPage>
    <LastPage>2363</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Hideki</FirstName>
        <LastName>Kamiya</LastName>
        <Affiliation>Division of Diabetes, Department of Internal Medicine, Aichi Medical University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryo</FirstName>
        <LastName>Suzuki</LastName>
        <Affiliation>Department of Diabetes, Metabolism and Endocrinology, Tokyo Medical University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Jun</FirstName>
        <LastName>Wada</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takahisa</FirstName>
        <LastName>Deguchi</LastName>
        <Affiliation>Department of Diabetes, Metabolism and Endocrinology, Kagoshima University Graduate School of Medical and Dental Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tatsuhito</FirstName>
        <LastName>Himeno</LastName>
        <Affiliation>Division of Diabetes, Department of Internal Medicine, Aichi Medical University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shuhei</FirstName>
        <LastName>Yamamoto</LastName>
        <Affiliation>Data Intelligence Department, Daiichi Sankyo Co., Ltd.</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Taiki</FirstName>
        <LastName>Toyama</LastName>
        <Affiliation>Primary Medical Science Department, Daiichi Sankyo Co., Ltd.</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Jiro</FirstName>
        <LastName>Nakamura</LastName>
        <Affiliation>Division of Diabetes, Department of Internal Medicine, Aichi Medical University School of Medicine</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Background/Objectives: The exact prevalence of and recent changes in diabetic polyneuropathy (DPN) and diabetic peripheral neuropathic pain (DPNP) in Japan are unclear. The oral gabapentinoid, mirogabalin besylate (mirogabalin), is effective with a good safety profile for DPNP with moderate-to-severe pain (numerical rating scale [NRS] scores&#8201;&#8805;&#8201;4). However, clinical evidence for mild pain (NRS scores&#8201;&#8804;&#8201;3) is unclear. The Dia-NeP study aims to examine: (1) the prevalences of DPN and DPNP and background factors in patients with type 2 diabetes mellitus (T2DM); and (2) the efficacy and safety of mirogabalin in patients with DPNP, including those with mild pain.&lt;br&gt;
Methods: The Dia-NeP study is a multicenter, prospective study consisting of two parts, a baseline survey and an interventional study, to be conducted from March 2025 to August 2026 in patients with T2DM in Japan. The baseline survey is the observational study investigating the epidemiology of DPN and DPNP, and the interventional study is an exploratory, single-arm, open-label study of 12-week mirogabalin treatment. Of patients with T2DM enrolled in the baseline survey, those diagnosed with DPNP who have an NRS score for pain&#8201;&#8805;&#8201;1 will be included in the interventional study. The target sample size is 1000 to 3000 patients for the baseline survey and 100 for the interventional study.&lt;br&gt;
Planned Outcomes: The primary endpoint is the change from baseline in the NRS score at week 12 in the interventional study. The safety endpoint is adverse events. This study will not only show the latest prevalence of DPN and DPNP in Japan, but is also the first study to investigate the efficacy and safety of mirogabalin in patients with DPNP having mild pain, as well as moderate-to-severe pain, and is expected to provide useful evidence for future DPN and DPNP treatment.&lt;br&gt;
Trial Registration: Japan Registry of Clinical Trials (jRCTs031240623, registered 20/January/2025, https://jrct.mhlw.go.jp/en-latest-detail/jRCTs031240623).</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Diabetic peripheral neuropathic pain</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Diabetic polyneuropathy</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Epidemiological survey</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Exploratory study</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Mirogabalin</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Quality of life</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2045-2322</Issn>
      <Volume>15</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Elucidation of puberulic acid&#8211;induced nephrotoxicity using stem cell-based kidney organoids</ArticleTitle>
    <FirstPage LZero="delete">42195</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Hiroyuki</FirstName>
        <LastName>Nakanoh</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kenji</FirstName>
        <LastName>Tsuji</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Naruhiko</FirstName>
        <LastName>Uchida</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuhiko</FirstName>
        <LastName>Fukushima</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Soichiro</FirstName>
        <LastName>Haraguchi</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shinji</FirstName>
        <LastName>Kitamura</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Jun</FirstName>
        <LastName>Wada</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Recent cases of acute kidney injury (AKI) in Japan have been linked to Beni-koji CholesteHelp supplements, with puberulic acid identified as a potential nephrotoxic contaminant. To address the need for a reliable in vitro nephrotoxicity testing platform, we developed a screening model using kidney organoids derived from adult rat kidney stem (KS) cells. The organoids were exposed to known nephrotoxicants, including cisplatin and gentamicin, to validate the system. Puberulic acid toxicity was evaluated in both KS cell-derived organoids and wild-type mice. The organoids recapitulated tubular injury induced by known nephrotoxins and showed significant Kim-1 mRNA upregulation. Puberulic acid-treated organoids and mice exhibited morphological features of acute tubular necrosis (ATN), mitochondrial damage, and reduced cytochrome c oxidase subunit IV (COX-IV) expression. Markers of oxidative stress and apoptosis, such as 8-hydroxy-2’-deoxyguanosine (8-OHdG) and cleaved caspase-3, were also elevated. These findings suggest that puberulic acid induces mitochondrial dysfunction and oxidative stress, leading to tubular cell death. Puberulic acid-induced nephrotoxicity was demonstrated using our kidney organoid model. KS cell-derived kidney organoids may provide a simple, reproducible, and rapid platform for nephrotoxicity assessment, which may complement conventional animal experiments.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Kidney organoid</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Kidney stem cell</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Puberulic acid</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Nephrotoxicity</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Mitochondrial dysfunction</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Wiley</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1467-7881</Issn>
      <Volume>26</Volume>
      <Issue>11</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Missing the Target: A Scoping Review of the Use of Percent Weight Loss for Obesity Management</ArticleTitle>
    <FirstPage LZero="delete">e13960</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Diana</FirstName>
        <LastName>Sherifali</LastName>
        <Affiliation>McMaster Evidence Review and Synthesis Team; School of Nursing, McMaster University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Megan</FirstName>
        <LastName>Racey</LastName>
        <Affiliation>McMaster Evidence Review and Synthesis Team; School of Nursing, McMaster University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Donna</FirstName>
        <LastName>Fitzpatrick‐Lewis</LastName>
        <Affiliation>McMaster Evidence Review and Synthesis Team; School of Nursing, McMaster University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Michelle</FirstName>
        <LastName>Greenway</LastName>
        <Affiliation>McMaster Evidence Review and Synthesis Team; School of Nursing, McMaster University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Sanjeev</FirstName>
        <LastName>Sockalingam</LastName>
        <Affiliation>Obesity Canada</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Jun</FirstName>
        <LastName>Wada</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Faculty of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Soo&#160;Huat</FirstName>
        <LastName>Teoh</LastName>
        <Affiliation>Department of Clinical Medicine, Advanced Medical and Dental Institute, Universiti Sains Malaysia</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ian</FirstName>
        <LastName>Patton</LastName>
        <Affiliation>Obesity Canada</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">David</FirstName>
        <LastName>Macklin</LastName>
        <Affiliation>Temerty Faculty of Medicine, University of Toronto</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Elizabeth&#160;F.&#160;C.</FirstName>
        <LastName>van Rossum</LastName>
        <Affiliation>Department of Internal Medicine, Division of Endocrinology, and Obesity Center CGG, Erasmus MC, University Medical Center Rotterdam</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Luca</FirstName>
        <LastName>Busetto</LastName>
        <Affiliation>Department of Medicine, University of Padova</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Deborah&#160;Bade</FirstName>
        <LastName>Horn</LastName>
        <Affiliation>Center of Obesity Medicine and Metabolic Performance, Department of Surgery, University of Texas McGovern Medical School</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">J.&#160;D.</FirstName>
        <LastName>Patricia&#160;Nece</LastName>
        <Affiliation>Obesity Action Coalition</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Morgan&#160;Emile&#160;Gabriel&#160;Salmon</FirstName>
        <LastName>Leguede</LastName>
        <Affiliation>ABHispalis Spain, Alianza Hispana de Personas con Obesidad Latin America</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Nicole</FirstName>
        <LastName>Pearce</LastName>
        <Affiliation>Obesity Canada</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Carel</FirstName>
        <LastName>Le&#160;Roux</LastName>
        <Affiliation>School of Medicine, University College Dublin</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Jamy</FirstName>
        <LastName>Ard</LastName>
        <Affiliation>School of Medicine, Wake Forest University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Angela&#160;S.</FirstName>
        <LastName>Alberga</LastName>
        <Affiliation>Department of Health, Kinesiology, and Applied Physiology, Concordia University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Lee</FirstName>
        <LastName>Kaplan</LastName>
        <Affiliation>Obesity, Metabolism and Nutrition Institute Massachusetts General Hospital and Harvard Medical School</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Arya&#160;M.</FirstName>
        <LastName>Sharma</LastName>
        <Affiliation>Department of Medicine, University of Alberta</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Sean</FirstName>
        <LastName>Wharton</LastName>
        <Affiliation>Temerty Faculty of Medicine, University of Toronto</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Introduction: To co-create comprehensive targets for obesity management, we need to understand the genesis and current use of percent weight loss targets in research. The goals of our scoping review are to (1) synthesize the literature on percent weight loss targets for adults with obesity and (2) discuss the percent weight loss targets in context with their health benefits.&lt;br&gt;
Methods: We searched Cochrane, MEDLINE, and EMBASE for English language, pharmaceutical, and/or behavioral intervention studies in adults with obesity where the explicit aim of the study was weight reduction defined as a percent of body weight. Reviewers screened citations and extracted data including study characteristics.&lt;br&gt;
Results: From 16,164 abstracts, we included 30 citations which were mostly randomized controlled trials (RCTs) (n&#8201;=&#8201;17) or quasi-experimental studies (n&#8201;=&#8201;12) published between 1992 and 2024. Most of the studies had target weight loss goals between 3% and 10% of body weight (n&#8201;=&#8201;28), while n&#8201;=&#8201;2 had body weight loss goals of 15% or 30%. The proportion of participants who met the percent weight loss target ranged from 5.9% (nutrition only study) to 85% (pharmaceutical study). The studies reported different reasons for targeting a percentage of weight loss such as disease-specific outcomes, reduced risk of disease, or patient-reported outcomes.&lt;br&gt;
Conclusion: Percent weight loss targets were based on similar research and were often not feasible nor sustainable for most participants. The design of these interventions and evaluation of obesity management would benefit from more patient-focused parameters which could help to co-design comprehensive targets for research and practice.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">obesity management</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">percent body weight</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">scoping review</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">target</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">weight loss</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0916-9636</Issn>
      <Volume>48</Volume>
      <Issue>11</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Efficacy and safety of esaxerenone with and without sodium&#8211;glucose cotransporter-2 inhibitor use in hypertensive patients with type 2 diabetes mellitus: a pooled analysis of five clinical studies</ArticleTitle>
    <FirstPage LZero="delete">2924</FirstPage>
    <LastPage>2937</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Hirohiko</FirstName>
        <LastName>Motoki</LastName>
        <Affiliation>Department of Cardiovascular Medicine, Shinshu University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Koichiro</FirstName>
        <LastName>Kuwahara</LastName>
        <Affiliation>Department of Cardiovascular Medicine, Shinshu University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Haruhito A.</FirstName>
        <LastName>Uchida</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Faculty of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Jun</FirstName>
        <LastName>Wada</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Faculty of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuomi</FirstName>
        <LastName>Kario</LastName>
        <Affiliation>Division of Cardiovascular Medicine, Department of Medicine, Jichi Medical University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomohiro</FirstName>
        <LastName>Katsuya</LastName>
        <Affiliation>Katsuya Clinic</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tatsuo</FirstName>
        <LastName>Shimosawa</LastName>
        <Affiliation>Department of Clinical Laboratory, School of Medicine, International University of Health and Welfare</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kenichi</FirstName>
        <LastName>Tsujita</LastName>
        <Affiliation>Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shoko</FirstName>
        <LastName>Suzuki</LastName>
        <Affiliation>Data Intelligence Department, Daiichi Sankyo Co. Ltd.</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomohiro</FirstName>
        <LastName>Suedomi</LastName>
        <Affiliation>Primary Medical Science Department, Daiichi Sankyo Co. Ltd.</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takashi</FirstName>
        <LastName>Taguchi</LastName>
        <Affiliation>Primary Medical Science Department, Daiichi Sankyo Co. Ltd.</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>This pooled subanalysis of five multicenter, prospective, open-label, single-arm studies on esaxerenone aimed to evaluate the efficacy, organ-protective effects, and safety of esaxerenone in hypertensive patients with type 2 diabetes mellitus (T2DM), with and without concomitant sodium&#8211;glucose cotransporter-2 inhibitor (SGLT2i) therapy. In total, 283 and 279 patients were included in the safety (with SGLT2i, 148; without, 135) and full analysis sets (with SGLT2i; 145; without, 134), respectively. Significant changes in morning home systolic/diastolic blood pressure (SBP/DBP) from baseline to Week 12 were shown in the overall population (mean change: −11.9/−5.2&#8201;mmHg, both P&#8201;&lt;&#8201;0.001) and both SGLT2i and non-SGLT2i subgroups (−11.3/−4.8 and −12.5/−5.7&#8201;mmHg, respectively, all P&#8201;&lt;&#8201;0.001). Similar findings were observed in bedtime home and office SBP/DBP. The proportions of patients who achieved target home SBP/DBP&#8201;&lt;&#8201;135/85&#8201;mmHg were 71.2% (overall population) and 70.5% and 71.9% in the SGLT2i and non-SGLT2i subgroups, respectively. The urine albumin-to-creatinine ratio significantly improved from baseline to Week 12 in the overall population and SGLT2i subgroups (percentage change in geometric mean from baseline: −42.8%, −43.0%, and −42.6%, respectively, all P&#8201;&lt;&#8201;0.001). N-terminal pro-B-type natriuretic peptide levels improved in all groups. The incidence of serum potassium &#8805;5.5&#8201;mEq/L was 2.0% vs 5.2% in the SGLT2i vs non-SGLT2i subgroups. Esaxerenone demonstrated significant BP-lowering effects, and improved renal and cardiovascular parameters, regardless of SGLT2i use. Safety was consistent across groups, with the numerically lower incidence of serum potassium &#8805;5.5&#8201;mEq/L in the SGLT2i subgroup suggesting a potential mitigating effect of SGLT2is on the risk of hyperkalemia.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Esaxerenone</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Hypertension</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Morning home blood pressure</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Sodium&#8211;glucose cotransporter-2 inhibitor</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Type 2 diabetes mellitus</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1342-1751</Issn>
      <Volume>29</Volume>
      <Issue>10</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>First-time diagnosis and referral practices for individuals with CKD by primary care physicians: a study of electronic medical records across multiple clinics in Japan</ArticleTitle>
    <FirstPage LZero="delete">1342</FirstPage>
    <LastPage>1353</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Haruhito A.</FirstName>
        <LastName>Uchida</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Jun</FirstName>
        <LastName>Wada</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuji</FirstName>
        <LastName>Nagao</LastName>
        <Affiliation>Medicine Division, Nippon Boehringer Ingelheim Co., Ltd.</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Katsuhito</FirstName>
        <LastName>Ihara</LastName>
        <Affiliation>Medicine Division, Nippon Boehringer Ingelheim Co., Ltd.</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Background Chronic kidney disease (CKD) is a major public health burden in Japan. Japanese primary care physicians (PCPs) are expected to play an important role in the early diagnosis and management of CKD, but comprehensive data on their role are limited.&lt;br&gt;
Methods This observational study examined data from individuals who underwent tests for CKD diagnosis between January 2017 and September 2023 in the Japan Medical Data Survey (JAMDAS) database of primary care clinics in Japan. The primary outcome was the proportion of individuals with CKD without the registration of a CKD-related disease code. Time to CKD diagnosis and referral were also assessed.&lt;br&gt;
Results Among 1,188,543 eligible individuals who underwent kidney-related laboratory tests, 183,473 (15.4%) met CKD diagnosis criteria according to the Japanese Clinical Practice Guideline for CKD. The mean (±&#8201;SD) age was 77.4&#8201;±&#8201;11.0 years, 57.1% were female, and 71.8% had CKD stage 3a. Over 98% of individuals who met CKD diagnosis criteria did not receive an insurance diagnosis code within 90 days after meeting the criteria. Among referrable individuals, 89.7% did not receive a referral within 90 days of meeting the referral criteria.&lt;br&gt;
Conclusion These results suggest CKD may be underdiagnosed and under-referred in Japanese clinics. Measures should be taken to increase detection and diagnosis according to the Japanese Clinical Practice Guideline for CKD.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Chronic kidney disease</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Electronic medical records</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Japan</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Primary care physician</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Disease code</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0916-9636</Issn>
      <Volume>48</Volume>
      <Issue>9</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Efficacy and safety of esaxerenone in hypertensive patients with chronic kidney disease, with or without type 2 diabetes mellitus: a pooled analysis of five clinical studies</ArticleTitle>
    <FirstPage LZero="delete">2413</FirstPage>
    <LastPage>2426</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Haruhito A.</FirstName>
        <LastName>Uchida</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Faculty of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Jun</FirstName>
        <LastName>Wada</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Faculty of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hirohiko</FirstName>
        <LastName>Motoki</LastName>
        <Affiliation>Department of Cardiovascular Medicine, Shinshu University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Koichiro</FirstName>
        <LastName>Kuwahara</LastName>
        <Affiliation>Department of Cardiovascular Medicine, Shinshu University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuomi</FirstName>
        <LastName>Kario</LastName>
        <Affiliation>Division of Cardiovascular Medicine, Department of Medicine, Jichi Medical University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomohiro</FirstName>
        <LastName>Katsuya</LastName>
        <Affiliation>Katsuya Clinic</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tatsuo</FirstName>
        <LastName>Shimosawa</LastName>
        <Affiliation>Department of Clinical Laboratory, School of Medicine, International University of Health and Welfare</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kenichi</FirstName>
        <LastName>Tsujita</LastName>
        <Affiliation>Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shoko</FirstName>
        <LastName>Suzuki</LastName>
        <Affiliation>Data Intelligence Department, Daiichi Sankyo Co., Ltd.</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomohiro</FirstName>
        <LastName>Suedomi</LastName>
        <Affiliation>Primary Medical Science Department, Daiichi Sankyo Co., Ltd.</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takashi</FirstName>
        <LastName>Taguchi</LastName>
        <Affiliation>Primary Medical Science Department, Daiichi Sankyo Co., Ltd.</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Effective management of blood pressure (BP) and albuminuria are crucial for suppressing chronic kidney disease (CKD) progression and cardiovascular risks in hypertension. This pooled analysis evaluated the antihypertensive effects, organ-protective effects, and safety of esaxerenone in hypertensive patients with CKD by integrating five clinical studies of esaxerenone. Patients were divided based on type 2 diabetes mellitus (T2DM) status (with or without T2DM) and creatinine-based estimated glomerular filtration rate (eGFRcreat) (30 to &lt;60 and &#8805;60&#8201;mL/min/1.73 m2). Significant changes in morning home BP from baseline at Week 12 were observed in the overall population (mean change −12.8/&#8201;−&#8201;5.4&#8201;mmHg), T2DM subgroups (&#8201;−&#8201;12.2/&#8201;−&#8201;4.5 and −14.5/&#8201;−&#8201;7.8&#8201;mmHg), and eGFRcreat subgroups (&#8201;−&#8201;12.5/&#8201;−&#8201;4.7 and −14.0/&#8201;−&#8201;6.9&#8201;mmHg) (all P&#8201;&lt;&#8201;0.001). Bedtime home and office BP showed similar tendencies. Urine albumin-to-creatinine ratio significantly improved from baseline at Week 12 in the overall population (mean change: −55.2%), T2DM subgroups (&#8201;−&#8201;56.5% and −52.0%), and eGFRcreat subgroups (&#8201;−&#8201;54.6% and −55.4%) (all P&#8201;&lt;&#8201;0.001). N-terminal pro-B-type natriuretic peptide levels significantly decreased in the overall population (percent change: −14.1%) and subgroup without T2DM (&#8201;−&#8201;25.3%). The incidence of serum potassium &#8805;5.5 mEq/L was lower in the subgroup with T2DM vs without T2DM (3.1% and 11.3%), potentially related to the use of sodium&#8211;glucose cotransporter 2 inhibitors. These findings highlight the sustained BP-lowering effect of esaxerenone throughout the day in hypertensive patients with CKD, irrespective of T2DM status, and its significant reduction in albuminuria. The data support the safety and efficacy of esaxerenone in this patient population, underscoring its potential as a valuable therapeutic option.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">albuminuria</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">chronic kidney disease</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">esaxerenone</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">morning hypertension</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">type 2 diabetes mellitus</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2045-2322</Issn>
      <Volume>15</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Hypoglycemia and hyperinsulinemia induced by phenolic uremic toxins in CKD and DKD patients</ArticleTitle>
    <FirstPage LZero="delete">5762</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Yoshiyasu</FirstName>
        <LastName>Tongu</LastName>
        <Affiliation>Tohoku University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomoko</FirstName>
        <LastName>Kasahara</LastName>
        <Affiliation>Department of Clinical Biology and Hormonal Regulation, Tohoku University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yasutoshi</FirstName>
        <LastName>Akiyama</LastName>
        <Affiliation>Laboratory of Oncology, Pharmacy Practice and Sciences, Tohoku University Graduate School of Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takehiro</FirstName>
        <LastName>Suzuki</LastName>
        <Affiliation>Department of Clinical Biology and Hormonal Regulation, Tohoku University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hsin-Jung</FirstName>
        <LastName>Ho</LastName>
        <Affiliation>Department of Clinical Biology and Hormonal Regulation, Tohoku University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yotaro</FirstName>
        <LastName>Matsumoto</LastName>
        <Affiliation>Laboratory of Oncology, Pharmacy Practice and Sciences, Tohoku University Graduate School of Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryota</FirstName>
        <LastName>Kujirai</LastName>
        <Affiliation>Laboratory of Oncology, Pharmacy Practice and Sciences, Tohoku University Graduate School of Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Koichi</FirstName>
        <LastName>Kikuchi</LastName>
        <Affiliation>Department of Clinical Biology and Hormonal Regulation, Tohoku University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Koji</FirstName>
        <LastName>Nata</LastName>
        <Affiliation>Department of Medical Biochemistry, School of Pharmacy, Iwate Medical University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Makoto</FirstName>
        <LastName>Kanzaki</LastName>
        <Affiliation>Department of Biomedical Engineering, Tohoku University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kenshin</FirstName>
        <LastName>Suzuki</LastName>
        <Affiliation>Tohoku University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shun</FirstName>
        <LastName>Watanabe</LastName>
        <Affiliation>Department of Clinical Biology and Hormonal Regulation, Tohoku University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Chiharu</FirstName>
        <LastName>Kawabe</LastName>
        <Affiliation>Department of Clinical Biology and Hormonal Regulation, Tohoku University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yui</FirstName>
        <LastName>Miyata</LastName>
        <Affiliation>Department of Clinical Biology and Hormonal Regulation, Tohoku University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shun</FirstName>
        <LastName>Itai</LastName>
        <Affiliation>Department of Clinical Biology and Hormonal Regulation, Tohoku University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takafumi</FirstName>
        <LastName>Toyohara</LastName>
        <Affiliation>Department of Clinical Biology and Hormonal Regulation, Tohoku University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Chitose</FirstName>
        <LastName>Suzuki</LastName>
        <Affiliation>Department of Clinical Biology and Hormonal Regulation, Tohoku University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tetsuhiro</FirstName>
        <LastName>Tanaka</LastName>
        <Affiliation>Division of Nephrology, Endocrinology, and Vascular Medicine, Tohoku University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Jun</FirstName>
        <LastName>Wada</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshihisa</FirstName>
        <LastName>Tomioka</LastName>
        <Affiliation>Laboratory of Oncology, Pharmacy Practice and Sciences, Tohoku University Graduate School of Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takaaki</FirstName>
        <LastName>Abe</LastName>
        <Affiliation>Department of Clinical Biology and Hormonal Regulation, Tohoku University Graduate School of Medicine</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Patients with end-stage renal disease have lower fasting plasma glucose and HbA1c levels, with significantly higher insulin levels. For a long time, it has been believed that this higher insulin level in renal failure is due to decreased insulin clearance caused by reduced renal function. However, here we reported that accumulation of the gut microbiota-derived uremic toxin, phenyl sulfate (PS) in the renal failure, increased insulin secretion from the pancreas by enhanced glucose-stimulated insulin secretion. Other endogenous sulfides compounds which accumulated as in the renal failure also increased glucose-stimulated insulin secretion from β&#65279;-cell. With RNA-seq analyses and gene knock down, we demonstrated that insulin secretion evoked by PS was mediated by Ddah2. In addition, we also found that PS increased insulin resistance through lncRNA expression and Erk phosphorylation in the adipocytes. To confirm the relationship between PS and glucose metabolism in human, we recruited 2 clinical cohort studies (DKD and CKD) including 462 patients, and found that there was a weak negative correlation between PS and HbA1c. Because these trials did not measure fasting insulin level, we alternatively used the urinary C-peptide/creatinine ratio (UCPCR) as an indicator of insulin resistance. We found that PS may induce insulin resistance in patients with eGFR&#8201;&lt;&#8201;60 mL/min/1.73 m2. These data suggest that the accumulation of uremic toxins modulates glucose metabolism and induced insulin resistance in CKD and DKD patients. Considering HbA1c as a reflection of chronic hyperglycemia and UCPCR as a reflection of chronic hyperinsulinemia, our findings indicate that PS is negatively associated with hyperglycemia independent of CKD, and positively associated with hyperinsulinemia in DKD patients.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">CKD, DKD, Phenyl sulfate, Uremic toxin, Insulin secretion, Insulin resistance, Gut microbiota</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2045-2322</Issn>
      <Volume>14</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2024</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Association between proteinuria and mineral metabolism disorders in chronic kidney disease: the Japan chronic kidney disease database extension (J-CKD-DB-Ex)</ArticleTitle>
    <FirstPage LZero="delete">27481</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Sho</FirstName>
        <LastName>Shimamoto</LastName>
        <Affiliation>Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takako</FirstName>
        <LastName>Nakahara</LastName>
        <Affiliation>Department of Medical Technology, Faculty of Health Science and Technology, Kawasaki University of Medical Welfare</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shunsuke</FirstName>
        <LastName>Yamada</LastName>
        <Affiliation>Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hajime</FirstName>
        <LastName>Nagasu</LastName>
        <Affiliation>Department of Nephrology and Hypertension, Kawasaki Medical School</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Seiji</FirstName>
        <LastName>Kishi</LastName>
        <Affiliation>Department of Nephrology and Hypertension, Kawasaki Medical School</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Naoki</FirstName>
        <LastName>Nakashima</LastName>
        <Affiliation>Department of Medical Informatics, Graduate School of Medical Science, Kyushu University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuhiko</FirstName>
        <LastName>Tsuruya</LastName>
        <Affiliation>Department of Nephrology, Nara Medical University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hirokazu</FirstName>
        <LastName>Okada</LastName>
        <Affiliation>Department of Nephrology, Faculty of Medicine, Saitama Medical University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kouichi</FirstName>
        <LastName>Tamura</LastName>
        <Affiliation>Department of Medical Science and Cardiorenal Medicine, Graduate School of Medicine, Yokohama City University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ichiei</FirstName>
        <LastName>Narita</LastName>
        <Affiliation>Division of Clinical Nephrology and Rheumatology, Niigata University Graduate School of Medical and Dental Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shoichi</FirstName>
        <LastName>Maruyama</LastName>
        <Affiliation>Department of Nephrology, Nagoya University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuichiro</FirstName>
        <LastName>Yano</LastName>
        <Affiliation>Department of General Medicine, Juntendo University Faculty of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takashi</FirstName>
        <LastName>Yokoo</LastName>
        <Affiliation>Division of Kidney and Hypertension, Department of Internal Medicine, Jikei University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takashi</FirstName>
        <LastName>Wada</LastName>
        <Affiliation>Department of Nephrology and Rheumatology, Kanazawa University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Jun</FirstName>
        <LastName>Wada</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Eiichiro</FirstName>
        <LastName>Kanda</LastName>
        <Affiliation>Department of Health Data Science, Kawasaki Medical School</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiromi</FirstName>
        <LastName>Kataoka</LastName>
        <Affiliation>Department of Medical Technology, Faculty of Health Science and Technology, Kawasaki University of Medical Welfare</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masaomi</FirstName>
        <LastName>Nangaku</LastName>
        <Affiliation>Division of Nephrology and Endocrinology, University of Tokyo Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Naoki</FirstName>
        <LastName>Kashihara</LastName>
        <Affiliation>Department of Nephrology and Hypertension, Kawasaki Medical School</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshiaki</FirstName>
        <LastName>Nakano</LastName>
        <Affiliation>Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Chronic kidney disease-mineral and bone disorder (CKD-MBD) are recognized as a systemic disease affecting the prognosis of patients with CKD. Proper management of CKD-MBD is important to improve the prognosis of patients with CKD. Although proteinuria is recognized as a poor prognostic factor in these patients, few reports have examined its association with CKD-MBD. We examined the association between proteinuria and CKD-MBD using data from the Japan Chronic Kidney Disease Database Extension (J-CKD-DB-Ex). Among the patients registered in the J-CKD-DB-Ex, 30,977 with CKD stages G2&#8211;G5 who had serum creatinine, albumin, calcium, and phosphate concentrations measured at least once and urinalysis performed were included. The patients were divided into four groups (negative, 1+, 2+, and 3+) according to the degree of proteinuria. The association between proteinuria and CKD-MBD was examined by a logistic regression analysis. In a model adjusted for age, sex, diabetes, and the estimated glomerular filtration rate (eGFR), the odds ratio of the 3&#8201;+&#8201;group compared with the negative group significantly increased to 2.67 (95% confidence interval, 2.29&#8211;3.13) for hyperphosphatemia, 2.68 (1.94&#8211;3.71) for hypocalcemia, and 1.56 (1.24&#8211;1.98) for hypomagnesemia. Proteinuria is associated with hyperphosphatemia, hypocalcemia, and hypomagnesemia in patients with CKD independently of eGFR.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">CKD-MBD</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Proteinuria</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Hyperphosphatemia</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Hypocalcemia</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Hypomagnesemia</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">J-CKD-DB-Ex</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0929-1903</Issn>
      <Volume/>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>p53-armed oncolytic adenovirus induces apoptosis in pancreatic cancer-associated stellate cells via macropinocytosis</ArticleTitle>
    <FirstPage LZero="delete"/>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Takeyoshi</FirstName>
        <LastName>Nishiyama</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroshi</FirstName>
        <LastName>Tazawa</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yasuo</FirstName>
        <LastName>Nagai</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryohei</FirstName>
        <LastName>Shoji</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshinori</FirstName>
        <LastName>Kajiwara</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Naoyuki</FirstName>
        <LastName>Hashimoto</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yosuke</FirstName>
        <LastName>Takahashi</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Satoru</FirstName>
        <LastName>Kikuchi</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shinji</FirstName>
        <LastName>Kuroda</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshiaki</FirstName>
        <LastName>Ohara</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuhiro</FirstName>
        <LastName>Noma</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryuichi</FirstName>
        <LastName>Yoshida</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuzo</FirstName>
        <LastName>Umeda</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroyoshi Y.</FirstName>
        <LastName>Tanaka</LastName>
        <Affiliation>Department of Pharmaceutical Biomedicine, Okayama University Graduate School of Interdisciplinary Science and Engineering in Health Systems</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Mitsunobu R.</FirstName>
        <LastName>Kano</LastName>
        <Affiliation>Department of Pharmaceutical Biomedicine, Okayama University Graduate School of Interdisciplinary Science and Engineering in Health Systems</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Atsushi</FirstName>
        <LastName>Masamune</LastName>
        <Affiliation>Division of Gastroenterology, Tohoku University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yasuo</FirstName>
        <LastName>Urata</LastName>
        <Affiliation>Oncolys BioPharma, Inc.</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shunsuke</FirstName>
        <LastName>Kagawa</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshiyoshi</FirstName>
        <LastName>Fujiwara</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Pancreatic ductal adenocarcinoma (PDAC)-associated pancreatic stellate cells (PSCs) promote PDAC tumor progression. Notably, PDAC tumors display enhanced macropinocytosis, resulting in enhanced uptake of extracellular particles, including nutrients and viruses. We previously demonstrated the therapeutic potential of telomerase-specific oncolytic adenoviruses OBP-301 and p53-armed OBP-702 against human PDAC cells. However, it remains unclear whether macropinocytosis promotes the virus sensitivity of PDAC-associated PSCs. Here, we show that PSCs activated by human PDAC cells (Panc-1 and BxPC-3) exhibit enhanced sensitivity to wild-type and oncolytic adenoviruses via enhanced macropinocytosis. The virus sensitivity of PSCs was analyzed for the infectivity, replication, and cytopathic activity of wild-type and oncolytic adenoviruses. PDAC-associated PSCs were more sensitive to wild-type and oncolytic adenoviruses than were control PSCs; this sensitivity was mediated by activation of macropinocytosis. In three-dimensional (3D) culture models, p53-armed OBP-702 decreased the viability of PDAC-associated PSCs more strongly than did non-armed OBP-301, reflecting induction of p53-mediated apoptosis. Co-inoculation of PSCs enhanced the growth of PDAC tumors, an effect that was attenuated by OBP-702-mediated p53 activation in the tumor stroma. Our results suggest that p53-armed oncolytic adenovirus OBP-702 eliminates PDAC-associated PSCs via enhancement of macropinocytosis-mediated virus entry and induction of p53-mediated apoptosis.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList/>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2168-8184</Issn>
      <Volume>17</Volume>
      <Issue>10</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Bladder Trigone as a Sensory Hub: A Narrative Review</ArticleTitle>
    <FirstPage LZero="delete">e94951</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Takuya</FirstName>
        <LastName>Sadahira</LastName>
        <Affiliation>Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuki</FirstName>
        <LastName>Maruyama</LastName>
        <Affiliation>Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yosuke</FirstName>
        <LastName>Mitsui</LastName>
        <Affiliation>Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takanori</FirstName>
        <LastName>Sekito</LastName>
        <Affiliation>Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomofumi</FirstName>
        <LastName>Watanabe</LastName>
        <Affiliation>Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masami</FirstName>
        <LastName>Watanabe</LastName>
        <Affiliation>Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>The bladder trigone is an anatomically and functionally distinct region within the lower urinary tract (LUT), characterized by a dense network of afferent sensory fibers, specialized urothelial interactions, and prominent mechanotransduction mechanisms. Its intricate neuroarchitecture enables precise detection of bladder filling and coordination of micturition, whereas dysregulation of these pathways contributes to lower urinary tract symptoms (LUTS), including urgency, frequency, and bladder pain. Despite its recognized clinical relevance, the structural and functional basis of trigonal sensory signaling - and its role - remain incompletely understood.&lt;br&gt;
This review synthesizes current evidence on trigonal afferent organization, integrating data from anatomical mapping, receptor profiling, electrophysiological characterization, and translational research. Seminal anatomical observations are combined with recent advances in mechanotransduction and purinergic, peptidergic, and transient receptor potential (TRP) signaling to provide a comprehensive perspective. The trigone exhibits three principal afferent classes: (1) intraepithelial fibers penetrating umbrella cells, marked by P2X purinoceptor 3 (P2X3), transient receptor potential vanilloid 1 (TRPV1), calcitonin gene-related peptide (CGRP), and substance P (SP); (2) subepithelial plexuses surrounding microvasculature, enriched in vasoactive neuropeptides and exhibiting plastic hypertrophy in overactive bladder (OAB) and interstitial cystitis/bladder pain syndrome (IC/BPS); and (3) encapsulated corpuscular endings at the lamina propria-detrusor junction, expressing PIEZO1/2 and acid-sensing ion channels (ASICs) for rapid adaptation. In trigeminal dorsal root ganglion (DRG) neurons, high expression of PIEZO2, P2RX3, and voltage-gated sodium channel, type 1.8 (Nav1.8) was observed, revealing their role as the foundation for multisensory information processing. Functional assays highlight distinct mechanotransductive and chemosensory pathways, with aging, inflammation, and neurotrophic factors driving afferent plasticity underlying abnormal bladder sensation, such as urgency, frequency, and pain. Early clinical trials of P2X3 antagonists and intravesical TRPV1 inhibitors demonstrate promising symptomatic benefits. Collectively, evidence positions the bladder trigone as a critical sensory hub where neuronal, urothelial, and immune signals converge to regulate bladder sensation. Understanding its molecular and structural specialization may inform the development of region-specific neuromodulatory therapies targeting sensory urgency and afferent-driven bladder dysfunction.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">bladder trigone</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">botulinum toxin</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">lower urinary tract symptoms</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">sensory afferents</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">varicosities</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
</ArticleSet>
